0001201800-12-000019.txt : 20120814 0001201800-12-000019.hdr.sgml : 20120814 20120814165920 ACCESSION NUMBER: 0001201800-12-000019 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20120630 FILED AS OF DATE: 20120814 DATE AS OF CHANGE: 20120814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VASOMEDICAL, INC CENTRAL INDEX KEY: 0000839087 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 112871434 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-18105 FILM NUMBER: 121033948 BUSINESS ADDRESS: STREET 1: 180 LINDEN AVENUE CITY: WESTBURY STATE: NY ZIP: 11590 BUSINESS PHONE: 516-997-4600 MAIL ADDRESS: STREET 1: 180 LINDEN AVENUE CITY: WESTBURY STATE: NY ZIP: 11590 FORMER COMPANY: FORMER CONFORMED NAME: VASOMEDICAL INC DATE OF NAME CHANGE: 19950517 FORMER COMPANY: FORMER CONFORMED NAME: FUTURE MEDICAL PRODUCTS INC /DE/ DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: FUTURE MEDICAL PRODUCTS INC /NY/ DATE OF NAME CHANGE: 19920506 10-Q 1 vaso10qjune30-2012.htm vaso10qjune30-2012.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
 
 
FORM 10-Q
 

[X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the quarterly period ended June 30, 2012

[   ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the transition period from _______________ to ______________

Commission File Number: 0-18105
 

 
VASOMEDICAL, INC.
(Exact name of registrant as specified in its charter)
 

               Delaware
                  11-2871434
  
(State or other jurisdiction of
(IRS Employer Identification Number)
 incorporation or organization)
  

 
180 Linden Ave., Westbury, New York 11590
(Address of principal executive offices)

Registrant’s Telephone Number           (516) 997-4600

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes [X]    No  [   ]


Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer.  Large Accelerated Filer [  ] Accelerated Filer [  ] Non-Accelerated Filer [  ] Smaller Reporting Company [X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes [   ] No  [X]

                Number of Shares Outstanding of Common Stock, $.001 Par Value, at August 10, 2012 – 158,746,910.

 
 
Page 1
 
Vasomedical, Inc. and Subsidiaries

 
INDEX
 
 
 
Page 2
 
Vasomedical, Inc. and Subsidiaries
(in thousands, except share data) 
   
June 30, 2012
    
December 31, 2011
  
ASSETS
  
(unaudited)
    
(audited)
  
CURRENT ASSETS
            
Cash and cash equivalents
   $ 11,783     $ 2,294  
Short-term investments
     110       110  
Accounts and other receivables, net of an allowance for doubtful
     -          
accounts and commission adjustments of $1,965 at June 30,
     -          
2012 and $2,163 at December 31, 2011
     8,984       20,695  
Receivables due from related parties
     10       196  
Inventories, net
     2,285       2,421  
Financing receivables, net
     20       19  
Deferred commission expense
     2,495       2,053  
Deferred related party consulting expense - current portion
     339       510  
Other current assets
     396       202  
 Total current assets
     26,422       28,500  
                 
PROPERTY AND EQUIPMENT, net of accumulated depreciation of
                
$1,540 at June 30, 2012 and $1,774 at December 31, 2011
     564       429  
GOODWILL
     3,968       3,939  
FINANCING RECEIVABLES, net
     5       16  
DEFERRED RELATED PARTY CONSULTING EXPENSE
     -       85  
OTHER ASSETS
     1,096       1,337  
    $ 32,055     $ 34,306  
LIABILITIES AND STOCKHOLDERS' EQUITY
                
CURRENT LIABILITIES
                
Accounts payable
   $ 456     $ 273  
Accrued commissions
     2,336       3,889  
Accrued expenses and other liabilities
     2,724       2,531  
Sales tax payable
     392       355  
Income taxes payable
     89       278  
Deferred revenue - current portion
     10,685       9,484  
Deferred gain on sale-leaseback of building - current portion
     4       31  
Deferred tax liability, net
     112       112  
Notes payable due to related party
     3       193  
Total current liabilities
     16,801       17,146  
                 
LONG-TERM LIABILITIES
                
Deferred revenue
     4,513       5,743  
Other long-term liabilities
     117       141  
Total long-term liabilities
     4,630       5,884  
                 
COMMITMENTS AND CONTINGENCIES (NOTE N)
                
                 
STOCKHOLDERS' EQUITY
                
Preferred stock, $.01 par value; 1,000,000 shares authorized; nil shares
                
 issued and outstanding at June 30, 2012, and December 31, 2011
     -       -  
Common stock, $.001 par value; 250,000,000 shares authorized;
                
158,746,910 and 153,186,295 shares issued and outstanding
                
 at June 30, 2012 and December 31, 2011
     159       153  
Additional paid-in capital
     60,771       60,188  
Accumulated deficit
     (50,304 )     (49,065 )
Accumulated other comprehensive loss
     (2 )     -  
Total stockholders’ equity
     10,624       11,276  
    $ 32,055     $ 34,306  
The accompanying notes are an integral part of these consolidated condensed financial statements.
 
Page 3
 
Vasomedical, Inc. and Subsidiaries

(Unaudited)
(in thousands, except per share data)
 
    Six months ended June 30,     Three months ended June 30,  
   
2012
    
2011
    
2012
    
2011
  
Revenues
                        
Equipment sales
   $ 2,509     $ 1,086     $ 1,056     $ 558  
Equipment rentals and services
     1,032       1,119       499       542  
Commissions
     10,199       7,815       6,142       4,075  
Total revenues
     13,740       10,020       7,697       5,175  
                                 
Cost of revenues
                                
Cost of sales, equipment
     1,022       748       416       355  
Cost of equipment rentals and services
     551       478       258       213  
Cost of commissions
     2,456       2,049       1,493       1,119  
Total cost of revenues
     4,029       3,275       2,167       1,687  
Gross profit
     9,711       6,745       5,530       3,488  
                                 
Operating expenses
                                
Selling, general and administrative
     10,665       7,944       5,335       4,314  
Research and development
     272       243       120       134  
Total operating expenses
     10,937       8,187       5,455       4,448  
Operating (loss) income
     (1,226 )     (1,442 )     75       (960 )
                                 
Other income (expenses)
                                
Interest and financing costs
     (3 )     (25 )     -       (24 )
Interest and other income, net
     30       18       58       17  
Amortization of deferred gain on
                                
sale-leaseback of building
     27       27       13       13  
Total other income (expenses), net
     54       20       71       6  
                                 
(Loss) income before income taxes
     (1,172 )     (1,422 )     146       (954 )
Income tax expense
     (116 )     -       (92 )     (2 )
Net (loss) income
     (1,288 )     (1,422 )     54       (956 )
                                 
Preferred stock dividends
     -       (279 )     -       (151 )
Net (loss) income applicable to
    common stockholders
     (1,288 )     (1,701 )     54       (1,107 )
                                 
Other comprehensive (loss) income
                                
Foreign currency translation (loss) gain
     (2 )     -       21       -  
Comprehensive (loss) income
   $ (1,290 )   $ (1,701 )   $ 75     $ (1,107 )
                                 
(Loss) earnings per common share
                                
- basic and diluted
   $ (0.01 )   $ (0.01 )   $ 0.00     $ (0.01 )
                                 
Weighted average common shares outstanding
                          
- basic
     156,225       114,077       158,072       116,198  
- diluted
     156,225       114,077       161,806       116,198  

The accompanying notes are an integral part of these consolidated condensed financial statements.
 
Page 4
 
Vasomedical, Inc. and Subsidiaries
(Unaudited)
(in thousands)
    Six months ended  
   
June 30, 2012
    
June 30, 2011
  
Cash flows from operating activities
            
Net  loss
   $ (1,288 )   $ (1,422 )
Adjustments to reconcile net loss to net cash
                
  provided by operating activities
                
Depreciation and amortization of property and equipment
     103       74  
Amortization of deferred gain on sale-leaseback of building
     (27 )     (27 )
Provision for doubtful accounts and commission adjustments
     (3 )     9  
Amortization of deferred distributor costs
     -       63  
Share-based compensation
     231       203  
Amortization of deferred consulting expense
     288       208  
Changes in operating assets and liabilities:
                
Accounts and other receivables
     11,716       8,653  
Receivables due from related parties
     186       -  
Inventories, net
     119       (257 )
Finance receivables
     9       9  
Deferred commission expense
     (442 )     (168 )
Other current assets
     (212 )     (96 )
Other assets
     230       (33 )
Accounts payable
     183       249  
Accrued commissions
     (1,553 )     (94 )
Accrued expenses and other liabilities
     203       (602 )
Sales tax payable
     36       9  
Income taxes payable
     (190 )     (1 )
Deferred revenue
     (29 )     (1,277 )
Trade payable due to related party
     -       (243 )
Other long-term liabilities
     (36 )     (591 )
Net cash provided by operating activities
     9,524       4,666  
                 
Cash flows from investing activities
                
Purchases of property and equipment
     (204 )     (16 )
Purchases of short-term investments
     -       (40 )
Net cash used in investing activities
     (204 )     (56 )
                 
Cash flows from financing activities
                
Proceeds from exercise of warrant
     343       -  
Repayment of note payable
     -       (294 )
Repayment of notes payable due to related party
     (190 )     -  
Proceeds from issuance of preferred stock
     -       150  
Net cash provided by (used in) financing activities
     153       (144 )
Effect of exchange rate differences on cash
     16       -  
                 
NET INCREASE IN CASH AND CASH EQUIVALENTS
     9,489       4,466  
Cash and cash equivalents - beginning of period
     2,294       3,101  
Cash and cash equivalents - end of period
   $ 11,783     $ 7,567  
                 
SUPPLEMENTAL DISCLOSURE OF CASH INFORMATION
                
Interest paid
   $ 5     $ 4  
Income taxes paid
   $ 242     $ 5  
                 
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES
          
Inventories transferred to property and equipment,
                
attributable to operating leases, net
   $ 20     $ 63  
Accrued preferred stock dividends
   $ -     $ 279  
Issuance of preferred stock in satisfaction of accrued dividend
   $ -     $ 101  
Common shares issued for consulting agreements
   $ -     $ 1,070  
 
The accompanying notes are an integral part of these consolidated condensed financial statements.
 
Page 5
 
Vasomedical, Inc. and Subsidiaries
 
 
NOTE A - ORGANIZATION AND PLAN OF OPERATIONS

Vasomedical, Inc. was incorporated in Delaware in July 1987. Unless the context requires otherwise, all references to “we”, “our”, “us”, “Company”, “registrant”, “Vasomedical” or “management” refer to Vasomedical, Inc. and its subsidiaries.  Until 2010, we were primarily engaged in designing, manufacturing, marketing and supporting EECP® enhanced external counterpulsation systems based on our unique proprietary technology currently indicated for use in cases of stable or unstable angina (i.e., chest pain), congestive heart failure (“CHF”), acute myocardial infarction (i.e., heart attack, (MI)) and cardiogenic shock.  In May 2010, the Company, through its wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, expanded into the sales representation business via its agreement with GE Healthcare (“GEHC”), the healthcare business unit of General Electric Company (NYSE: GE), to be GEHC’s exclusive sales representative for the sale of select GEHC diagnostic imaging products in specific market segments in the 48 contiguous states of the United States and the District of Columbia.   In June 2012, the Company entered into an amendment, effective July 1, 2012, of the sales representative agreement (“GEHC Agreement”) extending the initial term of three years commencing July 1, 2010 to five years through June 30, 2015, subject to earlier termination under certain circumstances.

In September 2011, the Company acquired Fast Growth Enterprises Limited (FGE), a British Virgin Islands company which, through its subsidiaries, owns and controls two Chinese operating companies - Life Enhancement Technologies Ltd. and Biox Instruments Co. Ltd., respectively – to expand its technical and manufacturing capabilities and to enhance its distribution network, technology, and product portfolio.  Also in September 2011, the Company restructured to further align its business management structure and long-term growth strategy and now operates through three wholly-owned subsidiaries.  Vaso Diagnostics d/b/a VasoHealthcare continues as the operating subsidiary for the sales representation of GE Healthcare diagnostic imaging products; Vasomedical Global Corp. operates the Company’s recently-acquired Chinese companies; and Vasomedical Solutions, Inc. manages and coordinates our EECP® therapy business as well as other medical equipment operations.

We report the operations of Vasomedical Global Corp. and Vasomedical Solutions, Inc. under our Equipment reportable segment.  VasoHealthcare activities are included under our Sales Representation reportable segment (See Note C).

NOTE B - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES

Basis of Presentation and Use of Estimates

The accompanying consolidated condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and pursuant to the accounting and disclosure rules and regulations of the Securities and Exchange Commission (the "SEC"). Certain information and disclosures normally included in the consolidated condensed financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these consolidated condensed financial statements should be read in connection with the audited consolidated financial statements and related notes thereto included in the Company's Transition Report on Form 10-K for the transition period ended December 31, 2011, as filed with the SEC. These consolidated condensed financial statements include the accounts of the companies over which we exercise control. In the opinion of management, the accompanying consolidated condensed financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of interim results for the Company. The results of operations for any interim period are not necessarily indicative of results to be expected for any other interim period or the full year.

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the consolidated condensed financial statements, the disclosure of contingent assets and liabilities in the consolidated condensed financial statements and the accompanying notes, and the reported amounts of revenues, expenses and cash flows during the periods presented. Actual amounts and results could differ from those estimates. The estimates and assumptions the Company makes are based on historical factors, current circumstances and the experience and judgment of the Company's management. The Company evaluates its estimates and assumptions on an ongoing basis.
 
 
 
Page 6
 
Vasomedical, Inc. and Subsidiarires
 
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

Significant Accounting Policies

Note B of the Notes to Consolidated Financial Statements, included in the Transition Report on Form 10-K for the seven months ended December 31, 2011, includes a summary of the significant accounting policies used in the preparation of the consolidated condensed financial statements.

Reclassifications

Certain reclassifications have been made to prior period amounts to conform with the current period presentation.

NOTE C – SEGMENT REPORTING AND CONCENTRATIONS

The Company views its business in two segments – the Equipment segment and the Sales Representation segment.  The Equipment segment is engaged in designing, manufacturing, marketing and supporting EECP® enhanced external counterpulsation systems both domestically and internationally, as well as the marketing of other medical devices.  The Sales Representation segment operates through the VasoHealthcare subsidiary and is currently engaged solely in the execution of the Company’s responsibilities under our agreement with GEHC.  The Company evaluates segment performance based on operating income.  Administrative functions such as finance, human resources, and information technology are centralized and related expenses allocated to each segment.  Other costs not directly attributable to operating segments, such as audit, legal, director fees, investor relations, and others, as well as certain assets – primarily cash balances – are reported in the Corporate entity below.  There are no intersegment revenues.  Summary financial information for the segments is set forth below:
 
                                                                                                                                                                                                              
      (in thousands)  
    As of or for the three months ended June 30, 2012  
   
Equipment Segment
    
Sales Representation Segment
    
Corporate
    
Consolidated
  
                         
Revenues from external customers
   $ 1,555     $ 6,142     $ -     $ 7,697  
Operating income/(loss)
   $ (197 )   $ 681     $ (409 )   $ 75  
Total assets
   $ 9,323     $ 11,558     $ 11,174     $ 32,055  
Accounts and other receivables, net
   $ 1,151     $ 7,833     $ -     $ 8,984  
Deferred commission expense
   $ -     $ 3,490     $ -     $ 3,490  

 
      As of or for the three months ended June 30, 2011  
   
Equipment Segment
    
Sales Representation Segment
    
Corporate
    
Consolidated
  
                         
Revenues from external customers
   $ 1,100     $ 4,075     $ -     $ 5,175  
Operating loss
   $ (475 )   $ (386 )   $ (99 )   $ (960 )
Total assets
   $ 4,440     $ 6,330     $ 7,687     $ 18,457  
Accounts and other receivables, net
   $ 749     $ 3,552     $ -     $ 4,301  
Deferred commission expense
   $ -     $ 2,703     $ -     $ 2,703  
                                 

 
Page 7
 
Vasomedical, Inc. and Subsidiarires
 
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
                                                                                                                                                                                                                     
    (In thousands)  
      As of or for the six months ended June 30, 2012  
   
Equipment Segment
    
Sales Representation Segment
    
Corporate
    
Consolidated
  
                         
Revenues from external customers
   $ 3,541     $ 10,199     $ -     $ 13,740  
Operating loss
   $ (353 )   $ (115 )   $ (758 )   $ (1,226 )
Total assets
   $ 9,323     $ 11,558     $ 11,174     $ 32,055  
Accounts and other receivables, net
   $ 1,151     $ 7,833     $ -     $ 8,984  
Deferred commission expense
   $ -     $ 3,490     $ -     $ 3,490  

      As of or for the six months ended June 30, 2011  
   
Equipment Segment
    
Sales Representation Segment
    
Corporate
    
Consolidated
  
                         
Revenues from external customers
   $ 2,205     $ 7,815     $ -     $ 10,020  
Operating loss
   $ (741 )   $ (418 )   $ (283 )   $ (1,442 )
Total assets
   $ 4,440     $ 6,330     $ 7,687     $ 18,457  
Accounts and other receivables, net
   $ 749     $ 3,552     $ -     $ 4,301  
Deferred commission expense
   $ -     $ 2,703     $ -     $ 2,703  
 
For the three months ended June 30, 2012 and 2011, GE Healthcare accounted for 80% and 79% of revenue, respectively.  For the six months ended June 30, 2012 and 2011, GE Healthcare accounted for 74% and 78% of revenue, respectively.   Also, GE Healthcare accounted for $7.7 million, or 86%, and $19.7 million, or 95%, of accounts and other receivables at June 30, 2012 and December 31, 2011, respectively.

NOTE D – SHARE-BASED COMPENSATION

The Company complies with ASC Topic 718 “Compensation – Stock Compensation” (“ASC 718”), which requires all share-based awards to employees, including grants of employee stock options, to be recognized in the consolidated condensed financial statements based on their estimated fair values.

During the six-month period ended June 30, 2012, the Company granted 500,000 restricted shares of common stock, valued at $120,000 to an officer, of which half vested immediately and the remainder one year thereafter.  During the three months ended June 30, 2011, 166,279 shares of restricted common stock valued at $73,500 were granted to directors, and 366,279 shares of restricted common stock valued at $135,500 were granted to directors during the six months ended June 30, 2011.

During the six-month periods ended June 30, 2012 and 2011, the Company did not grant any stock options.

For the three and six months ended June 30, 2012, the Company granted 2,190,000 shares of restricted common stock valued at $548,000 to non-officer employees in its VasoHealthcare subsidiary in conjunction with the extension of the GEHC Agreement in June 2012.  For the three and six months ended June 30, 2011, the Company granted 10,000 shares of restricted common stock valued at $6,800 to non-officer employees.

Share-based compensation expense recognized for the three and six months ended June 30, 2012 was $102,000 and $231,000, respectively,  and $77,000 and $203,000 for the three and six months ended June 30, 2011, respectively.  These expenses are included in cost of revenues; selling, general, and administrative expenses; and research and development expenses in the consolidated condensed statements of operations.  Expense for share-based arrangements was $136,000 and $288,000 for the three and six months ended June 30, 2012, respectively, and $162,000 and $208,000 for the three and six months ended June 30, 2011, respectively.  Unrecognized expense related to existing share-based arrangements is approximately $1.3 million at June 30, 2012 and will be recognized through July 2013.

 
Page 8
 
Vasomedical, Inc. and Subsidiarires
 
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
 
NOTE E – EARNINGS (LOSS) PER COMMON SHARE

 Basic earnings per common share is computed as earnings applicable to common stockholders divided by the weighted-average number of common shares outstanding for the period.  Diluted earnings per common share reflects the potential dilution that could occur if securities or other contracts to issue common shares were exercised or converted to common stock.

Basic and diluted (loss) per common share was ($0.01) for the six months ended June 30, 2012 and 2011.  Basic and diluted earnings (loss) per share for the three months ended June 30, 2012 and 2011 were $0.00 and ($0.01), respectively.

Diluted earnings per share were computed based on the weighted average number of shares outstanding plus all potentially dilutive common stock equivalents.  A reconciliation of basic to diluted shares used in the earnings per share calculation is as follows:

 
     Six months ended June 30,   Three months ended June 30,  
   
2012
    
2011
    
2012
    
2011
  
Basic weighted average shares outstanding
     156,225       114,077       158,072       116,198  
Dilutive effect of share-based compensation
     -       -       1,334       -  
Contingently issuable shares
     -       -       2,400       -  
Diluted weighted average shares outstanding
     156,225       114,077       161,806       116,198  
                                 
 
The following table represents common stock equivalents that were excluded from the computation of diluted earnings per share for the six and three months ended June 30, 2012 and 2011, because the effect of their inclusion would be anti-dilutive.
                                                                                                                                                        
     (in thousands)  
    For the six months ended     For the three months ended  
   
June 30, 2012
    
June 30, 2011
    
June 30, 2012
    
June 30, 2011
  
Stock options
     1,810       1,864       260       1,864  
Warrants
     1,500       4,286       1,500       4,286  
Contingently issuable shares
     2,400       -       -       -  
Convertible preferred stock
     -       30,668       -       30,668  
Common stock grants
     4,918       3,913       375       3,913  
      10,628       40,731       2,135       40,731  
 
NOTE F – FAIR VALUE MEASUREMENTS

The Company complies with the provisions of ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”).  Under ASC 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date.
 
 
Page 9
 
Vasomedical, Inc. and Subsidiarires
 
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
 
 
The following tables present information about the Company’s assets and liabilities measured at fair value as of June 30, 2012 and December 31, 2011:
 
    (in thousands)  
   
Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)
    
Significant
Other
Observable
Inputs 
(Level 2)
    
Significant
Unobservable
Inputs
(Level 3)
    
Balance
as of
June 30,
2012
  
Assets
                    
(unaudited)
  
Cash equivalents invested in money market funds
(included in cash and cash equivalents)
   $ 9,834     $ -     $ -     $ 9,834  
Investment in certificates of deposit
(included in short-term investments)
     110                       110  
    $ 9,944     $ -     $ -     $ 9,944  
                                 
   
Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)
    
Significant
Other
Observable
Inputs
(Level 2)
    
Significant
Unobservable
Inputs
(Level 3)
      
Balance
as of
December 31,
2011
  
Assets
                                
Cash equivalents invested in money market funds
(included in cash and cash equivalents)
   $ 1,313     $ -     $ -     $ 1,313  
Investment in certificates of deposit
(included in short-term investments)
     110                       110  
    $ 1,423     $ -     $ -     $ 1,423  
 
The fair values of the Company’s cash equivalents invested in money market funds are determined through market, observable and corroborated sources.

NOTE G – ACCOUNTS AND OTHER RECEIVABLES, NET

The following table presents information regarding the Company’s accounts and other receivables as of June 30, 2012 and December 31, 2011:
 
   
(in thousands)
  
   
June 30, 2012
    
December 31, 2011
  
   
(unaudited)
        
Trade receivables
   $ 10,804     $ 22,737  
Due from employees
     145       121  
Allowance for doubtful accounts and
                
commission adjustments
     (1,965 )     (2,163 )
Accounts and other receivables, net
   $ 8,984     $ 20,695  
 
Trade receivables include amounts due for shipped products and services rendered.  Amounts currently due under the GEHC Agreement are subject to adjustment in subsequent periods should the underlying sales order amount, upon which the receivable is based, change.

 
Page 10
 
Vasomedical, Inc. and Subsidiarires
 
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
 
Allowance for doubtful accounts and commission adjustments include estimated losses resulting from the inability of our customers to make required payments, and adjustments arising from subsequent changes in sales order amounts that may reduce the amount the Company will ultimately receive under the GEHC Agreement. Due from employees primarily reflects commission advances made to sales personnel.
 
NOTE H – INVENTORIES, NET

Inventories, net of reserves, consist of the following:
   
(in thousands)
  
   
June 30, 2012
    
December 31, 2011
  
   
(unaudited)
        
Raw materials
   $ 938     $ 842  
Work in process
     575       528  
Finished goods
     772       1,051  
    $ 2,285     $ 2.421  
 
At June 30, 2012 and December 31, 2011, the Company had reserves for excess and obsolete inventory of $546,000 and $606,000, respectively.

NOTE I– BUSINESS COMBINATION

On September 2, 2011, Vasomedical Global successfully completed the purchase of all the outstanding capital stock of privately-held Fast Growth Enterprises Limited (“FGE”), a British Virgin Islands company that owns subsidiaries which own and control Life Enhancement Technology Ltd (“LET”) and Biox Instruments Co. Ltd. (“Biox”), respectively, as per the stock purchase agreement signed on August 19, 2011. The consideration of this acquisition includes a cash payment of $1 million as well as the issuance of 5 million restricted shares of the Company’s common stock, up to 2.4 million shares of common stock contingently issuable upon the achievement of certain operating performance targets, and warrants covering 1.5 million shares of common stock.  The Company is completing its evaluation of FGE’s calendar year 2011 results and believes it is likely that the targets have been met and the shares will be issued.

LET, based in Foshan, Guangdong, China, is Vasomedical’s supplier for its proprietary Enhanced External Counterpulsation (EECP®) systems, including certain Lumenair systems and all AngioNew® systems. Biox, a developer and manufacturer of ambulatory monitoring devices, is located in Wuxi, Jiangsu, China, and is Vasomedical’s supplier of the BIOX series ECG Holter recorder and analysis software as well as ambulatory blood pressure monitoring systems. Vasomedical has obtained FDA clearance to market these products in the United States.  The acquisition of LET provides Vasomedical with consolidated technical and manufacturing capability in its EECP business which has significantly increased gross margins and will enable the Company to meet anticipated increasing demand for its EECP systems.  The acquisition of Biox greatly enhances Vasomedical's distribution network, technology and product portfolio, and with combined market and sales efforts of the two companies, has improved performance and profitability of Vasomedical's equipment segment.

The operating results of FGE are included in the accompanying Consolidated Condensed Statements of Operations and Comprehensive Income (Loss) and Cash Flows for the six and three months ended June 30, 2012.  The Consolidated Condensed Balance Sheet as of June 30, 2012 reflects the acquisition of FGE, effective September 2, 2011.  The acquisition date fair value of the total consideration transferred was $3.979 million, which consisted of the following:
     
(in thousands)
  
Cash
   $ 1,000  
Vasomedical, Inc. common stock ($0.42 per share)
     2,100  
Vasomedical, Inc. warrants to purchase common stock
     304  
Contingent issuance of Vasomedical, Inc. common stock ($0.42 per share)
     575  
Total purchase price
   $ 3,979  
 
In accordance with Accounting Standards Codification ("ASC") 805, Business Combinations ("ASC 805"), the total purchase consideration is allocated to the net tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of September 2, 2011 (the acquisition date).  The purchase price was allocated based on the information currently available, and may be adjusted after obtaining more information regarding, among other things, asset valuations, liabilities assumed, and revisions of preliminary estimates.  The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the acquisition date:
 
Page 11
 
Vasomedical, Inc. and Subsidiarires
 
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
 
                                                                                                                                                                                                                                                                                                                                                                                                            
  (in thousands)
Cash and cash equivalents
   $ 442  
Accounts receivable and other current assets
     283  
Inventories
     476  
Property and equipment
     32  
Goodwill
     3,968  
Accounts payable and other current liabilites
     (1,222 )
Net assets acquired
   $ 3,979  
 
The goodwill is attributable to the synergies expected to arise after the Company’s acquisition of FGE as well as FGE’s projected growth and profitability.  The goodwill is not expected to be deductible for tax purposes.

After elimination of intercompany transactions which reduce the income from FGE, the amounts of revenue and net loss of FGE included in the Company’s Consolidated Condensed Statement of Operations and Comprehensive Income (Loss) for the six months ended June 30, 2012 was $910,000 and $24,000, respectively, and $332,000 and $110,000, respectively, for the three months ended June 30, 2012.  The effect of FGE’s loss on earnings per share for the six and three months ended June 30, 2012 was $0.00.
 
The following supplemental pro forma information presents the financial results as if the acquisition of FGE had occurred June 1, 2009:
    (in thousands except per share data)  
   
Six months ended
June 30,
Three months ended
June 30,
  
   
2012
    
2011
    
2012
    
2011
  
Revenue
   $ 13,740     $ 10,621     $ 7,697     $ 5,401  
                                 
Net (loss) income
  $ (1,105 )   $ (957 )     65       (683 )
                                 
Basic and diluted (loss) earnings per share
   $ (0.01 )   $ (0.01 )   $ 0.00     $ (0.01 )
 
NOTE J – GOODWILL AND OTHER INTANGIBLES

Goodwill aggregating $3,968,000 and $3,939,000 was recorded on the Company’s Consolidated Condensed Balance Sheets at June 30, 2012 and December 31, 2011, respectively, pursuant to the acquisition of FGE in September 2011.  The increase in goodwill resulted from the recording of additional pre-acquisition dividend liabilities to prior owners. All of the goodwill was allocated to the Company’s Equipment segment.

The Company’s other intangible assets consist of capitalized patent costs, as follows:
                                                                                                                                                                                                                                                                                                                            
    (in thousands)  
   
June 30, 2012
    
December 31, 2011
  
   
(unaudited)
        
Patent Costs
            
Costs
   $ 469     $ 469  
Accumulated amortization
     (426 )     (413 )
    $ 43     $ 56  

Patents are included in other assets in the accompanying Consolidated Condensed Balance Sheets.  Amortization expense amounted to $6,000 and $9,000 for the three months ended June 30, 2012 and 2011, respectively, and $13,000 and $19,000 for the six months ended June 30, 2012 and 2011, respectively.

 
Page 12
 
Vasomedical, Inc. and Subsidiarires
 
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
 
NOTE K - DEFERRED REVENUE

The changes in the Company’s deferred revenues are as follows:
     (in thousands)  
   
 For the six months
ended June 30,
  For the three months
ended June 30,
  
   
2012
    
2011
    
2012
    
2011
  
   
(unaudited)
    
(unaudited)
    
(unaudited)
    
(unaudited)
  
Deferred revenue at the beginning of the period
   $ 15,227     $ 12,637     $ 14,781     $ 10,792  
Additions:
                                
Deferred extended service contracts
     700       730       373       333  
Deferred in-service and training
     20       18       15       10  
Deferred service arrangements
     55       45       30       30  
Deferred commission revenues
     4,080       4,143       2,731       3,117  
Recognized as revenue:
                                
Deferred extended service contracts
     (557 )     (604 )     (282 )     (290 )
Deferred in-service and training
     (15 )     (16 )     (13 )     (8 )
Deferred service arrangements
     (43 )     (35 )     (21 )     (19 )
Deferred commission revenues
     (4,269 )     (5,558 )     (2,416 )     (2,605 )
Deferred revenue at end of period
     15,198       11,360       15,198       11,360  
Less: current portion
     10,685       8,047       10,685       8,047  
Long-term deferred revenue at end of period
   $ 4,513     $ 3,313     $ 4,513     $ 3,313  
 
NOTE L – RELATED-PARTY TRANSACTIONS

On June 21, 2007, we entered into a Securities Purchase Agreement with Kerns Manufacturing Corp. (“Kerns”).  Pursuant to this agreement, a five-year warrant to purchase 4,285,714 shares of our common stock at an initial exercise price of $0.08 per share was issued to Kerns.  In March 2012, Kerns exercised its warrant and purchased 4,285,714 shares of common stock.  Concurrently with our entry into the Securities Purchase Agreement, we also entered into a Distribution Agreement and a Supplier Agreement with Living Data Technology Corporation (“Living Data”), an affiliate of Kerns.  Pursuant to the Distribution Agreement, as amended, we became the exclusive worldwide distributor of the AngioNew EECP® systems manufactured through Living Data. The Distribution Agreement had an initial term extending through May 31, 2012.  Subsequent to August 31, 2011 the Company acquired Life Enhancement Technology (LET) (see Note I), the manufacturer of the AngioNew EECP® system.  Consequently, the Distribution Agreement is no longer effective, and the Company wrote-off the remaining unamortized balance of Deferred Distributor Costs during the seven months ended December 31, 2011.

On February 28, 2011, David Lieberman and Edgar Rios were appointed by the Board of Directors as directors of the Company.  Mr. Lieberman, a practicing attorney in the State of New York, was appointed to serve as the Vice Chairman of the Board.  He is currently a senior partner at the law firm of Beckman, Lieberman & Barandes, LLP, which firm performs certain legal services for the Company.  Fees of approximately $82,000 and $149,000 were billed by the firm through the three and six months ended June 30, 2012, respectively, at which date no amounts were outstanding.

Mr. Rios is President of Edgary Consultants, LLC, and was appointed a director in conjunction with the Company’s consulting agreement (the “Agreement”) with Edgary Consultants, LLC (“Consultant”).  The Agreement commenced on March 1, 2011 and runs for a two year term.  The Agreement provides for the engagement of Consultant to assist the Company in seeking broader reimbursement coverage of EECP® therapy.  More specifically, Consultant will be assisting the Company in the following areas:
 
1.  
Engaging the adoption of EECP® therapy as a first line option for FDA cleared indications as it relates to CCS Class III/IV angina with a major commercial healthcare third-party payer.
2.  
Engaging a major commercial healthcare payer to formally collaborate and co-sponsor a study with Vasomedical for the efficacy, efficiency and/or cost effectiveness of the EECP® therapy for NYHA Class II/III heart failure.
3.  
Engaging final approval from the Centers for Medicare and Medicaid Services (“CMS”) of EECP® therapy as a first line treatment for CCS Class III/IV angina.
4.  
Engaging final approval from CMS to extend coverage and provide for the reimbursement of EECP® therapy for CCS Class II angina; and
5.  
Engaging final approval from CMS to extend coverage and provide for the reimbursement of EECP® therapy for NYHA Class II/III heart failure.
 
 
Page 13
 
Vasomedical, Inc. and Subsidiarires
 
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
 
In consideration for the services to be provided by Consultant under the Agreement, the Company has agreed to issue to Consultant or its designees, approximately 10% of the outstanding capital stock of the Company, of which the substantial portion (in excess of 82%) is performance based as referenced above. In conjunction with the Agreement, 3,000,000 shares of restricted common stock valued at $1,020,000 were issued in March 2011.  In connection with the Agreement, Mr. Lieberman received 600,000 of these restricted shares.  The Company has recorded the fair value of the shares issued to Consultant as a prepaid expense and is amortizing the cost ratably over the two year agreement.  The unamortized value is reported as Deferred Related Party Consulting Expense in our accompanying consolidated condensed balance sheets as of June 30, 2012 and December 31, 2011.

During the six months ended June 30, 2012, a director performed consulting services for the Company aggregating approximately $10,000.

Through the Company’s acquisition of FGE in September 2011, it assumed the liability for $288,000 in unsecured notes payable to the President of LET and his spouse, of which $95,000 was repaid in December 2011, and $190,000, bearing interest at 6% per annum, was paid in March 2012.  In addition, receivables due from FGE management aggregating $159,000 were collected during the six months ended June 30, 2012.

NOTE M – STOCKHOLDERS’ EQUITY

Common Stock

On June 17, 2010 the Board of Directors approved the 2010 Stock Plan (the “2010 Plan”) for officers, directors, employees and consultants of the Company.  The stock issuable under the 2010 Plan shall be shares of the Company’s authorized but unissued or reacquired common stock.  The maximum number of shares of common stock which may be issued under the 2010 Plan is 5,000,000 shares.

The 2010 Plan is comprised of two separate equity programs, the Options Grant Program, under which eligible persons may be granted options to purchase shares of common stock, and the Stock Issuance Program, under which eligible persons may be issued shares of common stock directly, either through the immediate purchase of such shares or as compensation for services rendered to the Company.

The 2010 Plan provides that the Board of Directors, or a committee of the Board of Directors, will administer it with full authority to determine the identity of the recipients of the options or shares and the number of options or shares.  Options granted under the 2010 Plan may be either incentive stock options or non-qualified stock options.  The option price shall be 100% of the fair market value of the common stock on the date of the grant ( or in the case of incentive stock options granted to any individual stockholder possessing more than 10% of the total combined voting power of all voting stock of the Company, 110% of such fair market value).  The term of any option may be fixed by the Board of Directors, or its authorized committee, but in no event shall it exceed five years from the date of grant.  Options are exercisable upon payment in full of the exercise price, either in cash or in common stock valued at fair market value on the date of exercise of the option.

As of June 30, 2012, 3,790,000 restricted shares of common stock were granted under the 2010 Plan to non-officer employees and consultants of the Company.  As of June 30, 2012, 755,000 shares have been forfeited.  In March 2012, 500,000 restricted shares of common stock were granted under the 2010 Plan to an officer, of which 250,000 vested immediately with the remainder vesting over a one year period.  In June 2012, 2,190,000 additional shares of restricted common stock were granted to non-officer employees in conjunction with the extension of the GEHC Agreement, vesting at various times through July 1, 2013.  In July 2012, 500,000 shares of restricted common stock were granted to non-officer employees, of which 250,000 vest within one year and the remainder one year thereafter.

No options were issued under the 2010 Plan during the six months ended June 30, 2012 and 2011.

 
Page 14
 
Vasomedical, Inc. and Subsidiarires
 
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
 
In September 2011, the Company issued 5,000,000 shares of restricted common stock and a two year common stock purchase warrant for 1,500,000 shares at an exercise price of $0.50 per share as partial consideration for the acquisition of FGE.  In addition, up to 2,400,000 shares of common stock are contingently issuable should FGE attain certain operating targets for the twelve months ending December 31, 2011.  The Company is completing its evaluation of FGE’s calendar year 2011 results and believes it is likely that the targets have been met and the shares will be issued.  The aggregate value of the aforementioned noncash consideration relative to the FGE acquisition was $2,979,000.

Preferred Stock

On June 24, 2010, the Company filed a Certificate of Designations of Preferences and Rights of Series E Convertible Preferred Stock (“Certificate of Designations”), as authorized by the Board of Directors, designating 350,000 shares of its 1,000,000 shares of preferred stock as Series E Convertible Preferred Stock (“Series E Preferred”). The conversion rights of the Series E Preferred are that each share will be convertible at any time on or after January 1, 2011, at the holder’s option into 100 shares of common stock (an exercise price of $.16 per share of common stock, the “Conversion Price”), subject to anti-dilution adjustment as set forth below.  Each share of outstanding Series E Preferred Stock shall automatically be converted into shares of common stock on or after July 1, 2011, at the then effective applicable conversion ratio, if, at any time following the Issuance Date, the price of the common stock for any 30 consecutive trading days equals or exceeds three times the Conversion Price and the average daily trading volume for the Company’s common stock for the 30 consecutive trading days exceeds 250,000 shares.

Pursuant to its conversion terms, the Series E Preferred was deemed automatically converted to common stock effective July 1, 2011.  As of June 30, 2012, 30,668,500 shares of common stock had been issued for 306,685 shares of Series E Preferred.

For the three and six months ended June 30, 2011, the Company sold 0 and 9,375 shares of Series E Preferred aggregating $150,000, and recorded dividends totaling $151,000 and $279,000, respectively.  Included in such dividends is the recognition of the value of the embedded beneficial conversion feature of the Series E Preferred, which reflects the difference between the conversion price and the market price at time of investment. The amounts included in the dividends reported attributable to this beneficial conversion feature are $91,000 and $156,000 for the three and six months ended June 30, 2011, respectively.  These are noncash dividends requiring no payment and ceased on conversion of the Series E Preferred to common stock.

NOTE N – COMMITMENTS AND CONTINGENCIES

Sales representation agreement

In June 2012, the Company concluded an amendment of the GEHC Agreement with GE Healthcare, originally signed on May 19, 2010.  The amendment, effective July 1, 2012, extends the initial term of three years commencing July 1, 2010 to five years through June 30, 2015, subject to earlier termination under certain circumstances.  These circumstances include not materially achieving certain sales goals, not maintaining a minimum number of sales representatives, and various legal and GEHC policy requirements.  Under the terms of the agreement, the Company is required to lease dedicated computer equipment from GEHC for connectivity to their network.

In conjunction with the extension of the GEHC Agreement, the Company granted VasoHealthcare employees both stock and cash-based performance incentives for the ensuing year.  The incentives provide for cash payments of up to $2.2 million and 2.2 million shares of restricted common stock grants and vest at various times through July 1, 2013.  A condition of the incentives is that the employees remain continuously employed through the vesting dates.
 
 
 
Page 15
 
Vasomedical, Inc. and Subsidiarires
 
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
 
NOTE O - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

Other Comprehensive Income: Presentation of Comprehensive Income

In June 2011, new guidance was issued that amends the current comprehensive income guidance. The new guidance allows the option to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single or continuous statement of comprehensive income or in two separate but consecutive statements. The amendments in this update do not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income. The new guidance is to be applied retrospectively and is effective for fiscal years, and interim periods, beginning after December 15, 2011, with early adoption permitted.  The adoption of this guidance did not have a material impact on the Company’s consolidated condensed financial statements.
 
In December 2011, the FASB issued authoritative guidance to defer the effective date for those aspects of the guidance relating to the presentation of reclassification adjustments out of accumulated other comprehensive income. The adoption of this new guidance will not have an impact on the Company’s consolidated financial position, results of operations or cash flows as it only requires a change in the format of the current presentation of other comprehensive income.
 
 
 
Page 16
 
Vasomedical, Inc. and Subsidiaries
 

 
 

Except for historical information contained in this report, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this report, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC Agreement and the risk factors reported from time to time in the Company’s SEC reports, including its recent transition report on Form 10-K.  The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.

General Overview

Vasomedical, Inc. was incorporated in Delaware in July 1987.  Unless the context requires otherwise, all references to “we”, “our”, “us”, “Company”, “registrant”, “Vasomedical” or “management” refer to Vasomedical, Inc. and its subsidiaries.  Until 2010, we were primarily engaged in designing, manufacturing, marketing and supporting EECP® Enhanced External Counterpulsation systems, based on our proprietary technology, to physicians and hospitals throughout the United States and in select international markets.
 
In May 2010, the Company, through its wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, expanded into the sales representation business via its agreement with GE Healthcare (“GEHC”), the healthcare business unit of General Electric Company (NYSE: GE), to be GEHC’s exclusive sales representative for the sale of select GEHC diagnostic imaging products in specific market segments in the 48 contiguous states of the United States and the District of Columbia.   In June 2012, the Company entered into an amendment, effective July 1, 2012, of the sales representative agreement (“GEHC Agreement”) extending the initial term of three years commencing July 1, 2010 to five years through June 30, 2015, subject to earlier termination under certain circumstances.
 
In September 2011, the Company acquired Fast Growth Enterprises Limited (FGE), a British Virgin Islands company, which, through its subsidiaries, owns and controls two Chinese operating companies - Life Enhancement Technology Ltd. and Biox Instruments Co. Ltd., respectively - to expand its technical and manufacturing capabilities and to enhance its distribution network, technology, and product portfolio.  Also in September 2011, the Company restructured to further align its business management structure and long-term growth strategy, and now operates through three wholly-owned subsidiaries.  Vaso Diagnostics d/b/a VasoHealthcare continues as the operating subsidiary for the sales representation of GE diagnostic imaging products; Vasomedical Global Corp. operates the Company’s newly-acquired Chinese companies; and Vasomedical Solutions, Inc. was formed to manage and coordinate our EECP® therapy business as well as other medical equipment operations.

We now report the operations of Vasomedical Global Corp. and Vasomedical Solutions, Inc. under our Equipment reportable segment.  VasoHealthcare activities are included under our Sales Representation reportable segment (see Note C).

The Company will seek to improve profitability through our recent accretive acquisition of the two Chinese medical device companies and by expanding our U.S. market product portfolio.  In addition, the Company plans to actively pursue other accretive acquisitions in the international market and is in preliminary discussions to secure a credit facility for up to $25 million to be utilized for this purpose.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations are based upon the accompanying unaudited consolidated condensed financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). The preparation of financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Although these estimates are based on our knowledge of current events, our actual amounts and results could differ from those estimates. The estimates made are based on historical factors, current circumstances, and the experience and judgment of our management, who continually evaluate the judgments, estimates and assumptions and may employ outside experts to assist in the evaluations.
 
 
Page 17
 
Vasomedical, Inc. and Subsidiaries

Certain of our accounting policies are deemed “critical”, as they are both most important to the financial statement presentation and require management’s most difficult, subjective or complex judgments as a result of the need to make estimates about the effect of matters that are inherently uncertain. For a discussion of our critical accounting policies, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Transition Report on Form 10-K for the seven months ended December 31, 2011.

On June 15, 2011, the Board of Directors approved a change of the Company’s fiscal year end from May 31st to December 31st.  As a result of this change, the Company filed a Transition Report on Form 10-K for the seven-month transition period ended December 31, 2011.  Going forward, references to our 2012 and 2011 fiscal years herein mean the fiscal years ended December 31, 2012 and December 31, 2011, respectively.

New Accounting Pronouncements - Adoption of New Standards
 
Other Comprehensive Income: Presentation of Comprehensive Income

In June 2011, new guidance was issued that amends the current comprehensive income guidance. The new guidance allows the option to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single or continuous statement of comprehensive income or in two separate but consecutive statements. The amendments in this update do not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income. The new guidance is to be applied retrospectively and is effective for fiscal years, and interim periods, beginning after December 15, 2011, with early adoption permitted.  The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements.

In December 2011, the FASB issued authoritative guidance to defer the effective date for those aspects of the guidance relating to the presentation of reclassification adjustments out of accumulated other comprehensive income. The adoption of this new guidance will not have an impact on the Company’s consolidated financial position, results of operations or cash flows as it only requires a change in the format of the current presentation of other comprehensive income.

Consolidated Results of Operations

Three Months Ended June 30, 2012 and June 30, 2011

Total revenue for the three months ended June 30, 2012 and June 30, 2011, was $7,697,000 and $5,175,000, respectively, an increase of $2,522,000, or 49%. Net income for the three months ended June 30, 2012 was $54,000 compared to a net loss of $956,000 for the three months ended June 30, 2011.  We reported net income applicable to common stockholders of $54,000 for the second quarter of fiscal year 2012 compared to a net loss applicable to common stockholders of $1,107,000 for the second quarter of fiscal year 2011. The change from net loss to net income applicable to common stockholders was primarily attributable to a $2,042,000 increase in gross profit, partially offset by a $1,021,000 increase in selling, general and administrative (“SG&A”) costs (of which $625,000 was attributable to VasoHealthcare).  Our total net earnings (loss) was $0.00 and ($0.01) per basic and diluted common share for the three months ended June 30, 2012 and 2011, respectively.

Revenues

Revenue in our Equipment segment increased by $455,000, or 41%, to $1,555,000 for the three-month period ended June 30, 2012 from $1,100,000 for the same period of the prior year.  Equipment segment revenue from equipment sales increased by $498,000, or 89%, to $1,056,000 for the three-month period ended June 30, 2012 as compared to $558,000 for the same period in the prior year. The increase in equipment sales is due primarily to an increase in the number of EECP® units shipped as well as an increase in the sales price per EECP® unit, partially offset by a decrease in sales of other medical equipment, and by the inclusion of $332,000 in equipment sales generated by our Chinese subsidiaries acquired in September, 2011.

 
Page 18
 
Vasomedical, Inc. and Subsidiaries
 
Current demand for EECP® systems will likely remain soft until there is greater clinical acceptance for the use of EECP® therapy in treating patients with angina or angina equivalent symptoms who meet the current reimbursement guidelines, or a favorable change in current reimbursement policies by CMS or third party payers to consider EECP therapy as a first-line treatment option for angina or cover some or all Class II & III heart failure patients. Patients with angina or angina equivalent symptoms eligible for reimbursement under current policies include many with serious comorbidities, such as heart failure, diabetes, peripheral vascular disease and/or others.  As described in Note L, we are pursuing initiatives to expand reimbursement that we expect should ultimately increase overall market demand for our EECP® systems.

Equipment segment revenue from equipment rental and services decreased 8% to $499,000 in the second quarter of 2012 from $542,000 in the second quarter of 2011. Revenue from equipment rental and services represented 32% and 49% of total Equipment segment revenue in the second quarters of fiscal 2012 and fiscal 2011, respectively.  The decrease in revenue generated from equipment rentals and services is due primarily to decreased accessory part revenue.

Commission revenues in the Sales Representation segment were $6,142,000 in the second quarter of 2012, as compared to $4,075,000 in the second quarter of 2011, an increase of 51%.  The increase in commission revenue in the second quarter of 2012 is due to increased volume of equipment delivered as well as higher blended commission rates.  The Company recognizes revenue when the underlying equipment has been accepted at the customer site in accordance with the specific terms of the sales agreement.  Consequently, amounts billable under the agreement with GE Healthcare prior to customer acceptance of the equipment are recorded as deferred revenue in the Consolidated Condensed Balance Sheet.  Due to the nature of our commission structure under the GEHC Agreement, wherein the Company earns progressively higher commission rates retroactively as calendar year targets are met, revenues earned in the first and fourth quarters typically reflect a higher blended commission rate than revenues earned in the second and third quarters.  As of June 30, 2012, $13,896,000 in deferred commission revenue was recorded in the Company’s consolidated condensed balance sheet, of which $4,068,000 is long-term.  At June 30, 2011, $10,275,000 in deferred commission revenue was recorded in the Company’s consolidated condensed balance sheet, of which $2,980,000 was long-term.

Gross Profit

The Company had a gross profit of $5,530,000 in the second quarter of 2012 compared to $3,488,000 in the second quarter of the prior year, an increase of 59%.  Equipment segment gross profit increased to $881,000, or 57% of Equipment segment revenues, for the second quarter of 2012 compared to $532,000 or 48% of Equipment segment revenues, for the same quarter of 2011.  Equipment segment gross profit was favorably impacted both in absolute dollars and gross profit percentage by the $332,000 in sales of other medical equipment sold through our Chinese subsidiaries in the second quarter of 2012.  In addition, gross profit on EECP® equipment improved due to lower costs arising from the acquisition of LET, our primary supplier of certain EECP® systems.  Gross profit in the Equipment segment is dependent on a number of factors, particularly the mix of new and refurbished EECP® systems and the mix of models sold, their respective average selling prices, the mix of EECP® units sold, rented or placed during the period, the ongoing costs of servicing EECP® systems, and certain fixed period costs, including facilities, payroll and insurance.

Sales Representation segment gross profit was $4,649,000, or 76%, for the three months ended June 30, 2012 as compared to $2,956,000, or 73%, for the three months ended June 30, 2011.  The increase was due both to higher sales volume and higher blended commission rates in the second quarter of 2012.  Cost of commissions of $1,493,000 and $1,119,000, for the three months ended June 30, 2012 and 2011, respectively, reflects commission expense associated with recognized commission revenues.  Commission expense associated with deferred revenue is recorded as deferred commission expense until the related commission revenue is earned.

 
 
Page 19
 
Vasomedical, Inc. and Subsidiaries
Operating Income (Loss)

Operating income was $75,000 for the three months ended June 30, 2012 as compared to an operating loss of $960,000 for the three months ended June 30, 2011, an improvement of $1,035,000.  The improvement in operating income was primarily attributable to improved operating performance in the Sales Representation segment, where operating income was $681,000 for the second quarter of 2012 compared to an operating loss of $386,000 in the same quarter of the prior year, partially offset by higher corporate expenses.

Selling, general and administrative (“SG&A”) expenses for the second quarter of 2012 and 2011 were $5,335,000, or 69% of revenues, and $4,314,000, or 83% of revenues, respectively, reflecting an increase of $1,021,000 or approximately 24%. The increase in SG&A expenditures in the second quarter of 2012 resulted primarily from increased sales and marketing costs in both segments, including SG&A costs of the recently acquired Chinese entities, and higher corporate compensation costs.
 
During the second quarter of 2012, the Company recorded a reduction in its provision for doubtful accounts and commission adjustments of $9,000 as compared to the second quarter of 2011 when the Company recorded a reduction in its provision for doubtful accounts and commission adjustments of $3,000.
 
Research and development (“R&D”) expenses of $120,000, or 2% of revenues, for the second quarter of 2012 decreased by $14,000, or 10%, from $134,000, or 3% of revenues, for the second quarter of 2011. The decrease is primarily attributable to a decrease in clinical research expenses.

Interest and Financing Costs

No interest and financing costs were incurred in the second quarter of 2012, as compared to $24,000 incurred in the second quarter of 2011.  Interest and financing costs for the second quarter of 2011 consisted of interest on a short-term note to finance the Company’s insurance premiums.

Interest and Other Income, Net

Interest and other income for the second quarters of 2012 and 2011, was $58,000 and $17,000, respectively. The increase of $41,000 in the second quarter of 2012 is due primarily to value-added tax refunds recognized by our Chinese subsidiaries, as well as to higher interest earned on the Company’s cash balances.

Amortization of Deferred Gain on Sale-leaseback of Building

The amortization of deferred gain on sale-leaseback of building for the second quarters of 2012 and 2011 was $13,000.   The gain resulted from the Company’s sale-leaseback of its facility.

Income Tax Expense, Net

During the second quarter of year 2012 we recorded a provision for income taxes of $84,000 as compared to a provision of $2,000 for the second quarter of 2011.  The increase arose primarily from foreign tax liabilities associated with the acquisition of FGE.
 
Six Months Ended June 30, 2012 and June 30, 2011

Total revenue for the six months ended June 30, 2012 and June 30, 2011, was $13,740,000 and $10,020,000, respectively, an increase of $3,720,000, or 37%. Net loss for the six months ended June 30, 2012 was $1,288,000 compared to a net loss of $1,422,000 for the six months ended June 30, 2011.  We reported net loss applicable to common stockholders of $1,288,000 for the first two quarters of 2012 compared to a net loss applicable to common stockholders of $1,701,000 for the first two quarters of 2011. The decrease in net loss applicable to common stockholders was primarily attributable to a $2,966,000 increase in gross profit and $279,000 reduction in preferred stock dividends, partially offset by a $2,721,000 increase in selling, general and administrative (“SG&A”) costs (of which $1,674,000 was attributable to VasoHealthcare).  Our total net loss was $0.01 per basic and diluted common share for the six months ended June 30, 2012 and 2011.
 
 
Page 20
 
Vasomedical, Inc. and Subsidiaries
 
Revenues

Revenue in our Equipment segment increased by $1,336,000, or 61%, to $3,541,000 for the six-month period ended June 30, 2012 from $2,205,000 for the same period of the prior year.  Equipment segment revenue from equipment sales increased by $1,423,000, or 131%, to $2,509,000 for the six-month period ended June 30, 2012 as compared to $1,086,000 for the same period in the prior year. The increase in equipment sales is due primarily to an increase in the number of EECP® units shipped as well as an increase in the sales price per EECP® unit, partially offset by a decrease in sales of other medical equipment, and by the inclusion of $910,000 in equipment sales generated by our Chinese subsidiaries acquired in September, 2011.

Current demand for EECP® systems will likely remain soft until there is greater clinical acceptance for the use of EECP® therapy in treating patients with angina or angina equivalent symptoms who meet the current reimbursement guidelines, or a favorable change in current reimbursement policies by CMS or third party payers to consider EECP therapy as a first-line treatment option for angina or cover some or all Class II & III heart failure patients. Patients with angina or angina equivalent symptoms eligible for reimbursement under current policies include many with serious comorbidities, such as heart failure, diabetes, peripheral vascular disease and/or others.  As described in Note L, we are pursuing initiatives to expand reimbursement that we expect should ultimately increase overall market demand for our EECP® systems.

Equipment segment revenue from equipment rental and services decreased 8% to $1,032,000 in the first six months of 2012 from $1,119,000 in the first six months of 2011. Revenue from equipment rental and services represented 29% and 51% of total Equipment segment revenue in the first six months of 2012 and 2011, respectively.  The decrease in revenue generated from equipment rentals and services is due primarily to decreased service revenue.

Commission revenues in the Sales Representation segment were $10,199,000 in the first six months of 2012, as compared to $7,815,000 in the first six months of 2011, an increase of 30%.  The increase in commission revenue in the first six months of 2012 is due to increased volume of equipment delivered as well as higher blended commission rates.  The Company recognizes revenue when the underlying equipment has been accepted at the customer site in accordance with the specific terms of the sales agreement.  Consequently, amounts billable under the agreement with GE Healthcare prior to customer acceptance of the equipment are recorded as deferred revenue in the Consolidated Condensed Balance Sheet.  Due to the nature of our commission structure under the GEHC Agreement, wherein the Company earns progressively higher commission rates retroactively as calendar year targets are met, revenues earned in the first and fourth fiscal quarters typically reflect a higher blended commission rate than revenues earned in the second and third fiscal quarters.  As of June 30, 2012, $13,896,000 in deferred commission revenue was recorded in the Company’s consolidated condensed balance sheet, of which $4,068,000 is long-term.  At June 30, 2011, $10,275,000 in deferred commission revenue was recorded in the Company’s consolidated condensed balance sheet, of which $2,980,000 was long-term.

Gross Profit

The Company had a gross profit of $9,711,000 in the first six months of 2012 compared to $6,745,000 in the first six months of the prior year, an increase of 44%.  Equipment segment gross profit increased to $1,968,000, or 56% of Equipment segment revenues, for the first six months of 2012 compared to $979,000 or 44% of Equipment segment revenues, for the first six months of 2011.  Equipment segment gross profit was favorably impacted both in absolute dollars and gross profit percentage by the $910,000 in sales of other medical equipment sold through our Chinese subsidiaries in the first six months of 2012.  In addition, gross profit on EECP® equipment improved due to lower costs arising from the acquisition of LET, our primary supplier of certain EECP® systems.  Gross profit in the Equipment segment is dependent on a number of factors, particularly the mix of new and refurbished EECP® systems and the mix of models sold, their respective average selling prices, the mix of EECP® units sold, rented or placed during the period, the ongoing costs of servicing EECP® systems, and certain fixed period costs, including facilities, payroll and insurance.

Sales Representation segment gross profit was $7,743,000 for the six months ended June 30, 2012 as compared to $5,766,000 for the six months ended June 30, 2011.  Cost of commissions of $2,456,000 and $2,048,000, for the six months ended June 30, 2012 and 2011, respectively, reflects commission expense associated with recognized commission revenues.  Commission expense associated with deferred revenue is recorded as deferred commission expense until the related commission revenue is earned.
 
 
 
Page 21
 
Vasomedical, Inc. and Subsidiaries
Operating Loss

Operating loss decreased by $216,000, or 15%, to $1,226,000 for the six months ended June 30, 2012 as compared to an operating loss of $1,442,000 for the six months ended June 30, 2011.  The decrease in operating loss was primarily attributable to lower operating losses in the Sales Representation segment of $303,000 and Equipment segment of $388,000, both arising from higher revenues and gross profit, partially offset by higher corporate expenses of $475,000.

Selling, general and administrative (“SG&A”) expenses for the first six months of 2012 and 2011 were $10,665,000, or 78% of revenues, and $7,944,000, or 79% of revenues, respectively, reflecting an increase of $2,721,000 or approximately 34%. The increase in SG&A expenditures in the first six months of 2012 resulted primarily from increased sales and marketing costs in both segments, including SG&A costs of the recently acquired Chinese entities, and higher corporate compensation costs.
 
During the first six months of 2012, the Company recorded a reduction in its provision for doubtful accounts and commission adjustments of $3,000 as compared to the first six months of 2011 when the Company increased its provision for doubtful accounts and commission adjustments by $9,000.
 
Research and development (“R&D”) expenses of $272,000, or 2% of revenues, for the first six months of 2012 increased by $29,000, or 12%, from $243,000, or 2% of revenues, for the first six months of 2011. The increase is primarily attributable to an increase in regulatory costs.

Interest and Financing Costs

Interest and financing costs for the first six months of 2012 and 2011 were $3,000 and $25,000, respectively.  Interest and financing costs for the first six months of 2012 consisted primarily of interest on the notes payable to a related party in one of the China subsidiaries.  Interest and financing costs for the first six months of 2011 consisted of interest on a short-term note to finance the Company’s insurance premiums.

Interest and Other Income, Net

Interest and other income for the first six months of 2012 and 2011, was $30,000 and $18,000, respectively. The increase of $12,000 in the first six months of 2012 is due primarily to value-added tax refunds recognized by our Chinese subsidiaries, as well as to higher interest earned on the Company’s cash balances.

Amortization of Deferred Gain on Sale-leaseback of Building

The amortization of deferred gain on sale-leaseback of building for the first six months of 2012 and 2011 was $27,000.   The gain resulted from the Company’s sale-leaseback of its facility.

Income Tax Expense, Net

During the first six months of 2012 we recorded a provision for income taxes of $108,000 as compared to the first six months of 2011 when no tax expense was recognized.  The increase arose primarily from foreign tax liabilities associated with the acquisition of FGE.

Liquidity and Capital Resources

Cash and Cash Flow

We have financed our operations primarily from working capital, and, in the first six months of 2011, from the issuance of the Company’s Series E Preferred Stock. At June 30, 2012, we had cash and cash equivalents of $11,783,000, short-term investments of $110,000 and working capital of $9,621,000 compared to cash and cash equivalents of $2,294,000, short-term investments of $110,000 and working capital of $11,354,000 at December 31, 2011.
 
 
Page 22
 
Vasomedical, Inc. and Subsidiaries

 
Cash provided by operating activities was $9,524,000 during the first six months of 2012, which consisted of a net loss after adjustments to reconcile net loss to net cash of $696,000, offset by cash provided by operating assets and liabilities of $10,220,000. The changes in the account balances primarily reflect a decrease in accounts and other receivables of $11,716,000, offset by a decrease in accrued commissions of $1,553,000 and an increase in deferred commission expense of $442,000.  As noted above, under the GEHC Agreement the Company earns progressively higher commission rates as calendar year targets are met, which also has a significant impact on our cash flows. As we achieve these targets the higher commission rates are retroactive to the beginning of the calendar year, and therefore, the significantly higher commission billings and recognized revenue generated in the fourth quarter of 2011 resulted in significant cash inflows in the first quarter of 2012.
 
Cash used in investing activities during the six-month period ended June 30, 2012 was $204,000 for the purchase of property and equipment.

Financing activities during the six-month period ended June 30, 2012 provided cash of $153,000, consisting of $343,000 provided through the exercise of warrants, offset by $190,000 for the repayment of notes payable to a related party.

Liquidity

The Company will seek to improve profitability through our recent accretive acquisition of the two Chinese medical device companies and by expanding our U.S. market product portfolio.  In addition, the Company plans to actively pursue other accretive acquisitions in the international market and is in preliminary discussions to secure a credit facility for up to $25 million to be utilized for this purpose.

While we expect to generate positive operating cash flows for 2012, the progressive nature of the commission rates under the GEHC Agreement can cause related cash inflows to vary widely during the year.



 

 
Page 23
 
Vasomedical, Inc. and Subsidiaries
 




 

Evaluation of Disclosure Controls and Procedures
 
Disclosure controls and procedures reporting as promulgated under the Exchange Act is defined as controls and procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act are recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms.  Disclosure controls and procedures include without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Our CEO and our CFO have evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of June 30, 2012 and have concluded that the Company’s disclosure controls and procedures were not effective as of June 30, 2012 due to insufficient controls and management review over the recording of certain transactions, and to lack of accounting personnel with appropriate level of knowledge and experience in accounting principles generally accepted in the United States of America and related accounting systems and closing process at our China subsidiaries.  The Company intends to engage additional accounting personnel, including an accounting controller, and strengthen its internal controls with regard to its closing process, related disclosures, and the approval of certain transactions.

Changes in Internal Control Over Financial Reporting

There was no change in the Company’s internal control over financial reporting during the Company’s last fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.
 
 





 

 
Page 24
 
Vasomedical, Inc. and Subsidiaries
 





 

 
Exhibits

31
Certifications of the Chief Executive Officer and the Chief Financial Officer pursuant to Rules 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32
Certifications of the Chief Executive Officer and the Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.








 

 
Page 25
 
Vasomedical, Inc. and Subsidiaries
 



In accordance with the requirements of the Exchange Act, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


VASOMEDICAL, INC.

By:           /s/ Jun Ma                                           
Jun Ma
 
President and Chief Executive Officer
 
(Principal Executive Officer)

/s/ Michael J. Beecher   .
Michael J. Beecher
 
Chief Financial Officer and Principal Accounting Officer

Date:  August 14, 2012
 
 
 
Page 26
 

GRAPHIC 2 vasologo.jpg begin 644 vasologo.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``34T`*@````@`!`$:``4` M```!````/@$;``4````!````1@$H``,````!``(```$Q``(````0````3@`` M``````!@`````0```&`````!4&%I;G0N3D54('8U+C`P`/_;`$,``0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`"L! M$`,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_ MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-CH.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($ M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B M7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X MN;K"P\3%QL?(RKR\_3U]O?X^?K_V@`,`P$` M`A$#$0`_`/[^**_FM_X+3?\`!4[]J7_@G[\9_AKX3^$EEX'N/"7CKP3>^(U? MQ'HLVI7AN["_@TVXC25;B!(D68RN`!*7!`(3;D]I_P`$2_\`@J+^T!_P4!\8 M?&7P[\:K+P?;V_@3PUH^M:+-X8TR3397GO\`5([2:&YC>:?>B0OE)`Z[FS^[ M&*_1*GAAQ/3X,CQVUE\LAE0AB%*&-C+%J$\7]2L\-R74XU[QG'FTBN;8_/X> M)7#<^,)<#IX^.>1KSP[C+!M85SAA/KMXXCGLX2H:QERZO2U]OZ'JHZCJFFZ1 M:R7VK:A9:99PJSRW5_=06EO&B`LS/-(XO@!\0--URW\+>'K>^EM;6?4/"NJ6VE:I?7,5ML\_P"W MS/YT<,C,HCW*Z.#Q^/\`%>;8GAGAK%\3?V9B+QRJO# M0K5Y*2ASJC4=HPG*R^%73/ZO^CAX.4OI!^,&1^$E/B[+>$L?G&59SG<,7CL- M6Q^(K8#(:-*OCZ>7X"A.D\5C'3JITH5<1AJ/NSXL?$_QS\(/JUN7232=*N9-1O1)'D,F((S#G*D9$I''N*^+?%O\`P7B_8X\. MRR0:78^/O%$JLRQOIVE6T%M*1T*W-S`_B5\1K];?POX M:\4>*;^>98FCT;2=2U.?S9`"%E^QV\@0D$-F9T4`Y+`&OOCX:_\`!(_]M[XD MI9WMC\*-2TG2[E8Y#?\`B2]L]'2-'SC]S/<-<%Q_%&T2<=&R<5^%KQ0XZSB; MCDF34.6]DL+@,7CY+;XJLI*E?S<8Q[KM_K;6_9Z_1`\+<)"MXM>+.;*O&,95 M9<0<8\-<&4JDK)OV&6TJ%7,N23ORQAB,1/5+G;U?[A:Q_P`'"7P93=_8/PF\ M57)`R/[0U#3(AR>.8+L@G&O'^KN#^ M)XKY<\&?\&^G[0NK1V\WB3XB^`_"H?!N()8=1U.>(-C*J;6?RV9>%W*A5SQ9]6I74OJ.<>(. M=*JM[E6W5:,J+_P<):C(^(O@3HI7N7\1W(YSQTE/YX]/6NFT MO_@OXEPR_P!H_!.QA4XW?9==FD89]/,F"GCU(]`2>OI^D?\`!`/X%6RK_:?Q M1\9SO@;S:6.CH"V.2HEM#WY'L:[NR_X(/_LO6P7[1XV^)%R5ZE;C3;:<3_LLZ2G3PO"7%>(TLJF# MPO&Z;VUC+%YU2\]91_R.5T#_`(+M?"R[V_VW\+?$5L2,G^S]0T^49XR%\^Z7 MGTSCT([U[CX:_P""SW[+^NE$O=&\>:)*Q4-]ITVUN8%SU/GV]QM(!XX!/?IS M7/6W_!#W]E2W`'_"0_$:0C`W-JMIG`X_Y]C_`)]3DG6A_P""*O[+]NH$/B+X MC(0W_D(!_GVXKJI4O'VA_R_X7Q2O\.(]BM/\5&G2?X[GY;G6,_9NYAS M?V?EWB[E$G\,\#]=E&-^U/'XO&Q:7FKGTQX:_P""D7[(_B)(F?XG6&B/*0!' MK,,UNRLW16*)(`>N1VQ7T+X;_:+^!OB_RQX;^*/A'53*`4$&IHA(.,<3K%CK MT./T-?GC%_P1O_9[M_\`CU\9?$.+C@27EC<`'CD+-"R@X&.`./>M*V_X)+?" MK3\?V;\1?&L)4D@O#I).<="PM"Q'8@D\5[.&S7QIP[BL;PMPGCXJW-+"YQ5P ME1][>T=6"^<.NETC\=SWAGZ'&,YY<-^)?BID\VWR4\XX3PV94(;6YGAJ>%K. MW;VE]]=%?]4[76M'OD62RU73;M'^X]M>VTZMGT,4K`]:T@P)V9QTZUZ;I/[.?[1_AV96 MT?\`:4U">U7&++5;.>X@.WINVQEC[\\^W2OH\+Q)Q>K+,N`<;2?6>79WE&.C MTUY:U7!2[Z:O3K<_*,TX'\-DY/(/&#+<9%*\89SPKQ%E%26ND>;#T,TIIVZR M<5Z'W=17SUH6C_M%:*BQ:KXG\$>)HU(4R_V=?6MR5Y^8LS+EOKQSSP*]9T:] M\4L`FMZ7;HW`,EG,#&.<$A7._'!(!YP17U&$S5XCE57+Q^>YADD<$Y.AG&39G33TJ8#%SO)=U2Q=#"UEZ.G?NCK**!GN,?K1 M7JGAA1110`45\^?M5?&^S_9Q_9Z^*_QJO3;@>`?".IZS:+=_\>TFI)%Y6FQS M#(W1/>R0B11RR;@.37\D7[)?_!=__@H!^TO^TC\)_@M8:)\+Y+;QSXWTG2M4 M%IX:N8;BUT&:[1]5F2X%Y*4>TT_SF24Q,&D1-R1*2R?><+>'7$?%^5YOG65K M`T\NR12>.KXW%QPR7L\//%5/9)PE[3V=&'-/:W-!:N1\1Q-X@\/<*9IE.3YI M+&3S#.7%8*A@\++$M\^(IX:G[5J453]I5J';+4=8^'7B#5;J_P!4LX$75KQ;VW"1 M2VQNRZ6ZH"-J;E?YL#^B3]@SXE_&;XQ?LK_"KXG?'W3+'1OB=XRT>36=;TG3 M["?3+>PBGN)%L(38W&9;>8VJI++&Q;:9``S8W&.(/#WB#AG(= M>P>"HTL;"MC;8C#?6XNMAHQ4J7)2Y?::2YI=%=] M#CS#'8;+,#C,QQDW3PN!PU;%XB:7,XT:%.52HU'[4N6+Y8KXG9=3[6HK^/#_ M`()U?\%JOV[OVR/VMOA9\$=4TKX;?\(?KFM2R>-;[3/#=U:7ECX:M;>5[J[A MG%W<".43>0BAEVD2'YU(57_K`T?XM^$];\;:A\/[4ZDOB+39)UFCFTZYCM'B M@BFE:>.\9!"R,L+A/FR6VCJ0*^FXOX#S_@K,(99G$<)/%2P*S&<$9+B[_9K\:B/]W9:1XF\/O+CO/?/? M+'G'JN['X_3Q+_@UMU;ROV@OV@=()(-U\,-'N-N>HBUX\D9R?]4,9'T)QQ^E MO_!RY\.=0\6?LI_#'Q#I-FMS=Z#\3([2X6>EZ#X=^"%Y-!#-,BR:EJT>HRR:;I\0+[W:ZN%6' M"!F7S-V,#!_IGAK"8[/_`*-N-PN!P>(Q5:E];R^E"A2G4E4Q"SW#5:5**BG[ M\Y8B"4=_>3ZW/YJXES+*^'_I&X*MF&88/!1K+"9A5>(KPI1XB%:M)3:M M",,-4RN#'>Z-X M*W+);6!,;;E;7RLT4J$H?LZENH`;X/\`^"=_@[]G3XC_`/!.VW^+/[:-QKWA MCX1?LM^//$7_``CTEHTUK-\1)/$EW-JEUX=T5U*OJ4XOU@T][*$,Q,N"-B.X M_*9?AG^T=_P5,_;HNKV^MKBY\0?%GQK)>7$?#NDV=SI7PY7 M3X-5USQ3K5G`!J/B1=,)11=7=X9KC[1(W$7C]P7QU1X%P_"F4YQPWPYQ1+'+"X?!?VM@YX#V7UI3A[*53#X MF6)Q;H3ABO;8FA1HN,^5P_GB'_!<;XB:;XIB^&W_``3T_9)\!>`-.CEGT[0H MX/"+^+/&/B"S@/_!,PZW\0==@;36US68GE*QI<+)%Y#Z2EVFCRRS^4 M[".6&=ES&Q=!)7Y%_P#!6'XZ?MU?M*_$?PIH/[4WPTT;X7:CX4T[^T=`\"V- MO`MWI5MK8<+]MO!)-*ACQ]UPSX>Y&\WP7#L/!K(>'\HC@9 MU9T?L$?L^QZM'9/4NU6)E#*?$_V7_P#@G-\;OBK_ M`,$6_BI:_"VQN9?B;\3_`(K:?XI_X16.1H)?%'AGP'?_`+JQMOF7SKB]B"]?\`>*=2TUM!\06WB/PDUW M;7NEK.MTUE7OA35_AXVB:G M>::\O^ML)X!<2/!,JLJ3V_FB,D;MK8`_IU_9X_X*0?"+XJ_L7VO[8WQ*$OP? M\+Z7%>V/C/3_`!$&ADT[Q%I:HMWIVD"X\F35/MDKA=*5`'NB<#`5F'\UGPI_ MX+K?%K4O&FAG]J/]EGX)?$^VBEM]-U/QC=>'[2?QAI&EB=#<'3EO;":V<1J9 M)5MVD"EP%1CZ):P:% M::GXG\3QRRR-JNF:<+>SDN-)2U$<8DB8QRN)%^;FN?.O"/'\19OP[PYBO#+# M\%8BK.KB\PXCR#&O%X#$X+!4X_7<+0P2I?N\16G5PZPOUJ2JTI2E+][34T;9 M-XQY+P_E/$7$.%\4O]5"G&EB'B? MJT94JBC&*]E4<&_IS]H[_@Y<^)/B#Q?>^%?V0OA/91:9#?/:Z/XB\6V,VN:O MK\(;"7"^'8K9S:!NJPDF4<[P%PS?,_@O_@Y)_;B\#^,(K7XN^#_`?B'2[2]7 M^UO#I\+'PMJPB+*9+=;E4:>V8ICRRZ)@,&Q@@U^J_P#P;Y?\$^OAOX)_9Z/[ M2OQ&\(:'XG^)?Q%U74;30)M>TVTU./PUX:TN:6T5;&WO(IX$GU-F6X>XV^:A M1A&5!!K\K_\`@XZ^'W@JY_:T\$0?"SPSX=TK5[;X>HGCP:':6FGBXUF?4`^G M->6]FD,8NTL<*S%=[(5+9+"NCAW*_#',^.L=X899X=T\>LLH8VEC,\Q%2MB, M:\7ET;8MS=U6ITXU7*@J].K2_?6<*,:=D\^(\Y\1,JX#P/B?FGB+_9T,SKX" MM@\GHPP^&P/U3,9)X-4Y-.C4G.C;$.C4I5?W'-SU934F?THM_P`%4_ACXM_X M)V>,?VYOA];*?^$8T62UO_"NI.K2Z)XZ;R8$T&[?Y5N%2XN8620!%FB)P.#G M\)/V>/\`@Y1^*FM_$FTA^/.A^#]&^&MAIFJ:EK,OA_1S)K-]-9HKV6F:>@5) M#<7SL85,6YE*Y"GDU^;8N?B?\+/^"3,?PR-K/:Q_';XZW.HRV$K%%ET+PQIE MG<0:DB%AO@N;FU:.-P-KX7DD`5]*?\$"?^"=7A/]H7XV>+OB?\<_"]IXD\$? M"6PLY=/\.:BGF:7JOB?5'D-A)=QG*W*:8+=;DV[9C?S/FZ4UX7<#\(<+%674 MJ.*]E2G!RA5E3C)*:DNN^.G_```O!<5W*NFV?B+1X MO$VKW%I%*RP37=S*(5BEN(0DDL<6](W'?"_A:V:S\/>+HI+*.==6O;I1Y>@6UO'/!\GAOP3:6_C6'P[9VVF6-]K&H2V]U82 MFSM4A@BEALQ)$X5>2Q)QTK]/?^"`_P#P37^$L7P.US]I+X]?#[0_%WBOQ3J5 M[IWA2#Q/:1:GHVE>$K."(W%]%972R6YNKJY24O.4.R--N6VJ5.(^'/"[!>&. M1\9YAP)B.>75\!A,)6E1S7&U*\I^RPE?,Y/,'FF.P"S&EF%?$TH5LNP-.@J4:V+HY9#E="OA:] M6%"E14U35>].K*I!._YMZK_P$;K3 M;J/7;.]E22X;Q'I;FUO=*T2$NCZC<7=W&XL;>$EG!QNPN:_@8_;U^&>FZI^V MA\>8O@]X4L])\#3?$S6[3POI&F!?LR6\=X;58K**/$:QR7`80QQJ$`*X`SS] M%_\`!0#5_B7X=^&?[.7[&OAT7%I\/O@]\/M-\4:CIZ3O%#JGC7QU;V^LZE/? MPJZK-/I;--#;M,C%%N#@[AQ[O$O@MPYQ-1X*PV3<-2X9K9E*.:8Z>$H3CBZ> M14\!2KXNC5A*4Z=;%?6,5@L/2K33<*M:'?&_-N&ZO&F)SGBS#\2 M4,KOE>$CBL52>$EGE7'5*&%J4Y14)T'?VAOAGX51K:2&[U+PIK/@F?P9K4UC,V0 M(IWA-Q$CH&"3*C@'T^[7G7_!*_\`:=\9_L'>`=?U71OV+=0^*GC?QIJ:7VO[*.O_``XO?"_AYM'O;BWT+6)[S5U-Q+,KW<[VH>40&4K&TC%E154< M5M@O#C(%J3 MITW&JVW4I2C^[!_`_AZWO+7QKI M>I2QR:AHOB;3@J7&@6B;D;4+B[N&$6EE`#=Y)7(1FK^:?]HK_@YC_:!\0^-+ MVR_9F\"^%_!_@ZVNY+;3Y_%FE)XDUO5K:.1EAO9[>1(TLI+I0'^RQ.[1A@C# M=N%?D1\2O#O[0OPL_90\"_`?69-3\/:5XM\6ZYXS\2>!KX36#_`()T?#V]\#^+OVG?C5X)T?Q7XCGUQ_#G MP\L])\->!/#3)>(> M-^(#\3>,?$K/,@X(X=SO#9!F4,GH8[B'&X91^M^UCAZ5?$UW27[W#T(PK8 M>,,/3=&<\37<*E2%-1BOSF_:F_X+J?$7]K+]BGQ=^SM\4O!MEI7Q*\1ZY8KJ MOB?P]"=/T?4_#]H\=PUE+I8P+2']OA'2?^$XL=`@MK"Q'BJ66X:9_L%HL5O;3-;-!YL<:* MN[!VKD`>J_!+P=K7[,'_``1+^-OC"WA_LCXH?M1_$33O`^E`MY4UWX-TNY6. M[E0G:TD+PF20;205)/3`K[:668"/AGEM#A?A_$Y!0\3,RRO"X?+;5*CI3S^M M1IX_V4GJZ4,JPF)G3Y;1C2M.,8)\J^+CG=9^)>9U.)N)<%GE?PSRS-,7B\>Y MTJ=Z>0TJD\%+$0O:-5YIC,-"HY^\ZUX2E*6K]%^$7_!>']H3X]_'SP5\,M%^ M!?P9O+SXC^/],\/6#77A.SN-4>#5M1CA5KBXDA_>745L6GFE9V.49OFQ@_NG M_P`%"O\`@L5\#OV`-+L?``L;/XB?'C^R+*2?X=^'[F.VTCPY))`HD_MV_MA* MFFJLVY[>Q6/SI(`"OS';7\C/_!)WX:ZWX(^-GCC]I#Q%H4=S8?L[?"OQC\2= M%:4!K=_&5E:QQ^'(=QROF&0W3`<'N.E>$?!_X)_%C]O']M[PQH_CR^O+S5/C M1\4Y+KQ-JUU)K3J5)TL/A,MPT:]54G"I4>(A M"$HJ3D=^2^,_$.$X>P=*EQ#ALUXGXUSIX'(ZF*GA)QP>$P]6E@IU,)1A"$*] M?%YEB)8>G[55*=/V$YRC-I1?Z?:__P`'$7_!1/Q;_:OB3X?^"?!NE>#M/N'E MD>W\!S:]#80`EA#>ZJ85C&Q/ON[*<#+**^M?V%O^#D#QWXU^*OA3X;?M5>$/ M#9T;QAK%CH,7CGPG:_V0=!OM2N8+*QFO=+6,PS63W,ZKOA1\)].^$'ACX5^![+P5I_A_^P;JVG\/Z3<37]L]F;6\N=1OKFT> MXN+FY5I))+B:0LC/E-FT`?`GAK_@B)_P3<\.^(KKQQ_PK)=4NX=4F\01->^* M[W^R-*=)S>!HK:"Y2WAM[67,B'*)&JKP`BX_&Y<<>#&9X+-L!C/#BIE4%&5' M*,;E"A5S";DI0IUZ]6=;#^PK0E&G4Y)3Q<*G-*G-2LW+]FAP7XPY9C,JQN$\ M0Z6:2YU5S7!YMSTL#%1<)5*%&C&AB%7I3BZE-3C'"SIM*<7&Z4(O@+:?M'^.= M/MK3PU^%_V(/\`@GAHOPL^#_AC0]1\KQ7J-O$` MR2&ZD:XFF#*66<,9=B:GA'+%9ABY498C/?$',\)D^4UH5K2 M3P%"O7I5TFI0C0HPPLZTU+GE4J2<8+Y7B7CJGF?$^886CXO4*&"P<:T:&0^' M^`Q.<9M1G1?+-8ZOAZ-:CHX5'7K3Q,*5-QY5"FDYGR?\#/\`@Y0_:C\/_$O2 M=`_:*\!^#]?\-G6K71_$-MH^B'PMKFE)+>Q6=[=;%C8FXT]7>8VTFWS#$8R, ML,_7_P#PWFTPW,0.=K MRWVW:<@2@@C%?R^_#WX5_%;]IK]JGPK'XEL8+KQ!\5?BOHK^('L8$@B#:[X@ MM)=4EBM[?]W#%';23N%4;55/7K^BW_!=._U_QK^UUIGPM\*2IJ/@?X"?#GPC M\,?#ZB7>(KO3-.A.M`8.%_TF&,$+SN5L]./U"MX79'@O$O@>>3\.0RK'8/+< MUS[-<%@:=9X5QP:PN%P-6-.>D91S+%N-.HH0]K3HMR@Y1LOS*EXL9CC/#7C9 MYMQ53S3+\3F>59!E>.QM>@L2IXQ8C%XVE.K"S?/EN%4YTY3J>RG45I.,_>^U MO^#7OX%2:M\3?C5\?;VV$MCX5T.W\#:9)+&"(M5UC[)J<\L3$'Y_L8V<8*E< MYR,5_:2MC9)=/>I:6Z7CIY;W*PQB=DSG:TH7>1GL37XP?\$%_P!GM_@7^P;X M1U+4;`Z?XC^*FJWWC/6H73;-L$LUEIAE[[OLB\`G@$`<8K]JJ_D_QASN6=^( MG$==2DZ.#Q2RF@KO2EEL8X62WM9UZ=6>FCYK[ZG]6^$63PR?P^X7=Z7K.GVFJ M:==)_)X:JYTJF;5\RHUX9A#"PIJ MO2P\?92IRPU9MQJ4'/G4E\2LDXW/R#QH^C=6\5N+0E;KPSX1DC\VRLU251-:WVH&:22_0A&VJB%=I7'\\/_!6VR^- M6K?MG_%&_P#B#HVOK##J5O9^'7:TU!]+?P[#;QC2_P"S9Q$;5HGB4/,+=L^< M#Y@)"FO[W(HHX(XX88TAAB18XHHD6...-`%1(T0!415`"JH"J```!7G_`(U^ M$?PH^)+P2?$7X8?#SQ]):KLM7\:^"O#?BI[9#_#`VNZ;?M"O^S&5'M7E<&>/ M>.R+Q)X@\0L_RB.>5\_PE7!.A3Q'L*N5X9UJ-3#8?+JM2G5A&A1I4*>&E2<8 M^TIWESJ3ES^MQQ]'?`<0>%_#GAMPYG+R##\.XNACO;U,,\11S;%*A6I8O$9E M2IU*4Y5\16KU,5&JI2]E4:@HN"CR_P`OW["7_!2BP^#W[.W@?X$_"#]CSQCX ML^-<2S:5_P`)!I&GVHT/7M?NGN);;7-:N4M6U&&)=Z).))52..+(`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`L?)]Q_X*R_\`!/+Q MQ^SYX^\*^)?AQX9USQ#\)9O!WA[0;/6=/LKO49;/7-'AG74H=46SCG:T2X>= M);:615B*@J6!Q7]K>@^&_#OA73X])\+Z!HOAO2H3F+3-!TJQT?3XC@#,=EIT M%O;(<`#Y8QP`.U6-7T?2-?T^YTG7=*TW6]*O$\N[TS5[&UU+3[J/.?+N;*\B MFMITR`=LL;+D9Q7O?\32Y]0XIR/,(<5B^+>(, MSHYS7XHA@,/AJ&%QE"=>JL+A_MXH\W4 M5O*28%5"Q&$==N17G'P-_8T_:T_X*6_M":G\2_B+I^NZ/H^O^(8]4\<^/O$N MF7NF6-EI[2IFUT:VNU@FNVCMHUMK"*U22*$@.6)!4_V@1_LM_LR0W0OH?V=/ M@3%?!_-%Y'\(OA^ET),Y\P7"^'A-OSSOW[L\YKVC3=,TW1K*WTW1].L=*TZT M01VNGZ;:6]C96T8Z1V]K:QQ00H.RQQJOM5XSZ1>0934SW-O#_P`.L%P[Q7Q) M[1YCQ%C<8\=6A4K3]K5JX?#*"I*2,%G@OHS<1YQ3 MX>R?Q'\3&XN9"(MTZL/WW_P"")'P>;X._L7IXQ\2:9<:/KOCC7=<\ M1:HMU;2072Z+IY)TUI(Y%64XMFD*C;_"0`2:_5G5_@W\(?$&H76KZ_\`"KX; MZWJM\Y>]U/5_`WAC4M0O'889[J]O=+FN;AV`P6FEWKXFK."H4W"IB\PQ-3&3(KA=;\=ZGIU@Z:3J3L] MGIMV='L-F+9E_>+:*T85L%75N]?V7:+9VG[&O_!-NTLOL=P;CP'\$WB\BRMI M9KR36=0S6DL:%5*I)$RK@8`P*T\0O&O`<;Y;P+D-#ANM ME>0<(8G"UL3@?K\*T\QHX.AA<)1I0G'#TH4''"T<1!2<*EI8ERM:-GGX;>!. M8:'X4UK4OAGXO MTS2KCPUJ^FV-Y?V=FVGV$-K>Z5>O:PR+9RVLBL8?.")+&#M(VJ&_LVT/X1?" M?PQJ4&L^&_AA\//#VL6JNEMJNA^"O#>DZE;K(,.L%]8:9;W42N``ZQRJ&`Y! MKJ/$/AGPWXMTR;1?%?A_1/$VCW!!GTGQ#I-AK6F3E<[3-8:E;W-K(5R<%XFQ MDXZU]OC?I48RIQQDO$V"X9]AD^79)B\DQ61U/P6!^B+@:7`.>\*X_BEXC.LSS_!9]A<^I9;R0PU3 M`8.MA*>%Q&$GB9SQ%&NL7C)UG&O3DIU*4X>]2M/^1K]DK_@LK)^S_P#LX^%O M@MXB_9WO/%OBGP1I-QH_AOQ!9QV-K:7,1EGFMI-3:5H>A>'Y)T M-PT.L7!MI+V>*T^6%88+AYIV4N(@Q8?O^G[*O[+\4PN8_P!F_P"`L=P&W"=/ M@_\`#U)@P.0PE7PZ'#9YR&SGFO8]$T#0?#.GQ:3X;T32/#^E0$F#3-$TVSTK M3X20`3%96$-O;1DA0#LC&0`.PKY#/O%CPTQ,,\Q>2>$>">>Y]6KXBMF'$6;8 MK,\-@L5B)2J5<3@L#!TXTYNK.=54XU*5-U&G-2IKV1]KP[X/>*6%GD&#S[QD MQW]@G?M'Z!\5/["OM1\*>*/`/A_2UU31]-N6T>VU?P]"+?4;9(RQ9FKR#]@#]O#]MOX/^![C]G;X#_#B'QT?$>I74GAR7 M4=`U:]N/#6H7\#/!_CK2GT+ MQOX4\->,M$EUO+1W&>&:$D=C7/>"_@]\(_AO- M/OEGTA,G7A MQEG`W$O`&"XFJ9+0HT<#/&8R5/+*E3!2F\OQ.)PU.FL0JF'A-TZD*-:,:\%* M+E"-6:/%S/Z-V=?\10S7Q`X6\1<=PK3SS$5JV80P6"C5S6G3QL:2S'"87%5: MCPSI8B=)5*4Z]"<\/-PDHSE1A)_YVWQF\'?'GQK\>?%4GQ'@\0^*/B#K/B[R MM>UEK#4+F.[UNZDMHGCBE6W\LPV\LB6<04J@2#`/!:OU+_X*L66M^`O@Y^Q[ M^R3X?T#699_A;\*=,\5>)_L&FWK)YHNS=G23.;H2_O!<>9YHD^ MUF_%M",16XO-1TZYN! M!$`!'")/+0#"J*]S%_2?P6,S?@G'5.#9T\%P?3Q]6&7X?,*5"CB,RQ.6PRO" MXFC"&%5/"X?!8>>,]CAE"HHNO34)15*[\#`_10QV`R;CO+Z?&\:N/XUJY=1J M9GB,MK5Z^'RO"YI/-L9AJ\YXSVN+Q./Q-/!>VQ4IP:WNK M68O;JES:3QNRB:%Y$92DR[@NT_Z-&@>&_#OA/38M&\+:!HOAK2(&=X=*T#2K M'1M-A>0YD:*QTZ"VM8V<\NR1`L>6)-^(5T+WQ]\*/AKXXO0JH+O MQAX$\+^);H(@PBBXUK2KV7:HX5=^`.`!7!D?TFZN#SOCFOG?"\,XX>XTQOUF M>5O&\E?`T5@*65?4G6E1E2Q6&K8"C2IU8.%%J<93IM>TDCT,^^BI2QF0<`8? M(.+*F2<2\"X+ZM#-XX#GPV/KRS&IF[QJH0KQJX7$T77@6;78(;;Q!K'A2PUG4?$=T`4$UII M;VL,S6EM=L661EC,VTA`.04[KX.?LJ?\%`-#_9&^+_QR\7>/OBEI/E^";^U\ M)_"E]2O9]6U_1]0B=-4UB[L7:2ZMS9PD&QM5"W3,LCYYV1?U,^&_V?/@)X,O MXM4\'_!#X0^%-3@=7AU'PW\-?!FA7\+JBVMQ&ZD`JR2`@C(->N.B2 M(\RO+&C7A25"5=5:E6E1E*-!4FW)^Y@/H^ M<29KFN)S_P`1O%+/N)(H5*5/%U,-AJ].GBI8>I5>( MAAG2I4JM91EB)5E%17^;E^SCXIA^#/[0_P`/_B'\3OAIK'Q`T'PCXKM]5USP M??6=PEQK$<,CDP2)?PJGG^:PE(N!AFSO#$XK]Y?VRO\`@HI^T!^TQ^S?X[T' M]G']FOQS\*_A!;VMCIGC_P`9:W8+:7UQIUTUN;?3O#L>G0VL7V21S&ES+;1R MM'"IB*$,0O\`1W>?LR_LVZCJ,NKZA^SY\$+_`%:>8W$VJ7GPG\!W6HS3LVYI MI;V?0'N9)F;YC(\IE2PU;&J7-]6Q.)BXTY*E.K1K*E""\#@_P"C9QGP MGP]Q)PK@_$ZC@9XBO4POU6E'$9IB*U3%4,"X*/UK"X22 ME4BZL*->@ZTZC_AZ_P""/WPWO;/]K*W^(WC7P_JL>C?"OP3XN\?O'>:7>*MQ MJ&BZ7,]A&AG@0-*'4O'&NYG;9@9Q7QOXR\.?$7]I/]IO6]9A\.^)'N?BG\3; MVXM9+G2]2#+#XAUZ5;?)>`*GDV,\;!=V$5/FZ&O]#32/A'\*/#TES+H'PQ^' MNARWEM)9W"_#>FR75G,GERVER]EIL+3VTJ?))!*6B=/E92.*IV'P4^#6 ME7MKJ>E_"3X8Z;J-C,MQ9:A8>`O"MG>V=PA)6>UNK?2HY[>9225EBD1P2<-7 MJ4_I3X6EQ-GW$ZX0Q,L9F619;DF74YYM3<,MI8&>.Q-2;?U/]\L3CL73KU$H MTWRT(PN])1\FK]$?%5>%.'>$Y<9X:."RKB'-,_S.I#)ZBGFE7,(9?A:=.SQG M[IX7`8.KAZ;E*HN:O*:4=8NQ\(/!EI\._A;\/_!%C;K;0>&O".@Z4854*%N+ M;3K=+HD``!FN?-8^YKT:BBOY`Q%>IBL17Q-:3G5Q%:I7JR;; EX-31 3 vaso10qjune30-2012ex31.htm vaso10qjune30-2012ex31.htm
EXHIBIT 31.1
 
CERTIFICATION PURSUANT TO RULE 13a/15d OF THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Jun Ma, certify that:

1.  
I have reviewed this quarterly report on Form 10-Q of Vasomedical, Inc. and subsidiaries (the “registrant”);

2.  
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.  
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.  
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.  
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.  
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.  
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.  
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.  
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

a.  
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and
b.  
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
/s/ Jun Ma                         .
Jun Ma
President and Chief Executive Officer

Date: August 14, 2012

 
 
 


EXHIBIT 31.2
 
CERTIFICATION PURSUANT TO RULE 13a/15d OF THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Michael J. Beecher, certify that:

1.  
I have reviewed this quarterly report on Form 10-Q of Vasomedical, Inc. and subsidiaries (the “registrant”);

2.  
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.  
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.  
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.  
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.  
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.  
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.  
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.  
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

a.  
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and
b.  
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
/s/ Michael J. Beecher           .
Michael J. Beecher
Chief Financial Officer

Date: August 14, 2012



 EX-32 4 vaso10qjune30-2012ex32.htm vaso10qjune30-2012ex32.htm



EXHIBIT 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Vasomedical, Inc. and subsidiaries (the “Company”) on Form 10-Q for the period ending June 30, 2012, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jun Ma, as President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


/s/ Jun Ma                          .
Jun Ma
President and Chief Executive Officer

Dated: August 14, 2012
 
 
 
 
 

 



EXHIBIT 32.2

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Vasomedical, Inc. and subsidiaries (the “Company”) on Form 10-Q for the period ending June 30, 2012, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael J. Beecher, as Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



/s/ Michael J. Beecher             .
               Michael J. Beecher
Dated: August 14, 2012                                                                                      Chief Financial Officer

 EX-101.INS 5 vaso-20120630.xml XBRL INSTANCE DOCUMENT 0000839087 2012-01-01 2012-06-30 0000839087 2012-08-10 0000839087 2012-06-30 0000839087 2011-12-31 0000839087 2011-01-01 2011-06-30 0000839087 2012-04-01 2012-06-30 0000839087 2011-04-01 2011-06-30 0000839087 2010-12-31 0000839087 2011-06-30 0000839087 us-gaap:PreferredStockMember 2012-06-30 0000839087 us-gaap:PreferredStockMember 2011-06-30 0000839087 vaso:EquipmentSegmentMember 2012-04-01 2012-06-30 0000839087 vaso:SalesRepresentationSegmentMember 2012-04-01 2012-06-30 0000839087 us-gaap:CorporateMember 2012-04-01 2012-06-30 0000839087 vaso:EquipmentSegmentMember 2011-04-01 2011-06-30 0000839087 vaso:SalesRepresentationSegmentMember 2011-04-01 2011-06-30 0000839087 us-gaap:CorporateMember 2011-04-01 2011-06-30 0000839087 vaso:EquipmentSegmentMember 2012-01-01 2012-06-30 0000839087 vaso:SalesRepresentationSegmentMember 2012-01-01 2012-06-30 0000839087 us-gaap:CorporateMember 2012-01-01 2012-06-30 0000839087 vaso:EquipmentSegmentMember 2011-01-01 2011-06-30 0000839087 vaso:SalesRepresentationSegmentMember 2011-01-01 2011-06-30 0000839087 us-gaap:CorporateMember 2011-01-01 2011-06-30 0000839087 vaso:EquipmentSegmentMember 2012-06-30 0000839087 vaso:SalesRepresentationSegmentMember 2012-06-30 0000839087 us-gaap:CorporateMember 2012-06-30 0000839087 vaso:EquipmentSegmentMember 2011-06-30 0000839087 vaso:SalesRepresentationSegmentMember 2011-06-30 0000839087 us-gaap:CorporateMember 2011-06-30 0000839087 vaso:GeHealthcareMember 2012-04-01 2012-06-30 0000839087 vaso:GeHealthcareMember 2011-04-01 2011-06-30 0000839087 vaso:GeHealthcareMember 2012-01-01 2012-06-30 0000839087 vaso:GeHealthcareMember 2011-01-01 2011-06-30 0000839087 vaso:GeHealthcareMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2012-06-30 0000839087 vaso:GeHealthcareMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2011-12-31 0000839087 vaso:GeHealthcareMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2012-01-01 2012-06-30 0000839087 vaso:GeHealthcareMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2011-01-01 2011-12-31 0000839087 us-gaap:RestrictedStockMember us-gaap:OfficerMember 2012-01-01 2012-06-30 0000839087 us-gaap:RestrictedStockMember us-gaap:DirectorMember 2011-04-01 2011-06-30 0000839087 us-gaap:RestrictedStockMember us-gaap:DirectorMember 2011-01-01 2011-06-30 0000839087 us-gaap:RestrictedStockMember 2012-01-01 2012-06-30 0000839087 us-gaap:RestrictedStockMember 2011-01-01 2011-06-30 0000839087 us-gaap:RestrictedStockMember us-gaap:DirectorMember 2012-01-01 2012-06-30 0000839087 us-gaap:RestrictedStockMember 2012-04-01 2012-06-30 0000839087 us-gaap:RestrictedStockMember 2011-04-01 2011-06-30 0000839087 us-gaap:StockCompensationPlanMember 2012-04-01 2012-06-30 0000839087 us-gaap:StockCompensationPlanMember 2012-01-01 2012-06-30 0000839087 us-gaap:StockCompensationPlanMember 2011-04-01 2011-06-30 0000839087 us-gaap:StockCompensationPlanMember 2011-01-01 2011-06-30 0000839087 us-gaap:StockOptionsMember 2012-01-01 2012-06-30 0000839087 us-gaap:StockOptionsMember 2011-01-01 2011-06-30 0000839087 us-gaap:StockOptionsMember 2012-04-01 2012-06-30 0000839087 us-gaap:StockOptionsMember 2011-04-01 2011-06-30 0000839087 us-gaap:WarrantMember 2012-01-01 2012-06-30 0000839087 us-gaap:WarrantMember 2011-01-01 2011-06-30 0000839087 us-gaap:WarrantMember 2012-04-01 2012-06-30 0000839087 us-gaap:WarrantMember 2011-04-01 2011-06-30 0000839087 us-gaap:ContingentlyIssuableSharesMember 2012-01-01 2012-06-30 0000839087 us-gaap:ContingentlyIssuableSharesMember 2011-01-01 2011-06-30 0000839087 us-gaap:ContingentlyIssuableSharesMember 2012-04-01 2012-06-30 0000839087 us-gaap:ContingentlyIssuableSharesMember 2011-04-01 2011-06-30 0000839087 us-gaap:ConvertiblePreferredStockMember 2012-01-01 2012-06-30 0000839087 us-gaap:ConvertiblePreferredStockMember 2011-01-01 2011-06-30 0000839087 us-gaap:ConvertiblePreferredStockMember 2012-04-01 2012-06-30 0000839087 us-gaap:ConvertiblePreferredStockMember 2011-04-01 2011-06-30 0000839087 us-gaap:CommonStockMember 2012-01-01 2012-06-30 0000839087 us-gaap:CommonStockMember 2011-01-01 2011-06-30 0000839087 us-gaap:CommonStockMember 2012-04-01 2012-06-30 0000839087 us-gaap:CommonStockMember 2011-04-01 2011-06-30 0000839087 us-gaap:FairValueInputsLevel1Member 2012-06-30 0000839087 us-gaap:FairValueInputsLevel2Member 2012-06-30 0000839087 us-gaap:FairValueInputsLevel3Member 2012-06-30 0000839087 us-gaap:FairValueInputsLevel1Member 2011-12-31 0000839087 us-gaap:FairValueInputsLevel2Member 2011-12-31 0000839087 us-gaap:FairValueInputsLevel3Member 2011-12-31 0000839087 us-gaap:ContingentConsiderationClassifiedAsEquityMember 2012-01-01 2012-06-30 0000839087 us-gaap:WarrantMember 2012-01-01 2012-06-30 0000839087 us-gaap:RestrictedStockMember 2012-01-01 2012-06-30 0000839087 vaso:FastGrowthEnterprisesLimitedFgeMember 2012-06-30 0000839087 vaso:FastGrowthEnterprisesLimitedFgeMember us-gaap:CommonStockMember 2012-06-30 0000839087 vaso:FastGrowthEnterprisesLimitedFgeMember us-gaap:WarrantMember 2012-06-30 0000839087 vaso:FastGrowthEnterprisesLimitedFgeMember us-gaap:ContingentConsiderationClassifiedAsEquityMember 2012-06-30 0000839087 us-gaap:CommonStockMember 2012-06-30 0000839087 us-gaap:ContingentConsiderationClassifiedAsEquityMember 2012-06-30 0000839087 2011-09-02 0000839087 vaso:FastGrowthEnterprisesLimitedFgeMember 2012-04-01 2012-06-30 0000839087 vaso:FastGrowthEnterprisesLimitedFgeMember 2012-01-01 2012-06-30 0000839087 vaso:FastGrowthEnterprisesLimitedFgeMember 2011-01-01 2011-06-30 0000839087 vaso:FastGrowthEnterprisesLimitedFgeMember 2011-04-01 2011-06-30 0000839087 us-gaap:PatentsMember 2012-06-30 0000839087 us-gaap:PatentsMember 2011-12-31 0000839087 2012-03-31 0000839087 2011-03-31 0000839087 vaso:ExtendedServiceContractsMember 2012-01-01 2012-06-30 0000839087 vaso:ExtendedServiceContractsMember 2011-01-01 2011-06-30 0000839087 vaso:ExtendedServiceContractsMember 2012-04-01 2012-06-30 0000839087 vaso:ExtendedServiceContractsMember 2011-04-01 2011-06-30 0000839087 vaso:In-ServiceAndTrainingMember 2012-01-01 2012-06-30 0000839087 vaso:In-ServiceAndTrainingMember 2011-01-01 2011-06-30 0000839087 vaso:In-ServiceAndTrainingMember 2012-04-01 2012-06-30 0000839087 vaso:In-ServiceAndTrainingMember 2011-04-01 2011-06-30 0000839087 vaso:ServiceArrangementsMember 2012-01-01 2012-06-30 0000839087 vaso:ServiceArrangementsMember 2011-01-01 2011-06-30 0000839087 vaso:ServiceArrangementsMember 2012-04-01 2012-06-30 0000839087 vaso:ServiceArrangementsMember 2011-04-01 2011-06-30 0000839087 vaso:CommissionRevenuesMember 2012-01-01 2012-06-30 0000839087 vaso:CommissionRevenuesMember 2011-01-01 2011-06-30 0000839087 vaso:CommissionRevenuesMember 2012-04-01 2012-06-30 0000839087 vaso:CommissionRevenuesMember 2011-04-01 2011-06-30 0000839087 2011-01-01 2011-03-31 0000839087 2012-01-01 2012-03-31 0000839087 us-gaap:DirectorMember 2012-04-01 2012-06-30 0000839087 us-gaap:DirectorMember 2012-01-01 2012-06-30 0000839087 vaso:DirectorDavidLiebermanMember 2011-01-01 2011-06-30 0000839087 vaso:ConsultantMember 2011-03-31 0000839087 vaso:ConsultantMember 2011-01-01 2011-03-31 0000839087 us-gaap:DirectorMember 2011-01-01 2011-03-31 0000839087 vaso:ConsultantMember 2012-01-01 2012-06-30 0000839087 us-gaap:SubsidiaryOfCommonParentMember 2011-09-02 0000839087 us-gaap:SubsidiaryOfCommonParentMember 2011-10-01 2011-12-31 0000839087 us-gaap:SubsidiaryOfCommonParentMember 2012-01-01 2012-03-31 0000839087 us-gaap:SubsidiaryOfCommonParentMember 2012-03-31 0000839087 vaso:Plan2010Member 2010-06-30 0000839087 vaso:Plan2010Member 2010-01-01 2010-06-30 0000839087 us-gaap:WarrantMember vaso:Plan2010Member 2011-07-01 2011-09-30 0000839087 us-gaap:RestrictedStockMember vaso:Plan2010Member 2012-06-30 0000839087 us-gaap:OfficerMember us-gaap:RestrictedStockMember vaso:Plan2010Member 2012-01-01 2012-03-31 0000839087 vaso:Non-OfficerEmployeeMember us-gaap:RestrictedStockMember vaso:Plan2010Member 2012-04-01 2012-06-30 0000839087 us-gaap:RestrictedStockMember vaso:Plan2010Member 2012-07-01 2012-07-30 0000839087 us-gaap:RestrictedStockMember 2012-01-01 2012-03-31 0000839087 us-gaap:RestrictedStockMember 2012-07-01 2012-07-30 0000839087 us-gaap:RestrictedStockMember 2011-07-01 2011-09-30 0000839087 us-gaap:WarrantMember 2011-07-01 2011-09-30 0000839087 2012-07-01 2012-07-30 0000839087 2011-10-01 2011-12-31 0000839087 2011-07-01 2011-09-30 0000839087 us-gaap:SeriesEPreferredStockMember 2010-06-30 0000839087 us-gaap:PreferredStockMember 2010-06-30 0000839087 us-gaap:SeriesEPreferredStockMember 2011-01-01 2011-06-30 0000839087 us-gaap:SeriesEPreferredStockMember 2011-04-01 2011-06-30 0000839087 us-gaap:SeriesEPreferredStockMember 2011-07-02 0000839087 us-gaap:SeriesEPreferredStockMember 2011-07-01 2011-07-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure false --12-31 2012-06-30 No No Yes Smaller Reporting Company VASOMEDICAL, INC 0000839087 158746910 2012 Q2 10-Q 8984000 20695000 1151000 7833000 0 749000 3552000 0 4301000 7700000 19700000 10804000 22737000 456000 273000 10000 196000 2336000 3889000 2724000 2531000 1540000 1774000 -2000 0 60771000 60188000 136000 288000 162000 208000 1965000 2163000 6000 9000 13000 19000 1810000 1864000 260000 1864000 1500000 4286000 1500000 4286000 2400000 0 0 0 0 30668000 0 30668000 4918000 3913000 375000 3913000 10628000 40731000 2135000 40731000 9944000 0 0 9944000 1423000 0 0 1423000 26422000 28500000 32055000 34306000 9323000 11558000 11174000 4440000 6330000 7687000 18457000 <div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE B - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Basis of Presentation and Use of Estimates</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The accompanying consolidated condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and pursuant to the accounting and disclosure rules and regulations of the Securities and Exchange Commission (the "SEC"). Certain information and disclosures normally included in the consolidated condensed financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these consolidated condensed financial statements should be read in connection with the audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the transition period ended December 31, 2011, as filed with the SEC. These consolidated condensed financial statements include the accounts of the companies over which we exercise control. In the opinion of management, the accompanying consolidated condensed financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of interim results for the Company. The results of operations for any interim period are not necessarily indicative of results to be expected for any other interim period or the full year.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the consolidated condensed financial statements, the disclosure of contingent assets and liabilities in the consolidated condensed financial statements and the accompanying notes, and the reported amounts of revenues, expenses and cash flows during the periods presented. Actual amounts and results could differ from those estimates. The estimates and assumptions the Company makes are based on historical factors, current circumstances and the experience and judgment of the Company's management. The Company evaluates its estimates and assumptions on an ongoing basis.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Significant Accounting Policies</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Note B of the Notes to Consolidated Financial Statements, included in the Transition Report on Form 10-K for the seven months ended December 31, 2011, includes a summary of the significant accounting policies used in the preparation of the consolidated condensed financial statements.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Reclassifications</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Certain reclassifications have been made to prior period amounts to conform with the current period presentation.</div><div style="text-indent: 0pt; display: block;"><br /></div></div> 1222000 2400000 1000000 3968000 13740000 10621000 7697000 5401000 <div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The following supplemental pro forma information presents the financial results as if the acquisition of FGE had occurred June 1, 2009 (amounts in thousands, except per share amounts):</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: right; font-style: italic; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(in thousands except per share data)</div><div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td align="left" valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div></div></td><td align="left" valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td align="left" colspan="2" valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; border-top: #4bacc6 0.5pt solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Six months ended June 30,</div></div></td><td align="left" valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td align="left" colspan="2" valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td align="left" valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td align="left" colspan="2" valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; border-top: #4bacc6 0.5pt solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Three months ended June 30,</div></div></td><td align="left" valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td align="left" colspan="2" valign="bottom" style="border-bottom: black 2px solid; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td></tr><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2012</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2011</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2012</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2011</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Revenue</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>13,740</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 13%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>10,621</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>7,697</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 13%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>5,401</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="white"><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 13%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 13%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Net income (loss)</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(1,105</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td valign="bottom" style="width: 13%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(957</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>65</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 13%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(683</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="white"><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 13%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 13%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Basic and diluted (loss) earnings per share</div></div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(0.01</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td valign="bottom" style="width: 13%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(0.01</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>0.00</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 13%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(0.01</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="white"><td valign="bottom" style="border-bottom: black 2px solid; width: 26%; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; width: 13%; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; width: 13%; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr></table></div></div></div> 3979000 442000 -1105000 -957000 65000 -683000 0.42 0.42 1500000 5000000 2400000 476000 2979000 2100000 304000 575000 283000 3979000 288000 32000 <div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE I- BUSINESS COMBINATION</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">On September 2, 2011, Vasomedical Global successfully completed the purchase of all the outstanding capital stock of privately-held Fast Growth Enterprises Limited ("FGE"), a British Virgin Islands company that owns subsidiaries which own and control Life Enhancement Technology Ltd ("LET") and Biox Instruments Co. Ltd. ("Biox"), respectively, as per the stock purchase agreement signed on August 19, 2011. The consideration of this acquisition includes a cash payment of $1 million as well as the issuance of 5 million restricted shares of the Company's common stock, up to 2.4 million shares of common stock contingently issuable upon the achievement of certain operating performance targets, and warrants covering 1.5 million shares of common stock.&#160;&#160;The Company is completing its evaluation of FGE's calendar year 2011 results and believes it is likely that the targets have been met and the shares will be issued.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">LET, based in Foshan, Guangdong, China, is Vasomedical's supplier for its proprietary Enhanced External Counterpulsation (EECP<font style="display: inline; font-size: 70%; vertical-align: text-top;">&#174;</font>) systems, including certain Lumenair systems and all AngioNew<font style="display: inline; font-size: 70%; vertical-align: text-top;">&#174;</font><font style="display: inline; font-size: 10pt;">&#160;</font>systems. Biox, a developer and manufacturer of ambulatory monitoring devices in China, is located in Wuxi, Jiangsu, China, and is Vasomedical's supplier of the BIOX series ECG Holter recorder and analysis software as well as ambulatory blood pressure monitoring systems. Vasomedical has obtained FDA clearance to market these products in the United States.&#160;&#160;The acquisition of LET provides Vasomedical with consolidated technical and manufacturing capability in its EECP business which has significantly increased gross margins and will enable the Company to meet anticipated increasing demand for its EECP systems.&#160;&#160;The acquisition of Biox greatly enhances Vasomedical's distribution network, technology and product portfolio, and with combined market and sales efforts of the two companies, has improved performance and profitability of Vasomedical's equipment segment.</div><div style="text-indent: 0pt; display: block;"><br /></div><div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The operating results of FGE are included in the accompanying Consolidated Condensed Statements of Operations and Comprehensive Income (Loss) and Cash Flows for the six and three months ended June 30, 2012.&#160;&#160;The Consolidated Condensed Balance Sheet as of June 30, 2012 reflects the acquisition of FGE, effective September 2, 2011.&#160;&#160;The acquisition date fair value of the total consideration transferred was $3.979 million, which consisted of the following:</div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;</div><div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td align="left" valign="bottom" style="width: 88%; border-top: #4bacc6 0.5pt solid;"><div></div></td><td align="left" valign="bottom" style="width: 1%; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div></div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div></div></td><td style="text-align: right; width: 9%; font-family: times new roman; white-space: nowrap; font-size: 10pt; vertical-align: bottom; border-top: #4bacc6 0.5pt solid;"><div><div style="text-align: center; font-style: italic; display: block; font-family: Times New Roman; font-size: 10pt; margin-right: 0pt;">(in thousands)</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div></div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 88%; border-top: #4bacc6 0.5pt solid;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Cash</div></div></td><td align="left" valign="bottom" style="width: 1%; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>1,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 88%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Vasomedical, Inc. common stock ($0.42 per share)</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>2,100</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 88%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Vasomedical, Inc. warrants to purchase common stock</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>304</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 88%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Contingent issuance of Vasomedical, Inc. common stock ($0.42 per share)</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>575</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 4px; width: 88%;"><div><div style="text-align: left; text-indent: 27pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Total purchase price</div></div></td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>3,979</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="white"><td valign="bottom" style="border-bottom: black 2px solid; width: 88%; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr></table></div></div></div><div style="text-indent: 0pt; display: block;">&#160;</div><div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">In accordance with Accounting Standards Codification ("ASC") 805, Business Combinations ("ASC 805"), the total purchase consideration is allocated to the net tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of September 2, 2011 (the acquisition date).&#160;&#160;The purchase price was allocated based on the information currently available, and may be adjusted after obtaining more information regarding, among other things, asset valuations, liabilities assumed, and revisions of preliminary estimates.&#160;&#160;The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the acquisition date:</div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic; display: inline; font-size: 10pt;">(in thousands)</font></div><div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 88%; border-top: #4bacc6 0.5pt solid;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Cash and cash equivalents</div></div></td><td align="left" valign="bottom" style="width: 1%; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>442</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 88%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accounts receivable and other current assets</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>283</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 88%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Inventories</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>476</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 88%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Property and equipment</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>32</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 88%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Goodwill</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>3,968</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 88%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accounts payable and other current liabilites</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(1,222</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 4px; width: 88%;"><div><div style="text-align: left; text-indent: 27pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Net assets acquired</div></div></td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>3,979</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="white"><td valign="bottom" style="border-bottom: black 2px solid; width: 88%; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr></table></div></div></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The goodwill is attributable to the synergies expected to arise after the Company's acquisition of FGE as well as FGE's projected growth and profitability.&#160;&#160;The goodwill is not expected to be deductible for tax purposes.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">After elimination of intercompany transactions which reduce the income from FGE, the amounts of revenue and net loss of FGE included in the Company's Consolidated Condensed Statement of Operations and Comprehensive Income (Loss)&#160;for the six months ended June 30, 2012 was $910,000 and $24,000, respectively, and $332,000 and $110,000, respectivley for the three months ended June 30, 2012.&#160;&#160;The effect of FGE's loss on earnings per share for the six and three months ended June 30, 2012 was $0.00.</div><div style="text-indent: 0pt; display: block;"><br /></div><div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The following supplemental pro forma information presents the financial results as if the acquisition of FGE had occurred June 1, 2009 (amounts in thousands, except per share amounts):</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: right; font-style: italic; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(in thousands except per share data)</div><div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td align="left" valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div></div></td><td align="left" valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td align="left" colspan="2" valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; border-top: #4bacc6 0.5pt solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Six months ended June 30,</div></div></td><td align="left" valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td align="left" colspan="2" valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td align="left" valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td align="left" colspan="2" valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; border-top: #4bacc6 0.5pt solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Three months ended June 30,</div></div></td><td align="left" valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td align="left" colspan="2" valign="bottom" style="border-bottom: black 2px solid; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td></tr><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2012</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2011</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2012</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2011</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Revenue</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>13,740</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 13%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>10,621</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>7,697</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 13%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>5,401</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="white"><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 13%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 13%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Net income (loss)</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(1,105</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td valign="bottom" style="width: 13%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(957</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>65</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 13%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(683</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="white"><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 13%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 13%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Basic and diluted (loss) earnings per share</div></div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(0.01</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td valign="bottom" style="width: 13%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(0.01</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>0.00</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 13%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(0.01</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="white"><td valign="bottom" style="border-bottom: black 2px solid; width: 26%; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; width: 13%; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; width: 13%; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr></table></div></div></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-indent: 0pt; display: block;"><br /></div></div> 11783000 2294000 3101000 7567000 9489000 4466000 9834000 0 0 9834000 1313000 0 0 1313000 0.08 4285714 <div><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE N - COMMITMENTS AND CONTINGENCIES</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Sales representation agreement</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">In June 2012, the Company concluded an amendment of the GEHC Agreement with GE Healthcare, originally signed on May 19, 2010.&#160;&#160;The amendment, effective July 1, 2012, extends the initial term of three years commencing July 1, 2010 to five years through June 30, 2015, subject to earlier termination under certain circumstances.&#160;&#160;These circumstances include not materially achieving certain sales goals, not maintaining a minimum number of sales representatives, and various legal and GEHC policy requirements.&#160;&#160;Under the terms of the agreement, the Company is required to lease dedicated computer equipment from GEHC for connectivity to their network.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">In conjunction with the extension of the GEHC Agreement, the Company granted VasoHealthcare employees both stock and cash-based performance incentives for the ensuing year.&#160;&#160;The incentives provide for cash payments of up to $2.2 million and 2.2 million shares of restricted common stock grants and vest at various times through July 1, 2013.&#160;&#160;A condition of the incentives is that the employees remain continuously employed through the vesting dates.</div><div style="text-indent: 0pt; display: block;"><br /></div></div> 158746910 153186295 159000 153000 158746910 153186295 30668500 0.001 0.001 250000000 250000000 -1290000 -1701000 75000 -1107000 0.86 0.95 306685 100 1022000 748000 416000 355000 4029000 3275000 2167000 1687000 551000 478000 258000 213000 0.06 2495000 2053000 15227000 12637000 14781000 10792000 15198000 11360000 <div><div style="text-align: left; text-indent: 36pt; display: block; font-family: Times New Roman; font-size: 10pt; margin-right: 0pt;">The changes in the Company's deferred revenues are as follows:</div><div style="text-align: right; font-style: italic; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 10pt;">(in thousands)</div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="vertical-align: bottom;"><div><div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 10pt;">&#160;</div></div></td><td valign="bottom" style="vertical-align: bottom;"><div>&#160;</div></td><td colspan="6" valign="bottom" style="vertical-align: bottom;"><div><div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 10pt;">For the six months ended June 30,</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="vertical-align: bottom;"><div>&#160;</div></td><td colspan="6" valign="bottom" style="vertical-align: bottom;"><div><div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 10pt;">For the three months ended June 30,</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"><div>&#160;</div></td></tr><tr style="height: 15px;"><td valign="bottom" style="vertical-align: bottom;"><div><div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 10pt;">&#160;</div></div></td><td valign="bottom" style="vertical-align: bottom;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: #000000 1px solid; vertical-align: bottom;"><div><div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 10pt;">2012</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="vertical-align: bottom;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: #000000 1px solid; vertical-align: bottom;"><div><div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 10pt;">2011</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="vertical-align: bottom;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: #000000 1px solid; vertical-align: bottom;"><div><div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 10pt;">2012</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="vertical-align: bottom;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: #000000 1px solid; vertical-align: bottom;"><div><div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 10pt;">2011</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"><div>&#160;</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div><div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 10pt;">&#160;</div></div></td><td valign="bottom" style="vertical-align: bottom;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div><div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 10pt;">(unaudited)</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="vertical-align: bottom;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div><div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 10pt;">(unaudited)</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="vertical-align: bottom;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div><div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 10pt;">(unaudited)</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="vertical-align: bottom;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div><div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 10pt;">(unaudited)</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"><div>&#160;</div></td></tr><tr style="background-color: #cceeff;"><td valign="bottom" style="width: 52%; vertical-align: bottom;"><div><div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 10pt;">Deferred revenue at the beginning of the period</div></div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">$</div></div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">15,227</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">$</div></div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">12,637</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">$</div></div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">14,781</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">$</div></div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">10,792</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td></tr><tr style="background-color: #ffffff;"><td valign="bottom" style="width: 52%; vertical-align: bottom;"><div><div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 10pt;">Additions:</div></div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td></tr><tr style="background-color: #cceeff;"><td valign="bottom" style="width: 52%; vertical-align: bottom;"><div><div style="text-align: left; text-indent: 27pt; font-family: 'Times New Roman', serif; font-size: 10pt;">Deferred extended service contracts</div></div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">700</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">730</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">373</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">333</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td></tr><tr style="background-color: #ffffff;"><td valign="bottom" style="width: 52%; vertical-align: bottom;"><div><div style="text-align: left; text-indent: 27pt; font-family: 'Times New Roman', serif; font-size: 10pt;">Deferred in-service and training</div></div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">20</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">18</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">15</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">10</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td></tr><tr style="background-color: #cceeff;"><td valign="bottom" style="width: 52%; vertical-align: bottom;"><div><div style="text-align: left; text-indent: 27pt; font-family: 'Times New Roman', serif; font-size: 10pt;">Deferred service arrangements</div></div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">55</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">45</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">30</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">30</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td></tr><tr style="background-color: #ffffff;"><td valign="bottom" style="width: 52%; vertical-align: bottom;"><div><div style="text-align: left; text-indent: 27pt; font-family: 'Times New Roman', serif; font-size: 10pt;">Deferred commission revenues</div></div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">4,080</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">4,143</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">2,731</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">3,117</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td></tr><tr style="background-color: #cceeff;"><td valign="bottom" style="width: 52%; vertical-align: bottom;"><div><div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 10pt;">Recognized as revenue:</div></div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td></tr><tr style="background-color: #ffffff;"><td valign="bottom" style="width: 52%; vertical-align: bottom;"><div><div style="text-align: left; text-indent: 27pt; font-family: 'Times New Roman', serif; font-size: 10pt;">Deferred extended service contracts</div></div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">(557</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">(604</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">(282</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">(290</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">)</div></td></tr><tr style="background-color: #cceeff;"><td valign="bottom" style="width: 52%; vertical-align: bottom;"><div><div style="text-align: left; text-indent: 27pt; font-family: 'Times New Roman', serif; font-size: 10pt;">Deferred in-service and training</div></div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">(15</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">(16</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">(13</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">(8</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">)</div></td></tr><tr style="background-color: #ffffff;"><td valign="bottom" style="width: 52%; vertical-align: bottom;"><div><div style="text-align: left; text-indent: 27pt; font-family: 'Times New Roman', serif; font-size: 10pt;">Deferred service arrangements</div></div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">(43</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">(35</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">(21</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">(19</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">)</div></td></tr><tr style="background-color: #cceeff;"><td valign="bottom" style="padding-bottom: 2px; width: 52%; vertical-align: bottom;"><div><div style="text-align: left; text-indent: 27pt; font-family: 'Times New Roman', serif; font-size: 10pt;">Deferred commission revenues</div></div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">(4,269</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">)</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">(5,558</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">)</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">(2,416</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">)</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">(2,605</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">)</div></td></tr><tr style="background-color: #ffffff; height: 16px;"><td valign="bottom" style="width: 52%; vertical-align: bottom;"><div><div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 10pt;">Deferred revenue at end of period</div></div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">15,198</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">11,360</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">15,198</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">11,360</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td></tr><tr style="background-color: #cceeff;"><td valign="bottom" style="padding-bottom: 2px; width: 52%; vertical-align: bottom;"><div><div style="text-align: left; text-indent: 27pt; font-family: 'Times New Roman', serif; font-size: 10pt;">Less: current portion</div></div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">10,685</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">8,047</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">10,685</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">8,047</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"><div>&#160;</div></td></tr><tr style="background-color: #ffffff;"><td valign="bottom" style="padding-bottom: 4px; width: 52%; vertical-align: bottom;"><div><div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 10pt;">Long-term deferred revenue at end of period</div></div></td><td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">$</div></div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">4,513</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">$</div></div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">3,313</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">$</div></div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">4,513</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">$</div></div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">3,313</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"><div>&#160;</div></td></tr></table></div></div> <div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE K - DEFERRED REVENUE</div><div style="text-indent: 0pt; display: block;"><br /></div><div><div style="text-align: left; text-indent: 36pt; display: block; font-family: Times New Roman; font-size: 10pt; margin-right: 0pt;">The changes in the Company's deferred revenues are as follows:</div></div><div><div><div style="text-align: right; font-style: italic; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 10pt;">(in thousands)</div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="vertical-align: bottom;"><div><div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 10pt;">&#160;</div></div></td><td valign="bottom" style="vertical-align: bottom;"><div>&#160;</div></td><td colspan="6" valign="bottom" style="vertical-align: bottom;"><div><div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 10pt;">For the six months ended June 30,</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="vertical-align: bottom;"><div>&#160;</div></td><td colspan="6" valign="bottom" style="vertical-align: bottom;"><div><div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 10pt;">For the three months ended June 30,</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"><div>&#160;</div></td></tr><tr style="height: 15px;"><td valign="bottom" style="vertical-align: bottom;"><div><div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 10pt;">&#160;</div></div></td><td valign="bottom" style="vertical-align: bottom;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: #000000 1px solid; vertical-align: bottom;"><div><div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 10pt;">2012</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="vertical-align: bottom;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: #000000 1px solid; vertical-align: bottom;"><div><div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 10pt;">2011</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="vertical-align: bottom;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: #000000 1px solid; vertical-align: bottom;"><div><div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 10pt;">2012</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="vertical-align: bottom;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: #000000 1px solid; vertical-align: bottom;"><div><div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 10pt;">2011</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"><div>&#160;</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div><div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 10pt;">&#160;</div></div></td><td valign="bottom" style="vertical-align: bottom;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div><div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 10pt;">(unaudited)</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="vertical-align: bottom;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div><div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 10pt;">(unaudited)</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="vertical-align: bottom;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div><div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 10pt;">(unaudited)</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="vertical-align: bottom;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div><div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 10pt;">(unaudited)</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"><div>&#160;</div></td></tr><tr style="background-color: #cceeff;"><td valign="bottom" style="width: 52%; vertical-align: bottom;"><div><div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 10pt;">Deferred revenue at the beginning of the period</div></div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">$</div></div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">15,227</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">$</div></div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">12,637</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">$</div></div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">14,781</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">$</div></div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">10,792</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td></tr><tr style="background-color: #ffffff;"><td valign="bottom" style="width: 52%; vertical-align: bottom;"><div><div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 10pt;">Additions:</div></div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td></tr><tr style="background-color: #cceeff;"><td valign="bottom" style="width: 52%; vertical-align: bottom;"><div><div style="text-align: left; text-indent: 27pt; font-family: 'Times New Roman', serif; font-size: 10pt;">Deferred extended service contracts</div></div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">700</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">730</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">373</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">333</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td></tr><tr style="background-color: #ffffff;"><td valign="bottom" style="width: 52%; vertical-align: bottom;"><div><div style="text-align: left; text-indent: 27pt; font-family: 'Times New Roman', serif; font-size: 10pt;">Deferred in-service and training</div></div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">20</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">18</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">15</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">10</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td></tr><tr style="background-color: #cceeff;"><td valign="bottom" style="width: 52%; vertical-align: bottom;"><div><div style="text-align: left; text-indent: 27pt; font-family: 'Times New Roman', serif; font-size: 10pt;">Deferred service arrangements</div></div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">55</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">45</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">30</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">30</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td></tr><tr style="background-color: #ffffff;"><td valign="bottom" style="width: 52%; vertical-align: bottom;"><div><div style="text-align: left; text-indent: 27pt; font-family: 'Times New Roman', serif; font-size: 10pt;">Deferred commission revenues</div></div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">4,080</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">4,143</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">2,731</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">3,117</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td></tr><tr style="background-color: #cceeff;"><td valign="bottom" style="width: 52%; vertical-align: bottom;"><div><div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 10pt;">Recognized as revenue:</div></div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td></tr><tr style="background-color: #ffffff;"><td valign="bottom" style="width: 52%; vertical-align: bottom;"><div><div style="text-align: left; text-indent: 27pt; font-family: 'Times New Roman', serif; font-size: 10pt;">Deferred extended service contracts</div></div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">(557</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">(604</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">(282</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">(290</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">)</div></td></tr><tr style="background-color: #cceeff;"><td valign="bottom" style="width: 52%; vertical-align: bottom;"><div><div style="text-align: left; text-indent: 27pt; font-family: 'Times New Roman', serif; font-size: 10pt;">Deferred in-service and training</div></div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">(15</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">(16</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">(13</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">(8</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">)</div></td></tr><tr style="background-color: #ffffff;"><td valign="bottom" style="width: 52%; vertical-align: bottom;"><div><div style="text-align: left; text-indent: 27pt; font-family: 'Times New Roman', serif; font-size: 10pt;">Deferred service arrangements</div></div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">(43</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">(35</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">(21</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">(19</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">)</div></td></tr><tr style="background-color: #cceeff;"><td valign="bottom" style="padding-bottom: 2px; width: 52%; vertical-align: bottom;"><div><div style="text-align: left; text-indent: 27pt; font-family: 'Times New Roman', serif; font-size: 10pt;">Deferred commission revenues</div></div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">(4,269</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">)</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">(5,558</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">)</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">(2,416</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">)</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">(2,605</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">)</div></td></tr><tr style="background-color: #ffffff; height: 16px;"><td valign="bottom" style="width: 52%; vertical-align: bottom;"><div><div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 10pt;">Deferred revenue at end of period</div></div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">15,198</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">11,360</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">15,198</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">11,360</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td></tr><tr style="background-color: #cceeff;"><td valign="bottom" style="padding-bottom: 2px; width: 52%; vertical-align: bottom;"><div><div style="text-align: left; text-indent: 27pt; font-family: 'Times New Roman', serif; font-size: 10pt;">Less: current portion</div></div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">10,685</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">8,047</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">10,685</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;"></div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">8,047</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"><div>&#160;</div></td></tr><tr style="background-color: #ffffff;"><td valign="bottom" style="padding-bottom: 4px; width: 52%; vertical-align: bottom;"><div><div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 10pt;">Long-term deferred revenue at end of period</div></div></td><td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">$</div></div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">4,513</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">$</div></div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">3,313</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">$</div></div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">4,513</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">$</div></div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"><div><div style="font-family: 'Times New Roman', serif; font-size: 10pt;">3,313</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"><div>&#160;</div></td></tr></table></div></div><div><br />&#160;</div></div></div> 700000 730000 373000 333000 20000 18000 15000 10000 55000 45000 30000 30000 4080000 4143000 2731000 3117000 4513000 5743000 3313000 10685000 9484000 8047000 -35000 -21000 -19000 -4269000 -5558000 -2416000 -2605000 -557000 -604000 -282000 -290000 -15000 -16000 -13000 -8000 -43000 112000 112000 103000 74000 <div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE O - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><br /></div><div style="text-align: justify; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Other Comprehensive Income: Presentation of Comprehensive Income</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">In June 2011, new guidance was issued that amends the current comprehensive income guidance. The new guidance allows the option to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single or continuous statement of comprehensive income or in two separate but consecutive statements. The amendments in this update do not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income. The new guidance is to be applied retrospectively and is effective for fiscal years, and interim periods, beginning after December 15, 2011, with early adoption permitted.&#160;&#160;The adoption of this guidance did not have a material impact on the Company's consolidated condensed financial statements.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">In December 2011, the FASB issued authoritative guidance to defer the effective date for those aspects of the guidance relating to the presentation of reclassification adjustments out of accumulated other comprehensive income. The adoption of this new guidance will not have an impact on the Company's consolidated financial position, results of operations or cash flows as it only requires a change in the format of the current presentation of other comprehensive income.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-indent: 0pt; display: block;"><br /></div></div> <div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE D - SHARE-BASED COMPENSATION</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The Company complies with ASC Topic 718 "Compensation - Stock Compensation" ("ASC 718"), which requires all share-based awards to employees, including grants of employee stock options, to be recognized in the consolidated condensed financial statements based on their estimated fair values.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">During the six-month period ended June 30, 2012, the Company granted 500,000 restricted shares of common stock, valued at $120,000 to an officer, of which half vested immediately and the remainder one year thereafter.&#160;&#160;During the three months ended June 30, 2011, 166,279 shares of restricted common stock valued at $73,500 were granted to directors, and 366,279 shares of restricted common stock valued at $135,500 were granted to directors during the six months ended June 30, 2011.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">During the six-month periods ended June 30, 2012 and 2011, the Company did not grant any stock options.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">For the three and six months ended June 30, 2012, the Company granted 2,190,000 shares of restricted common stock valued at $548,000 to non-officer employees in its VasoHealthcare subsidiary in conjunction with the extension of the GEHC Agreement in June 2012.&#160;&#160;For the three and six months ended June 30, 2011, the Company granted 10,000 shares of restricted common stock valued at $6,800 to non-officer employees.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Share-based compensation expense recognized for the three and six months ended June 30, 2012 was $102,000 and $231,000, respectively,&#160;&#160;and $77,000 and $203,000 for the three and six months ended June 30, 2011, respectively.&#160;&#160;These expenses are included in cost of revenues; selling, general, and administrative expenses; and research and development expenses in the consolidated condensed statements of operations.&#160;&#160;Expense for share-based arrangements was $136,000 and $288,000 for the three and six months ended June 30, 2012, respectively, and $162,000 and $208,000 for the three and six months ended June 30, 2011, respectively.&#160;&#160;Unrecognized expense related to existing share-based arrangements is approximately $1.3 million at June 30, 2012 and will be recognized through July 2013.</div><div style="text-indent: 0pt; display: block;"><br /></div></div> 0 279000 151000 279000 145000 121000 -0.01 -0.01 0.00 -0.01 <div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE E - EARNINGS (LOSS) PER COMMON SHARE</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;Basic earnings per common share is computed as earnings applicable to common stockholders divided by the weighted-average number of common shares outstanding for the period.&#160;&#160;Diluted earnings per common share reflects the potential dilution that could occur if securities or other contracts to issue common shares were exercised or converted to common stock.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Basic and diluted (loss) per common share was ($0.01) for the six months ended June 30, 2012 and 2011.&#160;&#160;Basic and diluted earnings (loss) per share for the three months ended June 30, 2012 and 2011 were $0.00 and ($0.01), respectively.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Diluted earnings per share were computed based on the weighted average number of shares outstanding plus all potentially dilutive common stock equivalents.&#160;&#160;A reconciliation of basic to diluted shares used in the earnings per share calculation is as follows:</div><div style="text-indent: 0pt; display: block;"><br /></div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="width: 40%; font-family: Times New Roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160; </td><td valign="bottom" style="width: 9%; font-family: Times New Roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160; </td><td valign="bottom" style="width: 7%; border-top: #4bacc6 0.5pt solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Six months ended June 30,</div></td><td valign="bottom" style="width: 9%; font-family: Times New Roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160; </td><td valign="bottom" style="width: 3%; font-family: Times New Roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160; </td><td valign="bottom" style="width: 9%; font-family: Times New Roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160; </td><td valign="bottom" style="width: 7%; border-top: #4bacc6 0.5pt solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Three months ended June 30,</div></td><td valign="bottom" style="width: 9%; font-family: Times New Roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160; </td></tr><tr><td valign="bottom" style="width: 40%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 9%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2012</div></td><td valign="bottom" style="border-bottom: black 2px solid; width: 7%; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 9%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2011</div></td><td valign="bottom" style="width: 3%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 9%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2012</div></td><td valign="bottom" style="border-bottom: black 2px solid; width: 7%; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 9%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2011</div></td></tr><tr><td align="left" valign="bottom" style="width: 40%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Basic weighted average shares outstanding</div></td><td align="left" valign="bottom" style="width: 9%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;156,225</div></td><td valign="bottom" style="width: 7%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 9%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;114,077</div></td><td valign="bottom" style="width: 3%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 9%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;158,072</div></td><td valign="bottom" style="width: 7%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 9%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;116,198</div></td></tr><tr><td align="left" valign="bottom" style="width: 40%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Dilutive effect of share-based compensation</div></td><td align="left" valign="bottom" style="width: 9%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td valign="bottom" style="width: 7%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 9%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td valign="bottom" style="width: 3%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 9%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,334</div></td><td valign="bottom" style="width: 7%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 9%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td></tr><tr><td align="left" valign="bottom" style="width: 40%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Contingently issuable shares</div></td><td align="left" valign="bottom" style="width: 9%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td valign="bottom" style="width: 7%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 9%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td valign="bottom" style="width: 3%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 9%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2,400</div></td><td valign="bottom" style="width: 7%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 9%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td></tr><tr><td align="left" valign="bottom" style="width: 40%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Diluted weighted average shares outstanding</div></td><td align="left" valign="bottom" style="border-bottom: black 4px double; width: 9%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;156,225</div></td><td valign="bottom" style="width: 7%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="border-bottom: black 4px double; width: 9%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;114,077</div></td><td valign="bottom" style="width: 3%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="border-bottom: black 4px double; width: 9%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;161,806</div></td><td valign="bottom" style="width: 7%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="border-bottom: black 4px double; width: 9%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;116,198</div></td></tr><tr><td valign="bottom" style="border-bottom: black 2px solid; width: 40%; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 9%; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 7%; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 9%; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 3%; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 9%; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 7%; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 9%; font-family: Times New Roman; font-size: 10pt;">&#160; </td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The following table represents common stock equivalents that were excluded from the computation of diluted earnings per share for the six and three months ended June 30, 2012 and 2011, because the effect of their inclusion would be anti-dilutive.</div><div style="text-align: center; font-style: italic; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(in thousands)</div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="width: 20%; font-family: Times New Roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160; </td><td valign="bottom" style="width: 2%; font-family: Times New Roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160; </td><td align="right" valign="bottom" style="width: 11%; border-top: #4bacc6 0.5pt solid;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">For the</div></td><td align="left" valign="bottom" style="width: 4%; border-top: #4bacc6 0.5pt solid;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">six</div></td><td align="left" valign="bottom" style="width: 12%; border-top: #4bacc6 0.5pt solid;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">months ended</div></td><td valign="bottom" style="width: 2%; font-family: Times New Roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160; </td><td align="right" valign="bottom" style="width: 10%; border-top: #4bacc6 0.5pt solid;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">For the</div></td><td align="left" valign="bottom" style="width: 5%; border-top: #4bacc6 0.5pt solid;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">three</div></td><td align="left" valign="bottom" style="width: 12%; border-top: #4bacc6 0.5pt solid;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">months ended</div></td></tr><tr><td valign="bottom" style="width: 20%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 2%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 11%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">June 30, 2012</div></td><td valign="bottom" style="width: 4%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 12%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">June 30, 2011</div></td><td valign="bottom" style="width: 2%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">June 30, 2012</div></td><td valign="bottom" style="width: 5%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 12%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">June 30, 2011</div></td></tr><tr><td align="left" valign="bottom" style="width: 20%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Stock options</div></td><td valign="bottom" style="width: 2%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 11%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,810</div></td><td valign="bottom" style="width: 4%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 12%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,864</div></td><td valign="bottom" style="width: 2%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 10%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;260</div></td><td valign="bottom" style="width: 5%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 12%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,864</div></td></tr><tr><td align="left" valign="bottom" style="width: 20%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Warrants</div></td><td valign="bottom" style="width: 2%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 11%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,500</div></td><td valign="bottom" style="width: 4%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 12%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;4,286</div></td><td valign="bottom" style="width: 2%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 10%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,500</div></td><td valign="bottom" style="width: 5%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 12%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;4,286</div></td></tr><tr><td align="left" valign="bottom" style="width: 20%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Contingently issuable shares</div></td><td valign="bottom" style="width: 2%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 11%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2,400</div></td><td valign="bottom" style="width: 4%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 12%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td valign="bottom" style="width: 2%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 10%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td valign="bottom" style="width: 5%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 12%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td></tr><tr><td align="left" valign="bottom" style="width: 20%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Convertible preferred stock</div></td><td valign="bottom" style="width: 2%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 11%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td valign="bottom" style="width: 4%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 12%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;30,668</div></td><td valign="bottom" style="width: 2%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 10%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td valign="bottom" style="width: 5%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 12%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;30,668</div></td></tr><tr><td align="left" valign="bottom" style="width: 20%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Common stock grants</div></td><td valign="bottom" style="width: 2%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 11%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;4,918</div></td><td valign="bottom" style="width: 4%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 12%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3,913</div></td><td valign="bottom" style="width: 2%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 10%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;375</div></td><td valign="bottom" style="width: 5%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 12%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3,913</div></td></tr><tr><td valign="bottom" style="width: 20%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 2%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="border-bottom: black 4px double; width: 11%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;10,628</div></td><td valign="bottom" style="width: 4%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="border-bottom: black 4px double; width: 12%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;40,731</div></td><td valign="bottom" style="width: 2%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="border-bottom: black 4px double; width: 10%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2,135</div></td><td valign="bottom" style="width: 5%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="border-bottom: black 4px double; width: 12%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;40,731</div></td></tr><tr><td valign="bottom" style="border-bottom: black 2px solid; width: 20%; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 2%; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 11%; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 4%; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 12%; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 2%; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 10%; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 5%; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 12%; font-family: Times New Roman; font-size: 10pt;">&#160; </td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div></div> 16000 0 1300000 0.8 0.79 0.74 0.78 <div><div style="text-align: left; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The following tables present information about the Company's assets and liabilities measured at fair value as of <font style="display: inline; font-family: Times New Roman;">June 30, 2012 and December 31, 2011</font>:</div><div style="text-align: center; font-style: italic; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(in thousands)</div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160; </td><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="2" valign="bottom" style="border-top: #4bacc6 0.5pt solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Quoted Prices</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="2" valign="bottom" style="border-top: #4bacc6 0.5pt solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Significant</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="2" valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="2" valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">in Active</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Other</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Significant</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Balance</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Markets for</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Observable</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Unobservable</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">as of</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Identical Assets</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Inputs</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Inputs</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">June 30,</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(Level 1)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(Level 2)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(Level 3)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td align="left" valign="bottom"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Assets</div></td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 18pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Cash equivalents invested in money market funds (included in cash and cash equivalents)</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">9,834</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">9,834</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 52%;"><div style="text-align: left; text-indent: 18pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Investment in certificates of deposit (included in short-term investments)</div></td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; padding-bottom: 2px; width: 9%; font-family: times new roman; font-size: 10pt;">110</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; padding-bottom: 2px; width: 9%; font-family: times new roman; font-size: 10pt;">110</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 4px; width: 52%; font-family: times new roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">9,944</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">9,944</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="width: 52%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Quoted Prices</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Significant</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">in Active</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Other</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Significant</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Balance</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Markets for</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Observable</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Unobservable</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">as of</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Identical Assets</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Inputs</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Inputs</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">December 31,</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(Level 1)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(Level 2)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(Level 3)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; font-family: times new roman; font-size: 10pt;">2011</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Assets</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 18pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Cash equivalents invested in money market funds (included in cash and cash equivalents)</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,313</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,313</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 18pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Investment in certificates of deposit (included in short-term investments)</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">110</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">110</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 4px; width: 52%; font-family: times new roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,423</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,423</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="border-bottom: black 2px solid; width: 52%; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div></div> <div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE F - FAIR VALUE MEASUREMENTS</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The Company complies with the provisions of ASC 820 "Fair Value Measurements and Disclosures" ("ASC 820").&#160;&#160;Under ASC 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the "exit price") in an orderly transaction between market participants at the measurement date.</div><div style="text-align: left; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The following tables present information about the Company's assets and liabilities measured at fair value as of <font style="display: inline; font-family: Times New Roman;">June 30, 2012 and December 31, 2011</font>:</div><div style="text-align: center; font-style: italic; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(in thousands)</div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160; </td><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="2" valign="bottom" style="border-top: #4bacc6 0.5pt solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Quoted Prices</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="2" valign="bottom" style="border-top: #4bacc6 0.5pt solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Significant</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="2" valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="2" valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">in Active</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Other</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Significant</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Balance</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Markets for</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Observable</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Unobservable</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">as of</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Identical Assets</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Inputs</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Inputs</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">June 30,</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(Level 1)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(Level 2)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(Level 3)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td align="left" valign="bottom"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Assets</div></td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 18pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Cash equivalents invested in money market funds (included in cash and cash equivalents)</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">9,834</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">9,834</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 52%;"><div style="text-align: left; text-indent: 18pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Investment in certificates of deposit (included in short-term investments)</div></td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; padding-bottom: 2px; width: 9%; font-family: times new roman; font-size: 10pt;">110</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; padding-bottom: 2px; width: 9%; font-family: times new roman; font-size: 10pt;">110</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 4px; width: 52%; font-family: times new roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">9,944</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">9,944</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="width: 52%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Quoted Prices</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Significant</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">in Active</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Other</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Significant</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Balance</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Markets for</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Observable</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Unobservable</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">as of</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Identical Assets</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Inputs</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Inputs</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">December 31,</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(Level 1)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(Level 2)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(Level 3)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; font-family: times new roman; font-size: 10pt;">2011</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Assets</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 18pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Cash equivalents invested in money market funds (included in cash and cash equivalents)</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,313</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,313</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 18pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Investment in certificates of deposit (included in short-term investments)</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">110</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">110</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 4px; width: 52%; font-family: times new roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,423</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,423</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="border-bottom: black 2px solid; width: 52%; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The fair values of the Company's cash equivalents invested in money market funds are determined through market, observable and corroborated sources.</div><div style="text-indent: 0pt; display: block;"><br /></div></div> 469000 469000 426000 413000 43000 56000 3968000 3939000 <div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE J - GOODWILL AND OTHER INTANGIBLES</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Goodwill aggregating $3,968,000 and $3,939,000&#160;was recorded on the Company's Consolidated Condensed Balance Sheets at June 30, 2012 and December 31, 2011, respectively, pursuant to the acquisition of FGE in September 2011.&#160; The increase in goodwill resulted from the recording of additional pre-acquisition dividend liabilities to prior owners. All of the goodwill was allocated to the Company's Equipment segment.</div><div style="text-indent: 0pt; display: block;"><br /></div><div><div style="text-align: left; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The Company's other intangible assets consist of capitalized patent costs, as follows:</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: center; font-style: italic; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(in thousands)</div><div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">June 30, 2012</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">December 31, 2011</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr><td align="left" valign="bottom"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Patent Costs</div></div></td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(unaudited)</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div><div style="text-align: left; text-indent: 27pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Costs</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>469</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>469</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 76%;"><div><div style="text-align: left; text-indent: 27pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accumulated amortization</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(426</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(413</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 4px; width: 76%; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>43</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>56</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="white"><td valign="bottom" style="border-bottom: black 2px solid; width: 76%; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr></table></div></div></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Patents are included in other assets in the accompanying Consolidated Condensed Balance Sheets.&#160;&#160;Amortization expense amounted to $6,000 and $9,000 for the three months ended June 30, 2012 and 2011, respectively, and $13,000 and $19,000 for the six months ended June 30, 2012 and 2011, respectively.</div><div style="text-indent: 0pt; display: block;"><br /></div></div> 9711000 6745000 5530000 3488000 -1172000 -1422000 146000 -954000 116000 0 92000 2000 242000 5000 442000 168000 -190000 -1000 203000 -602000 0 -243000 -186000 0 159000 212000 96000 183000 249000 -36000 -591000 -29000 -1277000 -11716000 -8653000 -230000 33000 -119000 257000 -9000 -9000 36000 9000 -1553000 -94000 0 0 1334000 0 0 0 2400000 0 3000 25000 0 24000 30000 18000 58000 17000 5000 4000 546000 606000 772000 1051000 938000 842000 <div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE H - INVENTORIES, NET</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Inventories, net of reserves, consist of the following:</div><div style="text-align: center; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(in thousands)</div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; border-top: #4bacc6 0.5pt solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">June 30, 2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; border-top: #4bacc6 0.5pt solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">December 31, 2011</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Raw materials</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">938</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">842</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Work in process</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">575</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">528</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Finished goods</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">772</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,051</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 4px; width: 76%; font-family: times new roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,285</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,421</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="border-bottom: black 2px solid; width: 76%; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">At June 30, 2012 and December 31, 2011, the Company had reserves for excess and obsolete inventory of $546,000 and $606,000, respectively.</div><div style="text-indent: 0pt; display: block;"><br /></div></div> 2285000 2421000 575000 528000 110000 110000 110000 110000 82000 149000 16801000 17146000 4630000 5884000 32055000 34306000 <div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE G - ACCOUNTS AND OTHER RECEIVABLES, NET</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The following table presents information regarding the Company's accounts and other receivables as of June 30, 2012 and December 31, 2011:</div><div style="text-align: center; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(in thousands)</div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; border-top: #4bacc6 0.5pt solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">June 30, 2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; border-top: #4bacc6 0.5pt solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">December 31, 2011</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Trade receivables</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">10,804</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">22,737</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Due from employees</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">145</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">121</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Allowance for doubtful accounts and</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 27pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">commission adjustments</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,965</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(2,163</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 4px; width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accounts and other receivables, net</div></td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,984</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">20,695</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="width: 76%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Trade receivables include amounts due for shipped products and services rendered.&#160;&#160;Amounts currently due under the GEHC Agreement are subject to adjustment in subsequent periods should the underlying sales order amount, upon which the receivable is based, change.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Allowance for doubtful accounts and commission adjustments include estimated losses resulting from the inability of our customers to make required payments, and adjustments arising from subsequent changes in sales order amounts that may reduce the amount the Company will ultimately receive under the GEHC Agreement.&#160;&#160;Due from employees primarily reflects commission advances made to sales personnel.</div></div> <div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE A - ORGANIZATION AND PLAN OF OPERATIONS</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Vasomedical, Inc. was incorporated in Delaware in July 1987. Unless the context requires otherwise, all references to "we", "our", "us", "Company", "registrant", "Vasomedical" or "management" refer to Vasomedical, Inc. and its subsidiaries. Until 2010, we were primarily engaged in designing, manufacturing, marketing and supporting EECP<font style="display: inline; font-size: 70%; vertical-align: text-top;">&#174;</font> enhanced external counterpulsation systems based on our unique proprietary technology currently indicated for use in cases of stable or unstable angina (i.e., chest pain), congestive heart failure ("CHF"), acute myocardial infarction (i.e., heart attack, (MI)) and cardiogenic shock.&#160;&#160;In May 2010, the Company, through its wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, expanded into the sales representation business via its agreement with GE Healthcare ("GEHC"), the healthcare business unit of General Electric Company (NYSE: GE), to be GEHC's exclusive sales representative for the sale of select GEHC diagnostic imaging products in specific market segments in the 48 contiguous states of the United States and the District of Columbia.&#160;&#160;&#160;In June 2012, the Company entered into an amendment, effective July 1, 2012, of the sales representative agreement ("GEHC Agreement") extending the initial term of three years commencing July 1, 2010 to five years through June 30, 2015, subject to earlier termination under certain circumstances.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">In September 2011, the Company acquired Fast Growth Enterprises Limited (FGE), a British Virgin Islands company which, through its subsidiaries, owns and controls two Chinese operating companies - Life Enhancement Technologies Ltd. and Biox Instruments Co. Ltd., respectively - to expand its technical and manufacturing capabilities and to enhance its distribution network, technology, and product portfolio.&#160;&#160;Also in September 2011, the Company restructured to further align its business management structure and long-term growth strategy and now operates through three wholly-owned subsidiaries.&#160;&#160;Vaso Diagnostics d/b/a VasoHealthcare continues as the operating subsidiary for the sales representation of GE Healthcare diagnostic imaging products; Vasomedical Global Corp. operates the Company's recently-acquired Chinese companies; and Vasomedical Solutions, Inc. manages and coordinates our EECP<font style="display: inline; font-size: 70%; vertical-align: text-top;">&#174; </font>therapy business as well as other medical equipment operations.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">We report the operations of Vasomedical Global Corp. and Vasomedical Solutions, Inc. under our Equipment reportable segment.&#160;&#160;VasoHealthcare activities are included under our Sales Representation reportable segment (See Note C).</div><div style="text-indent: 0pt; display: block;"><br /></div></div> -1288000 -1701000 54000 -1107000 -204000 -56000 153000 -144000 -1288000 -1422000 54000 -956000 110000 24000 9524000 4666000 54000 20000 71000 6000 5000 16000 20000 19000 3000 193000 48 2 10937000 8187000 5455000 4448000 -1226000 -1442000 75000 -960000 -197000 681000 -409000 -475000 -386000 -99000 -353000 -115000 -758000 -741000 -418000 -283000 396000 202000 0 63000 1096000 1337000 -2000 0 21000 0 0 3490000 0 3490000 0 2703000 0 2703000 117000 141000 204000 16000 0 40000 0 0 1000000 1000000 350000 1000000 0 0 0.01 0.01 0 279000 0 151000 0 0 343000 0 0 150000 10000 564000 429000 -3000 9000 <div><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 41.4pt;">NOTE L - RELATED-PARTY TRANSACTIONS</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">On June 21, 2007, we entered into a Securities Purchase Agreement with Kerns Manufacturing Corp. ("Kerns").&#160;&#160;Pursuant to this agreement, a five-year warrant to purchase 4,285,714 shares of our common stock at an initial exercise price of $0.08 per share was issued to Kerns.&#160;&#160;In March 2012, Kerns exercised its warrant and purchased 4,285,714 shares of common stock.&#160;&#160;Concurrently with our entry into the Securities Purchase Agreement, we also entered into a Distribution Agreement and a Supplier Agreement with Living Data Technology Corporation ("Living Data"), an affiliate of Kerns.&#160;&#160;Pursuant to the Distribution Agreement, as amended, we became the exclusive worldwide distributor of the AngioNew EECP<font style="display: inline; font-size: 70%; vertical-align: text-top;">&#174;</font> systems manufactured through Living Data. The Distribution Agreement had an initial term extending through May 31, 2012.&#160;&#160;Subsequent to August 31, 2011 the Company acquired Life Enhancement Technology (LET) (see Note I), the manufacturer of the AngioNew EECP<font style="display: inline; font-size: 70%; vertical-align: text-top;">&#174;</font> system.&#160;&#160;Consequently, the Distribution Agreement is no longer effective, and the Company wrote-off the remaining unamortized balance of Deferred Distributor Costs during the seven months ended December 31, 2011.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">On February 28, 2011, David&#160;Lieberman and Edgar Rios were appointed by the Board of Directors as directors of the Company.&#160;&#160;Mr. Lieberman, a practicing attorney in the State of New York, was appointed to serve as the Vice Chairman of the Board.&#160;&#160;He is currently a senior partner at the law firm of Beckman, Lieberman &amp; Barandes, LLP, which firm performs certain legal services for the Company.&#160;&#160;Fees of approximately $82,000 and $149,000 were billed by the firm through the three and six months ended June 30, 2012, respectively, at which date no amounts were outstanding.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Mr. Rios is President of Edgary Consultants, LLC,&#160;and was appointed a director in conjunction with the Company's consulting agreement (the "Agreement") with Edgary Consultants, LLC ("Consultant").&#160;&#160;The Agreement commenced on March 1, 2011 and runs for a two year term.&#160;&#160;The Agreement provides for the engagement of Consultant to assist the Company in seeking broader reimbursement coverage of EECP<font style="display: inline; font-size: 70%; vertical-align: text-top;">&#174;</font><font style="display: inline; font-size: 10pt;">&#160;</font>therapy.&#160;&#160;More specifically, Consultant will be assisting the Company in the following areas:</div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;</div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td align="right" style="width: 36pt;"><div style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="display: inline; font-size: 10pt;">1.</font>&#160;&#160;</div></td><td><div style="text-align: justify; text-indent: 0pt; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Engaging the adoption of EECP&#174; therapy as a first line option for FDA cleared indications as it relates to CCS Class III/IV angina with a major commercial healthcare third-party payer.</div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td align="right" style="width: 36pt;"><div style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="display: inline; font-size: 10pt;">2.</font>&#160;&#160;</div></td><td><div style="text-align: justify; text-indent: 0pt; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Engaging a major commercial healthcare payer to formally collaborate and co-sponsor a study with Vasomedical for the efficacy, efficiency and/or cost effectiveness of the EECP&#174; therapy for NYHA Class II/III heart failure.</div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td align="right" style="width: 36pt;"><div style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="display: inline; font-size: 10pt;">3.</font>&#160;&#160;</div></td><td><div style="text-align: justify; text-indent: 0pt; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Engaging final approval from the Centers for Medicare and Medicaid Services ("CMS") of EECP&#174; therapy as a first line treatment for CCS Class III/IV angina.</div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td align="right" style="width: 36pt;"><div style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="display: inline; font-size: 10pt;">4.</font>&#160;&#160;</div></td><td><div style="text-align: justify; text-indent: 0pt; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Engaging final approval from CMS to extend coverage and provide for the reimbursement of EECP&#174; therapy for CCS Class II angina; and</div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td align="right" style="width: 36pt;"><div style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="display: inline; font-size: 10pt;">5.</font>&#160;&#160;</div></td><td><div style="text-align: justify; text-indent: 0pt; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Engaging final approval from CMS to extend coverage and provide for the reimbursement of EECP&#174; therapy for NYHA Class II/III heart failure.</div></td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">In consideration for the services to be provided by Consultant under the Agreement, the Company has agreed to issue to Consultant or its designees,&#160;approximately 10% of the outstanding capital stock of the Company, of which the substantial portion (in excess of 82%) is performance based as referenced above. In conjunction with the Agreement, 3,000,000 shares of restricted common stock valued at $1,020,000 were issued in March 2011.&#160;&#160;In connection with the Agreement, Mr. Lieberman received 600,000 of these restricted shares.&#160;&#160;The Company has recorded the fair value of the shares issued to Consultant as a prepaid expense and is amortizing the cost ratably over the two year agreement.&#160;&#160;The unamortized value is reported as Deferred Related Party Consulting Expense in our accompanying consolidated condensed balance sheets as of June 30, 2012 and December 31, 2011.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">During the six months ended June 30, 2012, a director performed consulting services for the Company aggregating approximately $10,000.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Through the Company's acquisition of FGE in September 2011, it assumed the liability for $288,000 in unsecured notes payable to the President of LET and his spouse, of which $95,000 was repaid in December 2011, and $190,000, bearing interest at 6% per annum, was paid in March 2012.&#160;&#160;In addition, receivables due from FGE management aggregating $159,000 were collected during the six months ended June 30, 2012.</div><div style="text-indent: 0pt; display: block;"><br /></div></div> 190000 0 95000 190000 0 294000 272000 243000 120000 134000 -50304000 -49065000 1555000 6142000 0 7697000 1100000 4075000 0 5175000 3541000 10199000 0 13740000 2205000 7815000 0 10020000 1 150000 27000 27000 13000 13000 2509000 1086000 1056000 558000 13740000 10020000 7697000 5175000 332000 910000 392000 355000 1032000 1119000 499000 542000 <div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The operating results of FGE are included in the accompanying Consolidated Condensed Statements of Operations and Comprehensive Income (Loss) and Cash Flows for the six and three months ended June 30, 2012.&#160;&#160;The Consolidated Condensed Balance Sheet as of June 30, 2012 reflects the acquisition of FGE, effective September 2, 2011.&#160;&#160;The acquisition date fair value of the total consideration transferred was $3.979 million, which consisted of the following:</div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;</div><div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td align="left" valign="bottom" style="width: 88%; border-top: #4bacc6 0.5pt solid;"><div></div></td><td align="left" valign="bottom" style="width: 1%; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div></div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div></div></td><td style="text-align: right; width: 9%; font-family: times new roman; white-space: nowrap; font-size: 10pt; vertical-align: bottom; border-top: #4bacc6 0.5pt solid;"><div><div style="text-align: center; font-style: italic; display: block; font-family: Times New Roman; font-size: 10pt; margin-right: 0pt;">(in thousands)</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div></div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 88%; border-top: #4bacc6 0.5pt solid;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Cash</div></div></td><td align="left" valign="bottom" style="width: 1%; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>1,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 88%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Vasomedical, Inc. common stock ($0.42 per share)</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>2,100</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 88%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Vasomedical, Inc. warrants to purchase common stock</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>304</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 88%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Contingent issuance of Vasomedical, Inc. common stock ($0.42 per share)</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>575</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 4px; width: 88%;"><div><div style="text-align: left; text-indent: 27pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Total purchase price</div></div></td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>3,979</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="white"><td valign="bottom" style="border-bottom: black 2px solid; width: 88%; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr></table></div></div></div> <div><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Inventories, net of reserves, consist of the following:</div><div style="text-align: center; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(in thousands)</div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; border-top: #4bacc6 0.5pt solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">June 30, 2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; border-top: #4bacc6 0.5pt solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">December 31, 2011</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Raw materials</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">938</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">842</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Work in process</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">575</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">528</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Finished goods</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">772</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,051</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 4px; width: 76%; font-family: times new roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,285</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,421</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="border-bottom: black 2px solid; width: 76%; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div></div> <div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The following table represents common stock equivalents that were excluded from the computation of diluted earnings per share for the six and three months ended June 30, 2012 and 2011, because the effect of their inclusion would be anti-dilutive.</div><div style="text-align: center; font-style: italic; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(in thousands)</div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="width: 20%; font-family: Times New Roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160; </td><td valign="bottom" style="width: 2%; font-family: Times New Roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160; </td><td align="right" valign="bottom" style="width: 11%; border-top: #4bacc6 0.5pt solid;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">For the</div></td><td align="left" valign="bottom" style="width: 4%; border-top: #4bacc6 0.5pt solid;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">six</div></td><td align="left" valign="bottom" style="width: 12%; border-top: #4bacc6 0.5pt solid;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">months ended</div></td><td valign="bottom" style="width: 2%; font-family: Times New Roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160; </td><td align="right" valign="bottom" style="width: 10%; border-top: #4bacc6 0.5pt solid;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">For the</div></td><td align="left" valign="bottom" style="width: 5%; border-top: #4bacc6 0.5pt solid;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">three</div></td><td align="left" valign="bottom" style="width: 12%; border-top: #4bacc6 0.5pt solid;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">months ended</div></td></tr><tr><td valign="bottom" style="width: 20%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 2%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 11%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">June 30, 2012</div></td><td valign="bottom" style="width: 4%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 12%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">June 30, 2011</div></td><td valign="bottom" style="width: 2%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">June 30, 2012</div></td><td valign="bottom" style="width: 5%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 12%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">June 30, 2011</div></td></tr><tr><td align="left" valign="bottom" style="width: 20%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Stock options</div></td><td valign="bottom" style="width: 2%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 11%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,810</div></td><td valign="bottom" style="width: 4%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 12%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,864</div></td><td valign="bottom" style="width: 2%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 10%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;260</div></td><td valign="bottom" style="width: 5%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 12%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,864</div></td></tr><tr><td align="left" valign="bottom" style="width: 20%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Warrants</div></td><td valign="bottom" style="width: 2%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 11%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,500</div></td><td valign="bottom" style="width: 4%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 12%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;4,286</div></td><td valign="bottom" style="width: 2%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 10%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,500</div></td><td valign="bottom" style="width: 5%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 12%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;4,286</div></td></tr><tr><td align="left" valign="bottom" style="width: 20%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Contingently issuable shares</div></td><td valign="bottom" style="width: 2%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 11%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2,400</div></td><td valign="bottom" style="width: 4%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 12%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td valign="bottom" style="width: 2%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 10%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td valign="bottom" style="width: 5%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 12%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td></tr><tr><td align="left" valign="bottom" style="width: 20%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Convertible preferred stock</div></td><td valign="bottom" style="width: 2%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 11%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td valign="bottom" style="width: 4%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 12%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;30,668</div></td><td valign="bottom" style="width: 2%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 10%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td valign="bottom" style="width: 5%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 12%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;30,668</div></td></tr><tr><td align="left" valign="bottom" style="width: 20%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Common stock grants</div></td><td valign="bottom" style="width: 2%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 11%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;4,918</div></td><td valign="bottom" style="width: 4%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 12%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3,913</div></td><td valign="bottom" style="width: 2%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 10%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;375</div></td><td valign="bottom" style="width: 5%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 12%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3,913</div></td></tr><tr><td valign="bottom" style="width: 20%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 2%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="border-bottom: black 4px double; width: 11%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;10,628</div></td><td valign="bottom" style="width: 4%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="border-bottom: black 4px double; width: 12%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;40,731</div></td><td valign="bottom" style="width: 2%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="border-bottom: black 4px double; width: 10%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2,135</div></td><td valign="bottom" style="width: 5%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="border-bottom: black 4px double; width: 12%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;40,731</div></td></tr><tr><td valign="bottom" style="border-bottom: black 2px solid; width: 20%; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 2%; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 11%; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 4%; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 12%; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 2%; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 10%; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 5%; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 12%; font-family: Times New Roman; font-size: 10pt;">&#160; </td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div></div> <div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">In accordance with Accounting Standards Codification ("ASC") 805, Business Combinations ("ASC 805"), the total purchase consideration is allocated to the net tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of September 2, 2011 (the acquisition date).&#160;&#160;The purchase price was allocated based on the information currently available, and may be adjusted after obtaining more information regarding, among other things, asset valuations, liabilities assumed, and revisions of preliminary estimates.&#160;&#160;The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the acquisition date:</div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic; display: inline; font-size: 10pt;">(in thousands)</font></div><div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 88%; border-top: #4bacc6 0.5pt solid;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Cash and cash equivalents</div></div></td><td align="left" valign="bottom" style="width: 1%; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>442</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 88%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accounts receivable and other current assets</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>283</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 88%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Inventories</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>476</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 88%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Property and equipment</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>32</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 88%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Goodwill</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>3,968</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 88%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accounts payable and other current liabilites</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(1,222</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 4px; width: 88%;"><div><div style="text-align: left; text-indent: 27pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Net assets acquired</div></div></td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>3,979</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="white"><td valign="bottom" style="border-bottom: black 2px solid; width: 88%; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr></table></div></div></div> <div><div style="text-align: left; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The Company's other intangible assets consist of capitalized patent costs, as follows:</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: center; font-style: italic; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(in thousands)</div><div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">June 30, 2012</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">December 31, 2011</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr><td align="left" valign="bottom"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Patent Costs</div></div></td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(unaudited)</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div><div style="text-align: left; text-indent: 27pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Costs</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>469</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>469</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 76%;"><div><div style="text-align: left; text-indent: 27pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accumulated amortization</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(426</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(413</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 4px; width: 76%; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>43</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>56</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="white"><td valign="bottom" style="border-bottom: black 2px solid; width: 76%; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr></table></div></div></div> <div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Diluted earnings per share were computed based on the weighted average number of shares outstanding plus all potentially dilutive common stock equivalents.&#160;&#160;A reconciliation of basic to diluted shares used in the earnings per share calculation is as follows:</div><div style="text-indent: 0pt; display: block;"><br /></div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="width: 40%; font-family: Times New Roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160; </td><td valign="bottom" style="width: 9%; font-family: Times New Roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160; </td><td valign="bottom" style="width: 7%; border-top: #4bacc6 0.5pt solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Six months ended June 30,</div></td><td valign="bottom" style="width: 9%; font-family: Times New Roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160; </td><td valign="bottom" style="width: 3%; font-family: Times New Roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160; </td><td valign="bottom" style="width: 9%; font-family: Times New Roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160; </td><td valign="bottom" style="width: 7%; border-top: #4bacc6 0.5pt solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Three months ended June 30,</div></td><td valign="bottom" style="width: 9%; font-family: Times New Roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160; </td></tr><tr><td valign="bottom" style="width: 40%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 9%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2012</div></td><td valign="bottom" style="border-bottom: black 2px solid; width: 7%; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 9%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2011</div></td><td valign="bottom" style="width: 3%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 9%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2012</div></td><td valign="bottom" style="border-bottom: black 2px solid; width: 7%; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 9%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2011</div></td></tr><tr><td align="left" valign="bottom" style="width: 40%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Basic weighted average shares outstanding</div></td><td align="left" valign="bottom" style="width: 9%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;156,225</div></td><td valign="bottom" style="width: 7%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 9%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;114,077</div></td><td valign="bottom" style="width: 3%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 9%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;158,072</div></td><td valign="bottom" style="width: 7%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 9%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;116,198</div></td></tr><tr><td align="left" valign="bottom" style="width: 40%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Dilutive effect of share-based compensation</div></td><td align="left" valign="bottom" style="width: 9%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td valign="bottom" style="width: 7%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 9%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td valign="bottom" style="width: 3%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 9%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,334</div></td><td valign="bottom" style="width: 7%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 9%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td></tr><tr><td align="left" valign="bottom" style="width: 40%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Contingently issuable shares</div></td><td align="left" valign="bottom" style="width: 9%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td valign="bottom" style="width: 7%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 9%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td valign="bottom" style="width: 3%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 9%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2,400</div></td><td valign="bottom" style="width: 7%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 9%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td></tr><tr><td align="left" valign="bottom" style="width: 40%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Diluted weighted average shares outstanding</div></td><td align="left" valign="bottom" style="border-bottom: black 4px double; width: 9%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;156,225</div></td><td valign="bottom" style="width: 7%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="border-bottom: black 4px double; width: 9%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;114,077</div></td><td valign="bottom" style="width: 3%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="border-bottom: black 4px double; width: 9%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;161,806</div></td><td valign="bottom" style="width: 7%; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="border-bottom: black 4px double; width: 9%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;116,198</div></td></tr><tr><td valign="bottom" style="border-bottom: black 2px solid; width: 40%; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 9%; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 7%; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 9%; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 3%; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 9%; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 7%; font-family: Times New Roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="border-bottom: black 2px solid; width: 9%; font-family: Times New Roman; font-size: 10pt;">&#160; </td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div></div> <div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The Company views its business in two segments - the Equipment segment and the Sales Representation segment.&#160;&#160;The Equipment segment is engaged in designing, manufacturing, marketing and supporting EECP<font style="display: inline; font-size: 70%; vertical-align: text-top;">&#174;</font> enhanced external counterpulsation systems both domestically and internationally, as well as the marketing of other medical devices.&#160;&#160;The Sales Representation segment operates through the VasoHealthcare subsidiary and is currently engaged solely in the execution of the Company's responsibilities under our agreement with GEHC.&#160;&#160;The Company evaluates segment performance based on operating income.&#160;&#160;Administrative functions such as finance, human resources, and information technology are centralized and related expenses allocated to each segment.&#160;&#160;Other costs not directly attributable to operating segments, such as audit, legal, director fees, investor relations, and others, as well as certain assets - primarily cash balances - are reported in the Corporate entity below. There are no intersegment revenues.&#160;&#160;Summary financial information for the segments is set forth below:</div><div style="text-align: right; font-style: italic; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(in thousands)</div><div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div></div></td><td align="left" valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td align="left" colspan="2" valign="bottom" style="border-bottom: black 2px solid; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; border-top: #4bacc6 0.5pt solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">As of or for the three months ended June 30, 2012</div></div></td><td align="left" valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td align="left" colspan="2" valign="bottom" style="border-bottom: black 2px solid; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td></tr><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Equipment Segment</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Sales Representation Segment</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Corporate</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Consolidated</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Revenues from external customers</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>1,555</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>6,142</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>7,697</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Operating income/(loss)</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(197</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>681</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(409</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>75</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Total assets</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>9,323</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>11,558</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>11,174</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>32,055</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accounts and other receivables, net</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>1,151</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>7,833</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>8,984</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred commission expense</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>3,490</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>3,490</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="white"><td valign="bottom" style="border-bottom: black 2px solid; width: 26%; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; width: 26%; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 2px; width: 26%; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; width: 26%;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">As of or for the three months ended June 30, 2011</div></div></td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Equipment Segment</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Sales Representation Segment</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Corporate</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Consolidated</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Revenues from external customers</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>1,100</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>4,075</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>5,175</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Operating loss</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(475</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(386</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(99</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(960</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Total assets</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>4,440</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>6,330</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>7,687</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>18,457</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accounts and other receivables, net</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>749</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>3,552</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>4,301</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred commission expense</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>2,703</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>2,703</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="border-bottom: black 2px solid; width: 26%; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; width: 26%; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr></table></div></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-indent: 0pt; display: block;">(in thousands)</div><div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div></div></td><td align="left" valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td align="left" colspan="2" valign="bottom" style="border-bottom: black 2px solid; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; border-top: #4bacc6 0.5pt solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">As of or for the six months ended June 30, 2012</div></div></td><td align="left" valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td align="left" colspan="2" valign="bottom" style="border-bottom: black 2px solid; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td></tr><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Equipment Segment</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Sales Representation Segment</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Corporate</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Consolidated</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Revenues from external customers</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>3,541</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>10,199</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>13,740</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Operating loss</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(353</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(115</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(758</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(1,226</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Total assets</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>9,323</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>11,558</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>11,174</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>32,055</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accounts and other receivables, net</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>1,151</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>7,833</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>8,984</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred commission expense</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>3,490</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>3,490</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="white"><td valign="bottom" style="border-bottom: black 2px solid; width: 26%; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; width: 26%; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 2px; width: 26%; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; width: 26%;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">As of or for the six months ended June 30, 2011</div></div></td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Equipment Segment</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Sales Representation Segment</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Corporate</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Consolidated</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Revenues from external customers</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>2,205</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>7,815</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>10,020</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Operating loss</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(741</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(418</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(283</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(1,442</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Total assets</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>4,440</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>6,330</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>7,687</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>18,457</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accounts and other receivables, net</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>749</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>3,552</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>4,301</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred commission expense</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>2,703</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>2,703</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="border-bottom: black 2px solid; width: 26%; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; width: 26%; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr></table></div></div></div> <div><div><div style="text-align: left; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The following table presents information regarding the Company's accounts and other receivables as of June 30, 2012 and December 31, 2011:</div><div style="text-align: center; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(in thousands)</div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; border-top: #4bacc6 0.5pt solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">June 30, 2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; border-top: #4bacc6 0.5pt solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">December 31, 2011</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Trade receivables</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">10,804</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">22,737</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Due from employees</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">145</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">121</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Allowance for doubtful accounts and</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 27pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">commission adjustments</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,965</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(2,163</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 4px; width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accounts and other receivables, net</div></td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,984</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">20,695</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="width: 76%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div></div></div> <div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE C - SEGMENT REPORTING AND CONCENTRATIONS</div><div style="text-indent: 0pt; display: block;"><br /></div><div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The Company views its business in two segments - the Equipment segment and the Sales Representation segment.&#160;&#160;The Equipment segment is engaged in designing, manufacturing, marketing and supporting EECP<font style="display: inline; font-size: 70%; vertical-align: text-top;">&#174;</font> enhanced external counterpulsation systems both domestically and internationally, as well as the marketing of other medical devices.&#160;&#160;The Sales Representation segment operates through the VasoHealthcare subsidiary and is currently engaged solely in the execution of the Company's responsibilities under our agreement with GEHC.&#160;&#160;The Company evaluates segment performance based on operating income.&#160;&#160;Administrative functions such as finance, human resources, and information technology are centralized and related expenses allocated to each segment.&#160;&#160;Other costs not directly attributable to operating segments, such as audit, legal, director fees, investor relations, and others, as well as certain assets - primarily cash balances - are reported in the Corporate entity below. There are no intersegment revenues.&#160;&#160;Summary financial information for the segments is set forth below:</div><div style="text-align: right; font-style: italic; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(in thousands)</div><div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div></div></td><td align="left" valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td align="left" colspan="2" valign="bottom" style="border-bottom: black 2px solid; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; border-top: #4bacc6 0.5pt solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">As of or for the three months ended June 30, 2012</div></div></td><td align="left" valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td align="left" colspan="2" valign="bottom" style="border-bottom: black 2px solid; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td></tr><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Equipment Segment</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Sales Representation Segment</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Corporate</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Consolidated</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Revenues from external customers</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>1,555</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>6,142</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>7,697</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Operating income/(loss)</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(197</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>681</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(409</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>75</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Total assets</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>9,323</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>11,558</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>11,174</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>32,055</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accounts and other receivables, net</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>1,151</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>7,833</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>8,984</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred commission expense</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>3,490</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>3,490</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="white"><td valign="bottom" style="border-bottom: black 2px solid; width: 26%; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; width: 26%; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 2px; width: 26%; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; width: 26%;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">As of or for the three months ended June 30, 2011</div></div></td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Equipment Segment</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Sales Representation Segment</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Corporate</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Consolidated</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Revenues from external customers</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>1,100</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>4,075</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>5,175</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Operating loss</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(475</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(386</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(99</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(960</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Total assets</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>4,440</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>6,330</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>7,687</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>18,457</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accounts and other receivables, net</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>749</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>3,552</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>4,301</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred commission expense</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>2,703</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>2,703</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="border-bottom: black 2px solid; width: 26%; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; width: 26%; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr></table></div></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-indent: 0pt; display: block;">(in thousands)</div><div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div></div></td><td align="left" valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td align="left" colspan="2" valign="bottom" style="border-bottom: black 2px solid; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; border-top: #4bacc6 0.5pt solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">As of or for the six months ended June 30, 2012</div></div></td><td align="left" valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td align="left" colspan="2" valign="bottom" style="border-bottom: black 2px solid; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;"><div>&#160;</div></td></tr><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Equipment Segment</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Sales Representation Segment</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Corporate</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Consolidated</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Revenues from external customers</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>3,541</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>10,199</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>13,740</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Operating loss</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(353</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(115</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(758</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(1,226</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Total assets</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>9,323</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>11,558</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>11,174</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>32,055</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accounts and other receivables, net</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>1,151</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>7,833</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>8,984</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred commission expense</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>3,490</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>3,490</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="white"><td valign="bottom" style="border-bottom: black 2px solid; width: 26%; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; width: 26%; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 2px; width: 26%; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; width: 26%;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">As of or for the six months ended June 30, 2011</div></div></td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Equipment Segment</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Sales Representation Segment</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Corporate</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Consolidated</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Revenues from external customers</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>2,205</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>7,815</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>10,020</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Operating loss</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(741</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(418</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(283</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>(1,442</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Total assets</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>4,440</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>6,330</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>7,687</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>18,457</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accounts and other receivables, net</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>749</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>3,552</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>4,301</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 26%;"><div><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred commission expense</div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>2,703</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="width: 26%; display: inline; font-family: times new roman; font-size: 10pt;"><div></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>$</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>2,703</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="border-bottom: black 2px solid; width: 26%; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; width: 26%; font-family: times new roman; font-size: 10pt;"><div></div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"><div>&#160;</div></td></tr></table></div></div></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">For the three months ended June 30, 2012 and 2011, GE Healthcare accounted for 80% and 79% of revenue, respectively.&#160;&#160;For the six months ended June 30, 2012 and 2011, GE Healthcare accounted for 74% and 78% of revenue, respectively.&#160;&#160;&#160;Also, GE Healthcare accounted for $7.7 million, or 86%, and $19.7 million, or 95%, of accounts and other receivables at June 30, 2012 and December 31, 2011, respectively.</div><div style="text-indent: 0pt; display: block;"><br /></div></div> 10665000 7944000 5335000 4314000 231000 203000 102000 231000 77000 203000 755000 P1Y P1Y 500000 166279 366279 2190000 10000 250000 0 0.5 0.16 500000 2190000 500000 5000000 5000000 1500000 9375 0 5Y 2Y 110000 110000 3000000 600000 120000 73500 135500 548000 6800 1020000 10624000 11276000 <div><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE M - STOCKHOLDERS' EQUITY</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Common Stock</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">On June 17, 2010 the Board of Directors approved the 2010 Stock Plan (the "2010 Plan") for officers, directors, employees and consultants of the Company.&#160;&#160;The stock issuable under the 2010 Plan shall be shares of the Company's authorized but unissued or reacquired common stock.&#160;&#160;The maximum number of shares of common stock which may be issued under the 2010 Plan is 5,000,000 shares.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The 2010 Plan is comprised of two separate equity programs, the Options Grant Program, under which eligible persons may be granted options to purchase shares of common stock, and the Stock Issuance Program, under which eligible persons may be issued shares of common stock directly, either through the immediate purchase of such shares or as compensation for services rendered to the Company.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The 2010 Plan provides that the Board of Directors, or a committee of the Board of Directors, will administer it with full authority to determine the identity of the recipients of the options or shares and the number of options or shares.&#160;&#160;Options granted under the 2010 Plan may be either incentive stock options or non-qualified stock options.&#160;&#160;The option price shall be 100% of the fair market value of the common stock on the date of the grant ( or in the case of incentive stock options granted to any individual stockholder possessing more than 10% of the total combined voting power of all voting stock of the Company, 110% of such fair market value).&#160;&#160;The term of any option may be fixed by the Board of Directors, or its authorized committee, but in no event shall it exceed five years from the date of grant.&#160;&#160;Options are exercisable upon payment in full of the exercise price, either in cash or in common stock valued at fair market value on the date of exercise of the option.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">As of June 30, 2012, 3,790,000 restricted shares of common stock were granted under the 2010 Plan to non-officer employees and consultants of the Company.&#160;&#160;As of June 30, 2012, 755,000 shares have been forfeited.&#160;&#160;In March 2012, 500,000 restricted shares of common stock were granted under the 2010 Plan to an officer, of which 250,000 vested immediately with the remainder vesting over a one year period.&#160;&#160;In June 2012, 2,190,000 additional shares of restricted common stock were granted to non-officer employees in conjunction with the extension of the GEHC Agreement, vesting at various times through July 1, 2013.&#160;&#160;In July 2012, 500,000 shares of restricted common stock were granted to non-officer employees, of which 250,000 vest within one year and the remainder one year thereafter.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">No options were issued under the 2010 Plan during the six months ended June 30, 2012 and 2011.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">In September 2011, the Company issued 5,000,000 shares of restricted common stock and a two year common stock purchase warrant for 1,500,000 shares at an exercise price of $0.50 per share as partial consideration for the acquisition of FGE.&#160;&#160;In addition, up to 2,400,000 shares of common stock are contingently issuable should FGE attain certain operating targets for the twelve months ending December 31, 2011.&#160;&#160;The Company is completing its evaluation of FGE's calendar year 2011 results and believes it is likely that the targets have been met and the shares will be issued.&#160;&#160;The aggregate value of the aforementioned noncash consideration relative to the FGE acquisition was $2,979,000.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Preferred Stock</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">On June 24, 2010, the Company filed a Certificate of Designations of Preferences and Rights of Series E Convertible Preferred Stock ("Certificate of Designations"), as authorized by the Board of Directors, designating 350,000 shares of its 1,000,000 shares of preferred stock as Series E Convertible Preferred Stock ("Series E Preferred"). The conversion rights of the Series E Preferred are that each share will be convertible at any time on or after January 1, 2011, at the holder's option into 100 shares of common stock (an exercise price of $.16 per share of common stock, the "Conversion Price"), subject to anti-dilution adjustment as set forth below.&#160;&#160;Each share of outstanding Series E Preferred Stock shall automatically be converted into shares of common stock on or after July 1, 2011, at the then effective applicable conversion ratio, if, at any time following the Issuance Date, the price of the common stock for any 30 consecutive trading days equals or exceeds three times the Conversion Price and the average daily trading volume for the Company's common stock for the 30 consecutive trading days exceeds 250,000 shares.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Pursuant to its conversion terms, the Series E Preferred was deemed automatically converted to common stock effective July 1, 2011.&#160;&#160;As of June 30, 2012, 30,668,500 shares of common stock had been issued for 306,685 shares of Series E Preferred.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">For the three and six months ended June 30, 2011, the Company sold 0 and 9,375 shares of Series E Preferred aggregating $150,000, and recorded dividends totaling $151,000 and $279,000, respectively.&#160;&#160;Included in such dividends is the recognition of the value of the embedded beneficial conversion feature of the Series E Preferred, which reflects the difference between the conversion price and the market price at time of investment. The amounts included in the dividends reported attributable to this beneficial conversion feature are $91,000 and $156,000 for the three and six months ended June 30, 2011, respectively.&#160;&#160;These are noncash dividends requiring no payment and ceased on conversion of the Series E Preferred to common stock.</div><div style="text-indent: 0pt; display: block;"><br /></div></div> 89000 278000 156225000 114077000 158072000 116198000 156225000 114077000 158072000 116198000 156225000 114077000 161806000 116198000 3 2 0 1070000 0 101000 20000 63000 -288000 -208000 2456000 2049000 1493000 1119000 10199000 7815000 6142000 4075000 4000 31000 0 85000 339000 510000 P5Y -0.01 -0.01 0.00 -0.01 P5Y 4285714 P2Y 0.1 0.82 2 0.1 1.1 Each share of outstanding Series E Preferred Stock shall automatically be converted into shares of common stock on or after July 1, 2011, at the then effective applicable conversion ratio, if, at any time following the Issuance Date, the price of the common stock for any 30 consecutive trading days equals or exceeds three times the Conversion Price and the average daily trading volume for the Company's common stock for the 30 consecutive trading days exceeds 250,000 shares. 91000 156000 P3Y 2200000 2200000 3790000 P12M EX-101.SCH 6 vaso-20120630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 010000 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) link:presentationLink link:calculationLink link:definitionLink 010100 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 020000 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (unaudited) link:presentationLink link:calculationLink link:definitionLink 030000 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (unaudited) link:presentationLink link:calculationLink link:definitionLink 060100 - Disclosure - ORGANIZATION AND PLAN OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 060200 - Disclosure - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 060300 - Disclosure - SEGMENT REPORTING AND CONCENTRATIONS link:presentationLink link:calculationLink link:definitionLink 060400 - Disclosure - SHARE-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 060500 - Disclosure - EARNINGS (LOSS) PER COMMON SHARE link:presentationLink link:calculationLink link:definitionLink 060600 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 060700 - Disclosure - ACCOUNTS AND OTHER RECEIVABLES, NET link:presentationLink link:calculationLink link:definitionLink 060800 - Disclosure - INVENTORIES, NET link:presentationLink link:calculationLink link:definitionLink 060900 - Disclosure - BUSINESS COMBINATION link:presentationLink link:calculationLink link:definitionLink 061000 - Disclosure - GOODWILL AND OTHER INTANGIBLES link:presentationLink link:calculationLink link:definitionLink 061100 - Disclosure - DEFERRED REVENUE link:presentationLink link:calculationLink link:definitionLink 061200 - Disclosure - RELATED-PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 061300 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 061400 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 061500 - Disclosure - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS link:presentationLink link:calculationLink link:definitionLink 080300 - Disclosure - SEGMENT REPORTING AND CONCENTRATIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 080500 - Disclosure - EARNINGS (LOSS) PER COMMON SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 080600 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 080700 - Disclosure - ACCOUNTS AND OTHER RECEIVABLES, NET (Tables) link:presentationLink link:calculationLink link:definitionLink 080800 - Disclosure - INVENTORIES, NET (Tables) link:presentationLink link:calculationLink link:definitionLink 080900 - Disclosure - BUSINESS COMBINATION (Tables) link:presentationLink link:calculationLink link:definitionLink 081000 - Disclosure - GOODWILL AND OTHER INTANGIBLES (Tables) link:presentationLink link:calculationLink link:definitionLink 081100 - Disclosure - DEFERRED REVENUE (Tables) link:presentationLink link:calculationLink link:definitionLink 090100 - Disclosure - ORGANIZATION AND PLAN OF OPERATIONS (Details) link:presentationLink link:calculationLink link:definitionLink 090300 - Disclosure - SEGMENT REPORTING AND CONCENTRATIONS (Details) link:presentationLink link:calculationLink link:definitionLink 090400 - Disclosure - SHARE-BASED COMPENSATION (Details) link:presentationLink link:calculationLink link:definitionLink 090500 - Disclosure - EARNINGS (LOSS) PER COMMON SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 090600 - Disclosure - FAIR VALUE MEASUREMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 090700 - Disclosure - ACCOUNTS AND OTHER RECEIVABLES, NET (Details) link:presentationLink link:calculationLink link:definitionLink 090800 - Disclosure - INVENTORIES, NET (Details) link:presentationLink link:calculationLink link:definitionLink 090900 - Disclosure - BUSINESS COMBINATION (Details) link:presentationLink link:calculationLink link:definitionLink 091000 - Disclosure - GOODWILL AND OTHER INTANGIBLES (Details) link:presentationLink link:calculationLink link:definitionLink 091100 - Disclosure - DEFERRED REVENUE (Details) link:presentationLink link:calculationLink link:definitionLink 091200 - Disclosure - RELATED-PARTY TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 091300 - Disclosure - STOCKHOLDERS' EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 091400 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 vaso-20120630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 vaso-20120630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 vaso-20120630_lab.xml XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT Amendment Flag Current Fiscal Year End Date Document Period End Date Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Filer Category Entity Registrant Name Entity Central Index Key Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Document Type Award Type [Axis] BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES [Abstract] Accounts and other receivables Accounts and other receivables, net of an allowance for doubtful accounts and commission adjustments of $1,965 at June 30, 2012 and $2,163 at December 31, 2011 Accounts and other receivables, net Accounts and other receivables Trade receivables Accounts Receivable, Net, Current Accounts payable Accounts Payable, Current Receivables due from related parties Accounts Receivable, Related Parties Accounts and Other Receivables [Member] Accrued commissions Accrued Sales Commission, Current Accrued expenses and other liabilities Accrued Liabilities, Current PROPERTY AND EQUIPMENT, accumulated depreciation Accumulated other comprehensive income (loss) Additional paid-in capital Adjustments to reconcile net loss to net cash provided by operating activities Allocated share-based arrangements Allowance for doubtful accounts and commission adjustments Accounts and other receivables, allowance for doubtful accounts and commission adjustments Amortization expense Antidilutive securities excluded from computation of diluted earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities, Name [Domain] Antidilutive Securities [Axis] Assets Assets, Fair Value Disclosure CURRENT ASSETS ASSETS Total current assets Assets, Current Total Assets Total assets BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES Basis of Presentation and Significant Accounting Policies [Text Block] Accounts payable and other current liabilities Business Acquisition, Purchase Price Allocation, Current Liabilities, Accounts Payable Common stock contingently issuable Business Acquisition, Contingent Consideration, Shares Issuable Business Acquisition [Axis] Cash Supplemental pro forma information [Abstract] Goodwill Fair values of assets acquired and liabilities assumed [Abstract] Revenue Business Acquisition, Pro Forma Revenue Business Acquisition, Acquiree [Domain] Acquisition date fair value of total consideration transferred [Abstract] Supplemental pro forma information Net assets acquired Business Acquisition, Purchase Price Allocation, Assets Acquired (Liabilities Assumed), Net Cash and cash equivalents Business Acquisition, Purchase Price Allocation, Current Assets, Cash and Cash Equivalents Net Income Share price (in dollars per share) Business Acquisition, Share Price Number of shares of common stock issued relating to acquisition (in shares) Number of shares of common stock contingently issuable (in shares) BUSINESS COMBINATION [Abstract] Inventories Business Acquisition, Purchase Price Allocation, Current Assets, Inventory Aggregate value relative to the acquisition Business Acquisition, Equity Interest Issued or Issuable, Value Assigned Equity interests issued and issuable Accounts receivable and other current assets Business Acquisition [Line Items] Total purchase price Business Acquisition, Cost of Acquired Entity, Purchase Price Unsecured notes payable assumed Business Acquisition, Purchase Price Allocation, Notes Payable and Long-term Debt Property and equipment Business Acquisition, Purchase Price Allocation, Property, Plant and Equipment BUSINESS COMBINATION Business Combination Disclosure [Text Block] Cash and cash equivalents Cash and cash equivalents - beginning of period Cash and cash equivalents - end of period NET INCREASE IN CASH AND CASH EQUIVALENTS Cash and Cash Equivalents, Period Increase (Decrease) Cash equivalents invested in money market funds (included in cash and cash equivalents) Class of Stock [Line Items] Exercise price of warrants (in dollars per share) Class of Stock [Domain] Number of shares of common stock called by warrants (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] COMMITMENTS AND CONTINGENCIES [Abstract] COMMITMENTS AND CONTINGENCIES (NOTE N) Common Stock [Member] Common Stock Grants [Member] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Common stock, $.001 par value; 250,000,000 shares authorized; 158,746,910 and 153,186,295 shares issued and outstanding at June 30, 2012 and December 31, 2011 Common Stock, Value, Issued Common stock, shares issued (in shares) Common stock issued upon conversion of Series E preferred shares (in shares) Common stock, par value (in dollars per share) Common stock, shares authorized (in shares) Comprehensive (loss) income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Concentration Risk Type [Domain] Concentration Risk [Line Items] Concentration Risk Benchmark [Domain] Concentration Risk [Table] Concentration Risk Benchmark [Axis] Concentration Risk Type [Axis] Percentage of accounts and other receivables (in hundredths) Contingent Issuance of Common Stock [Member] Contingently Issuable Shares [Member] Shares issued (in shares) Convertible Preferred Stock [Member] Shares Issued upon conversion (in shares) Convertible Preferred Stock, Shares Issued upon Conversion Corporate [Member] Cost of sales, equipment Total cost of revenues Cost of Goods and Services Sold Cost of equipment rentals and services Cost of revenues Customer Concentration Risk [Member] Interest rate (in hundredths) Debt Instrument, Interest Rate, Stated Percentage Title of Individual [Axis] Deferred commission expense Deferred Costs, Current DEFERRED REVENUE [Abstract] Deferred revenue at the beginning of the period Deferred revenue at end of period Deferred Revenue Changes in deferred revenues DEFERRED REVENUE Deferred Revenue Disclosure [Text Block] Deferred Revenue Arrangement, by Type [Table] Additions: Deferred Revenue Arrangement Type [Domain] Deferred Revenue Arrangement [Line Items] Deferred revenue Long-term deferred revenue at end of period Deferred Revenue, Noncurrent Deferred Revenue Arrangement Type [Axis] Deferred revenue - current portion Less: current portion Recognized as revenue: Deferred tax liability, net Deferred Tax Liabilities, Net, Current Depreciation and amortization of property and equipment Depreciation, Depletion and Amortization RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS Description of New Accounting Pronouncements Not yet Adopted [Text Block] Director - David Lieberman [Member] Director [Member] SHARE-BASED COMPENSATION Disclosure of Compensation Related Costs, Share-based Payments [Text Block] SHARE-BASED COMPENSATION [Abstract] Dividends Payable [Table] Accrued preferred stock dividends Dividends Payable Dividends Payable [Line Items] Dividends recorded Due from employees Weighted average common shares outstanding - basic and diluted (in dollars per share) Basic and diluted loss per common share (in dollars per share) EARNINGS (LOSS) PER COMMON SHARE (Loss) earnings per common share EARNINGS (LOSS) PER COMMON SHARE [Abstract] Effect of exchange rate differences on cash Effect of Exchange Rate on Cash and Cash Equivalents Unrecognized expense related to existing share-based arrangements Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized Percentage of revenue (in hundredths) Entity-Wide Revenue, Major Customer, Percentage Revenue, Major Customer [Line Items] STOCKHOLDERS' EQUITY [Abstract] Equity Interest Type [Axis] Equity Component [Domain] Equity Interest Issued or Issuable, Type [Domain] Fair Value, Hierarchy [Axis] Fair Value Measurements, Recurring and Nonrecurring [Table] Assets and liabilities measured at fair value Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] FAIR VALUE MEASUREMENTS [Abstract] FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Fair Value, Inputs, Level 3 [Member] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Finite-Lived Intangible Assets, Major Class Name [Domain] Costs Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets by Major Class [Axis] Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Intangible assets, net Finite-Lived Intangible Assets, Net GOODWILL Goodwill GOODWILL AND OTHER INTANGIBLES Goodwill and Intangible Assets Disclosure [Text Block] GOODWILL AND OTHER INTANGIBLES [Abstract] Gross profit Gross Profit (Loss) income before income taxes Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (unaudited) [Abstract] Income tax expense Income Tax Expense (Benefit) Income taxes paid Deferred commission expense Increase (Decrease) in Deferred Charges Income taxes payable Accrued expenses and other liabilities Trade payable due to related party Receivables due from related parties Receivables collected from FGE Increase (Decrease) in Due from Related Parties, Current Other current assets Increase (Decrease) in Other Current Assets Accounts payable Other long-term liabilities Deferred revenue Accounts and other receivables Increase (Decrease) in Accounts and Other Receivables Other assets Increase (Decrease) in Other Noncurrent Assets Changes in operating assets and liabilities: Inventories, net Increase (Decrease) in Inventories Finance receivables Increase (Decrease) in Finance Receivables Sales tax payable Accrued commissions Dilutive effect of share-based compensation (in shares) Contingently issuable shares (in shares) Interest and financing costs Interest and Debt Expense Interest and other income, net Interest paid Reserves for excess and obsolete inventory Finished goods Inventory, Finished Goods, Net of Reserves Raw materials INVENTORIES, NET Inventory Disclosure [Text Block] Inventories, net Inventories, net Inventory, Net INVENTORIES, NET [Abstract] Work in process Investment in certificates of deposit (included in short-term investments) Fees for legal services Total current liabilities Liabilities, Current Total long-term liabilities Liabilities, Noncurrent CURRENT LIABILITIES LONG-TERM LIABILITIES LIABILITIES AND STOCKHOLDERS' EQUITY Total liabilities and stockholders' equity Liabilities and Equity ACCOUNTS AND OTHER RECEIVABLES, NET Loans, Notes, Trade and Other Receivables Disclosure [Text Block] Major Customers [Axis] Movements in deferred revenue [Roll Forward] Name of Major Customer [Domain] ORGANIZATION AND PLAN OF OPERATIONS Nature of Operations [Text Block] Cash flows from financing activities Net (loss) income applicable to common stockholders Net Income (Loss) Available to Common Stockholders, Basic Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Cash flows from investing activities Cash flows from operating activities Net loss Net loss Net (loss) income Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS [Abstract] SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES Total other income (expenses), net Nonoperating Income (Expense) Other income (expenses) FINANCING RECEIVABLES, net Financing receivables, net Notes payable due to related party Number of contiguous states in which VasoHealthcare has been appointed exclusive representative for GE Healthcare Diagnostic Imaging products Number of segments Officer [Member] Operating expenses Total operating expenses Operating Expenses Operating (loss) income Operating income/(loss) ORGANIZATION AND PLAN OF OPERATIONS [Abstract] Other current assets Other Assets, Current Amortization of deferred distributor costs Other Amortization of Deferred Charges OTHER ASSETS Foreign currency translation (loss) gain Other comprehensive (loss) income Deferred commission expense Other long-term liabilities Other Liabilities, Noncurrent Patent Costs [Member] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Purchases of short-term investments Payments to Acquire Short-term Investments Plan Name [Domain] Plan Name [Axis] Preferred stock, $.01 par value; 1,000,000 shares authorized; nil shares issued and outstanding at June 30, 2012, and December 31, 2011 Preferred Stock, Value, Issued Preferred stock, shares authorized (in shares) Preferred stock authorized (in shares) Preferred stock, shares issued (in shares) Preferred stock, par value (in dollars per share) Preferred stock dividends Preferred Stock Dividends, Income Statement Impact Preferred stock, shares outstanding (in shares) Preferred Stock [Member] Proceeds from exercise of warrant Proceeds from issuance of preferred stock Consulting services Professional Fees PROPERTY AND EQUIPMENT, net of accumulated depreciation of $1,540 at June 30, 2012 and $1,774 at December 31, 2011 Property, Plant and Equipment, Net Provision for doubtful accounts and commission adjustments Provision for Doubtful Accounts ACCOUNTS AND OTHER RECEIVABLES, NET [Abstract] RELATED-PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] Related Party Transaction [Line Items] Related Party [Domain] RELATED-PARTY TRANSACTIONS [Abstract] Related Party [Axis] Repayment of notes payable due to related party Debt repaid Repayments of Related Party Debt Repayment of note payable Repayments of Notes Payable Research and development Restricted Stock [Member] Accumulated deficit Revenues from external customers Option price as a percentage of fair market value (in hundredths) Aggregate value of shares sold Sale of Stock, Consideration Received Per Transaction Amortization of deferred gain on sale-leaseback of building Amortization of deferred gain on sale-leaseback of building Equipment sales Revenue Total revenues Revenues Revenue, Net [Abstract] Sales tax payable Sales and Excise Tax Payable, Current Equipment rentals and services Acquisition date fair value of total consideration transferred Inventories, net of reserves Antidilutive common stock equivalents excluded from computation of diluted earnings per share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Finite-Lived Intangible Assets [Table] Fair values of assets acquired and liabilities assumed Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Other intangible assets Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block] Schedule of Revenue by Major Customers, by Reporting Segments [Table] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Related Party Transactions, by Related Party [Table] Summary financial information for segments Schedule of Stock by Class [Table] Accounts and other receivables Segment Reporting Information [Line Items] SEGMENT REPORTING AND CONCENTRATIONS [Abstract] SEGMENT REPORTING AND CONCENTRATIONS Segment Reporting Disclosure [Text Block] Segment [Domain] Selling, general and administrative Series E Convertible Preferred Stock [Member] Series E Preferred Stock [Member] Share-based compensation Share-based compensation expense Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Remainder of vesting period Vesting Period Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Share Price (dollar per share) Share Price Granted during period (in shares) Number of shares authorized (in shares) Issued (in shares) Shares sold (in shares) Terms of award (in years) Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award Award Type [Domain] Short-term investments CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (unaudited) [Abstract] Business Segments [Axis] Equity Components [Axis] CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) [Abstract] Class of Stock [Axis] Restricted shares issued for consulting agreement (in shares) Value of stock granted Stock Compensation Plan [Member] Stock Options [Member] Restricted shares issued for consulting agreement Stock issued STOCKHOLDERS' EQUITY Total stockholders' equity Stockholders' Equity Attributable to Parent STOCKHOLDERS' EQUITY Stockholders' Equity Note Disclosure [Text Block] Fast Growth Enterprises Limited (FGE) [Member] Subsidiary of Common Parent [Member] SUPPLEMENTAL DISCLOSURE OF CASH INFORMATION Income taxes payable Taxes Payable, Current Title of Individual with Relationship to Entity [Domain] Warrant [Member] Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Basic weighted average shares outstanding (in shares) Weighted Average Number of Shares Issued, Basic - basic (in shares) Weighted Average Number of Shares Outstanding, Basic - diluted (in shares) Diluted weighted average shares outstanding (in shares) The number of wholly-owned subsidiaries owned by the entity Number of wholly-owned subsidiaries The number of companies acquired through business combination. Number of Chinese operating companies acquired Number of Chinese operating companies acquired Value of common stock issued for consulting services. Common Stock Issued for Consulting Agreements Common shares issued for consulting agreements Proceeds from issuance of preferred stock in satisfaction of accrued dividend. Issuance of preferred stock in satisfaction of accrued dividend The value of inventories transferred to property and equipment, attributable to operating leases in noncash financing and investing activities. Inventories transferred to property and equipment, attributable to operating leases, net Inventories transferred to property and equipment, attributable to operating leases, net The increase (decrease) during the reporting period in deferred costs capitalized as a result of related party transactions where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Increase Decrease Deferred Charges Related Party Amortization of deferred consulting expense Total costs related to commissions earned under the sales representative agreement with GE Healthcare. Cost Of Commissions Revenue Cost of commissions Aggregate revenue during the period from commissions earned from the sales representative agreement with GE Healthcare. Commissions Revenue Net Commissions The amount of the gain recorded in connection with the transaction involving the sale of property to another party and the lease of the property back to the seller to be recognized within one year or the normal operating cycle, if longer. Sale Leaseback Transaction Deferred Gain Gross Current Deferred gain on sale-leaseback of building - current portion The amount of deferred costs capitalized as a result of related party transactions where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date, which are expected to be recognized as a charge against earnings in periods after one year or beyond the normal operating cycle, if longer. Deferred Charges Related Party Noncurrent DEFERRED RELATED PARTY CONSULTING EXPENSE The amount of deferred costs capitalized as a result of related party transactions where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date, which will be charged against earnings within one year or the normal operating cycle, if longer. Deferred Charges Related Party Current Deferred related party consulting expense - current portion Document and Entity Information [Abstract] The amended terms of the Sales Representation Agreement. Term of Amended Sales Representation Agreement Amended term of sales representation agreement Component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. Equipment Segment [Member] Component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. Sales Representation Segment [Member] GE Healthcare is the entity's largest customer. GE Healthcare [Member] The acquisition of a privately-held Fast Growth Enterprises Limited ("FGE"), a British Virgin Islands company that owns subsidiaries which own and control Life Enhancement Technology Ltd ("LET") and Biox Instruments Co. Ltd. ("Biox"), respectively, as per the stock purchase agreement signed on August 19, 2011. Fast Growth Enterprises Limited (FGE) [Member] The pro forma basic and diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period. Business Acquisition, Pro Forma Earnings Per Share, Basic and Diluted Basic and diluted loss per share (in dollars per share) A type of deferred revenue by arrangement relating to extended service contracts. Extended Service Contracts [Member] A type of deferred revenue by arrangement relating to in-service and training. In-Service and Training [Member] A type of deferred revenue by arrangement relating to service arrangements. Service Arrangements [Member] A type of deferred revenue by arrangement relating to commission revenues. Commission Revenues [Member] David Lieberman who serves on the board of directors (who collectively have responsibility for governing the entity). Director David Lieberman [Member] Director - Edgar Rios [Member] The engagement of consultant to assist the Company. Consultant [Member] Consultant Managed by Director - Edgar Rios [Member] Refers to the president of an entity under the control of the same parent as another entity (that is, a sister company) and his/her spouse. President of Subsidiary of Common Parent and Spouse [Member] President of LET and His Spouse [Member] A period over which the holder of the warrant has the right to buy more shares of the same security at a certain price. Warrant, Term Term of warrant Number of shares issued on exercise of warrants. Shares issued on exercise of warrant Stock issued (in shares) Represents the term of an agreement the Company entered into. Term of agreement Term of agreement The percentage of the Company's outstanding capital stock, which the Company agreed to issue to the consultant or its designees. Outstanding Capital Stock Issuable to Consultant, Percentage Percentage of outstanding capital stock issuable to Consultant (in hundredths) The threshold percentage of the performance based stock to be issued to consultants as consideration. Performance based stock issuable, threshold, percentage Percentage of performance based stock threshold (in hundredths) The 2010 Plan was approved by the Board of Directors for officers, directors, employees and consultants of the Company. Plan 2010 [Member] 2010 Plan [Member] The number of equity programs in an equity-based payment arrangement. Number of equity programs Purchase price of common stock expressed as a percentage of its fair market value. Sharebased Compensation Arrangement by Sharebased Payment Award, Purchase Price of Common Stock, Threshold, Percent Threshold for paying more than 100 percent of fair value (in hundredths) Purchase price of common stock expressed as a percentage of its fair market value. Sharebased Compensation Arrangement by Sharebased Payment Award, Purchase Price of Common Stock For Ten Percent Shareholder, Percent Option price for ten percent shareholders as a percentage of fair market value (in hundredths) Description of the conversion terms of a debt instrument, including preferred stock, which may include the conversion ratio (including all potential conversion ratios if contingently adjustable), type of debt or equity security into which the debt is convertible, the dollars of debt or the number of shares into which the instrument is convertible (or potentially convertible into), the conversion period, any contingencies associated with the conversion terms, and the existence and amount of a beneficial conversion feature. Preferred Stock, Terms of Conversion Feature Terms of conversion Non-cash dividends declared and paid in preferred stock. Preferred Stock, Paid in Kind Dividends Beneficial conversion feature Sales Representation Agreement [Abstract] Sales Representation Agreement [Abstract] Initial term of Sales Representation Agreement. Initial Term of Sales Representation Agreement Initial term of sales representation agreement (in years) The maximum number of share issuable under the extended share-based employee incentive plan. Maximum Shares Issuable Under Extended Employee Incentive Maximum shares of issuable under extended performance incentive program (in shares) The maximum cash payout under the extended employee performance incentive plan. Maximum Cash Payout Extended Employee Performance Incentive Plan Maximum cash payment under extended performance incentive plan The number of grants made over the life of the plan on other than stock (or unit) options plans. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Granted to Date Granted to date An employee of the entity who is neither and officer or a member of the board of directors. Non-officer Employee [Member] Number of months for FGE to attain certain operating targets Number of months for FGE to attain certain operating targets Number of months for FGE to attain certain operating targets EX-101.PRE 10 vaso-20120630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R39.htm IDEA: XBRL DOCUMENT v2.4.0.6
RELATED-PARTY TRANSACTIONS (Details) (USD $)
 3 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended 3 Months Ended
Jun. 30, 2012
Mar. 31, 2012
Mar. 31, 2011
Jun. 30, 2012
Jun. 30, 2011
Jun. 30, 2012
Director - David Lieberman [Member]
Mar. 31, 2011
Director - David Lieberman [Member]
Jun. 30, 2012
Director - David Lieberman [Member]
Jun. 30, 2011
Director - Edgar Rios [Member]
Mar. 31, 2011
Consultant Managed by Director - Edgar Rios [Member]
Jun. 30, 2012
Consultant Managed by Director - Edgar Rios [Member]
Mar. 31, 2012
Fast Growth Enterprises Limited (FGE) [Member]
Dec. 31, 2011
Fast Growth Enterprises Limited (FGE) [Member]
Sep. 02, 2011
Fast Growth Enterprises Limited (FGE) [Member]
Related Party Transaction [Line Items]                            
Term of warrant     5 years                      
Number of shares of common stock called by warrants (in shares)     4,285,714                      
Exercise price of warrants (in dollars per share)     $ 0.08                      
Stock issued (in shares)   4,285,714                        
Fees for legal services           $ 82,000   $ 149,000            
Term of agreement                 2 years          
Percentage of outstanding capital stock issuable to Consultant (in hundredths)                   10.00%        
Percentage of performance based stock threshold (in hundredths)                   82.00%        
Restricted shares issued for consulting agreement (in shares)             600,000     3,000,000        
Restricted shares issued for consulting agreement                   1,020,000        
Consulting services                     10,000      
Unsecured notes payable assumed                           288,000
Debt repaid       190,000 0             190,000 95,000  
Interest rate (in hundredths)                       6.00%    
Receivables collected from FGE $ 159,000     $ (186,000) $ 0                  
XML 12 R33.htm IDEA: XBRL DOCUMENT v2.4.0.6
FAIR VALUE MEASUREMENTS (Details) (USD $)
In Thousands, unless otherwise specified
Jun. 30, 2012
Dec. 31, 2011
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents invested in money market funds (included in cash and cash equivalents) $ 9,834 $ 1,313
Investment in certificates of deposit (included in short-term investments) 110 110
Assets 9,944 1,423
Fair Value, Inputs, Level 1 [Member]
    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents invested in money market funds (included in cash and cash equivalents) 9,834 1,313
Investment in certificates of deposit (included in short-term investments) 110 110
Assets 9,944 1,423
Fair Value, Inputs, Level 2 [Member]
    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents invested in money market funds (included in cash and cash equivalents) 0 0
Assets 0 0
Fair Value, Inputs, Level 3 [Member]
    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents invested in money market funds (included in cash and cash equivalents) 0 0
Assets $ 0 $ 0
XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 R25.htm IDEA: XBRL DOCUMENT v2.4.0.6
INVENTORIES, NET (Tables)
 6 Months Ended
Jun. 30, 2012
INVENTORIES, NET [Abstract]  
Inventories, net of reserves
Inventories, net of reserves, consist of the following:
                                                                                                                                                                          (in thousands)
   
June 30, 2012
  
December 31, 2011
 
   
(unaudited)
    
Raw materials
 $938  $842 
Work in process
  575   528 
Finished goods
  772   1,051 
   $2,285  $2,421 
          
XML 15 R37.htm IDEA: XBRL DOCUMENT v2.4.0.6
GOODWILL AND OTHER INTANGIBLES (Details) (USD $)
 3 Months Ended 6 Months Ended
Jun. 30, 2012
Jun. 30, 2011
Jun. 30, 2012
Jun. 30, 2011
Dec. 31, 2011
GOODWILL AND OTHER INTANGIBLES [Abstract]          
Goodwill $ 3,968,000   $ 3,968,000   $ 3,939,000
Finite-Lived Intangible Assets [Line Items]          
Amortization expense 6,000 9,000 13,000 19,000  
Patent Costs [Member]
          
Finite-Lived Intangible Assets [Line Items]          
Costs 469,000   469,000   469,000
Accumulated amortization (426,000)   (426,000)   (413,000)
Intangible assets, net $ 43,000   $ 43,000   $ 56,000
XML 16 R9.htm IDEA: XBRL DOCUMENT v2.4.0.6
SHARE-BASED COMPENSATION
 6 Months Ended
Jun. 30, 2012
SHARE-BASED COMPENSATION [Abstract]  
SHARE-BASED COMPENSATION
NOTE D - SHARE-BASED COMPENSATION

The Company complies with ASC Topic 718 "Compensation - Stock Compensation" ("ASC 718"), which requires all share-based awards to employees, including grants of employee stock options, to be recognized in the consolidated condensed financial statements based on their estimated fair values.

During the six-month period ended June 30, 2012, the Company granted 500,000 restricted shares of common stock, valued at $120,000 to an officer, of which half vested immediately and the remainder one year thereafter.  During the three months ended June 30, 2011, 166,279 shares of restricted common stock valued at $73,500 were granted to directors, and 366,279 shares of restricted common stock valued at $135,500 were granted to directors during the six months ended June 30, 2011.

During the six-month periods ended June 30, 2012 and 2011, the Company did not grant any stock options.

For the three and six months ended June 30, 2012, the Company granted 2,190,000 shares of restricted common stock valued at $548,000 to non-officer employees in its VasoHealthcare subsidiary in conjunction with the extension of the GEHC Agreement in June 2012.  For the three and six months ended June 30, 2011, the Company granted 10,000 shares of restricted common stock valued at $6,800 to non-officer employees.

Share-based compensation expense recognized for the three and six months ended June 30, 2012 was $102,000 and $231,000, respectively,  and $77,000 and $203,000 for the three and six months ended June 30, 2011, respectively.  These expenses are included in cost of revenues; selling, general, and administrative expenses; and research and development expenses in the consolidated condensed statements of operations.  Expense for share-based arrangements was $136,000 and $288,000 for the three and six months ended June 30, 2012, respectively, and $162,000 and $208,000 for the three and six months ended June 30, 2011, respectively.  Unrecognized expense related to existing share-based arrangements is approximately $1.3 million at June 30, 2012 and will be recognized through July 2013.
EXCEL 17 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\U-#AA.6,S,U]A,3(V7S0Y939?83'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-/3E-/3$E$051%1%]#3TY$14Y3141?4U1!5$5- M13$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7 M;W)K#I7;W)K#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D9!25)?5D%,545?345!4U5214U%3E13/"]X M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I7;W)K#I7;W)K M#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/E-43T-+2$],1$524U]%455)5%D\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-%1TU%3E1?4D503U)424Y'7T%.1%]#3TY#14Y4 M4C$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I%>&-E;%=O M#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/DE.5D5.5$]224537TY%5%]486)L M97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7;W)K M#I%>&-E;%=O#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/E-(05)%0D%3141?0T]-4$5.4T%424].7T1E M=&%I;#PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D5! M4DY)3D=37TQ/4U-?4$527T-/34U/3E]32$%213(\+W@Z3F%M93X-"B`@("`\ M>#I7;W)K#I7;W)K#I%>&-E;%=O#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/D1%1D524D5$7U)%5D5.545?1&5T86EL#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/E)%3$%4141005)465]44D%.4T%#5$E/3E-? M1&5T83PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-4 M3T-+2$],1$524U]%455)5%E?1&5T86EL#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/D-/34U)5$U%3E137T%.1%]#3TY424Y'14Y# M24537SPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O6QE#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T'1087)T7S4T.&$Y8S,S7V$Q,C9?-#EE-E]A M-S=E7V%B9&-C-#)E-3(P8@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]# M.B\U-#AA.6,S,U]A,3(V7S0Y939?83'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^5D%33TU%1$E#04PL($E.0SQS<&%N/CPO'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^3F\\2!#=7)R96YT(%)E<&]R=&EN9R!3=&%T M=7,\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^,C`Q,CQS<&%N M/CPO'0^43(\'1087)T7S4T.&$Y8S,S7V$Q,C9?-#EE-E]A-S=E7V%B9&-C-#)E-3(P8@T* M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\U-#AA.6,S,U]A,3(V7S0Y M939?83'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!C;VYS=6QT:6YG(&5X<&5N M'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$"!L:6%B:6QI='DL(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$3PO=&0^#0H@("`@("`@(#QT9"!C;&%S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\U-#AA.6,S,U]A,3(V7S0Y939?83'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$F5D("AI;B!S:&%R97,I/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-3`L,#`P+#`P,#QS<&%N M/CPO3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\U-#AA.6,S,U]A,3(V7S0Y939?83'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'!E M;G-E'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'!E;G-EF%T:6]N(&]F(&1E9F5R'!E;G-E"!E M>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Y,BD\'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U-#AA.6,S M,U]A,3(V7S0Y939?83'0O:'1M;#L@8VAAF%T:6]N(&]F('!R M;W!EF%T:6]N(&]F(&1E M9F5R6%B;&4@9'5E('1O(')E;&%T960@<&%R='D\+W1D/@T*("`@ M("`@("`\=&0@8VQA2!O<&5R M871I;F<@86-T:79I=&EE'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA6%B;&4@9'5E('1O(')E;&%T960@ M<&%R='D\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6%B;&4@6TQI;F4@271E M;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U-#AA.6,S,U]A,3(V7S0Y M939?83'0O:'1M M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/&1I=CX\9&EV('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM M;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO M8VL[(&9O;G0M9F%M:6QY.B!4:6UE3H@ M:6YL:6YE.R!F;VYT+7-I>F4Z(#'0M M=&]P.R<^)B,Q-S0[/"]F;VYT/B!E;FAA;F-E9"!E>'1E2!T96-H;F]L;V=Y(&-U2!I;F1I8V%T960@9F]R('5S92!I M;B!C87-E2!687-O($1I86=N;W-T:6-S+"!);F,N(&0O8B]A M(%9A'!A;F1E9"!I;G1O('1H92!S86QE&-L=7-I=F4@3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE M2`M('1O(&5X<&%N9"!I=',@ M=&5C:&YI8V%L(&%N9"!M86YU9F%C='5R:6YG(&-A<&%B:6QI=&EE2!R97-T2UO=VYE9"!S=6)S:61I87)I97,N M)B,Q-C`[)B,Q-C`[5F%S;R!$:6%G;F]S=&EC2=S(')E8V5N=&QY+6%C<75I M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#'0M=&]P.R<^)B,Q-S0[(#PO9F]N=#YT:&5R M87!Y(&)U6QE/3-$)W1E>'0M:6YD96YT M.B`P<'0[(&1I3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F M=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!M M87)G:6XM3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`S-G!T M.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA M;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM M2P@=&AE2!F;W(@82!F86ER('!R97-E;G1A=&EO;B!O9B!I;G1E3H@8FQO M8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU M'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@ M9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM6EN9R!N;W1E'!E;G-E3H@8FQO8VL[(&9O;G0M M9F%M:6QY.B!4:6UE3H@8FQO M8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU M'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@ M9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM3L@=&5X="UI;F1E;G0Z(#,V<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F M;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M:6YD96YT M.B`P<'0[(&1I3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U-#AA.6,S M,U]A,3(V7S0Y939?83'0O:'1M;#L@8VAA'0^/&1I=CX\ M9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P M<'0[(&1I3H@5&EM97,@3F5W(%)O M;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE2!V:65W3H@:6YL:6YE.R!F;VYT+7-I>F4Z M(#'0M=&]P.R<^)B,Q-S0[/"]F;VYT M/B!E;FAA;F-E9"!E>'1E2P@87,@=V5L M;"!A2=S(')E'!E;G-E3H@8FQO8VL[(&9O;G0M9F%M M:6QY.B!4:6UE#L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R!B;W)D97(M=&]P.B`C-&)A8V,V(#`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`R<'@@F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^ M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@ M,G!X.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C M:R`R<'@@6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I M;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!S;VQI M9#LG/CQD:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('1E M>'0M:6YD96YT.B`P<'0[(&1I3H@ M=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z M(#$P<'0[(&UA3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P M.SPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@#L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`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`R-B4[)SX\9&EV M/CQD:78@3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I M=CXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF M(S$V,#L\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\ M9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY M.B!T:6UE3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/C8L,30R/"]D:78^/"]T M9#X\=&0@;F]W6QE/3-$)W=I9'1H M.B`R-B4[(&1I6QE/3-$)W=I9'1H M.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SX\9&EV/BT\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!A;&EG;CTS M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T M:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UEF4Z(#$P<'0[)SX\ M9&EV/C3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SX\9&EV/B0\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV M/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T M:6UE3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/C8X,3PO9&EV/CPO=&0^/'1D M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SX\9&EV/B0\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\ M9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY M.B!T:6UE3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/C6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD M96YT.B`P<'0[(&1I3H@=&EM97,@ M;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[ M(&UA3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B0\+V1I=CX\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^ M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXD/"]D:78^/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T M:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`R-B4[(&1I6QE/3-$)W=I9'1H.B`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`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M/&1I=CXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T M:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SX\9&EV/B0\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$ M;&5F="!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^/&1I=CXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\ M9&EV/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T M;VT@6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXD/"]D M:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXD/"]D:78^/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D M/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E969F/CQT9"!A;&EG;CTS1&QE9G0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`R-B4[)SX\9&EV/CQD M:78@3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV M/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T M:6UE3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/BT\+V1I=CX\+W1D/CQT9"!N M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\ M+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO M9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L M:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SX\9&EV/C,L-#DP/"]D:78^/"]T9#X\=&0@;F]W6QE/3-$)W=I9'1H.B`R-B4[(&1I6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@ M,24[(&9O;G0M9F%M:6QY.B!T:6UEF4Z(#$P<'0[)SX\9&EV M/BT\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`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`R<'@@'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I M=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@#L@=VED=&@Z(#$E.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV M/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@6QE M/3-$)W!A9&1I;F6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I M;F#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M M.B!B;&%C:R`R<'@@'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`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`R<'@@'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`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`R<'@@'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)V)O"!S;VQI9#L@=VED=&@Z(#(V)3LG/CQD:78^/&1I=B!S='EL93TS M1"=T97AT+6%L:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G M:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA#L@ M=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@ M'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF M(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@6QE/3-$)V)O"!S;VQI9#L@=&5X="UA M;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M M.B!B;&%C:R`R<'@@'0M86QI9VXZ(')I9VAT.R!W:61T:#H@ M.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SX\9&EV/CPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=P861D:6YG+6)O='1O;3H@,G!X.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO M=&0^/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B M;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV M/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=P861D:6YG+6)O='1O;3H@,G!X.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO M=&0^/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B M;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!S;VQI9#LG/CQD:78^/&1I=B!S='EL93TS1"=T97AT M+6%L:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F M=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UAF4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^ M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@ M,G!X.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C M:R`R<'@@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`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`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO M9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L M:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@ M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W M:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@ M.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO M=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXD/"]D:78^/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SX\9&EV/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F M="!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^/&1I=CXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\ M9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX] M,T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I M=CXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF M(S$V,#L\+V1I=CX\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E969F/CQT M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H M.B`R-B4[)SX\9&EV/CQD:78@3H@8FQO8VL[(&9O;G0M9F%M:6QY M.B!T:6UE6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`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`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXD/"]D:78^/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O M;G0M9F%M:6QY.B!T:6UE3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B@Y-C`\ M+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO M=&0^/"]T6QE/3-$)W=I9'1H.B`R-B4[)SX\9&EV/CQD M:78@3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H M.B`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`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXD/"]D M:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M M:6YD96YT.B`P<'0[(&1I3H@=&EM M97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P M<'0[(&UA6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@ M,24[(&9O;G0M9F%M:6QY.B!T:6UEF4Z(#$P<'0[)SX\9&EV M/C3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI M9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M/&1I=CXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T M:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I M=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/CPO9&EV M/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXD/"]D:78^/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXD/"]D:78^/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@ M.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CPO='(^/'1R M(&)G8V]L;W(],T1W:&ET93X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=W:61T:#H@,C8E.R<^/&1I=CX\9&EV('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`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`R<'@@'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V M86QI9VX],T1B;W1T;VT@#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO M9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M M8F]T=&]M.B!B;&%C:R`R<'@@6QE/3-$)W!A9&1I M;F6QE/3-$)V)O"!S;VQI M9#L@=&5X="UA;&EG;CH@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R M<'@@'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I M=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^ M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@#L@=VED=&@Z M(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/"]T3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M M:6YD96YT.B`P<'0[(&1I6QE/3-$)W!A9&1I;F3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O#L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!B;W)D M97(M=&]P.B`C-&)A8V,V(#`N-7!T('-O;&ED.R<^/&1I=CXF(S$V,#L\+V1I M=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R!B;W)D97(M=&]P.B`C-&)A8V,V(#`N-7!T('-O;&ED M.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI M9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[(&)O#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R!B;W)D97(M=&]P.B`C-&)A8V,V(#`N-7!T('-O M;&ED.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE"!M;VYT:',@96YD960@ M2G5N92`S,"P@,C`Q,CPO9&EV/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F M="!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R!B;W)D97(M=&]P.B`C-&)A8V,V(#`N-7!T('-O;&ED.R<^/&1I=CXF M(S$V,#L\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@8V]L6QE/3-$)V)O"!S;VQI9#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R!B;W)D97(M=&]P.B`C-&)A8V,V(#`N-7!T('-O;&ED M.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A M9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$ M)V)O"!S;VQI9#L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!B;W)D97(M=&]P M.B`C-&)A8V,V(#`N-7!T('-O;&ED.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D M/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$ M)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!S;VQI9#LG/CQD:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT M97([('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT M+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I M;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!S;VQI9#LG/CQD:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT M97([('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT M+7-I>F4Z(#$P<'0[(&UA#L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I M=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^/&1I=CX\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@#L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF M(S$V,#L\+V1I=CX\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T M;VT@6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE M6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE M/3-$)V)O"!S;VQI9#LG/CQD:78^/&1I M=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`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`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXD/"]D:78^ M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`R M-B4[(&1I6QE/3-$)W=I9'1H.B`Q M)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^ M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T M.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SX\9&EV/BT\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE M9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@ M,24[(&9O;G0M9F%M:6QY.B!T:6UEF4Z(#$P<'0[)SX\9&EV M/C$S+#3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/"]T6QE M/3-$)W=I9'1H.B`R-B4[)SX\9&EV/CQD:78@3H@8FQO8VL[(&9O M;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`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`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXD/"]D:78^ M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SX\9&EV/B0\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^*3PO=&0^/"]T6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXD/"]D:78^ M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I M=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W=I9'1H.B`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`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE M9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@ M,24[(&9O;G0M9F%M:6QY.B!T:6UEF4Z(#$P<'0[)SX\9&EV M/C,R+#`U-3PO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX] M,T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/"]T6QE M/3-$)W=I9'1H.B`R-B4[)SX\9&EV/CQD:78@3H@8FQO8VL[(&9O M;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXD/"]D:78^/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T M:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!A M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q M)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^ M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T M.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SX\9&EV/C6QE/3-$)W=I9'1H.B`R-B4[(&1I6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M M9F%M:6QY.B!T:6UE3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/BT\+V1I=CX\ M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V M,#L\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV M/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T M:6UE3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/C@L.3@T/"]D:78^/"]T9#X\ M=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD M96YT.B`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`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`R<'@@'0M86QI9VXZ(')I9VAT.R!W:61T:#H@ M.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W!A M9&1I;F6QE/3-$)V)O"!S M;VQI9#L@=&5X="UA;&EG;CH@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F#L@=VED=&@Z(#(V)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^/&1I=CX\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('!A9&1I;F#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C M,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B M;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\ M9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI M9VX],T1B;W1T;VT@#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV M/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T M=&]M.B!B;&%C:R`R<'@@6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\ M9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@'0M86QI M9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE M/3-$)V)O"!S;VQI9#LG/CQD:78^/&1I M=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`P M<'0[(&1I3H@=&EM97,@;F5W(')O M;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE M/3-$)V)O"!S;VQI9#LG/CQD:78^/&1I M=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`P M<'0[(&1I3H@=&EM97,@;F5W(')O M;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@#L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I M=CX\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT M9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@6QE/3-$ M)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!S;VQI9#LG/CQD:78^/&1I=B!S='EL93TS1"=T97AT+6%L M:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@ M,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UAF4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^ M/"]T6QE/3-$)W=I M9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV M/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T M:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`R-B4[(&1I6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I M=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\ M+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CPO M='(^/'1R(&)G8V]L;W(],T1W:&ET93X\=&0@86QI9VX],T1L969T('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,C8E.R<^/&1I=CX\9&EV('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I M3H@=&EM97,@;F5W(')O;6%N.R!M M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA'1E6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV M/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T M:6UE3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/C(L,C`U/"]D:78^/"]T9#X\ M=&0@;F]W3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,C8E.R!D M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SX\9&EV/B0\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SX\9&EV/B0\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E M969F/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W=I9'1H.B`R-B4[)SX\9&EV/CQD:78@3H@8FQO8VL[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`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`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXD/"]D:78^/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXI/"]T9#X\=&0@86QI9VX],T1L M969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SX\9&EV/B0\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^*3PO=&0^/"]T6QE/3-$)W=I9'1H.B`R-B4[ M)SX\9&EV/CQD:78@3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE M6QE M/3-$)W=I9'1H.B`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`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M/&1I=CXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T M:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT M+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W=I9'1H.B`Q M)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^ M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T M.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SX\9&EV/C3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$ M;&5F="!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^/&1I=CXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\ M9&EV/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T M;VT@6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXD/"]D M:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXD/"]D:78^/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D M/CPO='(^/'1R(&)G8V]L;W(],T1W:&ET93X\=&0@86QI9VX],T1L969T('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,C8E.R<^/&1I=CX\9&EV M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`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`R<'@@'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I M=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@#L@=VED=&@Z(#$E.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV M/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@6QE M/3-$)W!A9&1I;F6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I M;F#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M M.B!B;&%C:R`R<'@@'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO M9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@ M#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/"]T3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I2X\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P M<'0[(&1I3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U-#AA.6,S,U]A M,3(V7S0Y939?83'0O:'1M;#L@8VAA'0^ M/&1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD M96YT.B`P<'0[(&1I3H@5&EM97,@ M3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[ M(&UA3L@=&5X="UI;F1E;G0Z(#,V<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G M:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA65EF5D(&EN('1H92!C;VYS;VQI9&%T M960@8V]N9&5N6QE/3-$ M)W1E>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE M"UM;VYT:"!P M97)I;V0@96YD960@2G5N92`S,"P@,C`Q,BP@=&AE($-O;7!A;GD@9W)A;G1E M9"`U,#`L,#`P(')E6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[(&9O;G0M9F%M:6QY M.B!4:6UE"!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q,2P@=&AE($-O;7!A M;GD@9W)A;G1E9"`Q,"PP,#`@3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&IU'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B M;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE M9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM'!E;G-E(')E8V]G;FEZ960@ M9F]R('1H92!T:')E92!A;F0@2PF M(S$V,#LF(S$V,#MA;F0@)#F5D(&5X<&5N&ES=&EN9R!S:&%R M92UB87-E9"!A2`D,2XS(&UI M;&QI;VX@870@2G5N92`S,"P@,C`Q,B!A;F0@=VEL;"!B92!R96-O9VYI>F5D M('1H2`R,#$S+CPO9&EV/CQD:78@3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\+V1I M=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&IU'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B M;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE M9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM3L@=&5X="UI;F1E;G0Z(#,V<'0[ M(&1I3H@5&EM97,@3F5W(%)O;6%N M.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA2X\+V1I=CX\9&EV('-T M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[(&9O;G0M9F%M:6QY M.B!4:6UE6QE/3-$)W=I9'1H.B`T,"4[(&9O;G0M9F%M:6QY.B!4:6UE M3H@5&EM97,@ M3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O6QE/3-$)W=I9'1H.B`W)3L@8F]R9&5R+71O<#H@(S1B86-C-B`P M+C5P="!S;VQI9#LG/CQD:78@"!M;VYT:',@96YD M960@2G5N92`S,"P\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@5&EM97,@3F5W(%)O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[(&)O6QE M/3-$)W=I9'1H.B`S)3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R!B;W)D97(M=&]P.B`C-&)A8V,V(#`N-7!T('-O M;&ED.R<^)B,Q-C`[(#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!4:6UE'0M:6YD96YT M.B`P<'0[(&1I3H@5&EM97,@3F5W M(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA M6QE/3-$)W=I9'1H M.B`Y)3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R!B;W)D97(M=&]P.B`C-&)A8V,V(#`N-7!T('-O;&ED.R<^)B,Q M-C`[(#PO=&0^/"]T6QE/3-$)W1E M>'0M86QI9VXZ(&-E;G1E3H@ M8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE6QE/3-$ M)V)O"!S;VQI9#L@=VED=&@Z(#3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L@/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O M"!S;VQI9#L@=VED=&@Z(#DE.R<^/&1I M=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`P M<'0[(&1I3H@5&EM97,@3F5W(%)O M;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT M.B`P<'0[(&1I3H@5&EM97,@3F5W M(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA M6QE/3-$)W=I9'1H.B`Y)3LG M/CQD:78@3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE6QE/3-$)W=I9'1H.B`W)3L@9&ES<&QA>3H@:6YL:6YE.R!F M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L@/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=W:61T:#H@.24[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T M.R!F;VYT+7-I>F4Z(#$P<'0[(&UA3H@8FQO M8VL[(&9O;G0M9F%M:6QY.B!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT M+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W=I9'1H.B`Y)3LG/CQD:78@3H@8FQO8VL[(&9O M;G0M9F%M:6QY.B!4:6UE6QE/3-$)W=I9'1H.B`T,"4[)SX\9&EV('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F M=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W=I9'1H.B`Y)3LG/CQD:78@3H@8FQO M8VL[(&9O;G0M9F%M:6QY.B!4:6UE6QE/3-$ M)W=I9'1H.B`S)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM M97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\ M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T M:#H@.24[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M M:6YD96YT.B`P<'0[(&1I3H@5&EM M97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P M<'0[(&UA6QE/3-$)W=I9'1H M.B`Y)3LG/CQD:78@3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE M6QE/3-$)V)O"!D;W5B;&4[('=I9'1H.B`Y)3LG/CQD:78@3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE6QE/3-$)W=I9'1H.B`W)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@ M/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R!W:61T:#H@.24[ M)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT M.B`P<'0[(&1I3H@5&EM97,@3F5W M(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA M6QE/3-$)V)O"!D;W5B;&4[('=I9'1H.B`Y)3LG/CQD:78@3H@8FQO8VL[(&9O M;G0M9F%M:6QY.B!4:6UE6QE/3-$ M)V)O"!S;VQI9#L@=VED=&@Z(#0P)3L@ M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[(#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B M;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E M>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE&-L M=61E9"!F"!A;F0@=&AR964@;6]N=&AS(&5N9&5D M($IU;F4@,S`L(#(P,3(@86YD(#(P,3$L(&)E8V%U6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[ M(&9O;G0M9F%M:6QY.B!4:6UE6QE/3-$)W=I9'1H.B`R,"4[(&9O;G0M9F%M:6QY.B!4:6UE3H@5&EM97,@3F5W(%)O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[(&)O'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F M;VYT+7-I>F4Z(#$P<'0[(&UA#PO9&EV/CPO=&0^/'1D(&%L:6=N M/3-$;&5F="!V86QI9VX],T1B;W1T;VT@3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE3H@5&EM97,@3F5W M(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@ M,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA'0M:6YD96YT.B`P<'0[ M(&1I3H@5&EM97,@3F5W(%)O;6%N M.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE6QE/3-$)W=I9'1H.B`R)3L@9&ES<&QA M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)V)O"!S;VQI9#L@=VED M=&@Z(#$P)3LG/CQD:78@'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F M;VYT+7-I>F4Z(#$P<'0[(&UA3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE6QE/3-$)W=I9'1H.B`R)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L@/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=W:61T:#H@,3$E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@ M9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM6QE M/3-$)W=I9'1H.B`T)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]T M9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W M:61T:#H@,3(E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ M(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE M.B`Q,'!T.R!M87)G:6XM6QE/3-$)W=I9'1H.B`R)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L@/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=W:61T:#H@,3`E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@ M9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM3H@8FQO8VL[(&9O;G0M9F%M M:6QY.B!4:6UE3H@8FQO8VL[(&9O;G0M9F%M:6QY M.B!4:6UE3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE3H@ M8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE3H@8FQO8VL[(&9O;G0M M9F%M:6QY.B!4:6UE3H@8FQO8VL[(&9O;G0M9F%M M:6QY.B!4:6UE6QE/3-$)W=I9'1H.B`R)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L@/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=W:61T:#H@,3$E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF M86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N M="US:7IE.B`Q,'!T.R!M87)G:6XM6QE/3-$ M)W=I9'1H.B`T)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM M97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\ M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T M:#H@,3(E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I M;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q M,'!T.R!M87)G:6XM6QE/3-$)W=I9'1H.B`Q M,"4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD M96YT.B`P<'0[(&1I3H@5&EM97,@ M3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[ M(&UA3H@8FQO8VL[(&9O;G0M9F%M M:6QY.B!4:6UE3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE6QE/3-$)W=I9'1H.B`T)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L@/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=W:61T:#H@,3(E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF M86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N M="US:7IE.B`Q,'!T.R!M87)G:6XM3H@8FQO8VL[(&9O;G0M9F%M M:6QY.B!4:6UE6QE/3-$)W=I9'1H.B`U)3L@9&ES<&QA>3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L@/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=W:61T:#H@,3(E.R<^/&1I=B!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C M:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z M(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM3H@8FQO8VL[(&9O;G0M9F%M:6QY M.B!4:6UE6QE/3-$)W=I M9'1H.B`R)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@ M3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\=&0@ M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@ M,3$E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S M($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T M.R!M87)G:6XM6QE/3-$)W=I9'1H.B`T)3L@ M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\=&0@86QI9VX],T1L M969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,3(E.R<^/&1I M=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T M.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA M;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM M6QE/3-$)W=I M9'1H.B`R)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@ M3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\=&0@ M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@ M,3`E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S M($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T M.R!M87)G:6XM3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE6QE/3-$)V)O"!D;W5B;&4[('=I9'1H.B`Q,24[)SX\9&EV M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[ M(&1I3H@5&EM97,@3F5W(%)O;6%N M.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W=I9'1H.B`T)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L@/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R!W:61T M:#H@,3(E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I M;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q M,'!T.R!M87)G:6XM3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE M3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)V)O"!S;VQI9#L@=VED M=&@Z(#(E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)V)O"!S;VQI9#L@=VED=&@Z M(#$Q)3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[(#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L@/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O"!S;VQI9#L@=VED=&@Z(#4E.R!F;VYT+69A M;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L@/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O"!S;VQI9#L@=VED=&@Z(#$R)3L@9F]N="UF86UI M;'DZ(%1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[ M(#PO=&0^/"]T3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\+V1I M=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`S-G!T.R!D M:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@ M;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@ M3F5W(%)O;6%N.R<^2G5N92`S,"P@,C`Q,B!A;F0@1&5C96UB97(@,S$L(#(P M,3$\+V9O;G0^.CPO9&EV/CQD:78@6QE.B!I=&%L:6,[('1E>'0M:6YD96YT.B`S-G!T.R!D M:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@ M;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`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`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G M:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V M86QI9VX],T1B;W1T;VT^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT M97([('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT M+7-I>F4Z(#$P<'0[(&UA6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE M/3-$)V1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!T M:6UE3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C M;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT^/&1I=B!S='EL93TS1"=T97AT M+6%L:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`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`P<'0[ M(&1I3H@=&EM97,@;F5W(')O;6%N M.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS M<&%N/3-$,B!V86QI9VX],T1B;W1T;VT^/&1I=B!S='EL93TS1"=T97AT+6%L M:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@ M,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!T M:6UE3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C M;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT^/&1I=B!S='EL93TS1"=T97AT M+6%L:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F M=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)V1I M6QE/3-$)V1I6QE/3-$ M)V1IF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO M='(^/'1R/CQT9"!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO=&0^/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM M;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UAF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@#L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[ M/"]T9#X\=&0@8V]L6QE/3-$ M)V)O"!S;VQI9#LG/CQD:78@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('!A9&1I;F3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@ M'0M:6YD96YT.B`P M<'0[(&1I3H@=&EM97,@;F5W(')O M;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA#L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT M6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G M:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B M;VQD.R!M87)G:6XM6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI M9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE3H@8FQO8VL[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q M)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z M(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXY+#@S-#PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX] M,T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T1W:&ET93X\=&0@ M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG M+6)O='1O;3H@,G!X.R!W:61T:#H@-3(E.R<^/&1I=B!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,3AP=#L@9&ES<&QA>3H@8FQO M8VL[(&9O;G0M9F%M:6QY.B!T:6UE#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`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`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`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`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE M3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$ M,B!V86QI9VX],T1B;W1T;VT^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C M96YT97([('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F M;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`] M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX] M,T1B;W1T;VT^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('1E M>'0M:6YD96YT.B`P<'0[(&1I3H@ M=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z M(#$P<'0[(&UA3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT^/&1I=B!S='EL M93TS1"=T97AT+6%L:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`P<'0[(&1I M3H@=&EM97,@;F5W(')O;6%N.R!M M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O M;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E M3H@8FQO8VL[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N M/3-$,B!V86QI9VX],T1B;W1T;VT^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N M.B!C96YT97([('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T M.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE M3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT^/&1I=B!S='EL93TS M1"=T97AT+6%L:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G M:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$ M,B!V86QI9VX],T1B;W1T;VT^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C M96YT97([('1E>'0M:6YD96YT.B`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`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T M.R!F;VYT+7-I>F4Z(#$P<'0[(&UA3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@ M8V]L6QE/3-$)V)O"!S;VQI9#LG/CQD:78@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY M.B!T:6UE'0M86QI9VXZ(')I9VAT.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXR,#$Q M/"]T9#X\=&0@;F]W3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T1W:&ET93X\=&0@86QI M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@-3(E M.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!F M;VYT+7=E:6=H=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY!3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\+W1R/CQT3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`[/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ+#,Q M,SPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CPO='(^/'1R(&)G8V]L;W(],T1W:&ET93X\=&0@86QI9VX],T1L969T M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@-3(E.R<^/&1I=B!S M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,3AP=#L@ M9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UEF4Z(#$P<'0[)SXQ M,3`\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[ M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@ M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`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`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T M<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXM M/"]T9#X\=&0@;F]W#L@=VED M=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)V)O"!D;W5B M;&4[('1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY M.B!T:6UE3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!S;VQI9#L@ M=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$ M)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@ M;&5F=#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE M/3-$)W!A9&1I;F6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z M(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`] M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I M;F3H@8FQO8VL[)SX\8G(@+SX\+V1I M=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD M96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S M($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T M.R!M87)G:6XM2=S(&-A6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\U-#AA.6,S,U]A,3(V7S0Y939?83'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/&1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT M+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4 M:6UE2=S M(&%C8V]U;G1S(&%N9"!O=&AE6QE M/3-$)W1E>'0M86QI9VXZ(&-E;G1E#L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!B;W)D97(M=&]P.B`C M-&)A8V,V(#`N-7!T('-O;&ED.R<^)B,Q-C`[(#PO=&0^/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I M>F4Z(#$P<'0[(&UA#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R!B;W)D97(M=&]P.B`C-&)A8V,V(#`N-7!T('-O;&ED.R<^)B,Q-C`[ M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F6QE/3-$)W1E M>'0M86QI9VXZ(&-E;G1E3H@ M8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE#L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!B;W)D97(M=&]P.B`C-&)A8V,V M(#`N-7!T('-O;&ED.R<^)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)V1I6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V1I6QE/3-$ M)V1I3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E969F M/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I M9'1H.B`W-B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E M>'0M:6YD96YT.B`P<'0[(&1I3H@ M=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z M(#$P<'0[(&UA6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W=I9'1H.B`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`Q,'!T.R!M87)G:6XM65E3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ-#4\+W1D/CQT9"!N M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[ M(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE M3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R M(&)G8V]L;W(],T0C8V-E969F/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`W-B4[)SX\9&EV('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F M=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@6QE/3-$ M)W=I9'1H.B`W-B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('1E>'0M:6YD96YT.B`R-W!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US M:7IE.B`Q,'!T.R!M87)G:6XM6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@ M,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W!A9&1I M;F6QE/3-$)V)O"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T M=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@=VED M=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXX+#DX-#PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI M9VX],T1B;W1T;VT@#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M M.B!B;&%C:R`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z M(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXR,"PV.34\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@3H@8FQO8VL[ M)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[ M(&1I3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE2!D=64@=6YD97(@=&AE($=%2$,@ M06=R965M96YT(&%R92!S=6)J96-T('1O(&%D:G5S=&UE;G0@:6X@6EN9R!S86QE6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[ M(&1I3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE2!R961U8V4@=&AE(&%M;W5N="!T:&4@0V]M<&%N M>2!W:6QL('5L=&EM871E;'D@2!R969L96-T7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I M6QE/3-$)W1E>'0M86QI9VXZ(&-E M;G1E#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R!B;W)D97(M=&]P.B`C-&)A8V,V(#`N-7!T('-O;&ED.R<^)B,Q-C`[ M(#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O M='1O;3H@,G!X.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[(&)O'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM M;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!B;W)D97(M=&]P.B`C-&)A8V,V(#`N M-7!T('-O;&ED.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE#L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!B M;W)D97(M=&]P.B`C-&)A8V,V(#`N-7!T('-O;&ED.R<^)B,Q-C`[/"]T9#X\ M+W1R/CQT6QE/3-$)V1I6QE/3-$)W1E>'0M M86QI9VXZ(&-E;G1E3H@8FQO M8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R M(&)G8V]L;W(],T0C8V-E969F/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`W-B4[)SX\9&EV('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F M=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W=I9'1H.B`W-B4[ M)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT M.B`P<'0[(&1I3H@=&EM97,@;F5W M(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY M.B!T:6UE3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H M.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXW-S(\+W1D/CQT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L969T M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[ M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE#L@=VED=&@Z(##L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!W:61T M:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@ M.24[(&9O;G0M9F%M:6QY.B!T:6UE#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@'0M86QI9VXZ(')I9VAT.R!W:61T:#H@ M.24[(&9O;G0M9F%M:6QY.B!T:6UE#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/"]T M86)L93X\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I M3L@=&5X="UI;F1E;G0Z M(#,V<'0[(&1I3H@5&EM97,@3F5W M(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO M8VL[(&9O;G0M9F%M:6QY.B!4:6UE2!C;VUP;&5T960@=&AE('!U2!,=&0@*"),150B*2!A;F0@0FEO>"!);G-T2!I2!I3H@8FQO8VL[)SX\8G(@+SX\ M+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I M;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q M,'!T.R!M87)G:6XM6QE/3-$)V1I6QE/3-$ M)V1I7-T96US+B!":6]X+"!A(&1E=F5L;W!E&DL($II86YG2!E;FAA M;F-E6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)W1E>'0M86QI9VXZ M(&IU'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@ M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P M=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM"!A;F0@=&AR964@;6]N=&AS M(&5N9&5D($IU;F4@,S`L(#(P,3(N)B,Q-C`[)B,Q-C`[5&AE($-O;G-O;&ED M871E9"!#;VYD96YS960@0F%L86YC92!3:&5E="!A3H@ M8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE6QE/3-$)W=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!B;W)D97(M=&]P.B`C-&)A8V,V M(#`N-7!T('-O;&ED.R<^/&1I=CX\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M(&)O6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@ M.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[(&)O6QE/3-$)W=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R!B;W)D97(M=&]P.B`C-&)A8V,V(#`N-7!T('-O;&ED.R<^ M/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[(&)O6QE/3-$)W=I M9'1H.B`X."4[)SX\9&EV/CQD:78@3H@8FQO8VL[(&9O;G0M9F%M M:6QY.B!T:6UE6QE M/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P M.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I M=CX\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E969F/CQT9"!A;&EG;CTS M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`X."4[)SX\ M9&EV/CQD:78@3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H M.B`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`P<'0[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD M96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S M($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T M.R!M87)G:6XM2!B92!A9&IU2!E MF5S('1H92!E6QE/3-$)W1E>'0M86QI9VXZ M(&IU'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@ M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P M=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM6QE/3-$)V9O;G0M3H@:6YL:6YE M.R!F;VYT+7-I>F4Z(#$P<'0[)SXH:6X@=&AO=7-A;F1S*3PO9F]N=#X\+V1I M=CX\9&EV/CQD:78^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E M>'0M:6YD96YT.B`P<'0[(&1I3H@ M=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z M(#$P<'0[(&UA3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O6QE/3-$)W=I9'1H.B`X."4[)SX\9&EV/CQD:78@3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E M969F/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W=I9'1H.B`X."4[)SX\9&EV/CQD:78@3H@8FQO8VL[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF M(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF M(S$V,#L\+V1I=CX\+W1D/CPO='(^/'1R(&)G8V]L;W(],T1W:&ET93X\=&0@ M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@ M.#@E.R<^/&1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E M>'0M:6YD96YT.B`P<'0[(&1I3H@ M=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z M(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I M=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV M/B8C,38P.SPO9&EV/CPO=&0^/"]T3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO M9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L M:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/C,L.38X/"]D:78^/"]T M9#X\=&0@;F]W6%B;&4@86YD(&]T M:&5R(&-U6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^*3PO=&0^/"]T#L@=VED=&@Z(#@X)3LG/CQD:78^/&1I M=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,C=P M=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V)O M"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXD/"]D:78^/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)V)O"!D M;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F#L@=VED=&@Z(#$E.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO M=W)A<"!V86QI9VX],T1B;W1T;VT@#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C M,38P.SPO9&EV/CPO=&0^/"]T3H@8FQO M8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P M<'0[(&1I3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE6YE3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`S-G!T.R!D M:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@ M;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM2!T M2=S($-O;G-O;&ED871E9"!#;VYD96YS M960@4W1A=&5M96YT(&]F($]P97)A=&EO;G,@86YD($-O;7!R96AE;G-I=F4@ M26YC;VUE("A,;W-S*28C,38P.V9O3H@8FQO8VL[(&9O;G0M9F%M:6QY M.B!4:6UE3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM M;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA&-E<'0@<&5R M('-H87)E(&1A=&$I/"]D:78^/&1I=CX\9&EV/CQT86)L92!C96QL<&%D9&EN M9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SX\='(^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!B;W)D97(M=&]P.B`C-&)A8V,V M(#`N-7!T('-O;&ED.R<^/&1I=CX\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE M9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[(&)O#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R!B;W)D97(M=&]P.B`C-&)A8V,V(#`N-7!T('-O;&ED.R<^ M/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$ M)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UEF4Z(#$P<'0[(&)O6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('!A9&1I;FF4Z(#$P<'0[(&)O#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R!B;W)D97(M=&]P.B`C-&)A8V,V(#`N-7!T('-O;&ED.R<^ M/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I M;F6QE/3-$)V)O"!S;VQI9#L@ M8F]R9&5R+71O<#H@(S1B86-C-B`P+C5P="!S;VQI9#LG/CQD:78^/&1I=B!S M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`P<'0[ M(&1I3H@=&EM97,@;F5W(')O;6%N M.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O#L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R!B;W)D97(M=&]P.B`C-&)A8V,V(#`N-7!T('-O;&ED.R<^/&1I=CXF(S$V M,#L\+V1I=CX\+W1D/CPO='(^/'1R/CQT9"!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CX\+V1I=CX\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`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`R<'@@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A M9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!S;VQI9#LG/CQD:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C M96YT97([('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F M;VYT+7-I>F4Z(#$P<'0[(&UA#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@#L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CX\ M+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!C M;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E M>'0M86QI9VXZ(&-E;G1E3H@ M8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UEF4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/"]T M6QE/3-$)W=I9'1H.B`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`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V M,#L\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV M/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T M:6UE3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/C6QE/3-$)W=I9'1H.B`Q M,R4[(&1I6QE/3-$)W=I9'1H.B`Q M)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^ M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T M.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SX\9&EV/C4L-#`Q/"]D:78^/"]T9#X\=&0@;F]W6QE/3-$)W=I9'1H.B`Q)3L@9&ES M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T M:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q,R4[(&1I6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I M=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\ M+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`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`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO=&0^ M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,3,E.R!D:7-P M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SX\9&EV/B0\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C M,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I M=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/CPO9&EV/CPO=&0^/'1D(&%L M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`R-B4[(&1I M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I M=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`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`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO M9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L M:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT M.B`P<'0[(&1I3H@=&EM97,@;F5W M(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA M6QE/3-$)W=I9'1H.B`Q)3L@9&ES M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T M:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UEF4Z(#$P<'0[)SX\ M9&EV/B@P+C`Q/"]D:78^/"]T9#X\=&0@;F]W3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/CPO9&EV/CPO=&0^ M/'1D(&%L:6=N/3-$6QE/3-$)W=I M9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV M/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SX\9&EV/B@P+C`Q/"]D:78^/"]T9#X\=&0@;F]W3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SX\9&EV/B0\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE M/3-$)W=I9'1H.B`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`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`R<'@@'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&9O;G0M9F%M:6QY.B!T:6UE3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\+V1I=CX\'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA3H@8FQO8VL[(&9O;G0M M9F%M:6QY.B!4:6UE6QE M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4 M:6UE3H@8FQO M8VL[(&9O;G0M9F%M:6QY.B!4:6UE2=S(&]T:&5R(&EN=&%N9VEB;&4@87-S971S(&-O;G-I3H@8FQO M8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E M;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE#L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CX\ M+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!C M;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E M>'0M86QI9VXZ(&-E;G1E3H@ M8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UEF4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV M/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O M='1O;3H@,G!X.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D(&-O;'-P M86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M M.B!B;&%C:R`R<'@@F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV M/CPO=&0^/"]T6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M M:6YD96YT.B`P<'0[(&1I3H@=&EM M97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P M<'0[(&UA6QE/3-$)V1I6QE/3-$)W1E>'0M M86QI9VXZ(&-E;G1E3H@8FQO M8VL[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV M/CPO=&0^/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/"]T M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^/&1I=CXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SX\9&EV/B0\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I M=CXF(S$V,#L\+V1I=CX\+W1D/CPO='(^/'1R(&)G8V]L;W(],T1W:&ET93X\ M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T M:#H@-S8E.R<^/&1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('1E>'0M:6YD96YT.B`R-W!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US M:7IE.B`Q,'!T.R!M87)G:6XM6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C M,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXI/"]T9#X\+W1R/CQT M6QE M/3-$)W!A9&1I;F6QE M/3-$)V)O"!D;W5B;&4[('1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXD/"]D:78^/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O M;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$ M)W!A9&1I;F3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B0\+V1I=CX\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/"]T M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SX\9&EV/CPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@,24[(&9O;G0M M9F%M:6QY.B!T:6UE6QE M/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG M;CH@;&5F=#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^ M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B M;&%C:R`R<'@@'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W!A9&1I M;F6QE/3-$)V)O"!S;VQI M9#L@=&5X="UA;&EG;CH@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E M>'0M:6YD96YT.B`P<'0[(&1I3L@=&5X="UI;F1E;G0Z(#,V<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F M;VYT+7-I>F4Z(#$P<'0[(&UA7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@ M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R!M87)G:6XM6QE/3-$)W9E6QE M/3-$)W9E6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O M;6%N)RP@6QE/3-$)W9E6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`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`G5&EM97,@3F5W(%)O;6%N)RP@6QE/3-$)V9O;G0M9F%M:6QY.B`G M5&EM97,@3F5W(%)O;6%N)RP@3H@)U1I M;65S($YE=R!2;VUA;BF4Z(#$P<'0[)SXQ,BPV M,S<\+V1I=CX\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^ M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@ M=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78^ M/&1I=B!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$P<'0[)SXD/"]D:78^/"]D:78^/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@6QE/3-$)V)A8VMG6QE/3-$ M)W=I9'1H.B`U,B4[('9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@=F5R=&EC86PM M86QI9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI M9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^ M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!W:61T:#H@.24[('9E6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI M9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\+W1R/CQT6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('1E>'0M:6YD96YT.B`R-W!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE M=R!2;VUA;BF4Z(#$P<'0[)SY$969E'1E;F1E9"!S97)V:6-E(&-O;G1R86-T6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W M(%)O;6%N)RP@6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$P<'0[)SX\+V1I=CX\9&EV('-T>6QE/3-$)V9O;G0M9F%M M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$P<'0[ M)SX\+V1I=CX\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W M(%)O;6%N)RP@6QE/3-$)V)A8VMG6QE/3-$)W=I9'1H.B`U,B4[('9E6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC M86PM86QI9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[ M/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[('9E3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$P<'0[)SXR,#PO9&EV/CPO9&EV/CPO=&0^/'1D M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@F4Z(#$P<'0[)SXQ.#PO9&EV/CPO9&EV/CPO=&0^/'1D(&YO M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$P<'0[)SX\+V1I=CX\9&EV('-T>6QE/3-$)V9O;G0M9F%M M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@6QE/3-$)V9O;G0M9F%M:6QY M.B`G5&EM97,@3F5W(%)O;6%N)RP@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@=F5R=&EC86PM M86QI9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\+W1R/CQT M6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('1E>'0M:6YD96YT.B`R-W!T.R!F;VYT+69A;6EL>3H@)U1I;65S M($YE=R!2;VUA;BF4Z(#$P<'0[)SY$969E6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O M;6%N)RP@6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG M/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD M:78^)B,Q-C`[/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI M9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@ M.24[('9E6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD M:78^)B,Q-C`[/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78^ M)B,Q-C`[/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ M(&)O='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M('9E3H@ M)U1I;65S($YE=R!2;VUA;BF4Z(#$P<'0[)SXS M,#PO9&EV/CPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX] M,T1B;W1T;VT@3H@)U1I M;65S($YE=R!2;VUA;BF4Z(#$P<'0[)SX\+V1I M=CX\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N M)RP@6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@ M6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD M:78^)B,Q-C`[/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78^ M)B,Q-C`[/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ M(&)O='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M('9E3H@ M)U1I;65S($YE=R!2;VUA;BF4Z(#$P<'0[)SXT M+#$T,SPO9&EV/CPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI M9VX],T1B;W1T;VT@3H@ M)U1I;65S($YE=R!2;VUA;BF4Z(#$P<'0[)SX\ M+V1I=CX\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O M;6%N)RP@6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O M;6%N)RP@6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O M;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\+W1R/CQT6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O M='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O M;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@=F5R=&EC M86PM86QI9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@.24[('9E3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$P<'0[)SX\+V1I=CX\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G M5&EM97,@3F5W(%)O;6%N)RP@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@6QE/3-$ M)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD M:78@6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N M)RP@3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$P<'0[)SXI/"]D:78^/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI M9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^ M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!W:61T:#H@.24[('9E3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$P<'0[)SXH,CDP/"]D:78^/"]D:78^/"]T9#X\=&0@;F]W M6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N M)RP@6QE/3-$)V)A8VMG6QE/3-$)W=I9'1H.B`U,B4[('9E6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC M86PM86QI9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[ M/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[('9E3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$P<'0[)SXH,34\+V1I=CX\+V1I=CX\+W1D/CQT M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O M='1O;3LG/CQD:78@6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@ M3F5W(%)O;6%N)RP@3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$P<'0[ M)SXI/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I M9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[ M/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O M;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[('9E3H@)U1I;65S M($YE=R!2;VUA;BF4Z(#$P<'0[)SXH,3,\+V1I M=CX\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@=F5R M=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@6QE/3-$)V9O;G0M M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@=F5R M=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@3H@)U1I;65S($YE=R!2;VUA;BF4Z M(#$P<'0[)SX\+V1I=CX\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM M97,@3F5W(%)O;6%N)RP@3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$P M<'0[)SXI/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78^)B,Q M-C`[/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O M='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[('9E M6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$P<'0[)SX\+V1I=CX\9&EV('-T>6QE/3-$)V9O M;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@F4Z(#$P<'0[)SXI/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O M='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@=F5R M=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[('9E3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$P<'0[)SXH,3D\+V1I=CX\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@ M'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[('9E3H@)U1I;65S($YE=R!2 M;VUA;BF4Z(#$P<'0[)SXH-"PR-CD\+V1I=CX\ M+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@=VED M=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/&1I=CXF(S$V,#L\ M+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[('9E3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$P<'0[)SXH-2PU-3@\+V1I=CX\+V1I=CX\+W1D/CQT9"!N;W=R87`] M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('!A9&1I;F"!S;VQI M9#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG M;CH@8F]T=&]M.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[('9E3H@)U1I;65S($YE M=R!2;VUA;BF4Z(#$P<'0[)SXH,BPT,38\+V1I M=CX\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@ M=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/&1I=CXF(S$V M,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[('9E3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$P<'0[)SXH,BPV,#4\+V1I=CX\+V1I=CX\+W1D/CQT9"!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('!A9&1I;F3H@)U1I M;65S($YE=R!2;VUA;BF4Z(#$P<'0[)SY$969E M3H@)U1I;65S M($YE=R!2;VUA;BF4Z(#$P<'0[)SXQ-2PQ.3@\ M+V1I=CX\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=F5R M=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78^)B,Q M-C`[/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM M97,@3F5W(%)O;6%N)RP@6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N M)RP@#L@=VED=&@Z(#4R)3L@=F5R M=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78^/&1I=B!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,C=P=#L@9F]N="UF86UI;'DZ M("=4:6UE6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@ M3H@)U1I;65S($YE=R!2;VUA M;BF4Z(#$P<'0[)SX\+V1I=CX\9&EV('-T>6QE M/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@#L@=VED=&@Z(#$E.R!V M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@#L@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/&1I M=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG M/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@ M3F5W(%)O;6%N)RP@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!S;VQI M9#L@=&5X="UA;&EG;CH@3H@ M)U1I;65S($YE=R!2;VUA;BF4Z(#$P<'0[)SX\ M+V1I=CX\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O M;6%N)RP@#L@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/&1I=CXF M(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@#L@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG M;CH@8F]T=&]M.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@=F5R=&EC86PM M86QI9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O6QE/3-$)V9O;G0M M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@ M#L@ M=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/&1I=CXF(S$V M,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@ M.24[('9E6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$ M)V)O6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O M;6%N)RP@6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@"!D;W5B;&4[('1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`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`@("`\=&%B;&4@ M8VQA3L@=&5X="UI;F1E;G0Z M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`S-G!T.R!D:7-P M;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R M9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM2!#;W)P;W)A=&EO;B`H M(DQI=FEN9R!$871A(BDL(&%N(&%F9FEL:6%T92!O9B!+97)N&-L=7-I=F4@=V]R;&1W:61E M(&1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#'0M=&]P.R<^)B,Q-S0[/"]F;VYT/B!S>7-T96US(&UA;G5F M86-T=7)E9"!T:')O=6=H($QI=FEN9R!$871A+B!4:&4@1&ES=')I8G5T:6]N M($%G2`S,2P@,C`Q,BXF(S$V,#LF(S$V,#M3=6)S97%U96YT('1O($%U M9W5S="`S,2P@,C`Q,2!T:&4@0V]M<&%N>2!A8W%U:7)E9"!,:69E($5N:&%N M8V5M96YT(%1E8VAN;VQO9WD@*$Q%5"D@*'-E92!.;W1E($DI+"!T:&4@;6%N M=69A8W1U3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#'0M=&]P.R<^)B,Q-S0[/"]F;VYT/B!S>7-T96TN)B,Q-C`[)B,Q M-C`[0V]N6QE/3-$ M)W1E>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE M2`R."P@,C`Q,2P@ M1&%V:60F(S$V,#M,:65B97)M86X@86YD($5D9V%R(%)I;W,@=V5R92!A<'!O M:6YT960@8GD@=&AE($)O87)D(&]F($1I2`D.#(L,#`P(&%N9"`D,30Y M+#`P,"!W97)E(&)I;&QE9"!B>2!T:&4@9FER;2!T:')O=6=H('1H92!T:')E M92!A;F0@3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&IU'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B M;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE M9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM2!#;VYS=6QT86YT M3H@:6YL M:6YE.R!F;VYT+7-I>F4Z(#'0M=&]P M.R<^)B,Q-S0[/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M M:6YD96YT.B`P<'0[(&1I3H@5&EM M97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P M<'0[(&UA3L@=&5X="UI;F1E;G0Z(#!P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2 M;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G M:6XM65R+CPO9&EV/CPO=&0^/"]T6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[)SXR+CPO M9F]N=#XF(S$V,#LF(S$V,#L\+V1I=CX\+W1D/CQT9#X\9&EV('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'0[(&9O;G0M M9F%M:6QY.B!4:6UE2!C;VQL86)O2P@969F:6-I96YC>2!A;F0O;W(@ M8V]S="!E9F9E8W1I=F5N97-S(&]F('1H92!%14-0)B,Q-S0[('1H97)A<'D@ M9F]R($Y92$$@0VQA3H@:6YL:6YE.R!F M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3L@=&5X="UI;F1E;G0Z M(#!P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE M9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM2!A6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\='(@=F%L:6=N M/3-$=&]P/CQT9"!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W=I9'1H.B`S-G!T M.R<^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY M.B!4:6UE6QE/3-$)V1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F M;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z M(#$P<'0[)SXU+CPO9F]N=#XF(S$V,#LF(S$V,#L\+V1I=CX\+W1D/CQT9#X\ M9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT M.B`P<'0[(&9O;G0M9F%M:6QY.B!4:6UE'1E;F0@ M8V]V97)A9V4@86YD('!R;W9I9&4@9F]R('1H92!R96EM8G5R2!F;W(@3EE(02!#;&%S6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[(&9O;G0M9F%M M:6QY.B!4:6UE2!H87,@86=R M965D('1O(&ES2P@;V8@=VAI8V@@=&AE('-U8G-T M86YT:6%L('!O2!O M=F5R('1H92!T=V\@>65AF5D('9A;'5E(&ES(')E<&]R=&5D(&%S($1E9F5R6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[(&9O;G0M M9F%M:6QY.B!4:6UE"!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q,BP@82!D:7)E8W1O2`D,3`L,#`P+CPO9&EV/CQD:78@ M3H@8FQO8VL[)SX\ M8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI M;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US M:7IE.B`Q,'!T.R!M87)G:6XM2!F;W(@)#(X."PP,#`@:6X@=6YS M96-U6%B;&4@=&\@=&AE(%!R97-I9&5N="!O9B!,150@ M86YD(&AI"!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q M,BX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U-#AA.6,S,U]A,3(V7S0Y939? M83'0O:'1M;#L@ M8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/&1I=CX\9&EV('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM M;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE.B!I=&%L:6,[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM M;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA3L@=&5X="UI;F1E;G0Z(#,V<'0[ M(&1I3H@5&EM97,@3F5W(%)O;6%N M.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA65E&EM=6T@;G5M8F5R(&]F('-H87)E3L@=&5X="UI;F1E;G0Z(#,V<'0[(&1I M3H@5&EM97,@3F5W(%)O;6%N.R!M M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA2!P2X\+V1I M=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[(&9O M;G0M9F%M:6QY.B!4:6UE2!O9B!T:&4@2P@,3$P)2!O9B!S=6-H(&9A:7(@;6%R:V5T('9A;'5E*2XF(S$V M,#LF(S$V,#M4:&4@=&5R;2!O9B!A;GD@;W!T:6]N(&UA>2!B92!F:7AE9"!B M>2!T:&4@0F]A&5R8VES92!P&5R8VES92!O9B!T:&4@;W!T:6]N+CPO9&EV/CQD:78@3H@8FQO8VL[)SX\8G(@ M+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ M(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE M.B`Q,'!T.R!M87)G:6XM2XF(S$V,#LF(S$V,#M!65A65E'1E;G-I;VX@;V8@=&AE($=%2$,@06=R965M96YT+"!V M97-T:6YG(&%T('9A2`R,#$R+"`U,#`L,#`P('-H87)E3L@=&5X="UI;F1E;G0Z(#,V<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F M=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&IU'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B M;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE M9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM2!I65A2!I3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&IU3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[(&9O;G0M9F%M:6QY M.B!4:6UE2!F:6QE9"!A($-EF5D(&)Y('1H92!";V%R9"!O9B!$ M:7)E8W1O2!T:6UE(&]N(&]R(&%F=&5R($IA;G5A&5R8VES92!P2!B92!C;VYV97)T960@:6YT;R!S:&%R97,@;V8@8V]M;6]N('-T;V-K M(&]N(&]R(&%F=&5R($IU;'D@,2P@,C`Q,2P@870@=&AE('1H96X@969F96-T M:79E(&%P<&QI8V%B;&4@8V]N=F5R2!T M:6UE(&9O;&QO=VEN9R!T:&4@27-S=6%N8V4@1&%T92P@=&AE('!R:6-E(&]F M('1H92!C;VUM;VX@2`S,"!C;VYS96-U=&EV92!T7,@97%U86QS(&]R(&5X8V5E9',@=&AR964@=&EM97,@=&AE($-O M;G9E2=S(&-O;6UO;B!S=&]C:R!F;W(@=&AE M(#,P(&-O;G-E8W5T:79E('1R861I;F<@9&%Y&-E961S(#(U,"PP,#`@ M3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&IU'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y M.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN M+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM2!C;VYV M97)T960@=&\@8V]M;6]N('-T;V-K(&5F9F5C=&EV92!*=6QY(#$L(#(P,3$N M)B,Q-C`[)B,Q-C`[07,@;V8@2G5N92`S,"P@,C`Q,BP@,S`L-C8X+#4P,"!S M:&%R97,@;V8@8V]M;6]N('-T;V-K(&AA9"!B965N(&ES3H@8FQO8VL[)SX\ M8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI M;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US M:7IE.B`Q,'!T.R!M87)G:6XM"!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q,2P@=&AE($-O;7!A M;GD@2XF(S$V,#LF(S$V,#M4 M:&5S92!A6UE M;G0@86YD(&-E87-E9"!O;B!C;VYV97)S:6]N(&]F('1H92!397)I97,@12!0 M3H@8FQO8VL[)SX\8G(@+SX\+V1I M=CX\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA3L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES M<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&IU3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO M8VL[(&9O;G0M9F%M:6QY.B!4:6UE2!S:6=N960@;VX@36%Y(#$Y+"`R,#$P+B8C,38P.R8C,38P M.U1H92!A;65N9&UE;G0L(&5F9F5C=&EV92!*=6QY(#$L(#(P,3(L(&5X=&5N M9',@=&AE(&EN:71I86P@=&5R;2!O9B!T:')E92!Y96%R3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&IU'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B M;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE M9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM65A6UE;G1S M(&]F('5P('1O("0R+C(@;6EL;&EO;B!A;F0@,BXR(&UI;&QI;VX@65E65D('1H7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)W1E M>'0M86QI9VXZ(&IU3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE M3L@=&5X="UI;F1E;G0Z(#,V<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T M.R!F;VYT+7-I>F4Z(#$P<'0[(&UA2!A9&]P=&EO;B!P97)M:71T960N M)B,Q-C`[)B,Q-C`[5&AE(&%D;W!T:6]N(&]F('1H:7,@9W5I9&%N8V4@9&ED M(&YO="!H879E(&$@;6%T97)I86P@:6UP86-T(&]N('1H92!#;VUP86YY)W,@ M8V]N6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[ M(&9O;G0M9F%M:6QY.B!4:6UE3H@8FQO8VL[)SX\ M8G(@+SX\+V1I=CX\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!F:6YA;F-I86P@:6YF;W)M871I;VX@9F]R('-E9VUE;G1S/"]T M9#X-"B`@("`@("`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`Q,'!T.R!B;W)D97(M=&]P M.B`C-&)A8V,V(#`N-7!T('-O;&ED.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R!B;W)D97(M=&]P.B`C-&)A8V,V(#`N-7!T('-O;&ED.R<^/&1I M=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B M;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[(&)O#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R!B;W)D97(M=&]P.B`C-&)A8V,V(#`N-7!T('-O;&ED.R<^ M/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$ M)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M(&)O3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[(&)O#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R!B;W)D97(M=&]P.B`C-&)A8V,V(#`N-7!T('-O M;&ED.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@#L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!B;W)D97(M=&]P M.B`C-&)A8V,V(#`N-7!T('-O;&ED.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D M/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CX\+V1I=CX\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@#L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX] M,T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY M.B!T:6UE#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@#L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`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`R<'@@#L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I M=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`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`P<'0[(&1I M3H@=&EM97,@;F5W(')O;6%N.R!M M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA'1E6QE/3-$)W=I9'1H.B`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`R-B4[)SX\9&EV/CQD:78@3H@8FQO8VL[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^/&1I=CXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY M.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXI M/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=W:61T:#H@,24[(&1I3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B0\+V1I=CX\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SX\9&EV/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F M="!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^/&1I=CXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXI/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=W:61T:#H@,24[(&1I3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^ M/"]T6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXD/"]D:78^/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@ M.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!A;&EG M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`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`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF M(S$V,#L\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\ M9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY M.B!T:6UE3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/C,R+#`U-3PO9&EV/CPO M=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P M.SPO9&EV/CPO=&0^/"]T6QE/3-$)W=I9'1H.B`R-B4[ M)SX\9&EV/CQD:78@3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^/&1I=CXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O M;G0M9F%M:6QY.B!T:6UE3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/C6QE M/3-$)W=I9'1H.B`R-B4[(&1I6QE M/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P M.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/BT\+V1I=CX\+W1D/CQT9"!N;W=R87`] M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H M.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SX\9&EV/C@L.3@T/"]D:78^/"]T9#X\=&0@;F]W6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`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`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`R<'@@'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)W!A9&1I;F6QE M/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG M;CH@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F#L@=VED=&@Z(#(V)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CX\+V1I=CX\ M+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W!A9&1I;F6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^ M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B M;&%C:R`R<'@@'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV M/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@#L@ M=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@ M6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('!A9&1I;F#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C M,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B M;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\ M9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI M9VX],T1B;W1T;VT@#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV M/CPO=&0^/"]T#L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CX\ M+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!C M;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E M>'0M86QI9VXZ(&-E;G1E3H@ M8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE#L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\ M+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!C M;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E M>'0M86QI9VXZ(&-E;G1E3H@ M8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\ M9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/CPO9&EV/CPO=&0^ M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@ M,G!X.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C M:R`R<'@@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@#L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX] M,T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W=I M9'1H.B`R-B4[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I M=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`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`R-B4[)SX\9&EV/CQD:78@3H@8FQO8VL[ M(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXD/"]D:78^/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T M:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!A M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q M)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^ M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T M.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SX\9&EV/C0L,#6QE/3-$)W=I9'1H.B`R-B4[(&1I6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M M9F%M:6QY.B!T:6UE3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/BT\+V1I=CX\ M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V M,#L\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV M/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T M:6UE3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/C4L,36QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD M96YT.B`P<'0[(&1I3H@=&EM97,@ M;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[ M(&UA6QE M/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P M.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B@T-S4\+V1I=CX\+W1D/CQT9"!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO=&0^/'1D(&%L:6=N/3-$;&5F M="!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^/&1I=CXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXI/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`R M-B4[(&1I6QE/3-$)W=I9'1H.B`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`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G M:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SX\9&EV/B0\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F M="!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^/&1I=CXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV M/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@ M6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXD/"]D:78^ M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I M=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W=I9'1H.B`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`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF M(S$V,#L\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\ M9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY M.B!T:6UE3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/C,L-34R/"]D:78^/"]T M9#X\=&0@;F]W6QE/3-$)W=I9'1H M.B`R-B4[(&1I6QE/3-$)W=I9'1H M.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SX\9&EV/BT\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!A;&EG;CTS M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T M:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UEF4Z(#$P<'0[)SX\ M9&EV/C0L,S`Q/"]D:78^/"]T9#X\=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^/&1I=CXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F M="!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^/&1I=CXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV M/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@ M6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXD/"]D:78^ M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO M=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXD/"]D:78^/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`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`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`R<'@@'0M M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\='(^/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R!B;W)D97(M=&]P.B`C-&)A8V,V(#`N-7!T('-O M;&ED.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@ M8V]L6QE/3-$)V)O"!S;VQI9#L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!B;W)D97(M=&]P.B`C-&)A8V,V M(#`N-7!T('-O;&ED.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!S;VQI9#L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R!B;W)D97(M=&]P.B`C-&)A8V,V(#`N-7!T('-O;&ED.R<^/&1I=CXF(S$V M,#L\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE M/3-$)V)O"!S;VQI9#L@8F]R9&5R+71O M<#H@(S1B86-C-B`P+C5P="!S;VQI9#LG/CQD:78^/&1I=B!S='EL93TS1"=T M97AT+6%L:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`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`R<'@@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV M/B8C,38P.SPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A M9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE M/3-$)V)O"!S;VQI9#LG/CQD:78^/&1I M=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`P M<'0[(&1I3H@=&EM97,@;F5W(')O M;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C M,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P M861D:6YG+6)O='1O;3H@,G!X.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^ M/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D M97(M8F]T=&]M.B!B;&%C:R`R<'@@#L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`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`R-B4[)SX\9&EV/CQD:78@3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXD/"]D:78^/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\ M+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W=I9'1H.B`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`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I M=CXF(S$V,#L\+V1I=CX\+W1D/CPO='(^/'1R(&)G8V]L;W(],T1W:&ET93X\ M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T M:#H@,C8E.R<^/&1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I M>F4Z(#$P<'0[(&UA6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\ M9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY M.B!T:6UE3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B@S-3,\+V1I=CX\+W1D M/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO=&0^/'1D(&%L M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^/&1I=CXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXI/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W=I9'1H.B`R-B4[(&1I6QE/3-$ M)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO M9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L M:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SX\9&EV/B@W-3@\+V1I=CX\+W1D/CQT9"!N;W=R87`] M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO=&0^/'1D(&%L:6=N/3-$;&5F="!V M86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^/&1I=CXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)W=I9'1H.B`R-B4[)SX\ M9&EV/CQD:78@3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$ M)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO M9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L M:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SX\9&EV/CDL,S(S/"]D:78^/"]T9#X\=&0@;F]W3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B0\+V1I=CX\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SX\9&EV/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V M86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^/&1I=CXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY M.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\ M9&EV/B0\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I M=CXF(S$V,#L\+V1I=CX\+W1D/CPO='(^/'1R(&)G8V]L;W(],T1W:&ET93X\ M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T M:#H@,C8E.R<^/&1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I M>F4Z(#$P<'0[(&UA6QE/3-$)W=I9'1H.B`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`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXD/"]D:78^ M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO M=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXD/"]D:78^/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SX\9&EV/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F M="!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^/&1I=CXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\ M9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX] M,T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I M=CXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF M(S$V,#L\+V1I=CX\+W1D/CPO='(^/'1R(&)G8V]L;W(],T1W:&ET93X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O"!S;VQI9#L@=VED=&@Z(#(V)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CX\+V1I=CX\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R M<'@@'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`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`R<'@@'0M86QI9VXZ(')I9VAT.R!W:61T M:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$ M)V)O"!S;VQI9#L@=VED=&@Z(#(V)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^/&1I=CX\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C M,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B M;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`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`R<'@@'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE M6QE M/3-$)W!A9&1I;F6QE M/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG M;CH@;&5F=#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^ M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B M;&%C:R`R<'@@'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W!A9&1I M;F6QE/3-$)V)O"!S;VQI M9#L@=&5X="UA;&EG;CH@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$ M)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE"!M;VYT:',@96YD960@2G5N92`S M,"P@,C`Q,3PO9&EV/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI M9VX],T1B;W1T;VT@#L@=VED M=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`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`R<'@@'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\ M9&EV/CPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P M861D:6YG+6)O='1O;3H@,G!X.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^ M/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D M97(M8F]T=&]M.B!B;&%C:R`R<'@@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C M,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P M861D:6YG+6)O='1O;3H@,G!X.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^ M/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D M97(M8F]T=&]M.B!B;&%C:R`R<'@@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!S;VQI9#LG/CQD:78^/&1I=B!S='EL93TS1"=T97AT+6%L M:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@ M,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UAF4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R M<'@@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`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`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV M/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`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`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXD/"]D:78^/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T M:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SX\9&EV/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V M86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^/&1I=CXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY M.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV M/B8C,38P.SPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B M;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXD M/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E M>'0M:6YD96YT.B`P<'0[(&1I3H@ M=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z M(#$P<'0[(&UA6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV M/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T M:6UE3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B@W-#$\+V1I=CX\+W1D/CQT M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO=&0^/'1D(&%L:6=N M/3-$;&5F="!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^/&1I=CXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O M;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXI/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I M9'1H.B`R-B4[(&1I6QE/3-$)W=I M9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV M/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SX\9&EV/B@R.#,\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^*3PO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI M9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M/&1I=CXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T M:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P M<'0[(&1I3H@=&EM97,@;F5W(')O M;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B0\+V1I=CX\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D(&%L M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^/&1I=CXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SX\9&EV/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX] M,T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I M=CXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF M(S$V,#L\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W=I9'1H.B`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`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O M;G0M9F%M:6QY.B!T:6UE3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/C,L-34R M/"]D:78^/"]T9#X\=&0@;F]W6QE M/3-$)W=I9'1H.B`R-B4[(&1I6QE M/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P M.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/BT\+V1I=CX\+W1D/CQT9"!N;W=R87`] M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H M.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SX\9&EV/C0L,S`Q/"]D:78^/"]T9#X\=&0@;F]W6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXD/"]D:78^/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D(&%L M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^/&1I=CXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SX\9&EV/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX] M,T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I M=CXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE M3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P M.SPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@ M6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXD/"]D:78^ M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`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`R<'@@'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A M9&1I;F3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV M/CPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D M:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@=VED M=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)W!A9&1I;F6QE M/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG M;CH@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE6QE M/3-$)W=I9'1H.B`T,"4[(&9O;G0M9F%M:6QY.B!4:6UE3H@5&EM97,@3F5W(%)O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[(&)O6QE/3-$ M)W=I9'1H.B`W)3L@8F]R9&5R+71O<#H@(S1B86-C-B`P+C5P="!S;VQI9#LG M/CQD:78@"!M;VYT:',@96YD960@2G5N92`S,"P\ M+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[(&)O6QE/3-$)W=I9'1H.B`S M)3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R!B;W)D97(M=&]P.B`C-&)A8V,V(#`N-7!T('-O;&ED.R<^)B,Q-C`[ M(#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@.24[ M(&9O;G0M9F%M:6QY.B!4:6UE'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G M:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W=I9'1H.B`Y)3L@9F]N="UF M86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!B;W)D M97(M=&]P.B`C-&)A8V,V(#`N-7!T('-O;&ED.R<^)B,Q-C`[(#PO=&0^/"]T M6QE/3-$)W1E>'0M86QI9VXZ(&-E M;G1E3H@8FQO8VL[(&9O;G0M M9F%M:6QY.B!4:6UE6QE/3-$)V)O"!S;VQI9#L@=VED=&@Z(#3H@ M5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O"!S;VQI9#L@=VED=&@Z(#DE.R<^/&1I=B!S='EL93TS1"=T M97AT+6%L:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM M;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G M:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W=I9'1H.B`Y)3LG/CQD:78@3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE6QE M/3-$)W=I9'1H.B`W)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]T M9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W M:61T:#H@.24[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E M>'0M:6YD96YT.B`P<'0[(&1I3H@ M5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z M(#$P<'0[(&UA3H@8FQO8VL[(&9O;G0M9F%M M:6QY.B!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD M96YT.B`P<'0[(&1I3H@5&EM97,@ M3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[ M(&UA6QE/3-$)W=I M9'1H.B`Y)3LG/CQD:78@6QE M/3-$)W=I9'1H.B`T,"4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT M+7-I>F4Z(#$P<'0[(&UA6QE M/3-$)W=I9'1H.B`Y)3LG/CQD:78@3H@8FQO8VL[(&9O;G0M9F%M M:6QY.B!4:6UE6QE/3-$)W=I9'1H.B`S)3L@ M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\=&0@86QI9VX],T1L M969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@.24[)SX\9&EV M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[ M(&1I3H@5&EM97,@3F5W(%)O;6%N M.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W=I9'1H.B`Y)3LG/CQD:78@ M3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE6QE/3-$)V)O"!D;W5B;&4[('=I9'1H.B`Y)3LG/CQD:78@3H@8FQO8VL[ M(&9O;G0M9F%M:6QY.B!4:6UE6QE/3-$)W=I9'1H M.B`W)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W M(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\=&0@86QI M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T M=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R!W:61T:#H@.24[)SX\9&EV('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G M:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)V)O"!D;W5B;&4[('=I M9'1H.B`Y)3LG/CQD:78@6QE/3-$)V)O"!S;VQI9#L@=VED=&@Z(#0P)3L@9F]N="UF86UI;'DZ M(%1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M M.B!B;&%C:R`R<'@@3H@8FQO M8VL[)SX\8G(@+SX\+V1I=CX\+V1I=CX\'0^/&1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&IU'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@ M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P M=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM6QE.B!I=&%L:6,[('1E>'0M:6YD96YT.B`S M-G!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2 M;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G M:6XM6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@ M,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM M;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W=I9'1H.B`Q,B4[(&)O6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT M+7-I>F4Z(#$P<'0[(&UA6QE M/3-$)W=I9'1H.B`R,"4[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E M3H@8FQO8VL[(&9O;G0M9F%M M:6QY.B!4:6UE6QE/3-$)W=I9'1H M.B`T)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W M(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O"!S;VQI9#L@=VED=&@Z(#$R)3LG/CQD:78@'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM M;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE6QE/3-$)W=I9'1H.B`Q,24[)SX\9&EV M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[ M(&1I3H@5&EM97,@3F5W(%)O;6%N M.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W=I9'1H.B`Q,B4[)SX\9&EV('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM M;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W=I9'1H.B`Q,"4[)SX\9&EV M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[ M(&1I3H@5&EM97,@3F5W(%)O;6%N M.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W=I9'1H.B`U)3L@9&ES<&QA M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\=&0@86QI9VX],T1L969T('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,3(E.R<^/&1I=B!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P M;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R M9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM6QE/3-$)W=I9'1H.B`R)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@ M/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=W:61T:#H@,3$E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T M.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI M;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US M:7IE.B`Q,'!T.R!M87)G:6XM6QE/3-$)W=I M9'1H.B`T)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@ M3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\=&0@ M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@ M,3(E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S M($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T M.R!M87)G:6XM6QE/3-$)W=I9'1H.B`R)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@ M/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=W:61T:#H@,3`E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T M.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI M;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US M:7IE.B`Q,'!T.R!M87)G:6XM6QE/3-$)W=I9'1H.B`U)3L@9&ES M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\=&0@86QI9VX],T1L969T M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,3(E.R<^/&1I=B!S M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!D M:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@ M;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM2!I6QE/3-$)W=I9'1H.B`Q,24[)SX\9&EV('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I M3H@5&EM97,@3F5W(%)O;6%N.R!M M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W=I9'1H.B`Q,B4[)SX\9&EV('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F M=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA3H@8FQO8VL[ M(&9O;G0M9F%M:6QY.B!4:6UE6QE/3-$)W=I9'1H.B`U)3L@9&ES<&QA M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\=&0@86QI9VX],T1L969T('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,3(E.R<^/&1I=B!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P M;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R M9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM6QE/3-$ M)W=I9'1H.B`R,"4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('1E>'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I M>F4Z(#$P<'0[(&UA6QE/3-$)W=I9'1H.B`R)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@ M/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=W:61T:#H@,3$E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T M.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI M;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US M:7IE.B`Q,'!T.R!M87)G:6XM6QE/3-$)W=I9'1H.B`Q,B4[)SX\9&EV('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I M3H@5&EM97,@3F5W(%)O;6%N.R!M M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W=I9'1H.B`R)3L@9&ES<&QA M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\=&0@86QI9VX],T1L969T('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,3`E.R<^/&1I=B!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P M;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R M9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM6QE/3-$)W=I9'1H.B`Q,B4[ M)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT M.B`P<'0[(&1I3H@5&EM97,@3F5W M(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA M6QE/3-$)W=I9'1H.B`Q,24[)SX\9&EV('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@ M,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE M/3-$)W=I9'1H.B`Q,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT M+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W=I9'1H.B`Q,"4[)SX\9&EV('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@ M,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W=I9'1H.B`U)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L@/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=W:61T:#H@,3(E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@ M9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM6QE/3-$)W=I9'1H.B`R M,"4[(&1I3H@8FQO8VL[(&9O;G0M9F%M M:6QY.B!4:6UE6QE/3-$)V)O"!D;W5B;&4[('=I9'1H.B`Q,B4[)SX\9&EV('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F M=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W=I9'1H.B`R)3L@9&ES<&QA>3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L@/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE M.R!W:61T:#H@,3`E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T M.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI M;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US M:7IE.B`Q,'!T.R!M87)G:6XM6QE/3-$)W=I9'1H.B`U)3L@9&ES M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\=&0@86QI9VX],T1L969T M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C M:R`T<'@@9&]U8FQE.R!W:61T:#H@,3(E.R<^/&1I=B!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C M:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z M(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM3H@5&EM97,@ M3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O"!S;VQI9#L@=VED=&@Z(#0E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W M(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O"!S;VQI9#L@=VED=&@Z(#$R)3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2 M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO=&0^/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@ M3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^ M/&1I=B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C M:SLG/CQB7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT M+7-I>F4Z(#$P<'0[(&UA2=S(&%S3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I M>F4Z(#$P<'0[(&UA6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE'0M:6YD96YT M.B`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`P<'0[ M(&1I3H@=&EM97,@;F5W(')O;6%N M.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)V1I6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT^/&1I=B!S='EL93TS M1"=T97AT+6%L:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G M:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI M9VX],T1B;W1T;VT^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([ M('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I M>F4Z(#$P<'0[(&UA3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT^/&1I=B!S='EL M93TS1"=T97AT+6%L:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`P<'0[(&1I M3H@=&EM97,@;F5W(')O;6%N.R!M M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('!A9&1I;F3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX] M,T1B;W1T;VT@'0M M:6YD96YT.B`P<'0[(&1I3H@=&EM M97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P M<'0[(&UA3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O"!S;VQI9#LG/CQD:78@#L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`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`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^ M/'1R(&)G8V]L;W(],T0C8V-E969F/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`Q.'!T.R!D:7-P;&%Y M.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN M+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`[/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXM/"]T M9#X\=&0@;F]W3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@ M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`Q M.'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G M:6XM#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ,3`\+W1D/CQT9"!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I M;F6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A M9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!S;VQI9#L@ M=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F#L@=VED=&@Z(#DE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXQ,3`\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A M9&1I;F6QE/3-$)W!A M9&1I;F6QE/3-$)V)O"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@ M=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXY+#DT-#PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V M86QI9VX],T1B;W1T;VT@#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I M;F6QE/3-$)V)O"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T M=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@=VED M=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXM/"]T9#X\=&0@;F]W3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY M.B!T:6UE3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$ M)V1I6QE M/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N M/3-$,B!V86QI9VX],T1B;W1T;VT^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N M.B!C96YT97([('1E>'0M:6YD96YT.B`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`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`P<'0[(&1I3H@ M=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z M(#$P<'0[(&UA6QE/3-$)V1I6QE M/3-$)V1I6QE/3-$)V1I6QE/3-$)W!A9&1I M;F#L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[ M/"]T9#X\=&0@8V]L6QE/3-$ M)V)O"!S;VQI9#LG/CQD:78@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('!A9&1I;F3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@ M'0M:6YD96YT.B`P M<'0[(&1I3H@=&EM97,@;F5W(')O M;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UAF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@ M;&5F=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG M;CH@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I M;F6QE/3-$)W=I9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!M87)G:6XM6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@ M.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[ M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@ M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(] M,T0C8V-E969F/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W=I9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('1E>'0M:6YD96YT.B`Q.'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@ M9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@ M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@ M,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT M+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXM/"]T9#X\=&0@;F]W3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I M9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E M>'0M:6YD96YT.B`Q.'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE M.B`Q,'!T.R!M87)G:6XM6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H M.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ,3`\+W1D M/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M+W1R/CQT6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R!T97AT+6%L M:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ+#0R,SPO=&0^/'1D(&YO=W)A M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@#L@=VED=&@Z(#$E.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`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`@("`\=&%B;&4@8VQA'0^/&1I=CX\9&EV M/CQD:78@3H@5&EM97,@3F5W M(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA M3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE6QE/3-$ M)W!A9&1I;F#L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!B;W)D97(M=&]P.B`C M-&)A8V,V(#`N-7!T('-O;&ED.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O"!S;VQI9#L@8F]R9&5R+71O<#H@(S1B86-C-B`P+C5P="!S;VQI M9#LG/CQD:78@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;FF4Z(#$P M<'0[(&)O'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T M.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I M;FF4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT^ M/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('1E>'0M:6YD96YT M.B`P<'0[(&1I3H@=&EM97,@;F5W M(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA M6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ,"PX,#0\+W1D M/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T M:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXR,BPW,S<\+W1D/CQT M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R M/CQT3H@ M8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ,C$\+W1D/CQT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@ M.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T1W:&ET93X\=&0@ M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@ M-S8E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN M9&5N=#H@,C=P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXI/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O M;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXI M/"]T9#X\+W1R/CQT6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@ M.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\+V1I=CX\+V1I M=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3L@ M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY M.B!4:6UE3H@8FQO8VL[(&9O M;G0M9F%M:6QY.B!4:6UE6QE/3-$)W!A9&1I;F#L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!B;W)D M97(M=&]P.B`C-&)A8V,V(#`N-7!T('-O;&ED.R<^)B,Q-C`[/"]T9#X\=&0@ M8V]L6QE/3-$)V)O"!S;VQI9#L@8F]R9&5R+71O<#H@(S1B86-C-B`P M+C5P="!S;VQI9#LG/CQD:78@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;FF4Z(#$P<'0[(&)O'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM M;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('!A9&1I;F3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX] M,T1B;W1T;VT^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('1E M>'0M:6YD96YT.B`P<'0[(&1I3H@ M=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z M(#$P<'0[(&UA6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!T:6UE6QE M/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M M:6QY.B!T:6UE3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I M9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T M:6UE3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXU-S4\+W1D/CQT9"!N;W=R87`],T1N;W=R M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L969T('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C M8V-E969F/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W=I9'1H.B`W-B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT M+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXQ+#`U,3PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B M;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T1W:&ET93X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!D;W5B;&4[('1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U M8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXR+#(X-3PO M=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@#L@=VED M=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F6QE M/3-$)V)O"!D;W5B;&4[('1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`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`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$ M)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@ M;&5F=#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U-#AA M.6,S,U]A,3(V7S0Y939?83'0O:'1M;#L@8VAA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^ M/&1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I M;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q M,'!T.R!M87)G:6XM"!A;F0@=&AR964@;6]N=&AS(&5N9&5D($IU;F4@,S`L M(#(P,3(N)B,Q-C`[)B,Q-C`[5&AE($-O;G-O;&ED871E9"!#;VYD96YS960@ M0F%L86YC92!3:&5E="!A3H@8FQO8VL[(&9O;G0M9F%M M:6QY.B!4:6UE6QE/3-$)W=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R!B;W)D97(M=&]P.B`C-&)A8V,V(#`N-7!T('-O;&ED.R<^ M/&1I=CX\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY M.B!T:6UE3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[(&)O6QE/3-$)W=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!B;W)D M97(M=&]P.B`C-&)A8V,V(#`N-7!T('-O;&ED.R<^/&1I=CXF(S$V,#L\+V1I M=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O6QE/3-$)W=I9'1H.B`X."4[)SX\9&EV M/CQD:78@3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@ M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W M:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@ M.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CPO='(^/'1R M(&)G8V]L;W(],T0C8V-E969F/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`X."4[)SX\9&EV/CQD:78@3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`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`T<'@@9&]U8FQE.R!T97AT M+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SX\9&EV/C,L.36QE/3-$)W!A9&1I;F6QE/3-$)V)O M"!S;VQI9#L@=&5X="UA;&EG;CH@6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('!A9&1I;F'0^/&1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF M86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N M="US:7IE.B`Q,'!T.R!M87)G:6XM2!B92!A9&IU2!EF5S('1H92!E6QE/3-$)V9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[)SXH:6X@=&AO=7-A;F1S M*3PO9F]N=#X\+V1I=CX\9&EV/CQD:78^/'1A8FQE(&-E;&QP861D:6YG/3-$ M,"!C96QL6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T M.R!F;VYT+7-I>F4Z(#$P<'0[(&UA3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[(&)O3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O M6QE/3-$)W=I9'1H.B`X."4[)SX\ M9&EV/CQD:78@3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CPO='(^/'1R(&)G M8V]L;W(],T0C8V-E969F/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W=I9'1H.B`X."4[)SX\9&EV/CQD:78@3H@ M8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CPO='(^/'1R(&)G8V]L;W(] M,T1W:&ET93X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=W:61T:#H@.#@E.R<^/&1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T M.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/"]T3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\ M9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/C,L M.38X/"]D:78^/"]T9#X\=&0@;F]W6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO=&0^/"]T#L@=VED=&@Z(#@X M)3LG/CQD:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT M+6EN9&5N=#H@,C=P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T M:6UE6QE/3-$)V)O"!D;W5B;&4[('1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXD/"]D:78^/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@ M.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('!A9&1I;F6QE/3-$)V)O"!S;VQI9#L@=VED=&@Z(#@X)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CX\+V1I=CX\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@#L@ M=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@ M'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF M(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@'0^/&1I=CX\9&EV M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`S M-G!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2 M;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G M:6XM6QE/3-$)W1E>'0M M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[(&9O;G0M M9F%M:6QY.B!4:6UEF4Z(#$P<'0[(&)O#L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!B;W)D97(M M=&]P.B`C-&)A8V,V(#`N-7!T('-O;&ED.R<^/&1I=CXF(S$V,#L\+V1I=CX\ M+W1D/CQT9"!A;&EG;CTS1&QE9G0@8V]L6QE/3-$)W!A9&1I;F3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O M"!M;VYT M:',@96YD960@2G5N92`S,"P\+V1I=CX\+V1I=CX\+W1D/CQT9"!A;&EG;CTS M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[(&)O#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R!B;W)D97(M=&]P.B`C-&)A8V,V(#`N-7!T('-O;&ED M.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O M#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R!B;W)D97(M=&]P.B`C-&)A8V,V(#`N-7!T('-O;&ED.R<^/&1I=CXF M(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M M86QI9VXZ(&-E;G1E3H@8FQO M8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W!A9&1I M;F3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)OF4Z(#$P<'0[)SX\9&EV/CPO9&EV/CPO=&0^/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV M/B8C,38P.SPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE M/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!S;VQI9#LG/CQD:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C M96YT97([('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F M;VYT+7-I>F4Z(#$P<'0[(&UA#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@#L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`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`R M<'@@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@ M,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I M=CXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$ M)W=I9'1H.B`Q,R4[(&1I6QE/3-$ M)W=I9'1H.B`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`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXD/"]D:78^/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T M:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SX\9&EV/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V M86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^/&1I=CXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CPO='(^/'1R(&)G8V]L;W(],T1W:&ET M93X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`R-B4[(&1I M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I M=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`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`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO M9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L M:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT M.B`P<'0[(&1I3H@=&EM97,@;F5W M(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA M6QE M/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P M.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B@Q+#$P-3PO9&EV/CPO=&0^/'1D(&YO M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXI/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q,R4[(&1I6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M M:6QY.B!T:6UE3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B@Y-3<\+V1I=CX\ M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO=&0^/'1D M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`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`],T1N;W=R87`@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`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`Q)3L@9&ES<&QA>3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[ M(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\ M9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$ M)W=I9'1H.B`Q,R4[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CPO='(^/'1R M(&)G8V]L;W(],T0C8V-E969F/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`R-B4[)SX\9&EV/CQD:78@3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I M=CXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO=&0^ M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,3,E.R!D:7-P M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^/&1I=CXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^*3PO=&0^/'1D(&%L:6=N/3-$6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV M/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T M:6UE3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/C`N,#`\+V1I=CX\+W1D/CQT M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I M=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/CPO9&EV/CPO=&0^/'1D(&%L M:6=N/3-$6QE/3-$)W=I9'1H.B`Q M)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^ M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T M.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SX\9&EV/B@P+C`Q/"]D:78^/"]T9#X\=&0@;F]W6QE/3-$)V)O"!S;VQI9#L@=VED=&@Z(#(V)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CX\+V1I=CX\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C M:R`R<'@@'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO M=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@#L@=VED M=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('!A9&1I;F#L@=VED=&@Z(#$E.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV M/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V M86QI9VX],T1B;W1T;VT@#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO M9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M M8F]T=&]M.B!B;&%C:R`R<'@@6QE/3-$)W!A9&1I M;F6QE/3-$)V)O"!S;VQI M9#L@=&5X="UA;&EG;CH@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA3H@8FQO8VL[(&9O;G0M9F%M M:6QY.B!4:6UE2=S M(&]T:&5R(&EN=&%N9VEB;&4@87-S971S(&-O;G-I3H@8FQO8VL[)SX\8G(@+SX\ M+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E#L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CX\+V1I=CX\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!C;VQS<&%N/3-$,B!V M86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&-E M;G1E3H@8FQO8VL[(&9O;G0M M9F%M:6QY.B!T:6UEF4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@ MF4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO=&0^/"]T6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`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`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I M=CXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE M3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B0\+V1I M=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V,#L\+V1I M=CX\+W1D/CPO='(^/'1R(&)G8V]L;W(],T1W:&ET93X\=&0@86QI9VX],T1L M969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@-S8E.R<^/&1I M=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT M.B`R-W!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M M87)G:6XM6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CXF(S$V M,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H M.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV/B8C,38P.SPO9&EV/CPO M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXI/"]T9#X\+W1R/CQT6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`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`R<'@@'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)W!A9&1I;F6QE M/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG M;CH@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-T>6QE M.B!I=&%L:6,[('1E>'0M:6YD96YT.B`S-G!T.R!F;VYT+69A;6EL>3H@)U1I M;65S($YE=R!2;VUA;BF4Z(#$P<'0[)SXH:6X@ M=&AO=7-A;F1S*3PO9&EV/CQD:78^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C M96QLF4Z(#$P<'0[)SX\='(^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=V M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/&1I=CX\9&EV('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N M)RP@3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$P<'0[)SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('9E3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$P<'0[)SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@ M3H@)U1I;65S($YE=R!2 M;VUA;BF4Z(#$P<'0[)SY&;W(@=&AE('1H6QE/3-$)W9E6QE/3-$)W9E M"!S;VQI9#L@=F5R=&EC86PM86QI9VXZ M(&)O='1O;3LG/CQD:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT M97([(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('9E3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$P<'0[)SXR,#$Q/"]D:78^/"]D:78^/"]T9#X\=&0@;F]W6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W9E"!S;VQI9#L@=F5R=&EC86PM86QI9VXZ(&)O='1O M;3LG/CQD:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O M;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('9E6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N M)RP@6QE M/3-$)W9E3H@)U1I;65S($YE M=R!2;VUA;BF4Z(#$P<'0[)SXH=6YA=61I=&5D M*3PO9&EV/CPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX] M,T1B;W1T;VT@6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('9E6QE/3-$)V)A M8VMG6QE/3-$)W=I9'1H.B`U,B4[('9E6QE/3-$)V9O;G0M9F%M:6QY M.B`G5&EM97,@3F5W(%)O;6%N)RP@3H@ M)U1I;65S($YE=R!2;VUA;BF4Z(#$P<'0[)SXQ M-2PR,C<\+V1I=CX\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[/"]D M:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q M)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^ M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD M:78^/&1I=B!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA M;BF4Z(#$P<'0[)SXD/"]D:78^/"]D:78^/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[('9E6QE/3-$)V9O M;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM M97,@3F5W(%)O;6%N)RP@3H@)U1I;65S M($YE=R!2;VUA;BF4Z(#$P<'0[)SXQ,"PW.3(\ M+V1I=CX\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T M9#X\+W1R/CQT6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N M)RP@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@=F5R=&EC86PM M86QI9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI M9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^ M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!W:61T:#H@.24[('9EF4Z(#$P<'0[)SX\+V1I=CX\9&EV('-T>6QE/3-$)V9O;G0M M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$P M<'0[)SXW,S`\+V1I=CX\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[ M/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H M.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[/"]D M:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG M/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[('9E3H@)U1I;65S($YE M=R!2;VUA;BF4Z(#$P<'0[)SXS-S,\+V1I=CX\ M+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@=F5R=&EC M86PM86QI9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM M86QI9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[/"]D M:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!W:61T:#H@.24[('9EF4Z(#$P<'0[)SXS,S,\+V1I=CX\+V1I=CX\+W1D/CQT9"!N M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O M;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\+W1R/CQT6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M M:6YD96YT.B`R-W!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$P<'0[)SY$969E6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78^)B,Q M-C`[/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I M9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[ M/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O M;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[('9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[ M/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H M.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[/"]D M:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG M/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[('9E3H@)U1I;65S($YE M=R!2;VUA;BF4Z(#$P<'0[)SXQ-3PO9&EV/CPO M9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@ M3H@)U1I;65S($YE=R!2 M;VUA;BF4Z(#$P<'0[)SX\+V1I=CX\9&EV('-T M>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$P<'0[)SX\+V1I=CX\9&EV('-T>6QE/3-$)V9O;G0M9F%M M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@6QE/3-$)V9O;G0M9F%M:6QY M.B`G5&EM97,@3F5W(%)O;6%N)RP@6QE/3-$)V9O;G0M9F%M:6QY.B`G M5&EM97,@3F5W(%)O;6%N)RP@6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI M9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ M(&)O='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[('9E3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$P<'0[)SXS,#PO9&EV/CPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@6QE/3-$)V)A8VMG6QE M/3-$)W=I9'1H.B`U,B4[('9E3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$P<'0[)SX\+V1I=CX\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G M5&EM97,@3F5W(%)O;6%N)RP@6QE/3-$)V9O;G0M9F%M:6QY.B`G M5&EM97,@3F5W(%)O;6%N)RP@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@=F5R=&EC86PM M86QI9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI M9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^ M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!W:61T:#H@.24[('9E3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$P<'0[)SXR+#3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$P<'0[)SX\+V1I=CX\9&EV('-T>6QE/3-$)V9O;G0M9F%M M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@F4Z(#$P<'0[)SY296-O9VYI M>F5D(&%S(')E=F5N=64Z/"]D:78^/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O M='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@=F5R M=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[('9E6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O M='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O M;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@=F5R=&EC M86PM86QI9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@.24[('9E6QE/3-$)V)A8VMG6QE/3-$)W=I9'1H.B`U,B4[('9E6QE/3-$)W=I9'1H.B`Q)3L@ M=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78^ M)B,Q-C`[/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[('9E3H@)U1I;65S($YE=R!2;VUA M;BF4Z(#$P<'0[)SXH-34W/"]D:78^/"]D:78^ M/"]T9#X\=&0@;F]W6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM M97,@3F5W(%)O;6%N)RP@3H@ M)U1I;65S($YE=R!2;VUA;BF4Z(#$P<'0[)SXH M-C`T/"]D:78^/"]D:78^/"]T9#X\=&0@;F]W6QE/3-$)V9O M;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$P<'0[)SX\+V1I=CX\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY M.B`G5&EM97,@3F5W(%)O;6%N)RP@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@6QE M/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$P<'0[)SXI/"]D:78^/"]T9#X\+W1R/CQT6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M M:6YD96YT.B`R-W!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$P<'0[)SY$969E6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$P<'0[)SXH,38\+V1I=CX\+V1I=CX\+W1D/CQT M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O M='1O;3LG/CQD:78@6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@ M3F5W(%)O;6%N)RP@6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W M(%)O;6%N)RP@3H@)U1I;65S M($YE=R!2;VUA;BF4Z(#$P<'0[)SX\+V1I=CX\ M9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@ M6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W M(%)O;6%N)RP@6QE/3-$)V)A8VMG6QE/3-$)W=I9'1H.B`U,B4[('9E M6QE/3-$)W=I9'1H.B`Q)3L@=F5R M=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78^)B,Q M-C`[/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[('9E3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$P<'0[)SXH-#,\+V1I=CX\+V1I=CX\+W1D M/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ M(&)O='1O;3LG/CQD:78@6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM M97,@3F5W(%)O;6%N)RP@3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$P M<'0[)SXI/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78^)B,Q M-C`[/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O M='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[('9E M3H@)U1I M;65S($YE=R!2;VUA;BF4Z(#$P<'0[)SXH,C$\ M+V1I=CX\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@6QE/3-$)V9O M;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@6QE/3-$)V9O;G0M M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@6QE/3-$)V)A8VMG6QE M/3-$)W!A9&1I;F#L@ M=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/&1I=CXF(S$V M,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78^ M)B,Q-C`[/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)V)O6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O M;6%N)RP@6QE/3-$)V9O;G0M M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@#L@=VED=&@Z(#$E.R!V97)T:6-A;"UA M;&EG;CH@8F]T=&]M.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@=F5R=&EC M86PM86QI9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O6QE/3-$)V9O M;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O M;6%N)RP@#L@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/&1I=CXF M(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD M:78^)B,Q-C`[/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W M(%)O;6%N)RP@6QE/3-$)V9O M;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@#L@=VED=&@Z(#$E.R!V97)T:6-A M;"UA;&EG;CH@8F]T=&]M.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@=F5R M=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O6QE/3-$ M)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W M(%)O;6%N)RP@6QE/3-$)V)A8VMG6QE/3-$)W=I9'1H.B`U,B4[('9E M6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O M='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@=F5R M=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@ M3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$P<'0[)SX\+V1I=CX\9&EV('-T>6QE/3-$ M)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$P<'0[)SX\+V1I=CX\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY M.B`G5&EM97,@3F5W(%)O;6%N)RP@6QE/3-$)V)A8VMG6QE/3-$)W!A9&1I M;F"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!V M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@'0M86QI9VXZ(')I9VAT.R!W:61T:#H@ M.24[('9E3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$P<'0[ M)SXQ,"PV.#4\+V1I=CX\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A M9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$P<'0[)SX\+V1I=CX\9&EV('-T>6QE/3-$)V9O M;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F M=#L@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/&1I=CXF M(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@'0M86QI9VXZ M(')I9VAT.R!W:61T:#H@.24[('9E3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$P<'0[)SXQ,"PV.#4\+V1I=CX\+V1I=CX\+W1D/CQT9"!N M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE M/3-$)V)O3H@)U1I;65S M($YE=R!2;VUA;BF4Z(#$P<'0[)SX\+V1I=CX\ M9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@ M#L@=VED=&@Z(#4R)3L@=F5R=&EC86PM86QI9VXZ(&)O M='1O;3LG/CQD:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F M;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$P<'0[)SY,;VYG+71E6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$ M)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@6QE/3-$)V9O;G0M9F%M:6QY M.B`G5&EM97,@3F5W(%)O;6%N)RP@"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`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`G5&EM97,@3F5W(%)O;6%N)RP@ M6QE/3-$ M)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\U-#AA.6,S,U]A,3(V7S0Y939?83'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'1E'!E;G-E/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XS+#0Y,#QS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA6UE;G0@07=A'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$65A65A'!E;G-E M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%SF5D(&5X<&5N&ES=&EN9R!S:&%R92UB87-E9"!A M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\U-#AA.6,S,U]A,3(V7S0Y939?83'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R&-E<'0@4&5R(%-H87)E(&1A=&$L('5N;&5S&-L=61E9"!F&-L=61E9"!F&-L=61E9"!F&-L=61E9"!F3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U-#AA.6,S M,U]A,3(V7S0Y939?83'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$65E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\6%B;&4@86YD(&]T M:&5R(&-U'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M2!I M;G1E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'10 M87)T7S4T.&$Y8S,S7V$Q,C9?-#EE-E]A-S=E7V%B9&-C-#)E-3(P8@T*0V]N M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\U-#AA.6,S,U]A,3(V7S0Y939? M83'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XV+#`P,#QS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U-#AA.6,S,U]A,3(V M7S0Y939?83'0O M:'1M;#L@8VAA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F5D(&%S(')E=F5N=64Z/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R,2D\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$65A2!W87)R86YT'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$&5R8VES92!P'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAAF5D("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$6EN9R!M;W)E('1H86X@,3`P('!E M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^-5D\ M'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2!I'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$F5D("AI;B!S:&%R97,I/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S2!T7,@97AC965D7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A65A M&EM=6T@&UL/@T* M+2TM+2TM/5].97AT4&%R=%\U-#AA.6,S,U]A,3(V7S0Y939?83 XML 18 R29.htm IDEA: XBRL DOCUMENT v2.4.0.6
ORGANIZATION AND PLAN OF OPERATIONS (Details)
Jun. 30, 2012
ORGANIZATION AND PLAN OF OPERATIONS [Abstract]  
Number of contiguous states in which VasoHealthcare has been appointed exclusive representative for GE Healthcare Diagnostic Imaging products 48
Number of Chinese operating companies acquired 2
Number of wholly-owned subsidiaries 3
XML 19 R28.htm IDEA: XBRL DOCUMENT v2.4.0.6
DEFERRED REVENUE (Tables)
 6 Months Ended
Jun. 30, 2012
DEFERRED REVENUE [Abstract]  
Changes in deferred revenues
The changes in the Company's deferred revenues are as follows:
(in thousands)
 
 
For the six months ended June 30,
 
 
For the three months ended June 30,
 
 
 
2012
 
 
2011
 
 
2012
 
 
2011
 
 
 
(unaudited)
 
 
(unaudited)
 
 
(unaudited)
 
 
(unaudited)
 
Deferred revenue at the beginning of the period
 
$
15,227
 
 
$
12,637
 
 
$
14,781
 
 
$
10,792
 
Additions:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Deferred extended service contracts
 
 
700
 
 
 
730
 
 
 
373
 
 
 
333
 
Deferred in-service and training
 
 
20
 
 
 
18
 
 
 
15
 
 
 
10
 
Deferred service arrangements
 
 
55
 
 
 
45
 
 
 
30
 
 
 
30
 
Deferred commission revenues
 
 
4,080
 
 
 
4,143
 
 
 
2,731
 
 
 
3,117
 
Recognized as revenue:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Deferred extended service contracts
 
 
(557
)
 
 
(604
)
 
 
(282
)
 
 
(290
)
Deferred in-service and training
 
 
(15
)
 
 
(16
)
 
 
(13
)
 
 
(8
)
Deferred service arrangements
 
 
(43
)
 
 
(35
)
 
 
(21
)
 
 
(19
)
Deferred commission revenues
 
 
(4,269
)
 
 
(5,558
)
 
 
(2,416
)
 
 
(2,605
)
Deferred revenue at end of period
 
 
15,198
 
 
 
11,360
 
 
 
15,198
 
 
 
11,360
 
Less: current portion
 
 
10,685
 
 
 
8,047
 
 
 
10,685
 
 
 
8,047
 
Long-term deferred revenue at end of period
 
$
4,513
 
 
$
3,313
 
 
$
4,513
 
 
$
3,313
 
XML 20 R30.htm IDEA: XBRL DOCUMENT v2.4.0.6
SEGMENT REPORTING AND CONCENTRATIONS (Details) (USD $)
In Thousands, unless otherwise specified
 3 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended 3 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended
Jun. 30, 2012
Jun. 30, 2011
Jun. 30, 2012
Jun. 30, 2011
Dec. 31, 2011
Jun. 30, 2012
GE Healthcare [Member]
Jun. 30, 2011
GE Healthcare [Member]
Jun. 30, 2012
GE Healthcare [Member]
Jun. 30, 2011
GE Healthcare [Member]
Jun. 30, 2012
GE Healthcare [Member]
Accounts and Other Receivables [Member]
Customer Concentration Risk [Member]
Dec. 31, 2011
GE Healthcare [Member]
Accounts and Other Receivables [Member]
Customer Concentration Risk [Member]
Jun. 30, 2012
Equipment Segment [Member]
Jun. 30, 2011
Equipment Segment [Member]
Jun. 30, 2012
Equipment Segment [Member]
Jun. 30, 2011
Equipment Segment [Member]
Jun. 30, 2012
Corporate [Member]
Jun. 30, 2011
Corporate [Member]
Jun. 30, 2012
Corporate [Member]
Jun. 30, 2011
Corporate [Member]
Jun. 30, 2012
Sales Representation Segment [Member]
Jun. 30, 2011
Sales Representation Segment [Member]
Jun. 30, 2012
Sales Representation Segment [Member]
Jun. 30, 2011
Sales Representation Segment [Member]
SEGMENT REPORTING AND CONCENTRATIONS [Abstract]                                              
Number of segments     2                                        
Segment Reporting Information [Line Items]                                              
Revenues from external customers $ 7,697 $ 5,175 $ 13,740 $ 10,020               $ 1,555 $ 1,100 $ 3,541 $ 2,205 $ 0 $ 0 $ 0 $ 0 $ 6,142 $ 4,075 $ 10,199 $ 7,815
Operating income/(loss) 75 (960) (1,226) (1,442)               (197) (475) (353) (741) (409) (99) (758) (283) 681 (386) (115) (418)
Total assets 32,055 18,457 32,055 18,457 34,306             9,323 4,440 9,323 4,440 11,174 7,687 11,174 7,687 11,558 6,330 11,558 6,330
Accounts and other receivables, net 8,984 4,301 8,984 4,301 20,695         7,700 19,700 1,151 749 1,151 749 0 0 0 0 7,833 3,552 7,833 3,552
Deferred commission expense 3,490 2,703 3,490 2,703               0 0 0 0 0 0 0 0 3,490 2,703 3,490 2,703
Revenue, Major Customer [Line Items]                                              
Percentage of revenue (in hundredths)           80.00% 79.00% 74.00% 78.00%                            
Concentration Risk [Line Items]                                              
Accounts and other receivables $ 8,984 $ 4,301 $ 8,984 $ 4,301 $ 20,695         $ 7,700 $ 19,700 $ 1,151 $ 749 $ 1,151 $ 749 $ 0 $ 0 $ 0 $ 0 $ 7,833 $ 3,552 $ 7,833 $ 3,552
Percentage of accounts and other receivables (in hundredths)                   86.00% 95.00%                        
XML 21 R31.htm IDEA: XBRL DOCUMENT v2.4.0.6
SHARE-BASED COMPENSATION (Details) (USD $)
 1 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended
Jul. 30, 2012
Jun. 30, 2012
Jun. 30, 2011
Jun. 30, 2012
Restricted Stock [Member]
Sep. 30, 2011
Restricted Stock [Member]
Jun. 30, 2011
Restricted Stock [Member]
Jun. 30, 2012
Restricted Stock [Member]
Jun. 30, 2011
Restricted Stock [Member]
Jun. 30, 2012
Restricted Stock [Member]
Officer [Member]
Jun. 30, 2011
Restricted Stock [Member]
Director [Member]
Jun. 30, 2012
Restricted Stock [Member]
Director [Member]
Jun. 30, 2011
Restricted Stock [Member]
Director [Member]
Jun. 30, 2012
Stock Compensation Plan [Member]
Jun. 30, 2011
Stock Compensation Plan [Member]
Jun. 30, 2012
Stock Compensation Plan [Member]
Jun. 30, 2011
Stock Compensation Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                
Granted (in shares)             2,190,000 10,000 500,000 166,279   366,279        
Value of stock granted             $ 548,000 $ 6,800 $ 120,000 $ 73,500   $ 135,500        
Remainder of vesting period 1 year                   1 year          
Issued (in shares)         5,000,000                      
Share-based compensation expense   231,000 203,000 102,000   77,000 231,000 203,000                
Allocated share-based arrangements                         136,000 162,000 288,000 208,000
Unrecognized expense related to existing share-based arrangements   $ 1,300,000                            
XML 22 R8.htm IDEA: XBRL DOCUMENT v2.4.0.6
SEGMENT REPORTING AND CONCENTRATIONS
 6 Months Ended
Jun. 30, 2012
SEGMENT REPORTING AND CONCENTRATIONS [Abstract]  
SEGMENT REPORTING AND CONCENTRATIONS
NOTE C - SEGMENT REPORTING AND CONCENTRATIONS

The Company views its business in two segments - the Equipment segment and the Sales Representation segment.  The Equipment segment is engaged in designing, manufacturing, marketing and supporting EECP® enhanced external counterpulsation systems both domestically and internationally, as well as the marketing of other medical devices.  The Sales Representation segment operates through the VasoHealthcare subsidiary and is currently engaged solely in the execution of the Company's responsibilities under our agreement with GEHC.  The Company evaluates segment performance based on operating income.  Administrative functions such as finance, human resources, and information technology are centralized and related expenses allocated to each segment.  Other costs not directly attributable to operating segments, such as audit, legal, director fees, investor relations, and others, as well as certain assets - primarily cash balances - are reported in the Corporate entity below. There are no intersegment revenues.  Summary financial information for the segments is set forth below:
(in thousands)
 
 
 
 
 
 
As of or for the three months ended June 30, 2012
 
 
 
 
 
 
 
Equipment Segment
 
 
Sales Representation Segment
 
 
Corporate
 
 
Consolidated
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenues from external customers
 
$
1,555
 
 
$
6,142
 
 
$
-
 
 
$
7,697
 
Operating income/(loss)
 
$
(197
)
 
$
681
 
 
$
(409
)
 
$
75
 
Total assets
 
$
9,323
 
 
$
11,558
 
 
$
11,174
 
 
$
32,055
 
Accounts and other receivables, net
 
$
1,151
 
 
$
7,833
 
 
$
-
 
 
$
8,984
 
Deferred commission expense
 
$
-
 
 
$
3,490
 
 
$
-
 
 
$
3,490
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As of or for the three months ended June 30, 2011
 
 
 
 
 
 
 
 
 
Equipment Segment
 
 
Sales Representation Segment
 
 
Corporate
 
 
Consolidated
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenues from external customers
 
$
1,100
 
 
$
4,075
 
 
$
-
 
 
$
5,175
 
Operating loss
 
$
(475
)
 
$
(386
)
 
$
(99
)
 
$
(960
)
Total assets
 
$
4,440
 
 
$
6,330
 
 
$
7,687
 
 
$
18,457
 
Accounts and other receivables, net
 
$
749
 
 
$
3,552
 
 
$
-
 
 
$
4,301
 
Deferred commission expense
 
$
-
 
 
$
2,703
 
 
$
-
 
 
$
2,703
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

(in thousands)
 
 
 
 
 
 
As of or for the six months ended June 30, 2012
 
 
 
 
 
 
 
Equipment Segment
 
 
Sales Representation Segment
 
 
Corporate
 
 
Consolidated
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenues from external customers
 
$
3,541
 
 
$
10,199
 
 
$
-
 
 
$
13,740
 
Operating loss
 
$
(353
)
 
$
(115
)
 
$
(758
)
 
$
(1,226
)
Total assets
 
$
9,323
 
 
$
11,558
 
 
$
11,174
 
 
$
32,055
 
Accounts and other receivables, net
 
$
1,151
 
 
$
7,833
 
 
$
-
 
 
$
8,984
 
Deferred commission expense
 
$
-
 
 
$
3,490
 
 
$
-
 
 
$
3,490
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As of or for the six months ended June 30, 2011
 
 
 
 
 
 
 
 
 
Equipment Segment
 
 
Sales Representation Segment
 
 
Corporate
 
 
Consolidated
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenues from external customers
 
$
2,205
 
 
$
7,815
 
 
$
-
 
 
$
10,020
 
Operating loss
 
$
(741
)
 
$
(418
)
 
$
(283
)
 
$
(1,442
)
Total assets
 
$
4,440
 
 
$
6,330
 
 
$
7,687
 
 
$
18,457
 
Accounts and other receivables, net
 
$
749
 
 
$
3,552
 
 
$
-
 
 
$
4,301
 
Deferred commission expense
 
$
-
 
 
$
2,703
 
 
$
-
 
 
$
2,703
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


For the three months ended June 30, 2012 and 2011, GE Healthcare accounted for 80% and 79% of revenue, respectively.  For the six months ended June 30, 2012 and 2011, GE Healthcare accounted for 74% and 78% of revenue, respectively.   Also, GE Healthcare accounted for $7.7 million, or 86%, and $19.7 million, or 95%, of accounts and other receivables at June 30, 2012 and December 31, 2011, respectively.
XML 23 R32.htm IDEA: XBRL DOCUMENT v2.4.0.6
EARNINGS (LOSS) PER COMMON SHARE (Details) (USD $)
In Thousands, except Per Share data, unless otherwise specified
 3 Months Ended 6 Months Ended
Jun. 30, 2012
Jun. 30, 2011
Jun. 30, 2012
Jun. 30, 2011
EARNINGS (LOSS) PER COMMON SHARE [Abstract]        
Basic and diluted loss per common share (in dollars per share) $ 0.00 $ (0.01) $ (0.01) $ (0.01)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of diluted earnings per share (in shares) 2,135 40,731 10,628 40,731
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]        
Basic weighted average shares outstanding (in shares) 158,072 116,198 156,225 114,077
Dilutive effect of share-based compensation (in shares) 1,334 0 0 0
Contingently issuable shares (in shares) 2,400 0 0 0
Diluted weighted average shares outstanding (in shares) 161,806 116,198 156,225 114,077
Stock Options [Member]
        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of diluted earnings per share (in shares) 260 1,864 1,810 1,864
Warrant [Member]
        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of diluted earnings per share (in shares) 1,500 4,286 1,500 4,286
Contingently Issuable Shares [Member]
        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of diluted earnings per share (in shares) 0 0 2,400 0
Convertible Preferred Stock [Member]
        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of diluted earnings per share (in shares) 0 30,668 0 30,668
Common Stock Grants [Member]
        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of diluted earnings per share (in shares) 375 3,913 4,918 3,913
XML 24 R40.htm IDEA: XBRL DOCUMENT v2.4.0.6
STOCKHOLDERS' EQUITY (Details) (USD $)
 1 Months Ended 3 Months Ended 6 Months Ended 1 Months Ended 3 Months Ended 6 Months Ended 1 Months Ended 3 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended 1 Months Ended 3 Months Ended
Jul. 30, 2012
Dec. 31, 2011
Sep. 30, 2011
Jun. 30, 2011
Jun. 30, 2012
Jun. 30, 2011
Sep. 02, 2011
Jul. 31, 2011
Series E Convertible Preferred Stock [Member]
Jun. 30, 2011
Series E Convertible Preferred Stock [Member]
Jun. 30, 2011
Series E Convertible Preferred Stock [Member]
Jul. 02, 2011
Series E Convertible Preferred Stock [Member]
Jun. 30, 2010
Series E Convertible Preferred Stock [Member]
Jun. 30, 2010
Preferred Stock [Member]
Jul. 30, 2012
Restricted Stock [Member]
Mar. 31, 2012
Restricted Stock [Member]
Sep. 30, 2011
Restricted Stock [Member]
Jun. 30, 2012
Restricted Stock [Member]
Sep. 30, 2011
Warrant [Member]
Jun. 30, 2010
2010 Plan [Member]
Jul. 30, 2012
2010 Plan [Member]
Restricted Stock [Member]
Jun. 30, 2012
2010 Plan [Member]
Restricted Stock [Member]
Sep. 30, 2011
2010 Plan [Member]
Warrant [Member]
Mar. 31, 2012
2010 Plan [Member]
Officer [Member]
Restricted Stock [Member]
Jun. 30, 2012
2010 Plan [Member]
Non-officer Employee [Member]
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                                
Number of shares authorized (in shares)                                     5,000,000          
Number of equity programs                                     2          
Option price as a percentage of fair market value (in hundredths)                                     100.00%          
Threshold for paying more than 100 percent of fair value (in hundredths)                                     10.00%          
Option price for ten percent shareholders as a percentage of fair market value (in hundredths)                                     110.00%          
Terms of award (in years)                                     5Y     2Y    
Granted to date                                         3,790,000      
Granted during period (in shares)                                       500,000     500,000 2,190,000
Forfeited (in shares)                                 755,000              
Vested (in shares)                           0 250,000                  
Issued (in shares)                 0 9,375           5,000,000   1,500,000            
Share Price (dollar per share)   $ 0.5                   $ 0.16                        
Vesting Period 1 year                                              
Number of shares of common stock contingently issuable (in shares)   2,400,000                                            
Aggregate value relative to the acquisition             $ 2,979,000                                  
Number of months for FGE to attain certain operating targets     12 months                                          
Class of Stock [Line Items]                                                
Preferred stock authorized (in shares)   1,000,000     1,000,000             350,000 1,000,000                      
Shares Issued upon conversion (in shares)                       100                        
Share Price   $ 0.5                   $ 0.16                        
Shares sold (in shares)                 0 9,375           5,000,000   1,500,000            
Aggregate value of shares sold                   150,000                            
Dividends recorded                 151,000 279,000                            
Common stock issued upon conversion of Series E preferred shares (in shares)   153,186,295     158,746,910           30,668,500                          
Shares issued (in shares)               306,685                                
Terms of conversion         Each share of outstanding Series E Preferred Stock shall automatically be converted into shares of common stock on or after July 1, 2011, at the then effective applicable conversion ratio, if, at any time following the Issuance Date, the price of the common stock for any 30 consecutive trading days equals or exceeds three times the Conversion Price and the average daily trading volume for the Company's common stock for the 30 consecutive trading days exceeds 250,000 shares.                                      
Beneficial conversion feature       $ 91,000   $ 156,000                                    
XML 25 R2.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) (USD $)
In Thousands, unless otherwise specified
Jun. 30, 2012
Dec. 31, 2011
CURRENT ASSETS    
Cash and cash equivalents $ 11,783 $ 2,294
Short-term investments 110 110
Accounts and other receivables, net of an allowance for doubtful accounts and commission adjustments of $1,965 at June 30, 2012 and $2,163 at December 31, 2011 8,984 20,695
Receivables due from related parties 10 196
Inventories, net 2,285 2,421
Financing receivables, net 20 19
Deferred commission expense 2,495 2,053
Deferred related party consulting expense - current portion 339 510
Other current assets 396 202
Total current assets 26,422 28,500
PROPERTY AND EQUIPMENT, net of accumulated depreciation of $1,540 at June 30, 2012 and $1,774 at December 31, 2011 564 429
GOODWILL 3,968 3,939
FINANCING RECEIVABLES, net 5 16
DEFERRED RELATED PARTY CONSULTING EXPENSE 0 85
OTHER ASSETS 1,096 1,337
Total Assets 32,055 34,306
CURRENT LIABILITIES    
Accounts payable 456 273
Accrued commissions 2,336 3,889
Accrued expenses and other liabilities 2,724 2,531
Sales tax payable 392 355
Income taxes payable 89 278
Deferred revenue - current portion 10,685 9,484
Deferred gain on sale-leaseback of building - current portion 4 31
Deferred tax liability, net 112 112
Notes payable due to related party 3 193
Total current liabilities 16,801 17,146
LONG-TERM LIABILITIES    
Deferred revenue 4,513 5,743
Other long-term liabilities 117 141
Total long-term liabilities 4,630 5,884
COMMITMENTS AND CONTINGENCIES (NOTE N)      
STOCKHOLDERS' EQUITY    
Preferred stock, $.01 par value; 1,000,000 shares authorized; nil shares issued and outstanding at June 30, 2012, and December 31, 2011 0 0
Common stock, $.001 par value; 250,000,000 shares authorized; 158,746,910 and 153,186,295 shares issued and outstanding at June 30, 2012 and December 31, 2011 159 153
Additional paid-in capital 60,771 60,188
Accumulated deficit (50,304) (49,065)
Accumulated other comprehensive income (loss) (2) 0
Total stockholders' equity 10,624 11,276
Total liabilities and stockholders' equity $ 32,055 $ 34,306
XML 26 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6
ORGANIZATION AND PLAN OF OPERATIONS
 6 Months Ended
Jun. 30, 2012
ORGANIZATION AND PLAN OF OPERATIONS [Abstract]  
ORGANIZATION AND PLAN OF OPERATIONS
NOTE A - ORGANIZATION AND PLAN OF OPERATIONS

Vasomedical, Inc. was incorporated in Delaware in July 1987. Unless the context requires otherwise, all references to "we", "our", "us", "Company", "registrant", "Vasomedical" or "management" refer to Vasomedical, Inc. and its subsidiaries. Until 2010, we were primarily engaged in designing, manufacturing, marketing and supporting EECP® enhanced external counterpulsation systems based on our unique proprietary technology currently indicated for use in cases of stable or unstable angina (i.e., chest pain), congestive heart failure ("CHF"), acute myocardial infarction (i.e., heart attack, (MI)) and cardiogenic shock.  In May 2010, the Company, through its wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, expanded into the sales representation business via its agreement with GE Healthcare ("GEHC"), the healthcare business unit of General Electric Company (NYSE: GE), to be GEHC's exclusive sales representative for the sale of select GEHC diagnostic imaging products in specific market segments in the 48 contiguous states of the United States and the District of Columbia.   In June 2012, the Company entered into an amendment, effective July 1, 2012, of the sales representative agreement ("GEHC Agreement") extending the initial term of three years commencing July 1, 2010 to five years through June 30, 2015, subject to earlier termination under certain circumstances.

In September 2011, the Company acquired Fast Growth Enterprises Limited (FGE), a British Virgin Islands company which, through its subsidiaries, owns and controls two Chinese operating companies - Life Enhancement Technologies Ltd. and Biox Instruments Co. Ltd., respectively - to expand its technical and manufacturing capabilities and to enhance its distribution network, technology, and product portfolio.  Also in September 2011, the Company restructured to further align its business management structure and long-term growth strategy and now operates through three wholly-owned subsidiaries.  Vaso Diagnostics d/b/a VasoHealthcare continues as the operating subsidiary for the sales representation of GE Healthcare diagnostic imaging products; Vasomedical Global Corp. operates the Company's recently-acquired Chinese companies; and Vasomedical Solutions, Inc. manages and coordinates our EECP® therapy business as well as other medical equipment operations.

We report the operations of Vasomedical Global Corp. and Vasomedical Solutions, Inc. under our Equipment reportable segment.  VasoHealthcare activities are included under our Sales Representation reportable segment (See Note C).
XML 27 R35.htm IDEA: XBRL DOCUMENT v2.4.0.6
INVENTORIES, NET (Details) (USD $)
Jun. 30, 2012
Dec. 31, 2011
INVENTORIES, NET [Abstract]    
Raw materials $ 938,000 $ 842,000
Work in process 575,000 528,000
Finished goods 772,000 1,051,000
Inventories, net 2,285,000 2,421,000
Reserves for excess and obsolete inventory $ 546,000 $ 606,000
XML 28 R22.htm IDEA: XBRL DOCUMENT v2.4.0.6
EARNINGS (LOSS) PER COMMON SHARE (Tables)
 6 Months Ended
Jun. 30, 2012
EARNINGS (LOSS) PER COMMON SHARE [Abstract]  
Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block]
Diluted earnings per share were computed based on the weighted average number of shares outstanding plus all potentially dilutive common stock equivalents.  A reconciliation of basic to diluted shares used in the earnings per share calculation is as follows:

   
Six months ended June 30,
     
Three months ended June 30,
 
 
2012
 
2011
 
2012
 
2011
Basic weighted average shares outstanding
       156,225
 
       114,077
 
       158,072
 
       116,198
Dilutive effect of share-based compensation
                -
 
                -
 
           1,334
 
                -
Contingently issuable shares
                -
 
                -
 
           2,400
 
                -
Diluted weighted average shares outstanding
       156,225
 
       114,077
 
       161,806
 
       116,198
               

Antidilutive common stock equivalents excluded from computation of diluted earnings per share
The following table represents common stock equivalents that were excluded from the computation of diluted earnings per share for the six and three months ended June 30, 2012 and 2011, because the effect of their inclusion would be anti-dilutive.
                                                 (in thousands)
   
For the
six
months ended
 
For the
three
months ended
   
June 30, 2012
 
June 30, 2011
 
June 30, 2012
 
June 30, 2011
Stock options
 
                 1,810
 
                    1,864
 
                  260
 
                     1,864
Warrants
 
                 1,500
 
                    4,286
 
               1,500
 
                     4,286
Contingently issuable shares
 
                 2,400
 
                          -
 
                     -
 
                          -
Convertible preferred stock
 
                       -
 
                  30,668
 
                     -
 
                   30,668
Common stock grants
 
                 4,918
 
                    3,913
 
                  375
 
                     3,913
   
               10,628
 
                  40,731
 
               2,135
 
                   40,731
                 

XML 29 R36.htm IDEA: XBRL DOCUMENT v2.4.0.6
BUSINESS COMBINATION (Details) (USD $)
 3 Months Ended 6 Months Ended
Jun. 30, 2012
Dec. 31, 2011
Jun. 30, 2011
Jun. 30, 2012
Jun. 30, 2011
Sep. 02, 2011
Business Acquisition [Line Items]            
Number of shares of common stock issued relating to acquisition (in shares)   2,400,000        
Fair values of assets acquired and liabilities assumed [Abstract]            
Cash and cash equivalents           $ 442,000
Accounts receivable and other current assets           283,000
Inventories           476,000
Property and equipment           32,000
Goodwill           3,968,000
Accounts payable and other current liabilities           (1,222,000)
Net assets acquired           3,979,000
Revenue 7,697,000   5,175,000 13,740,000 10,020,000  
Net loss 54,000   (956,000) (1,288,000) (1,422,000)  
Restricted Stock [Member]
            
Business Acquisition [Line Items]            
Number of shares of common stock issued relating to acquisition (in shares)       5,000,000    
Common Stock [Member]
            
Acquisition date fair value of total consideration transferred [Abstract]            
Share price (in dollars per share) $ 0.42     $ 0.42    
Warrant [Member]
            
Business Acquisition [Line Items]            
Number of shares of common stock issued relating to acquisition (in shares)       1,500,000    
Contingent Issuance of Common Stock [Member]
            
Business Acquisition [Line Items]            
Common stock contingently issuable       2,400,000    
Acquisition date fair value of total consideration transferred [Abstract]            
Share price (in dollars per share) $ 0.42     $ 0.42    
Fast Growth Enterprises Limited (FGE) [Member]
            
Acquisition date fair value of total consideration transferred [Abstract]            
Cash 1,000,000     1,000,000    
Total purchase price 3,979,000     3,979,000    
Fair values of assets acquired and liabilities assumed [Abstract]            
Revenue 332,000     910,000    
Net loss 110,000     24,000    
Supplemental pro forma information [Abstract]            
Basic and diluted loss per share (in dollars per share) $ 0.00   $ (0.01) $ (0.01) $ (0.01)  
Revenue 7,697,000   5,401,000 13,740,000 10,621,000  
Net Income 65,000   (683,000) (1,105,000) (957,000)  
Fast Growth Enterprises Limited (FGE) [Member] | Common Stock [Member]
            
Acquisition date fair value of total consideration transferred [Abstract]            
Equity interests issued and issuable 2,100,000     2,100,000    
Fast Growth Enterprises Limited (FGE) [Member] | Warrant [Member]
            
Acquisition date fair value of total consideration transferred [Abstract]            
Equity interests issued and issuable 304,000     304,000    
Fast Growth Enterprises Limited (FGE) [Member] | Contingent Issuance of Common Stock [Member]
            
Acquisition date fair value of total consideration transferred [Abstract]            
Equity interests issued and issuable $ 575,000     $ 575,000    
XML 30 R24.htm IDEA: XBRL DOCUMENT v2.4.0.6
ACCOUNTS AND OTHER RECEIVABLES, NET (Tables)
 6 Months Ended
Jun. 30, 2012
ACCOUNTS AND OTHER RECEIVABLES, NET [Abstract]  
Accounts and other receivables
The following table presents information regarding the Company's accounts and other receivables as of June 30, 2012 and December 31, 2011:
              (in thousands)
   
June 30, 2012
  
December 31, 2011
 
   
(unaudited)
    
Trade receivables
 $10,804  $22,737 
Due from employees
  145   121 
Allowance for doubtful accounts and
        
commission adjustments
  (1,965)  (2,163)
Accounts and other receivables, net
 $8,984  $20,695 
          
XML 31 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'
'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 32 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6
BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES
 6 Months Ended
Jun. 30, 2012
BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES [Abstract]  
BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES
NOTE B - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES

Basis of Presentation and Use of Estimates

The accompanying consolidated condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and pursuant to the accounting and disclosure rules and regulations of the Securities and Exchange Commission (the "SEC"). Certain information and disclosures normally included in the consolidated condensed financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these consolidated condensed financial statements should be read in connection with the audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the transition period ended December 31, 2011, as filed with the SEC. These consolidated condensed financial statements include the accounts of the companies over which we exercise control. In the opinion of management, the accompanying consolidated condensed financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of interim results for the Company. The results of operations for any interim period are not necessarily indicative of results to be expected for any other interim period or the full year.

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the consolidated condensed financial statements, the disclosure of contingent assets and liabilities in the consolidated condensed financial statements and the accompanying notes, and the reported amounts of revenues, expenses and cash flows during the periods presented. Actual amounts and results could differ from those estimates. The estimates and assumptions the Company makes are based on historical factors, current circumstances and the experience and judgment of the Company's management. The Company evaluates its estimates and assumptions on an ongoing basis.

Significant Accounting Policies

Note B of the Notes to Consolidated Financial Statements, included in the Transition Report on Form 10-K for the seven months ended December 31, 2011, includes a summary of the significant accounting policies used in the preparation of the consolidated condensed financial statements.

Reclassifications

Certain reclassifications have been made to prior period amounts to conform with the current period presentation.
XML 33 R3.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) (Parenthetical) (USD $)
In Thousands, except Share data, unless otherwise specified
Jun. 30, 2012
Dec. 31, 2011
CURRENT ASSETS    
Accounts and other receivables, allowance for doubtful accounts and commission adjustments $ 1,965 $ 2,163
PROPERTY AND EQUIPMENT, accumulated depreciation $ 1,540 $ 1,774
STOCKHOLDERS' EQUITY    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 1,000,000 1,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 250,000,000 250,000,000
Common stock, shares issued (in shares) 158,746,910 153,186,295
Common stock, shares outstanding (in shares) 158,746,910 153,186,295
XML 34 R17.htm IDEA: XBRL DOCUMENT v2.4.0.6
RELATED-PARTY TRANSACTIONS
 6 Months Ended
Jun. 30, 2012
RELATED-PARTY TRANSACTIONS [Abstract]  
RELATED-PARTY TRANSACTIONS
NOTE L - RELATED-PARTY TRANSACTIONS

On June 21, 2007, we entered into a Securities Purchase Agreement with Kerns Manufacturing Corp. ("Kerns").  Pursuant to this agreement, a five-year warrant to purchase 4,285,714 shares of our common stock at an initial exercise price of $0.08 per share was issued to Kerns.  In March 2012, Kerns exercised its warrant and purchased 4,285,714 shares of common stock.  Concurrently with our entry into the Securities Purchase Agreement, we also entered into a Distribution Agreement and a Supplier Agreement with Living Data Technology Corporation ("Living Data"), an affiliate of Kerns.  Pursuant to the Distribution Agreement, as amended, we became the exclusive worldwide distributor of the AngioNew EECP® systems manufactured through Living Data. The Distribution Agreement had an initial term extending through May 31, 2012.  Subsequent to August 31, 2011 the Company acquired Life Enhancement Technology (LET) (see Note I), the manufacturer of the AngioNew EECP® system.  Consequently, the Distribution Agreement is no longer effective, and the Company wrote-off the remaining unamortized balance of Deferred Distributor Costs during the seven months ended December 31, 2011.

On February 28, 2011, David Lieberman and Edgar Rios were appointed by the Board of Directors as directors of the Company.  Mr. Lieberman, a practicing attorney in the State of New York, was appointed to serve as the Vice Chairman of the Board.  He is currently a senior partner at the law firm of Beckman, Lieberman & Barandes, LLP, which firm performs certain legal services for the Company.  Fees of approximately $82,000 and $149,000 were billed by the firm through the three and six months ended June 30, 2012, respectively, at which date no amounts were outstanding.

Mr. Rios is President of Edgary Consultants, LLC, and was appointed a director in conjunction with the Company's consulting agreement (the "Agreement") with Edgary Consultants, LLC ("Consultant").  The Agreement commenced on March 1, 2011 and runs for a two year term.  The Agreement provides for the engagement of Consultant to assist the Company in seeking broader reimbursement coverage of EECP® therapy.  More specifically, Consultant will be assisting the Company in the following areas:
 
1.  
Engaging the adoption of EECP® therapy as a first line option for FDA cleared indications as it relates to CCS Class III/IV angina with a major commercial healthcare third-party payer.
2.  
Engaging a major commercial healthcare payer to formally collaborate and co-sponsor a study with Vasomedical for the efficacy, efficiency and/or cost effectiveness of the EECP® therapy for NYHA Class II/III heart failure.
3.  
Engaging final approval from the Centers for Medicare and Medicaid Services ("CMS") of EECP® therapy as a first line treatment for CCS Class III/IV angina.
4.  
Engaging final approval from CMS to extend coverage and provide for the reimbursement of EECP® therapy for CCS Class II angina; and
5.  
Engaging final approval from CMS to extend coverage and provide for the reimbursement of EECP® therapy for NYHA Class II/III heart failure.

In consideration for the services to be provided by Consultant under the Agreement, the Company has agreed to issue to Consultant or its designees, approximately 10% of the outstanding capital stock of the Company, of which the substantial portion (in excess of 82%) is performance based as referenced above. In conjunction with the Agreement, 3,000,000 shares of restricted common stock valued at $1,020,000 were issued in March 2011.  In connection with the Agreement, Mr. Lieberman received 600,000 of these restricted shares.  The Company has recorded the fair value of the shares issued to Consultant as a prepaid expense and is amortizing the cost ratably over the two year agreement.  The unamortized value is reported as Deferred Related Party Consulting Expense in our accompanying consolidated condensed balance sheets as of June 30, 2012 and December 31, 2011.

During the six months ended June 30, 2012, a director performed consulting services for the Company aggregating approximately $10,000.

Through the Company's acquisition of FGE in September 2011, it assumed the liability for $288,000 in unsecured notes payable to the President of LET and his spouse, of which $95,000 was repaid in December 2011, and $190,000, bearing interest at 6% per annum, was paid in March 2012.  In addition, receivables due from FGE management aggregating $159,000 were collected during the six months ended June 30, 2012.
XML 35 R1.htm IDEA: XBRL DOCUMENT v2.4.0.6
Document and Entity Information
 6 Months Ended
Jun. 30, 2012
Aug. 10, 2012
Document and Entity Information [Abstract]    
Entity Registrant Name VASOMEDICAL, INC  
Entity Central Index Key 0000839087  
Current Fiscal Year End Date --12-31  
Entity Well-known Seasoned Issuer No  
Entity Voluntary Filers No  
Entity Current Reporting Status Yes  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   158,746,910
Document Fiscal Year Focus 2012  
Document Fiscal Period Focus Q2  
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Jun. 30, 2012  
XML 36 R18.htm IDEA: XBRL DOCUMENT v2.4.0.6
STOCKHOLDERS' EQUITY
 6 Months Ended
Jun. 30, 2012
STOCKHOLDERS' EQUITY [Abstract]  
STOCKHOLDERS' EQUITY
NOTE M - STOCKHOLDERS' EQUITY

Common Stock

On June 17, 2010 the Board of Directors approved the 2010 Stock Plan (the "2010 Plan") for officers, directors, employees and consultants of the Company.  The stock issuable under the 2010 Plan shall be shares of the Company's authorized but unissued or reacquired common stock.  The maximum number of shares of common stock which may be issued under the 2010 Plan is 5,000,000 shares.

The 2010 Plan is comprised of two separate equity programs, the Options Grant Program, under which eligible persons may be granted options to purchase shares of common stock, and the Stock Issuance Program, under which eligible persons may be issued shares of common stock directly, either through the immediate purchase of such shares or as compensation for services rendered to the Company.

The 2010 Plan provides that the Board of Directors, or a committee of the Board of Directors, will administer it with full authority to determine the identity of the recipients of the options or shares and the number of options or shares.  Options granted under the 2010 Plan may be either incentive stock options or non-qualified stock options.  The option price shall be 100% of the fair market value of the common stock on the date of the grant ( or in the case of incentive stock options granted to any individual stockholder possessing more than 10% of the total combined voting power of all voting stock of the Company, 110% of such fair market value).  The term of any option may be fixed by the Board of Directors, or its authorized committee, but in no event shall it exceed five years from the date of grant.  Options are exercisable upon payment in full of the exercise price, either in cash or in common stock valued at fair market value on the date of exercise of the option.

As of June 30, 2012, 3,790,000 restricted shares of common stock were granted under the 2010 Plan to non-officer employees and consultants of the Company.  As of June 30, 2012, 755,000 shares have been forfeited.  In March 2012, 500,000 restricted shares of common stock were granted under the 2010 Plan to an officer, of which 250,000 vested immediately with the remainder vesting over a one year period.  In June 2012, 2,190,000 additional shares of restricted common stock were granted to non-officer employees in conjunction with the extension of the GEHC Agreement, vesting at various times through July 1, 2013.  In July 2012, 500,000 shares of restricted common stock were granted to non-officer employees, of which 250,000 vest within one year and the remainder one year thereafter.

No options were issued under the 2010 Plan during the six months ended June 30, 2012 and 2011.

In September 2011, the Company issued 5,000,000 shares of restricted common stock and a two year common stock purchase warrant for 1,500,000 shares at an exercise price of $0.50 per share as partial consideration for the acquisition of FGE.  In addition, up to 2,400,000 shares of common stock are contingently issuable should FGE attain certain operating targets for the twelve months ending December 31, 2011.  The Company is completing its evaluation of FGE's calendar year 2011 results and believes it is likely that the targets have been met and the shares will be issued.  The aggregate value of the aforementioned noncash consideration relative to the FGE acquisition was $2,979,000.

Preferred Stock

On June 24, 2010, the Company filed a Certificate of Designations of Preferences and Rights of Series E Convertible Preferred Stock ("Certificate of Designations"), as authorized by the Board of Directors, designating 350,000 shares of its 1,000,000 shares of preferred stock as Series E Convertible Preferred Stock ("Series E Preferred"). The conversion rights of the Series E Preferred are that each share will be convertible at any time on or after January 1, 2011, at the holder's option into 100 shares of common stock (an exercise price of $.16 per share of common stock, the "Conversion Price"), subject to anti-dilution adjustment as set forth below.  Each share of outstanding Series E Preferred Stock shall automatically be converted into shares of common stock on or after July 1, 2011, at the then effective applicable conversion ratio, if, at any time following the Issuance Date, the price of the common stock for any 30 consecutive trading days equals or exceeds three times the Conversion Price and the average daily trading volume for the Company's common stock for the 30 consecutive trading days exceeds 250,000 shares.

Pursuant to its conversion terms, the Series E Preferred was deemed automatically converted to common stock effective July 1, 2011.  As of June 30, 2012, 30,668,500 shares of common stock had been issued for 306,685 shares of Series E Preferred.

For the three and six months ended June 30, 2011, the Company sold 0 and 9,375 shares of Series E Preferred aggregating $150,000, and recorded dividends totaling $151,000 and $279,000, respectively.  Included in such dividends is the recognition of the value of the embedded beneficial conversion feature of the Series E Preferred, which reflects the difference between the conversion price and the market price at time of investment. The amounts included in the dividends reported attributable to this beneficial conversion feature are $91,000 and $156,000 for the three and six months ended June 30, 2011, respectively.  These are noncash dividends requiring no payment and ceased on conversion of the Series E Preferred to common stock.
XML 37 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (unaudited) (USD $)
In Thousands, except Per Share data, unless otherwise specified
 3 Months Ended 6 Months Ended
Jun. 30, 2012
Jun. 30, 2011
Jun. 30, 2012
Jun. 30, 2011
Revenues        
Equipment sales $ 1,056 $ 558 $ 2,509 $ 1,086
Equipment rentals and services 499 542 1,032 1,119
Commissions 6,142 4,075 10,199 7,815
Total revenues 7,697 5,175 13,740 10,020
Cost of revenues        
Cost of sales, equipment 416 355 1,022 748
Cost of equipment rentals and services 258 213 551 478
Cost of commissions 1,493 1,119 2,456 2,049
Total cost of revenues 2,167 1,687 4,029 3,275
Gross profit 5,530 3,488 9,711 6,745
Operating expenses        
Selling, general and administrative 5,335 4,314 10,665 7,944
Research and development 120 134 272 243
Total operating expenses 5,455 4,448 10,937 8,187
Operating (loss) income 75 (960) (1,226) (1,442)
Other income (expenses)        
Interest and financing costs 0 (24) (3) (25)
Interest and other income, net 58 17 30 18
Amortization of deferred gain on sale-leaseback of building 13 13 27 27
Total other income (expenses), net 71 6 54 20
(Loss) income before income taxes 146 (954) (1,172) (1,422)
Income tax expense (92) (2) (116) 0
Net (loss) income 54 (956) (1,288) (1,422)
Preferred stock dividends 0 (151) 0 (279)
Net (loss) income applicable to common stockholders 54 (1,107) (1,288) (1,701)
Other comprehensive (loss) income        
Foreign currency translation (loss) gain 21 0 (2) 0
Comprehensive (loss) income $ 75 $ (1,107) $ (1,290) $ (1,701)
(Loss) earnings per common share        
- basic and diluted (in dollars per share) $ 0.00 $ (0.01) $ (0.01) $ (0.01)
Weighted average common shares outstanding        
- basic (in shares) 158,072 116,198 156,225 114,077
- diluted (in shares) 161,806 116,198 156,225 114,077
XML 38 R12.htm IDEA: XBRL DOCUMENT v2.4.0.6
ACCOUNTS AND OTHER RECEIVABLES, NET
 6 Months Ended
Jun. 30, 2012
ACCOUNTS AND OTHER RECEIVABLES, NET [Abstract]  
ACCOUNTS AND OTHER RECEIVABLES, NET
NOTE G - ACCOUNTS AND OTHER RECEIVABLES, NET

The following table presents information regarding the Company's accounts and other receivables as of June 30, 2012 and December 31, 2011:
              (in thousands)
   
June 30, 2012
  
December 31, 2011
 
   
(unaudited)
    
Trade receivables
 $10,804  $22,737 
Due from employees
  145   121 
Allowance for doubtful accounts and
        
commission adjustments
  (1,965)  (2,163)
Accounts and other receivables, net
 $8,984  $20,695 
          


Trade receivables include amounts due for shipped products and services rendered.  Amounts currently due under the GEHC Agreement are subject to adjustment in subsequent periods should the underlying sales order amount, upon which the receivable is based, change.

Allowance for doubtful accounts and commission adjustments include estimated losses resulting from the inability of our customers to make required payments, and adjustments arising from subsequent changes in sales order amounts that may reduce the amount the Company will ultimately receive under the GEHC Agreement.  Due from employees primarily reflects commission advances made to sales personnel.
XML 39 R11.htm IDEA: XBRL DOCUMENT v2.4.0.6
FAIR VALUE MEASUREMENTS
 6 Months Ended
Jun. 30, 2012
FAIR VALUE MEASUREMENTS [Abstract]  
FAIR VALUE MEASUREMENTS
NOTE F - FAIR VALUE MEASUREMENTS

The Company complies with the provisions of ASC 820 "Fair Value Measurements and Disclosures" ("ASC 820").  Under ASC 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the "exit price") in an orderly transaction between market participants at the measurement date.
The following tables present information about the Company's assets and liabilities measured at fair value as of June 30, 2012 and December 31, 2011:
                                                                                                                                                                                        (in thousands)
   
Quoted Prices
  
Significant
       
   
in Active
  
Other
  
Significant
  
Balance
 
   
Markets for
  
Observable
  
Unobservable
  
as of
 
   
Identical Assets
  
Inputs
  
Inputs
  
June 30,
 
   
(Level 1)
  
(Level 2)
  
(Level 3)
  
2012
 
Assets
          
(unaudited)
 
Cash equivalents invested in money market funds (included in cash and cash equivalents)
 $9,834  $-  $-  $9,834 
Investment in certificates of deposit (included in short-term investments)
  110           110 
   $9,944  $-  $-  $9,944 
                  
   
Quoted Prices
  
Significant
         
   
in Active
  
Other
  
Significant
  
Balance
 
   
Markets for
  
Observable
  
Unobservable
  
as of
 
   
Identical Assets
  
Inputs
  
Inputs
  
December 31,
 
   
(Level 1)
  
(Level 2)
  
(Level 3)
   2011 
Assets
                
Cash equivalents invested in money market funds (included in cash and cash equivalents)
 $1,313  $-  $-  $1,313 
Investment in certificates of deposit (included in short-term investments)
  110           110 
   $1,423  $-  $-  $1,423 
                  


The fair values of the Company's cash equivalents invested in money market funds are determined through market, observable and corroborated sources.
XML 40 R23.htm IDEA: XBRL DOCUMENT v2.4.0.6
FAIR VALUE MEASUREMENTS (Tables)
 6 Months Ended
Jun. 30, 2012
FAIR VALUE MEASUREMENTS [Abstract]  
Assets and liabilities measured at fair value
The following tables present information about the Company's assets and liabilities measured at fair value as of June 30, 2012 and December 31, 2011:
                                                                                                                                                                                        (in thousands)
   
Quoted Prices
  
Significant
       
   
in Active
  
Other
  
Significant
  
Balance
 
   
Markets for
  
Observable
  
Unobservable
  
as of
 
   
Identical Assets
  
Inputs
  
Inputs
  
June 30,
 
   
(Level 1)
  
(Level 2)
  
(Level 3)
  
2012
 
Assets
          
(unaudited)
 
Cash equivalents invested in money market funds (included in cash and cash equivalents)
 $9,834  $-  $-  $9,834 
Investment in certificates of deposit (included in short-term investments)
  110           110 
   $9,944  $-  $-  $9,944 
                  
   
Quoted Prices
  
Significant
         
   
in Active
  
Other
  
Significant
  
Balance
 
   
Markets for
  
Observable
  
Unobservable
  
as of
 
   
Identical Assets
  
Inputs
  
Inputs
  
December 31,
 
   
(Level 1)
  
(Level 2)
  
(Level 3)
   2011 
Assets
                
Cash equivalents invested in money market funds (included in cash and cash equivalents)
 $1,313  $-  $-  $1,313 
Investment in certificates of deposit (included in short-term investments)
  110           110 
   $1,423  $-  $-  $1,423 
                  
XML 41 R19.htm IDEA: XBRL DOCUMENT v2.4.0.6
COMMITMENTS AND CONTINGENCIES
 6 Months Ended
Jun. 30, 2012
COMMITMENTS AND CONTINGENCIES [Abstract]  
COMMITMENTS AND CONTINGENCIES
NOTE N - COMMITMENTS AND CONTINGENCIES

Sales representation agreement

In June 2012, the Company concluded an amendment of the GEHC Agreement with GE Healthcare, originally signed on May 19, 2010.  The amendment, effective July 1, 2012, extends the initial term of three years commencing July 1, 2010 to five years through June 30, 2015, subject to earlier termination under certain circumstances.  These circumstances include not materially achieving certain sales goals, not maintaining a minimum number of sales representatives, and various legal and GEHC policy requirements.  Under the terms of the agreement, the Company is required to lease dedicated computer equipment from GEHC for connectivity to their network.

In conjunction with the extension of the GEHC Agreement, the Company granted VasoHealthcare employees both stock and cash-based performance incentives for the ensuing year.  The incentives provide for cash payments of up to $2.2 million and 2.2 million shares of restricted common stock grants and vest at various times through July 1, 2013.  A condition of the incentives is that the employees remain continuously employed through the vesting dates.
XML 42 R15.htm IDEA: XBRL DOCUMENT v2.4.0.6
GOODWILL AND OTHER INTANGIBLES
 6 Months Ended
Jun. 30, 2012
GOODWILL AND OTHER INTANGIBLES [Abstract]  
GOODWILL AND OTHER INTANGIBLES
NOTE J - GOODWILL AND OTHER INTANGIBLES

Goodwill aggregating $3,968,000 and $3,939,000 was recorded on the Company's Consolidated Condensed Balance Sheets at June 30, 2012 and December 31, 2011, respectively, pursuant to the acquisition of FGE in September 2011.  The increase in goodwill resulted from the recording of additional pre-acquisition dividend liabilities to prior owners. All of the goodwill was allocated to the Company's Equipment segment.

The Company's other intangible assets consist of capitalized patent costs, as follows:

                                                                                                                                                        (in thousands)
 
June 30, 2012
 
 
December 31, 2011
 
Patent Costs
 
(unaudited)
 
 
 
 
Costs
 
$
469
 
 
$
469
 
Accumulated amortization
 
 
(426
)
 
 
(413
)
 
$
43
 
 
$
56
 
 
 
 
 
 
 
 
 


Patents are included in other assets in the accompanying Consolidated Condensed Balance Sheets.  Amortization expense amounted to $6,000 and $9,000 for the three months ended June 30, 2012 and 2011, respectively, and $13,000 and $19,000 for the six months ended June 30, 2012 and 2011, respectively.
XML 43 R13.htm IDEA: XBRL DOCUMENT v2.4.0.6
INVENTORIES, NET
 6 Months Ended
Jun. 30, 2012
INVENTORIES, NET [Abstract]  
INVENTORIES, NET
NOTE H - INVENTORIES, NET

Inventories, net of reserves, consist of the following:
                                                                                                                                                                          (in thousands)
   
June 30, 2012
  
December 31, 2011
 
   
(unaudited)
    
Raw materials
 $938  $842 
Work in process
  575   528 
Finished goods
  772   1,051 
   $2,285  $2,421 
          


At June 30, 2012 and December 31, 2011, the Company had reserves for excess and obsolete inventory of $546,000 and $606,000, respectively.
XML 44 R14.htm IDEA: XBRL DOCUMENT v2.4.0.6
BUSINESS COMBINATION
 6 Months Ended
Jun. 30, 2012
BUSINESS COMBINATION [Abstract]  
BUSINESS COMBINATION
NOTE I- BUSINESS COMBINATION

On September 2, 2011, Vasomedical Global successfully completed the purchase of all the outstanding capital stock of privately-held Fast Growth Enterprises Limited ("FGE"), a British Virgin Islands company that owns subsidiaries which own and control Life Enhancement Technology Ltd ("LET") and Biox Instruments Co. Ltd. ("Biox"), respectively, as per the stock purchase agreement signed on August 19, 2011. The consideration of this acquisition includes a cash payment of $1 million as well as the issuance of 5 million restricted shares of the Company's common stock, up to 2.4 million shares of common stock contingently issuable upon the achievement of certain operating performance targets, and warrants covering 1.5 million shares of common stock.  The Company is completing its evaluation of FGE's calendar year 2011 results and believes it is likely that the targets have been met and the shares will be issued.

LET, based in Foshan, Guangdong, China, is Vasomedical's supplier for its proprietary Enhanced External Counterpulsation (EECP®) systems, including certain Lumenair systems and all AngioNew® systems. Biox, a developer and manufacturer of ambulatory monitoring devices in China, is located in Wuxi, Jiangsu, China, and is Vasomedical's supplier of the BIOX series ECG Holter recorder and analysis software as well as ambulatory blood pressure monitoring systems. Vasomedical has obtained FDA clearance to market these products in the United States.  The acquisition of LET provides Vasomedical with consolidated technical and manufacturing capability in its EECP business which has significantly increased gross margins and will enable the Company to meet anticipated increasing demand for its EECP systems.  The acquisition of Biox greatly enhances Vasomedical's distribution network, technology and product portfolio, and with combined market and sales efforts of the two companies, has improved performance and profitability of Vasomedical's equipment segment.

The operating results of FGE are included in the accompanying Consolidated Condensed Statements of Operations and Comprehensive Income (Loss) and Cash Flows for the six and three months ended June 30, 2012.  The Consolidated Condensed Balance Sheet as of June 30, 2012 reflects the acquisition of FGE, effective September 2, 2011.  The acquisition date fair value of the total consideration transferred was $3.979 million, which consisted of the following:
 
(in thousands)
Cash
 
$
1,000
 
Vasomedical, Inc. common stock ($0.42 per share)
 
 
2,100
 
Vasomedical, Inc. warrants to purchase common stock
 
 
304
 
Contingent issuance of Vasomedical, Inc. common stock ($0.42 per share)
 
 
575
 
Total purchase price
 
$
3,979
 
 
 
 
 
 
In accordance with Accounting Standards Codification ("ASC") 805, Business Combinations ("ASC 805"), the total purchase consideration is allocated to the net tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of September 2, 2011 (the acquisition date).  The purchase price was allocated based on the information currently available, and may be adjusted after obtaining more information regarding, among other things, asset valuations, liabilities assumed, and revisions of preliminary estimates.  The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the acquisition date:
                                                                                                                                       (in thousands)
Cash and cash equivalents
 
$
442
 
Accounts receivable and other current assets
 
 
283
 
Inventories
 
 
476
 
Property and equipment
 
 
32
 
Goodwill
 
 
3,968
 
Accounts payable and other current liabilites
 
 
(1,222
)
Net assets acquired
 
$
3,979
 
 
 
 
 


The goodwill is attributable to the synergies expected to arise after the Company's acquisition of FGE as well as FGE's projected growth and profitability.  The goodwill is not expected to be deductible for tax purposes.

After elimination of intercompany transactions which reduce the income from FGE, the amounts of revenue and net loss of FGE included in the Company's Consolidated Condensed Statement of Operations and Comprehensive Income (Loss) for the six months ended June 30, 2012 was $910,000 and $24,000, respectively, and $332,000 and $110,000, respectivley for the three months ended June 30, 2012.  The effect of FGE's loss on earnings per share for the six and three months ended June 30, 2012 was $0.00.

The following supplemental pro forma information presents the financial results as if the acquisition of FGE had occurred June 1, 2009 (amounts in thousands, except per share amounts):

                                                                                                                                          (in thousands except per share data)
 
 
 
Six months ended June 30,
 
 
 
 
 
 
Three months ended June 30,
 
 
 
 
2012
 
 
2011
 
 
2012
 
 
2011
 
Revenue
 
$
13,740
 
 
$
10,621
 
 
$
7,697
 
 
$
5,401
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income (loss)
 
$
(1,105
)
 
$
(957
)
 
 
65
 
 
 
(683
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Basic and diluted (loss) earnings per share
 
$
(0.01
)
 
$
(0.01
)
 
$
0.00
 
 
$
(0.01
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
XML 45 R16.htm IDEA: XBRL DOCUMENT v2.4.0.6
DEFERRED REVENUE
 6 Months Ended
Jun. 30, 2012
DEFERRED REVENUE [Abstract]  
DEFERRED REVENUE
NOTE K - DEFERRED REVENUE

The changes in the Company's deferred revenues are as follows:
(in thousands)
 
 
For the six months ended June 30,
 
 
For the three months ended June 30,
 
 
 
2012
 
 
2011
 
 
2012
 
 
2011
 
 
 
(unaudited)
 
 
(unaudited)
 
 
(unaudited)
 
 
(unaudited)
 
Deferred revenue at the beginning of the period
 
$
15,227
 
 
$
12,637
 
 
$
14,781
 
 
$
10,792
 
Additions:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Deferred extended service contracts
 
 
700
 
 
 
730
 
 
 
373
 
 
 
333
 
Deferred in-service and training
 
 
20
 
 
 
18
 
 
 
15
 
 
 
10
 
Deferred service arrangements
 
 
55
 
 
 
45
 
 
 
30
 
 
 
30
 
Deferred commission revenues
 
 
4,080
 
 
 
4,143
 
 
 
2,731
 
 
 
3,117
 
Recognized as revenue:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Deferred extended service contracts
 
 
(557
)
 
 
(604
)
 
 
(282
)
 
 
(290
)
Deferred in-service and training
 
 
(15
)
 
 
(16
)
 
 
(13
)
 
 
(8
)
Deferred service arrangements
 
 
(43
)
 
 
(35
)
 
 
(21
)
 
 
(19
)
Deferred commission revenues
 
 
(4,269
)
 
 
(5,558
)
 
 
(2,416
)
 
 
(2,605
)
Deferred revenue at end of period
 
 
15,198
 
 
 
11,360
 
 
 
15,198
 
 
 
11,360
 
Less: current portion
 
 
10,685
 
 
 
8,047
 
 
 
10,685
 
 
 
8,047
 
Long-term deferred revenue at end of period
 
$
4,513
 
 
$
3,313
 
 
$
4,513
 
 
$
3,313
 

 
XML 46 R34.htm IDEA: XBRL DOCUMENT v2.4.0.6
ACCOUNTS AND OTHER RECEIVABLES, NET (Details) (USD $)
In Thousands, unless otherwise specified
Jun. 30, 2012
Dec. 31, 2011
Jun. 30, 2011
ACCOUNTS AND OTHER RECEIVABLES, NET [Abstract]      
Trade receivables $ 10,804 $ 22,737  
Due from employees 145 121  
Allowance for doubtful accounts and commission adjustments (1,965) (2,163)  
Accounts and other receivables $ 8,984 $ 20,695 $ 4,301
XML 47 R21.htm IDEA: XBRL DOCUMENT v2.4.0.6
SEGMENT REPORTING AND CONCENTRATIONS (Tables)
 6 Months Ended
Jun. 30, 2012
SEGMENT REPORTING AND CONCENTRATIONS [Abstract]  
Summary financial information for segments
The Company views its business in two segments - the Equipment segment and the Sales Representation segment.  The Equipment segment is engaged in designing, manufacturing, marketing and supporting EECP® enhanced external counterpulsation systems both domestically and internationally, as well as the marketing of other medical devices.  The Sales Representation segment operates through the VasoHealthcare subsidiary and is currently engaged solely in the execution of the Company's responsibilities under our agreement with GEHC.  The Company evaluates segment performance based on operating income.  Administrative functions such as finance, human resources, and information technology are centralized and related expenses allocated to each segment.  Other costs not directly attributable to operating segments, such as audit, legal, director fees, investor relations, and others, as well as certain assets - primarily cash balances - are reported in the Corporate entity below. There are no intersegment revenues.  Summary financial information for the segments is set forth below:
(in thousands)
 
 
 
 
 
 
As of or for the three months ended June 30, 2012
 
 
 
 
 
 
 
Equipment Segment
 
 
Sales Representation Segment
 
 
Corporate
 
 
Consolidated
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenues from external customers
 
$
1,555
 
 
$
6,142
 
 
$
-
 
 
$
7,697
 
Operating income/(loss)
 
$
(197
)
 
$
681
 
 
$
(409
)
 
$
75
 
Total assets
 
$
9,323
 
 
$
11,558
 
 
$
11,174
 
 
$
32,055
 
Accounts and other receivables, net
 
$
1,151
 
 
$
7,833
 
 
$
-
 
 
$
8,984
 
Deferred commission expense
 
$
-
 
 
$
3,490
 
 
$
-
 
 
$
3,490
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As of or for the three months ended June 30, 2011
 
 
 
 
 
 
 
 
 
Equipment Segment
 
 
Sales Representation Segment
 
 
Corporate
 
 
Consolidated
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenues from external customers
 
$
1,100
 
 
$
4,075
 
 
$
-
 
 
$
5,175
 
Operating loss
 
$
(475
)
 
$
(386
)
 
$
(99
)
 
$
(960
)
Total assets
 
$
4,440
 
 
$
6,330
 
 
$
7,687
 
 
$
18,457
 
Accounts and other receivables, net
 
$
749
 
 
$
3,552
 
 
$
-
 
 
$
4,301
 
Deferred commission expense
 
$
-
 
 
$
2,703
 
 
$
-
 
 
$
2,703
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

(in thousands)
 
 
 
 
 
 
As of or for the six months ended June 30, 2012
 
 
 
 
 
 
 
Equipment Segment
 
 
Sales Representation Segment
 
 
Corporate
 
 
Consolidated
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenues from external customers
 
$
3,541
 
 
$
10,199
 
 
$
-
 
 
$
13,740
 
Operating loss
 
$
(353
)
 
$
(115
)
 
$
(758
)
 
$
(1,226
)
Total assets
 
$
9,323
 
 
$
11,558
 
 
$
11,174
 
 
$
32,055
 
Accounts and other receivables, net
 
$
1,151
 
 
$
7,833
 
 
$
-
 
 
$
8,984
 
Deferred commission expense
 
$
-
 
 
$
3,490
 
 
$
-
 
 
$
3,490
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As of or for the six months ended June 30, 2011
 
 
 
 
 
 
 
 
 
Equipment Segment
 
 
Sales Representation Segment
 
 
Corporate
 
 
Consolidated
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenues from external customers
 
$
2,205
 
 
$
7,815
 
 
$
-
 
 
$
10,020
 
Operating loss
 
$
(741
)
 
$
(418
)
 
$
(283
)
 
$
(1,442
)
Total assets
 
$
4,440
 
 
$
6,330
 
 
$
7,687
 
 
$
18,457
 
Accounts and other receivables, net
 
$
749
 
 
$
3,552
 
 
$
-
 
 
$
4,301
 
Deferred commission expense
 
$
-
 
 
$
2,703
 
 
$
-
 
 
$
2,703
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
XML 48 R26.htm IDEA: XBRL DOCUMENT v2.4.0.6
BUSINESS COMBINATION (Tables)
 6 Months Ended
Jun. 30, 2012
BUSINESS COMBINATION [Abstract]  
Acquisition date fair value of total consideration transferred
The operating results of FGE are included in the accompanying Consolidated Condensed Statements of Operations and Comprehensive Income (Loss) and Cash Flows for the six and three months ended June 30, 2012.  The Consolidated Condensed Balance Sheet as of June 30, 2012 reflects the acquisition of FGE, effective September 2, 2011.  The acquisition date fair value of the total consideration transferred was $3.979 million, which consisted of the following:
 
(in thousands)
Cash
 
$
1,000
 
Vasomedical, Inc. common stock ($0.42 per share)
 
 
2,100
 
Vasomedical, Inc. warrants to purchase common stock
 
 
304
 
Contingent issuance of Vasomedical, Inc. common stock ($0.42 per share)
 
 
575
 
Total purchase price
 
$
3,979
 
 
 
 
 
Fair values of assets acquired and liabilities assumed
In accordance with Accounting Standards Codification ("ASC") 805, Business Combinations ("ASC 805"), the total purchase consideration is allocated to the net tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of September 2, 2011 (the acquisition date).  The purchase price was allocated based on the information currently available, and may be adjusted after obtaining more information regarding, among other things, asset valuations, liabilities assumed, and revisions of preliminary estimates.  The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the acquisition date:
                                                                                                                                       (in thousands)
Cash and cash equivalents
 
$
442
 
Accounts receivable and other current assets
 
 
283
 
Inventories
 
 
476
 
Property and equipment
 
 
32
 
Goodwill
 
 
3,968
 
Accounts payable and other current liabilites
 
 
(1,222
)
Net assets acquired
 
$
3,979
 
 
 
 
 
Supplemental pro forma information
The following supplemental pro forma information presents the financial results as if the acquisition of FGE had occurred June 1, 2009 (amounts in thousands, except per share amounts):

                                                                                                                                          (in thousands except per share data)
 
 
 
Six months ended June 30,
 
 
 
 
 
 
Three months ended June 30,
 
 
 
 
2012
 
 
2011
 
 
2012
 
 
2011
 
Revenue
 
$
13,740
 
 
$
10,621
 
 
$
7,697
 
 
$
5,401
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income (loss)
 
$
(1,105
)
 
$
(957
)
 
 
65
 
 
 
(683
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Basic and diluted (loss) earnings per share
 
$
(0.01
)
 
$
(0.01
)
 
$
0.00
 
 
$
(0.01
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
XML 49 R41.htm IDEA: XBRL DOCUMENT v2.4.0.6
COMMITMENTS AND CONTINGENCIES (Details) (USD $)
In Millions, unless otherwise specified
 6 Months Ended
Jun. 30, 2012
Sales Representation Agreement [Abstract]  
Initial term of sales representation agreement (in years) 3 years
Amended term of sales representation agreement 5 years
Maximum cash payment under extended performance incentive plan $ 2.2
Maximum shares of issuable under extended performance incentive program (in shares) 2.2
XML 50 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (unaudited) (USD $)
 6 Months Ended
Jun. 30, 2012
Jun. 30, 2011
Cash flows from operating activities    
Net loss $ (1,288,000) $ (1,422,000)
Adjustments to reconcile net loss to net cash provided by operating activities    
Depreciation and amortization of property and equipment 103,000 74,000
Amortization of deferred gain on sale-leaseback of building (27,000) (27,000)
Provision for doubtful accounts and commission adjustments (3,000) 9,000
Amortization of deferred distributor costs 0 63,000
Share-based compensation 231,000 203,000
Amortization of deferred consulting expense 288,000 208,000
Changes in operating assets and liabilities:    
Accounts and other receivables 11,716,000 8,653,000
Receivables due from related parties 186,000 0
Inventories, net 119,000 (257,000)
Finance receivables 9,000 9,000
Deferred commission expense (442,000) (168,000)
Other current assets (212,000) (96,000)
Other assets 230,000 (33,000)
Accounts payable 183,000 249,000
Accrued commissions (1,553,000) (94,000)
Accrued expenses and other liabilities 203,000 (602,000)
Sales tax payable 36,000 9,000
Income taxes payable (190,000) (1,000)
Deferred revenue (29,000) (1,277,000)
Trade payable due to related party 0 (243,000)
Other long-term liabilities (36,000) (591,000)
Net cash provided by operating activities 9,524,000 4,666,000
Cash flows from investing activities    
Purchases of property and equipment (204,000) (16,000)
Purchases of short-term investments 0 (40,000)
Net cash used in investing activities (204,000) (56,000)
Cash flows from financing activities    
Proceeds from exercise of warrant 343,000 0
Repayment of note payable 0 (294,000)
Repayment of notes payable due to related party (190,000) 0
Proceeds from issuance of preferred stock 0 150,000
Net cash provided by (used in) financing activities 153,000 (144,000)
Effect of exchange rate differences on cash 16,000 0
NET INCREASE IN CASH AND CASH EQUIVALENTS 9,489,000 4,466,000
Cash and cash equivalents - beginning of period 2,294,000 3,101,000
Cash and cash equivalents - end of period 11,783,000 7,567,000
SUPPLEMENTAL DISCLOSURE OF CASH INFORMATION    
Interest paid 5,000 4,000
Income taxes paid 242,000 5,000
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES    
Inventories transferred to property and equipment, attributable to operating leases, net 20,000 63,000
Dividends Payable [Line Items]    
Issuance of preferred stock in satisfaction of accrued dividend 0 101,000
Common shares issued for consulting agreements 0 1,070,000
Preferred Stock [Member]
    
Dividends Payable [Line Items]    
Accrued preferred stock dividends $ 0 $ 279,000
XML 51 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6
EARNINGS (LOSS) PER COMMON SHARE
 6 Months Ended
Jun. 30, 2012
EARNINGS (LOSS) PER COMMON SHARE [Abstract]  
EARNINGS (LOSS) PER COMMON SHARE
NOTE E - EARNINGS (LOSS) PER COMMON SHARE

 Basic earnings per common share is computed as earnings applicable to common stockholders divided by the weighted-average number of common shares outstanding for the period.  Diluted earnings per common share reflects the potential dilution that could occur if securities or other contracts to issue common shares were exercised or converted to common stock.

Basic and diluted (loss) per common share was ($0.01) for the six months ended June 30, 2012 and 2011.  Basic and diluted earnings (loss) per share for the three months ended June 30, 2012 and 2011 were $0.00 and ($0.01), respectively.

Diluted earnings per share were computed based on the weighted average number of shares outstanding plus all potentially dilutive common stock equivalents.  A reconciliation of basic to diluted shares used in the earnings per share calculation is as follows:

   
Six months ended June 30,
     
Three months ended June 30,
 
 
2012
 
2011
 
2012
 
2011
Basic weighted average shares outstanding
       156,225
 
       114,077
 
       158,072
 
       116,198
Dilutive effect of share-based compensation
                -
 
                -
 
           1,334
 
                -
Contingently issuable shares
                -
 
                -
 
           2,400
 
                -
Diluted weighted average shares outstanding
       156,225
 
       114,077
 
       161,806
 
       116,198
               


The following table represents common stock equivalents that were excluded from the computation of diluted earnings per share for the six and three months ended June 30, 2012 and 2011, because the effect of their inclusion would be anti-dilutive.
                                                 (in thousands)
   
For the
six
months ended
 
For the
three
months ended
   
June 30, 2012
 
June 30, 2011
 
June 30, 2012
 
June 30, 2011
Stock options
 
                 1,810
 
                    1,864
 
                  260
 
                     1,864
Warrants
 
                 1,500
 
                    4,286
 
               1,500
 
                     4,286
Contingently issuable shares
 
                 2,400
 
                          -
 
                     -
 
                          -
Convertible preferred stock
 
                       -
 
                  30,668
 
                     -
 
                   30,668
Common stock grants
 
                 4,918
 
                    3,913
 
                  375
 
                     3,913
   
               10,628
 
                  40,731
 
               2,135
 
                   40,731
                 

XML 52 R27.htm IDEA: XBRL DOCUMENT v2.4.0.6
GOODWILL AND OTHER INTANGIBLES (Tables)
 6 Months Ended
Jun. 30, 2012
GOODWILL AND OTHER INTANGIBLES [Abstract]  
Other intangible assets
The Company's other intangible assets consist of capitalized patent costs, as follows:

                                                                                                                                                        (in thousands)
 
June 30, 2012
 
 
December 31, 2011
 
Patent Costs
 
(unaudited)
 
 
 
 
Costs
 
$
469
 
 
$
469
 
Accumulated amortization
 
 
(426
)
 
 
(413
)
 
$
43
 
 
$
56
 
 
 
 
 
 
 
 
 
XML 53 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 142 236 1 false 37 0 false 4 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://vasomedical.com/role/DocumentAndEntityInformation Document and Entity Information true false R2.htm 010000 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) Sheet http://vasomedical.com/role/ConsolidatedCondensedBalanceSheetsUnaudited CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) false false R3.htm 010100 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) (Parenthetical) Sheet http://vasomedical.com/role/ConsolidatedCondensedBalanceSheetsUnauditedParenthetical CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) (Parenthetical) false false R4.htm 020000 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (unaudited) Sheet http://vasomedical.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (unaudited) false false R5.htm 030000 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (unaudited) Sheet http://vasomedical.com/role/ConsolidatedCondensedStatementsOfCashFlowsUnaudited CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (unaudited) false false R6.htm 060100 - Disclosure - ORGANIZATION AND PLAN OF OPERATIONS Sheet http://vasomedical.com/role/OrganizationAndPlanOfOperations ORGANIZATION AND PLAN OF OPERATIONS false false R7.htm 060200 - Disclosure - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES Sheet http://vasomedical.com/role/BasisOfPresentationAndCriticalAccountingPolicies BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES false false R8.htm 060300 - Disclosure - SEGMENT REPORTING AND CONCENTRATIONS Sheet http://vasomedical.com/role/SegmentReportingAndConcentrations SEGMENT REPORTING AND CONCENTRATIONS false false R9.htm 060400 - Disclosure - SHARE-BASED COMPENSATION Sheet http://vasomedical.com/role/SharebasedCompensation SHARE-BASED COMPENSATION false false R10.htm 060500 - Disclosure - EARNINGS (LOSS) PER COMMON SHARE Sheet http://vasomedical.com/role/EarningsLossPerCommonShare EARNINGS (LOSS) PER COMMON SHARE false false R11.htm 060600 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://vasomedical.com/role/FairValueMeasurements FAIR VALUE MEASUREMENTS false false R12.htm 060700 - Disclosure - ACCOUNTS AND OTHER RECEIVABLES, NET Sheet http://vasomedical.com/role/AccountsAndOtherReceivablesNet ACCOUNTS AND OTHER RECEIVABLES, NET false false R13.htm 060800 - Disclosure - INVENTORIES, NET Sheet http://vasomedical.com/role/InventoriesNet INVENTORIES, NET false false R14.htm 060900 - Disclosure - BUSINESS COMBINATION Sheet http://vasomedical.com/role/BusinessCombination BUSINESS COMBINATION false false R15.htm 061000 - Disclosure - GOODWILL AND OTHER INTANGIBLES Sheet http://vasomedical.com/role/GoodwillAndOtherIntangibles GOODWILL AND OTHER INTANGIBLES false false R16.htm 061100 - Disclosure - DEFERRED REVENUE Sheet http://vasomedical.com/role/DeferredRevenue DEFERRED REVENUE false false R17.htm 061200 - Disclosure - RELATED-PARTY TRANSACTIONS Sheet http://vasomedical.com/role/RelatedpartyTransactions RELATED-PARTY TRANSACTIONS false false R18.htm 061300 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://vasomedical.com/role/StockholdersEquity STOCKHOLDERS' EQUITY false false R19.htm 061400 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://vasomedical.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES false false R20.htm 061500 - Disclosure - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS Sheet http://vasomedical.com/role/RecentlyIssuedAccountingPronouncements RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS false false R21.htm 080300 - Disclosure - SEGMENT REPORTING AND CONCENTRATIONS (Tables) Sheet http://vasomedical.com/role/SegmentReportingAndConcentrationsTables SEGMENT REPORTING AND CONCENTRATIONS (Tables) false false R22.htm 080500 - Disclosure - EARNINGS (LOSS) PER COMMON SHARE (Tables) Sheet http://vasomedical.com/role/EarningsLossPerCommonShareTables EARNINGS (LOSS) PER COMMON SHARE (Tables) false false R23.htm 080600 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://vasomedical.com/role/FairValueMeasurementsTables FAIR VALUE MEASUREMENTS (Tables) false false R24.htm 080700 - Disclosure - ACCOUNTS AND OTHER RECEIVABLES, NET (Tables) Sheet http://vasomedical.com/role/AccountsAndOtherReceivablesNetTables ACCOUNTS AND OTHER RECEIVABLES, NET (Tables) false false R25.htm 080800 - Disclosure - INVENTORIES, NET (Tables) Sheet http://vasomedical.com/role/InventoriesNetTables INVENTORIES, NET (Tables) false false R26.htm 080900 - Disclosure - BUSINESS COMBINATION (Tables) Sheet http://vasomedical.com/role/BusinessCombinationTables BUSINESS COMBINATION (Tables) false false R27.htm 081000 - Disclosure - GOODWILL AND OTHER INTANGIBLES (Tables) Sheet http://vasomedical.com/role/GoodwillAndOtherIntangiblesTables GOODWILL AND OTHER INTANGIBLES (Tables) false false R28.htm 081100 - Disclosure - DEFERRED REVENUE (Tables) Sheet http://vasomedical.com/role/DeferredRevenueTables DEFERRED REVENUE (Tables) false false R29.htm 090100 - Disclosure - ORGANIZATION AND PLAN OF OPERATIONS (Details) Sheet http://vasomedical.com/role/OrganizationAndPlanOfOperationsDetails ORGANIZATION AND PLAN OF OPERATIONS (Details) false false R30.htm 090300 - Disclosure - SEGMENT REPORTING AND CONCENTRATIONS (Details) Sheet http://vasomedical.com/role/SegmentReportingAndConcentrationsDetails SEGMENT REPORTING AND CONCENTRATIONS (Details) false false R31.htm 090400 - Disclosure - SHARE-BASED COMPENSATION (Details) Sheet http://vasomedical.com/role/SharebasedCompensationDetails SHARE-BASED COMPENSATION (Details) false false R32.htm 090500 - Disclosure - EARNINGS (LOSS) PER COMMON SHARE (Details) Sheet http://vasomedical.com/role/EarningsLossPerCommonShareDetails EARNINGS (LOSS) PER COMMON SHARE (Details) false false R33.htm 090600 - Disclosure - FAIR VALUE MEASUREMENTS (Details) Sheet http://vasomedical.com/role/FairValueMeasurementsDetails FAIR VALUE MEASUREMENTS (Details) false false R34.htm 090700 - Disclosure - ACCOUNTS AND OTHER RECEIVABLES, NET (Details) Sheet http://vasomedical.com/role/AccountsAndOtherReceivablesNetDetails ACCOUNTS AND OTHER RECEIVABLES, NET (Details) false false R35.htm 090800 - Disclosure - INVENTORIES, NET (Details) Sheet http://vasomedical.com/role/InventoriesNetDetails INVENTORIES, NET (Details) false false R36.htm 090900 - Disclosure - BUSINESS COMBINATION (Details) Sheet http://vasomedical.com/role/BusinessCombinationDetails BUSINESS COMBINATION (Details) false false R37.htm 091000 - Disclosure - GOODWILL AND OTHER INTANGIBLES (Details) Sheet http://vasomedical.com/role/GoodwillAndOtherIntangiblesDetails GOODWILL AND OTHER INTANGIBLES (Details) false false R38.htm 091100 - Disclosure - DEFERRED REVENUE (Details) Sheet http://vasomedical.com/role/DeferredRevenueDetails DEFERRED REVENUE (Details) false false R39.htm 091200 - Disclosure - RELATED-PARTY TRANSACTIONS (Details) Sheet http://vasomedical.com/role/RelatedpartyTransactionsDetails RELATED-PARTY TRANSACTIONS (Details) false false R40.htm 091300 - Disclosure - STOCKHOLDERS' EQUITY (Details) Sheet http://vasomedical.com/role/StockholdersEquityDetails STOCKHOLDERS' EQUITY (Details) false false R41.htm 091400 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://vasomedical.com/role/CommitmentsAndContingenciesDetails COMMITMENTS AND CONTINGENCIES (Details) false false All Reports Book All Reports Element us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued had a mix of decimals attribute values: -6 -5 0. Element us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent had a mix of decimals attribute values: -3 0. Element us-gaap_NetIncomeLoss had a mix of decimals attribute values: -3 0. Element us-gaap_RepaymentsOfRelatedPartyDebt had a mix of decimals attribute values: -3 0. Element us-gaap_SalesRevenueNet had a mix of decimals attribute values: -3 0. Element us-gaap_ShareBasedCompensation had a mix of decimals attribute values: -3 0. Element us-gaap_SharePrice had a mix of decimals attribute values: 1 2. 'Monetary' elements on report '090800 - Disclosure - INVENTORIES, NET (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '090900 - Disclosure - BUSINESS COMBINATION (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '091000 - Disclosure - GOODWILL AND OTHER INTANGIBLES (Details)' had a mix of different decimal attribute values. Process Flow-Through: 010000 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) Process Flow-Through: Removing column 'Jun. 30, 2011' Process Flow-Through: Removing column 'Dec. 31, 2010' Process Flow-Through: 010100 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) (Parenthetical) Process Flow-Through: 020000 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (unaudited) Process Flow-Through: 030000 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (unaudited) vaso-20120630.xml vaso-20120630.xsd vaso-20120630_cal.xml vaso-20120630_def.xml vaso-20120630_lab.xml vaso-20120630_pre.xml true true XML 54 R38.htm IDEA: XBRL DOCUMENT v2.4.0.6
DEFERRED REVENUE (Details) (USD $)
In Thousands, unless otherwise specified
 3 Months Ended 6 Months Ended
Jun. 30, 2012
Jun. 30, 2011
Jun. 30, 2012
Jun. 30, 2011
Dec. 31, 2011
Movements in deferred revenue [Roll Forward]          
Deferred revenue at the beginning of the period $ 14,781 $ 10,792 $ 15,227 $ 12,637  
Additions:              
Deferred revenue at end of period 15,198 11,360 15,198 11,360  
Less: current portion 10,685 8,047 10,685 8,047 9,484
Long-term deferred revenue at end of period 4,513 3,313 4,513 3,313 5,743
Extended Service Contracts [Member]
          
Movements in deferred revenue [Roll Forward]          
Additions: 373 333 700 730  
Recognized as revenue: (282) (290) (557) (604)  
In-Service and Training [Member]
          
Movements in deferred revenue [Roll Forward]          
Additions: 15 10 20 18  
Recognized as revenue: (13) (8) (15) (16)  
Service Arrangements [Member]
          
Movements in deferred revenue [Roll Forward]          
Additions: 30 30 55 45  
Recognized as revenue: (21) (19) (43) (35)  
Commission Revenues [Member]
          
Movements in deferred revenue [Roll Forward]          
Additions: 2,731 3,117 4,080 4,143  
Recognized as revenue: $ (2,416) $ (2,605) $ (4,269) $ (5,558)  
ZIP 55 0001201800-12-000019-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001201800-12-000019-xbrl.zip M4$L#!!0````(`'6'#D$M9WGNI;L``#DL#@`1`!P`=F%S;RTR,#$R,#8S,"YX M;6Q55`D``SV\*E`]O"I0=7@+``$$)0X```0Y`0``[%WK<^(XMO]^J^[_H.7# MWIFJD&`@(P/%>VT5D'$UAV#VB\?*AZO8JY36OG' MQ__^KY__5JU^)C9AV"4&>IZ@IZ%C<<=&C\1S10.HK>O$%%6J4/CMF9E(M&WS M:_A)/U2&KCNZ/CM[?7T]A2>G#GLYJ]=JC3-JOV`\BFH- M,'^6/00O,JH8A&9W(EYD%+<]*WL,ALO.W,F(G(D2A%$]JN#8*]1Q[&JJGNYX MMLLFV;0%+S/HTSW&YM01;P2`LRK9F.H\NY9\!56TZ2J=.'V17@3<88QI@[407XPR(&U;%YJCN6+%Z[:-2"PJNHG%!5A'X&';GF M$OV/9("DSER#R#Y4.+5&)JB"?#9D9/"A`OU6P\Y.W[A106=^0U+5A5!ME[RY MB!H?*KHLI]4TUXG(DV6CTL1VJ3L)GD5/J0'/!Y0P)`DC4Z,)N=2Y^[7RL2;^ M73:N:I>MG\_2E<.NSC+Z"GH:"3PZ1KI_P1_FW@I3]S$40DT+6XG?I2H1VTA4 MN:@V:G''1J)"^#31=?@HX-UB=EYJY6"B#S,WX,=E58OX$;YY'WZ4!533_$CB MXSWYH6EU83!*Q@^M*EC2T'+A1V1^M-(@9::Q$[ MRXO.==F9(SIK931^M3R-7UE`->4,\-^JZC?V^_ M4?[/!Q'A$C&%,.2CK\1Z)FP/[(M5C;P`G='CX(4AR'@;F52GKD\C,J@HY\_B M@VG@]=Q15CZ&1;*&^_-99@\Q96=9I!4V&E("+Z#`<]7PJ?@D%OV-QZE-.._[ MP^!2_-U_>70$?P9/#P0`66.M?(2)^W7VB'>%@0)'8NL!IX]-PA_)B!$NGF%7 MR.%H(+1L[`I,:X*IX["1`POK!XV=L%AJM`HMZ4F@\EG%]5G%FNZN!QSELPKF ML\H,)N6SCALMJ:]ZRF<5UV<5[?OE.L!1/JM@/JO,8%(^Z[C1DOH4K'Q6<7U6 ML3YZKP<T:#,_L&(.[UOY"O^RV$=C[N.19@O[<_D%X)-=ZAC5G*! MSPXN4/'9(:I-(C.?9Q4TU+?8.5]!%#34)X\YBXT*&FIE<6I%H>/8NA@.DX'T M(^7?;R8WQ-:'%F;^"8FV+@_BBY!;)W2,G\V`@UDUGR8CXH>D@1!FR@1U%0Q7 M@^$ZW2Z39!Q"SQ-ISM2$Z$C$\HMAF;TC>E;SLY^)^.BI7F*H2PGOONFF9Q#C$W,L8*7G'\OK#;J8 MV=1^X0^$^3/+278#,>9Z(ZC)2PZU_+B4`NX4NY3OF[5J"J\*KX6VKTUE7Q5> M2S,#G9E;*+PJO!9XEK/+^/4/#%]52IZ!8R=0G>*4BEIW&K4JE)8'I<<;JRJ4 ME@>EQQNA*I26!Z7'&Y=V1-^BL.";.;GCW(-C5;*6FE4M!^XRYJGH=:?1J\+R MH6'Y>&-5#P_+Q1L(*RX>&Y:..E\>$N51(X9!NA]\5E!?Q3D7+NXZ6%9(/ M",E''2LK)!\0DH\Z4E9(/B`D'W.<;%F.K;"[*G93W%*Q\(YC8876LJ'UF.-= MA=:RH?688UJ%UK*AM6AQ*V#T$Z;L=VQZ@I'1SU^$B#'3AY,O9$S\?##1NSM; MR(++%UJY@;?:R&,,+6#!KM"TRVM/MP!&70&CKH"1P96&`D;C$('A9X]7KJ2< MKB3'^T"V!H9R)7MT)44&AG(E>W0E.[Q!"*X?=R=WHA`CW(6M.L3HL7#+3O*6 MD6A'C_C%A=3\"R0Z)N8TN=]6N8&S*C^RMCJMQ!BU1KXY!@_B<,KZ"-O_ M29,#P<]!I:-<'T?%R519-#P!BFX\3FW">5L7C.54YA3VHR/N?F;.JSOL`J]' MC'+"OU"+"CY^>BGY]5ES!AW0=R>/F`< M(*H/(DHK/:+W$C0>()J/9-Y;>KP7=!J^2XTXOKA#.?IM@7`4QDU9D_4^'M2N M:O4]R'K+-?/:5;56ST>IIG=)JI6"8J\4%'@+8WKI4D&I7%`JT*IE^J2!@E*) MH%2L8P#IC=4*2N6"4O%V/5-;,.8+'1-#1-W8?H'SC6W."5R^^!7_Y3`924M0 M/8BN;;?D2576&'`\R9@:^8%-(?S]1PH&)8!!KKN-&@VM;#-)H1:-O+;EE9$? M6G[\2$^'PHM]'\F8V!Y)W.D;+5EUWX2V&,3H$S:F.H&%&H;ULAN.Y0,/XI#% MPU?3HIEID8)4"2%5K.E1>OU/0:J$D"K6.F!ZQJT@54)(%6WFO78L=6=7`W:V M;>.)80I'OX\$3PO&KJ*H3:(H!:;B@*GT\9,"4W'`5/K(28&I.&`J?TKWPDIFC:>!!$39Z$MG.LPRYW?C-)OI'&[I8RHKL.*[>) M6WW`\6[3,D@;!$3U+30 M#[_6`14I$=XY+M`IE!X*RHJU<*VR5&EN[2:=0DV'U@XGM>VSY M7VGA#WA3;L$GAQ0$QM,#VX,<:_EEBZE%3D5)=*=6O[:^U:_E.=%I1:LN5W"_ M\RMF1G9:^4.$R-1P-TSD7GY("CRVUE_"N&B/U?L%XL)*2\1RG/817)Y$[O MS"D?.XNU!25EI\K(SB(IN__)M>^*]L">R0LJ>@/I&L.L,)3P[@,+5EL.(#"8 M.]C$-HKYHSZT;^^+Q7]D>!7?, M.S,?RU:F)\G@[!83W=T2V[&HO;C#9Y5V-9<*.V1^+F:0/Y6 MK;:%-AB@$>B3B5^J5?^%0>AU]`9>H`!_CV20>7:S\G&`32ZZG:D9]=3Q&)/] M4*YC$_U),$-=VT"`_V2_03F_&)3J^CJRG(1JN*:RJ)F(GEM']^3`'Z2V9=(2 MEO&+K$Q(\L/[W&8B0KK2^*`_B&E6O]O.JXWZ0FJ.30QTQ[E'6)(BOS"4_16* MAB7]@LLINW=\BA8VDZ;L=\?T;&';)D)V)F%\EIZHA%]@73I2U=/]A\AY)".' MN=1^0>`KO`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`[)=/#?>R`B=-V?,T+M04WSVK&3B6JT9[+XO>Q(-!B&Q[EBBX2%L M41@31&WQ-T$_F`[G/R[@C8S8.LFJ=[+F%U%/Q!*]P1-^VP@AU9D)^3I=%F.< MJXCZ/<9H&!2DCDTTPM2H4AOI>$1=;,X,*"KY(`K>V1V_V$8"NJBU6BF;E=UZ MCG2NPN"+FG9YN1Z=INGH$C%RGT/U&3($()RX"+0JOV*A9)(!!+HV?ZX7-AFG M'$A6[K[!SZPO.(NR2$@BDLT`"4LG8?`=*!V$K$1=(?FCY<&?>AHP9>5/>F?N M>^'GHGXH_-'RX$^]MAU^EJQ78='<*[9U@@8.0X;C/;L#SX3()JZF1Q$YPL9? M'G=]OF:P3;;TR6&W03NSTZFM%DNN+LYG>+%REZ5CR4JQOG;1>`^6).(]1'P( MS0PF409RVKA"PZAHJ\TY<;.6#Z;C->V2PUJ>BX$YYSH'I.37S$`W?0,X28&S+%D#.\%'QV=`9(5 MQ#N"F4WM%XY&L,<;;"WZ0029_F[5'P.GTAO)?,GS74F"@GY$0#?H_Y/HOA/W MWAMT@SX?")/678S3R[25J4AENUYN)MD-Q'XK&&:6N])FC/1E>E'P/7AP\#*= MB1Z*)=.+II+I!GK:+*Z>UB^4FFZBIDVEICG(-,B02!.,HCTR*P@\MZQMU:*O3_%WJFO/EK%CM-= M'+2+CM)GK+9JB>(DFC1O.V:$FV=*X$6VZL>C8KNPV$N M^X)3NZB7U8?MPULMBP@@P:IBY\JN8ME7"JU15NN]#SN];W#*?:8GZ!.F#/V. M38^@6\IUTX%A5MSI5X$KM373F>3&S\:1>!' M8]?\V&ZHQ4'S>^BXGY.1BO&IG8SA[&9ND4-Q_1EOD2->W\_'+EP:V0 M^G#SD:R7VU`@,)U9(T]PY9;@L]E,YT_9$;AVD(SS0J:WS1M;[Y\WLW5QV7IO M>[G*">O+YOG"?F\PIQP6!QZ2\H<3T7WZ8M,!U6&K<7#@&!*^/SAPFPSL;'J" MFWIN3$?_/L-6V6IOD&RS;1N)%N,&P_:@-=G8\DSE?S?=GPPZ_ON+^U/P$W%W M8I(/%:A7Q:;HYQJ99.#^A.03:L,%/=>H-A)/#,I')IYS)R_;JN(.>;,$ER5P7(!834M@@3>H]^J'P[[9^BS^WV M0^5'*<61Q[@')L9U9-5$5_#:B*<0S(-.X2$C+Y`(29X6%(U#M7@)4);HONE# MR!>2R(:'?H!RE7ZW4_GQ%'4(<[&@EMH#AUDQJ.+^.++A#0Q/C-A?5`V&MPZ# M%[$UXD5"#'%S#D..15WH(\DD[NG#;%Z<2C/-X,8, M"'\J*#/%NXAZ(?]3]+0V:P*"DQ"-L.>K'D#/&8O>7X=42.B5(/)&F$Z#Q#+, M,4_1G3]:9T3M8$E>Z#[VT]J<1&UOI,B,#$PA*W[ZEU2K`5D#3S!G0C`[/69?X5ND2(9SX`Y8`-,(5P:EC!4C8E(" M!C(&+TC#PM^%/$)O+)5?A+.>%1SK=H=8H',P`)"Z$A:@X9#:R8JTR0]_954S MSFT)6ARH&JA"K'8K:X>O6PE?(IK0H^WK\[K=P-I#$S-J+$W?2?0N:^",C(GM M0:D@%TN0E`CS(1J8SBM'AB?5%1KP0V*-,] M"ZYQTDG,'!@BHP3<(#SZRS/\R68@U]@7Q/CR:0RI(&-L>I)6*@8XGW+IT\7_ M+PZP[ADBR;UH?@'#ZB63NV.UC_="5<6<+4#BO1^S.)"W/S8!GR+%[R<,3#JB M>8J#E$6Q#`?%1Y8@;\CGAS%!XP+A(ORS+/#*`8D\(<=DE!Y.TCT>DY0R_&O: MMOWZ3%^`4.`:03I.JN]S:O](=+B25S)>FIICU9=P&L72#$G,:"P,<;,#,T!X$&G&('GJ/H&@RZ,P7A.'O>+%LFW6L>(DM6#T4AE8$3KY1.$$/ M'A-S5`ZG$*CPA$$62)I(VSZ=:3Q]B\',DEO02Z*3L`O90]Q!T'RB]=3M!!DK MC5>PM+AXI;&>^C#VC@0M865\$E%::IC!!)P,#F&&QQ,31S7]9Q"#_(>]9^UM M&U?V^P7N?^#-=N])`#N5_(R[IP62-.UFT29%D]V]P.)B04NTK5U9\A&E)#Z_ M_LR0>MF68]F6'-EA/S2R39'#X;PY'((HS)6OFC&?I+N9<>6H\4G05><",,;O M3Z_190%;1MPX:]YZT>OI&UBRA[L,68^9YUSVM3H;M9UQCG[3"<:K[1GOUAC$38X_O3YZF0])'/_=B"^`,<4NL3;0F$D+,^\ M9%,HHY=PSYS[$K049"%@GX8Y-XFT/&A;#G*,K<^N:SY:]D)YZ_Q\$_6P-,5N M-=W,G>S8=?96T\UQA_5"PAH2K4SR=UDDSF(=X# M',Z?@"F7TSH-_0!Q.'_FI$P<=CN][@&BTS:GP+IA,;.%`X;T& M@#FQW9#>=L@C_L/.KY.W"M\MK8(W@3&>@8OUKM&'Y2M1%[D&,D:5.*U1Z(MR M8@W">%R,3+3W@![!03&):PA?PR2_!`XCPMW6>N0X6\0ZSO?B)Y,(1?;^"+7,$7D(/_5=WW?'\:`A7'7Y]3O2F#RM.SCINY[) MO+KO3MZ1'UI]:A@=HIVV`6DB])U`EQ$)%,^^N0]0)Y22'W[#Q96&CXV]G(OC M/GIT\OY(_ETZA<6MN"I/:LDDPN$BB/LV!=L?X`Y'VXC*EYB6>+LS\];>7UE` MV>9FY)WU-+LG)NSSIE9;%K%7?%KEN1PDGRH"J\Y<#I+`E"+`B)#'F%(%ZW'J M*@JIR+0.CVG?IOP;;S4G%S"/]7R7'<*1DP:VI^:]$F<8E,\OMUZ200I66HK4 M7R&IZXK4%8DI:;H?)%85.!2IOT)I.F,XD_X05M?UWA_]8!B,#09'J:GE\>7" MG8I&Y\=U%GFC0QH%+G&8.5*L6QMMVOR8FH?EV);#7EB$+6(^!>IVD+W9&J`P MMR*$J+4>Q1!F1%\TGI M&UA50>*+Z0S%!XH/*H1$17>*[I3\57R@^$`%^L/#J^*3&T@(F5WG:8BSE:J<@JV`T4SNM:';<_@3M M%9TK.B\C;*_HJOIT!62ECC@I\?K:V6!_Q.N6D?I558;2D?P7<)@SCS)719"L MPEUU1>`ZD.^=T[W7-)-63HK?%+\I?BNAR$I5@%,$K0A:*9#JX$[QVVOEMY07 M]5;QM>5)@#I.WO:I6#P&>\LAUWD<0#7L<)U(QW5&U] M7ZL<`;L]=TS\D^I\(Y2V6EM>V/H<1#%&<<&OQ9&7$N^)@T'D&%]ZM@Y"`K;W16.]W81N+L)L%]$!I?7DL.3(='"_>@J3PFA/256='TXWO#Y$IOEG6K]H8WEH?PYKJ/7&^OOEA[@\D4B?[O,"@L M*8K%M0GY1=#UV@W504)&FTAM-_1FT:4M:QUN MJN4O7>[?#B(7'08"R#*Y!!S-:%9+[(&M[,C";*T%0A+6+!!OG^+?!6AO\"";2[*YWOK4C@W##D[?,>,YCU(-"' MR^_Z(["6C%";4Z'V"E+AW^.1-@LD-E9[UVN"L4*-(X*1AN-(ML3QO!U4?&PC M:V5GIE8&I1<0&5\)]^;VY8WK`T:_T6E,J5]<9UB'V8S)1];WZW=!'YC.HF`A M)F+G&Q5DO`;JEU"0&#X<'=@)Q[Z'H7'D;%H&7\BF@%Z`P)_>@^3GU!#QGXMI M^A>Q/`GHMP,)N(1[Y;J@V79VMB%3/#.ES9?IF^=.F"=XQ$:5C@N%,FDRAOEL MCOZH6]$I`!MWN=DFSZ8;$DO!6$08K&/?29F>7.+D% M0XE-?,'VI%$C2,_H*7)WS$S+H#;Y;+M]^,,#PP!*&02VC0[Q>&(S5#2@N\DD M8DZ0@M2VQ7=NX',?6!',$V+0B>5C%\(B@T:@#1Y`'MG3^HC9)EFIS(Y`FQV= MU`@E%QXP"Q^1WRR<#9A]P!8F%_!09PHC4U"?CPX'<$,!ASO`CR/+&.'W0C@@ M-7NN#=T/&(PW0KM1,/8],T:.:[O#*?GBX[!?KNZ/3L0[%Y;[!,XU][U@++8E M+]U3;'0*K?`WA`[,GPD#B?L`$P-8Y;$ZQ(6<=XPE.O28'#!TG8%?SX,A$`/1 M>W(%3LG]2&C`O@F.E;.5VW,A+(H!)U`J;7TK<_H//Q+!J))@0WR6-TU;Q?<0C2)7`$'V@8I%L`<7Y5'Z-PC8`_.PJ7[: M7@'-:2KW(7ZZ3Z8)`$;4C1U:T#M[H'80KP&0(J("]X)-ZI$I@_]PR1"!@0W- M$;(^LW%.X.7XV*%M_0TT(:D3IQS.@HSH`X.VS"%C)A67(!<)^"/,`WX,':73 MURJ@@`=KI`]\`WZB0SZY@!U0^I^!@H@2D$<^&BOA6P/EL(3R!L'A-,E^B8@>@*;R[4^OKJZ_(;(04@C[&2? M/Y'3Z&H__D2`$'T$($*AP)SO3L(UD"37;U$;0"8K948#C@`8RM<"NA@ M%F@6>S&<#?%OZ7IE#U0,$D!B;D1Z7.IZ@HP=FEEFQ&C4"`U.;'^99A'X`#/@ M$1=*6Q%ZNIV$9IRD;*1DCXV@)5B+8;X*.?XBJC+$*7:?;/>1"S(65H'U%%H( M8#VB%/%'L)P.0O5+X##2U(3IV'C&P,F$\X+:@GCN1H*E!+0S'0)"!C9#,>,O M,@I@J(;D*NW>156S_(LW>Q'7P:D00.%V<,8K1&?^80: MT>>Y,[6:MGDV<>J8Y5KU4\[.8,PP?1O,CG?DAU8?6*I#M-/VQ'_F%MO""G^N M-^&"82W_5&S!`!=PN%BQ\[+QL5`:;L`Q4K%&6?S='Z8NDFQ**;RTL>"H:&4F5//Y":)B,JXR MI1/6!OWE:RNL#;)>TZI7A*0/\ZM3BW'O63O>Q/#=9(LHS>^*NRL$6='?5K05RX]J_UNKV2)$(%Z&0W M=1A%4%"5]5%E?519GU++^F2IW=7)`3GW,*NZ!WOMB,U^SQ3VO$C;"(^QX-;_ M'6:X4L_$=%!3Y+3(S+&C\[O+HQ-RIK5K)"L]F\LFV``31Y/-[E0`(+WKC5F? M=I39Y+OB!0?3@*@SM*+#"1;B!X`0N\"6D_PF:R/1Z$0)MK53Y9&HK!44YMC) MI$S+(PR0/Q8#)COS/,P/6-CF)\?SN0&XIW^R=/=_UD`2._G)!-.`P$3B.E'1 M$2%[2N@#M6QYJ%6F(DTQ4Y*:2#(XQ0%F:\DL*ERGL>O-]N2Q(2R;A>F#%)RQ M87@&R1_A=1@UB3(2IWW"-QD(DT-[[`&FC$LJ\IJ9;8UAD;UIC+_E.4=Q4@*1 M._?0*U`AT*3,M,A>@#"A(>^BA@FG\RNSIVD0ZDD]J2?UI)[6?[)GT[>?S7]Y M-J4[(Y\EG2->R3PUE8"R/`%%GHG"!Y84.2PM#%V%#`.5E5(0R*U6HVKQ;)63 M4HZD6*=X@]K#JA!DA>>CG#6KQO,5V,/:3Z:.BHM93/'L(?-LJ]LY9)Y]16HX M*@QL)<3UCA4R9A4BQ2&J8:SM;)7*R1E"X-)PM(3CSW+]G54!8^72C>M31O M,`VNX_HS0/49,1E6'!.IGZ)V%'W"=,N)RS$5\96N\KE8I3`Y,UH7<1=!7#DV M52\[K"+E(2)9F(4J*G0-@-=ER2N15#F6OB%TY;$'Y@32/<3$7!M+V85+/U\\ M+*&3597#UBLPM(3H_$VCA<\+E6SQIV:SD;33Y4NI MAC:;DFC8C2N4R3IB29%5B46',.IA&B]/CDF2=:NBR<6(,EY>'(B)K$-42X)%P4 M'==$ZY'CB(/2&64UD&<&F_BIQ0Z;G:S,6BY#?(5F3%:^G$J*5D_J23VIIX-\ MFDET7M1*8+;1A7(-E$P[LW>]X69P53:E=[,INCTU[Y4XPY!_?KGUD@Q2L-)2I/X* M25U7I*Y(3$G3_2"QJL"A2/T52M-2#F$U.GMUIN.[S-4IUJU]C:K/6;1W&91G+$1C!T2R!UA0?'`8?:+5.8U&/[2D?*+K;%[KKUCJ][J&0G1*_ MB@TVO.:CUM(.0_IN>4@LY2#LEE<4>^S#F>K2-["J@L07TQF*#Q0?5`B)BNX4 MW2GYJ_A`\8$*\I=?Z24\M'MLB].Q\_A2?O;>^]G'>DW7JGFCYGQ-I@KJ)D7G M>T/GO78UHZH95*ZH:N_,GTXU1>@!F/^*&?:.&8X[%;W?(&>51Q6:5VR@7.(] MT`V*#Q0?5`B)BNX4W2GYJ_A`\8$*S9<;FK^@W#)$T4;3L@,L?2DC]!EE'A

/_SW?Q'RS_^IUR\IEY?'&?C`_A58L*IX5U.]+MM$_6+#<\?$ M/U=)JW/_DGK>%!;W-VH'C!BP5C#&=S9X?V1@X3>MT]2.2.!8\KM?-:UQ1$QF M6&-J\_=']>;1!UWOGC4U34OFD&NL74U!UQM-?<44&HU>J[HST'+,H`FMJCL# M/0<9==N=;A$S$`^I%VKD&_,LU\3K\CQ&.2/''YE\.LDW._E^]'KT<@:OP!KX M;DZNZ;7.>CFFFSUVA6:MQ[/.L\BM5J=3T*Q31$HLYX%Q7UZR.'8=-L7=Y[^9 M3P8!7MYSG+Z$T5A&ZB?U3]3RB""K&N!M$B`:O[`'9A.=_/&5C?O,^_]\R,.> M1$>)[,Z6K7_&+2^F\>//%O.H9XRF8O#S)XLGS2161;!L0O MB.]&%?'=R(7O/<-TLXJ8;NXOIHM%XB'R=AFR5!AYY\R9.G6 M^%:R=%>85K(TGP]8`&]?/3'/P&OA)YYE,+P!^1%\%8H8P=LD3=>VJ9=*<%R< MH4TYOQW\+M^Z];YCI"CJ]1MV&O_(PU]YAD7>G)]L,SW9!JSVJ7:6FN@&HR9K MCR_C5,,6Q/6(:%(C-P$2'OYVQXS`LWR+<7!4;!L6OC^-7N#Q&XO.9A9@LM?; M0=*G[/)BN@EF]#1F-'!0&F?MKMY:@9S\,"1X4G*?OUZ_7]UZN;^SMR?O,1/M_<7]]\OKJYO+ZZVVG<;QXY7Q11+WAO^K4C[S5##JB)&^N!HR;4 MF2*KA"J)`IX`1R;B"647MOI\]?,E.8^P1QXM?P3?D9\9M?V1`9*\!D+,@A%! M"DP)A_E"1X#PKW1*]![>=Z]KIZDX=_QT/V+):#7"!@-F^-8#`S"A([T60@H8 M8Z@X$18+I)=%;4"C-Y;PX=UM4X::Q0#Y@.+`&:8[T(COD@'V*EO!&VXP',57 MO&&;=HWPH/\7C(Z-H9D-UH48(PQ"@]0TX1N#>3Y%K6UY1C#F/G4,QI=-#<-% MZ78DU/O$<7U8(NC=$@BCQLAB#PAUU#T7Y#MT02S7PM:6@[]@(TH`*&L*,D8B1AJ%K)"^Q8`(, MAP=(F,A>2]D\]=[$R(O-TA0-GNTW*`)"7>(276R)T@ MUAJY!8<4U(#82,Z`Q75$>]DZU38/=N:->+U]UFUU>KHVN]C+AM@1X!E87`2\ MJ9]U&KWV5H!'L0G.`V8^`_(66[[MN;VKN4Y+`2R7$]]NK@48EX"%`M42@`E? M77Z3R34SJR'G4A:1RMYW!71!!+HAT'=@#<(O5^2;QP;,0P-*=+H\II9W6EI7 M:_QY!S:A,`I"AUZ\)X)F%CQ2U;0;!X93:W3.6LO(;<2WK]1[]834S(%77]CGA@P#R'.!(.:(ABDZ9ES6#;*"\XG@T9+FT](JS3P M1^#=_7M-)CM/7MM`.C2`KL2_9X@K&6'7$\@A*3:?`+AP([3JP5^]#FNX?L$3 MXC6"95W!!KVG3S5R[H/AVP]$+A@:S+"VP-P9DTJZD[U!)[<#Z&++_(VZWN@M M3&_96%68WGJ)&G6].Y]05.WI-;36&JO7;>_3W/1X;OF6#C7>NM,#68A>'1V* M?0MJ&&X0>9#@%H,,]YC!K`>CE>ZJ7 MN-UE``)K#+^"&X)`>#+B]-WBSVG_5%-LF4Q`7\7:?RZ\?#&]^`][5][;N)'L M_U]@OT.O=X)X`#+#0Y\ZW,I>CEQ?NQ^L/;'8;#?*27/[,+-)0^![8_[U`D?64)@SU.RQT&'F MMS#X-*A/0E`2S0"+\V9W91KO:W%\>=(^0R_S3I:7]W*3U`#_U,4YH#*E.8[2 M,$NR2_/<]3(W*,PJ/_N^1>]\M\SOK>)AJ8JF%::QA>9K)Z^:AS3LC5JEKIJ# MTU,'+?.NBHNB]XO^UWKJ^"]\J@%E^.*P4A)[;@V1EYZ5/EH#%'N*5DQXK>JI M!=JKX537EIS=`])>#<6:6MP3<%B^5\&X.ACM3/N\.LA"!VB2CX,FKY0/(1OE M?E#O]XMA7[[Q9BFMN)=@6&:`VZ&T(HS[AZ.T&FBUXAJXJWP7/5#'?BVN6Y:.#3WIKN_PY(PA?[@/#HP:O']-W+_E?8B<>ZDJ8-2TE*6JV-FFTV^ZG:0&^'&FUYQ>0R-6"(U5:H M*5F_61(U#"^TEGBS3:%4O1BUQ)MM=NKJ`V4K:JXFAO?$%VQ!$PEA0?S,T@14 M:./=RR5;`OO$@]D&5Z66'&2[RZ*D;9<@L24\YIPKN85%W])E'A&6+#/8"B'7 M];_2MUNNM4I.!MBXE#0>Z,+`OBV,[%N)>0S.XXK]]^=\#'Y$P;58OAXO]S%. M8YNVZR:G`+#4`O].9X:9?B^68;8<());;'5AFG:V^WQ\K.IW?4C";$[(E@-EY8?@RH73R",^ER M8L=F&YQC]M-7;:6,"T'D+4^2%)^[.X#OPS1[1C`$T><$K0?^C<2B+`=3SR#,BRPEM:RGK(CA>498H2Y0E MRA)EV7*FXL$P_WH*_,BS9'YY"+AA\8V!VZ0MDI1\7_NF#E=M?Q?B?:%40I+= MPP_VD^/Q[?W)+N,9/P-R;S\C=TQQ.TJW]HSJW22P#[^7K^[99T#+1U>W/R*U M+VG:L`7%;ATZB-6CPZHF#73$*F*U"UCM2<-1&TD4Q"IB=5^L*M+PHHV\;D/0 MV=;/?^3_=='/O[3B0X.6USZ=B/K61\+N"M?TQ3!HR1$*"`6$`D(!H2"B^W38 M-.G"DFUMN.^2[2QS&I\&:V=;POB*^L`P0XJNUA'$-L5!U-3L4%&Z&R\A8D5& M[%!':"&TNF0,]:&.B$7$=@FQ>H<1VXUT9U/^NN/)J:?.#G(`5YW?8X#..FK[ MZN7,W55V!*S(@%5'B"Q$5H=,H=I'P")@NP38#L_=IYU8S[ST^0$VF%)'35_9 M;!^G)@1L(X#M(;(065TRA5@!0L`B8`7STH\SG#B5[NB&$80"0@&A@%!`*"`4,*6*.PJ[H$G"1T_G_;YX MP5,=`UL^-1*1W@VDGP^4'D(2(2D0))LROMI(O/.O$.F(]`:0?B%>_;9II'CG.H;%B$B1$-F4Z=7$6WR.0$>@-Q!M7YP< MT.NOALP,RW*\I^QB<>6\-K]R7@!C4XW(8S9' M/4D;M&&1:@#GX>9CU"S4K.K+*Z5^OXV,(VH6:M9I:98F]5HISJ)FH6:=FF8- ME#8RCAW0K(JE,S*Q&2Z@]0&,Y4"%M%I"TR0>)49(;,\B_B.9P6N^M7=\BEFM MPQL.M2^I%^+5P6O@-*)+`'2IDCX0;[4WHNLHT-60TX,F$4';/=!VW-)B22B5 MY*\VI6^)&8'O[85DY@.1OK>WKXW1/T;_U6\^D0:CCD3_-VRMX\X'"T`ZFQ&J\ M?+*.(0?78B"&6'[TX-HUV9KZU.W5WIRO.&813%=/ZK>RK5<,4(I!!:I&)U1# MEW14#50-5`V<-42@`E6C$ZIQC+-&+FA[$QK`]M)Q)9]_>!-1^X>:KD^CP+Z'H;US??.OG_[^-T)^^(WX_?D=OSO\?7G\9I,Q$9J,V@\!.3-BK1&=;[H@^J,V98-]Q.;F!,&*4H< MCX3P]Z6SY*/Z*&9]&E1:FYCUQ+B6F[;F(G?CQ3SOAW.C/,]'MA^8>B?+.9//Z7 MS>FP7)IGI747(3&SQOY5G:QJ=@-,G\D*NAFLG!6$8.`&B]-V1R:HFAWLU]4' M/^#&A#K/9`H/3"B)[TWX5^391%>D%N;W=IQ*Q*P('=6)V7`2V/91H+:T5)#M MGNAOMWM""+B)/\=H*V6\(@13Y]6X_5ET><$K0?^C<2B+`=3SR#,BRPEM:WDKL-AX15FB+%&6*$N496;7JPGQR/W=G$UB^R/YST$1"+$CALZ5RTNKC:ES1-O'MD:X`.8O7H ML*I)`QVQBECM`E9[TG`DWIGHB%7$:MF>O^&%>-<9U^[G'_:6I'TD=&E!`.;X MWOK544>LOB(<*K,E#:)I!T(!H8!00"@@%!`*'4Z3-G63"S0;+\=+;YMD>Q$" MP\2K)H\BMBD.HJ9FATJ'#^]#Q(J,V*&.T$)H=LPBXZ@Y;Z(#..FK[ZN7,W55V!*S(@%7QW@%$5I=,H=K& MT:X(6`1L?6L3N@O8TTZL9U[Z_'0A3*FCIJ]LMH]3$P*V$<#V$%F(K"Z90JP` M(6`1L()YZ<>93C?]Z=2AU/&][$!&=-)1T5>?,*V,.JSKB-F3Q*S:ZW"Y%S%[ M@IC5I*&.NP<1LUW"K"ZI:H=W9W/7;II'>C=0N[IA$*R&*E1!PGQ!.AZ<, M]'-U@(A$1`J$R,9,KWAKE1#H"/3Z@2[>WGE1XI#CK(O@AE`T$)4,A("K=G$F M/&6@G^L8%B,B14)D4Z97$V_Q.0(=@=Y`M'UQ,65\]K\RGD!C$TU(H_9'/4D;="&1:H!G(>;CU&S4+.J M+Z^4^OTV,HZH6:A9IZ59FM1KI3B+FH6:=6J:-5#:R#AV0+,JEL[(Q&:X@-8' M,)8#%=)J"4V3>)08(;$]B_B/9`:O^=;>\2EFM0YO.-2^I%Z(5P>O@=.(+@'0 MI4KZ0+S5WHBNHT!70TX/FD0$;?=`VW%+BR6A5)*_VI2^)68$OK<7DID/1/K> MWKXV1O\8_5>_^40:C#H2_=<@=S&H0!7IDHJ,)*77QJ$98F!3#"I00[JD(3B) M"(\^5!&<1,0_@*U(?:^I>&ZOX,T'"D,[F!*K\?+).H8<7(N!&&+YT8-KUV1K MZE.W5WMSON*813!=/:G?RK9>,4`I!A6H&IU0#5W24350-5`U<-80@0I4C4ZH MQC'.&KF@[4UH`-M+Q[7(R_3C0T#>;.BHY/,/;R(J/QG&[&VZW.PV#I?>.]1T M?1H%]CVPY)WKFW_]]/>_$?+#/V3Y$CC"BF+TK3Q.3[J^2XYVN/*3DZ[)[[_9 MTP<[^*\LQR^NZ"AKC!^2#7W=VH\_GIF:HL(_10U]_FF@*W\47YP?(G'_,K,O MGQWZ1TI.0DU&3$S*&8D\)V[_LZ)H9Q`CFL[4<.F/9[)^]M.0@WXE1S)"V^:# MFO%!;8JWC0.2/$XX.:\:$=/.CZ[GSXZ,EWN9,G[Y.3)P]B'.:T M7'I62LE6'-!V5XC&&+"#5=B=`>I(/`;L8`[V8$!?/`;L8`?V8,#N*I"./D?0 M8;R#=.@Y.K8:>W]WX3Q]T0;^PYJO^O8]_"#FI)[98T_P-BOYDB+K6)LV;;YA85=5T=9.K.%QO0-LC=@O.ZOKN MG$U75FLG@"*QY1=) M[^7V9O_+6CY@V"/K:X&V1.MA&=-B3"1K:YTDP1C38L`DJQ>U,F8/CW(;P+05 M3-QIM:PLUSS1MX"=%FO.\OKLC'C<:;4@+=?K/#<=H+=6K);7 M)R!7,R;+/]T;S^17QWAP7"=T;"J1:SN4R-7ZC"2\E'MGKRR?6C[KEO;0*O7; M9/UVI7X60#,&R_))!+ZY-OO(]?1RRK)__V>49P#G[V5O@2;EWZE<=RDF78MX MVMSE8<:UJ:936.58=(`K#8N:@3/C5/B/?,GRI6GZD1_HI\#WX;"9&Y-H/ MR8L=DDO+GX4`T-_9@EK"5]26&):LX9M':';>ZF*CT.9_[#!M<9.`?ZJR^W+A M-!VVVII8#IVYQLM;\L!H+NS/+"S:_IY,C>#)\6366/)^B^ MOKD?DQLBD]OQU?CZ_M?_D(]W=Y_'[\GEU=7-Y^O[C]<_DT^W-]?P^6K\&SQQ MMV8_\"X#6R9]!:4+ZZVWH^'/B(;.XTO*#?;`6^*$\*MY2)[?A!,[@#AD"NB? MV!YUOMCDHV?Z4WCQ4V!3H,A(85[VU*;1KQO4WJQ]PBP7,>&*3T5WXE_-(3 M/D=&*:6VPW]SP(X3"K;)!;(";H4<+_(C"D(S0FZH5I'$GH?7PZ\^H?;,".!Q M\A#Q&9?:9A2R)[-&:,P1SL?8I+)7)PXET>(2?8+XUN<=(U+Z4(/4KB(Y`$ZP7*\$2O#]U0F#-=[F] M(]DGSOKT4>`&9WPV%LNQ..\G!I!I@+8PDH!,9SHS3!"_Q\7!+(?AO7S+UR/P MLR6,9-X"W:7PZ='QH#GV8D[J)VQ;,LG%4F,\_'!Y]RZU*T843OS`8:;YR]QP M,%3Q4P_X\W/T(N@8,`[Y1M66F^P*4U MHVX5SWLU5K8[;`?'=.XO9YO)4C\".!.S[-:.T7+ETQ!,V-W$"&SYP6!&X9/Q MDH3AZSSFK.F;QWS#2;N\6=[H.]9FVF2VI^VH?.?WX#O?_7)Y.Y;?7=Z!WWQU M\]NG\?7=Y?W'F^M3-:;WGSDF&:HC;I2+`$+@1VTU* MG@(C\;/2GX&!K,?8)L*SL8L0S'-*B1FJ,(.2F)389#H!L4$&V2^%(D+M-P#U]7N.^D2?EY)Y8?/-)7%(GME`8( MA(%CLC]Q%-#$\X568\%*,;LM=@S1*[`M_"V0L<%F#9A2[4!BK\2HFACN(_D" M33*Q3Z>VY8#4$L>041'84X,Q+0#9VMPE9'\.;.[VE7IQN<&&DP#0QH=+2P8* M[H8Z&$C:\"(WDMSP\H/*CVFH2\`,\A7(R+C#'!+0#C/T4Y]5WZ5I5>^O;YM8 M"[)<,SA$^S+:RQBE<6G-O<\4]ZF_SZ5`V%\6S-;)LO>#'^24B_%N+0Y76!-- M4B]BRU!)/_J]46I./-^3$WLRGWC8U.'`=/!O@_J_V(8;3DQHG=#H@3I@6H(7 M]@!,)7^"&\>G/SX_\B""E89IYJ3;Y.?Q+U?D\@D&R<-[9YX&T4KM3D6^J.5\ M47=@RD`:K6')R0(U[V";>9?'?F:?%SR.QXJ@YJFO5ZJB<6FQYU]INLJ^\"@L M2W!(94CACP^'N5<5G7^I2(6ZV->JG`:UTQ&#[Q;8B6L6NUDF!`TQRN+56=\3 M:KLNF$^)/-D>A)!N/)D9UM3Q'$!B'(>G[7W/?V1QH1'`9,Z^6-"2Z\^XSF3= MKG?H5M MA/?9RT%TCMHXC&3^]C.(A,UU*QGA4)9Z"_QG[@V#7_5*_4XGH&HN3VN$)3,A M3T(X:GF&GSLB?@K2:&H=! M*^O@Z9O)BTE9\]*S-NWY^>,NA?<52RK=//*.>.$[ZYS_::N:=[Z.MP5)AQJY M6O_(P9=>+&/N-GP&ZP"4D2V#8`'RF%1GQ`+Q&]>&K.9"3,*X(C,4=D:#NH(7 M"TT=:/AJT\-?#845PX]@O@C\Z=PI6AI<9'^`!\;I[WNMZB@>)%#>=@/4;;5J MH[BK90-U,DNM.&8\MSMNQ*:>G@:-9LY"V.!@:CB#R8 MM:MG:A+-^/+V^N/USW?D_->;N[O7Y-/XEB6I?[NY3O+6&\9PG&G[,9'))LZ< M:K@Z=_LYIECIFB."`S\-_2<\@*,\GN78AD`G>Y`7V4WF"['@()\MF/BN9;/D M(9\H+?+PPD.5K_S>8'`&C"\0P9M7&DGA!>C+M/ M5.BE.II(F?$MLS#YREIF,21BV2D!#1>0VQ9'BFX9ILX09KQ>$+(AY]ONKL M;=-8R`[IY3;:M%TW.7*7137\.YT99OJ]<).JHGQ30$/(T<#6D@0Q&E;>)).[ M(673C:V]I6Z60+<$L>1,Y="?O27_[#T8ICD@RG?]69CW>Z6AM<:6EBT>2@%PZ#DS?K_8/NH7JA7NM MJMGOC->.YSJ>797RG8%4.%S_P35@:L_=LC;GI?@X8KYD'3<,K&+"L#*@4"RQ M6-1]]%A']4#U.&JQK%./57-*PAC6X" M!TWJ*0IJ_!%+&)V5/5;WM5("*:V?]6;/Q/(C\)&J%-`.S;>:(J@CJI&@<(O" M/:(B"@JW*-R!*HV4`6KN40IWYS+,?@M'=EA2W<):%L$H$G*]CV`455_&?'H\ M.@$+MBLM4P M.5R'[^A/SYJ.YJ>F+FUT6][AQG;4Q>??;;G3C9V';!H1M7/'X2;'6#E!?-X/ M/]GJ*]]0R8YC]D)'3C=B;=P"5UC<&#-SS;'NA]HWBY^.^],YW]/G1Q1P3U^7 MH#8SV0+OK],$W%^G'8*DA"*NSIM2;JI:P]8DWM,AHYCDA,#:BH6]&IARZ,@. MYKK_9^]:>]O&F?7W!?8_<+U]L2E@MY)\25*T!9Q;-XLTZ4G<+@X6BT*1Z5B[ MLN0C2DW\_OI#4K(M7W67*'F`Q9:.*'(X\W`XI(8SF?%#5FK`D.!RG^880OPY M+<&79@'H5$`B M2M4DDNKJ:17F2(1OVV)))-4U0M;XF+8ZP*,P\/127=,03K=40+&7+_;X):672L<4 M8B.!CA&\%*9M#L2P^Y-GUW#`IH,)M7.B=--=2`";KL[PV%_J-)635,ZGPNF6 M"NCT\L6>BQX!NZTN4,A3HQR(W9;\\G;%]"W8+@5;KL[PR*^4ZLZZ M<#JI`NM#^2(7"D)@.P*$L@;=X5B:++V4SNS+Z2*U)K\R4BNE#H:F(*54BAX, MU,.`55MJ]GK[;CY73P%58"TH7^Y"*1NP*@\-0J%JYV",PL#%X2?X@@P3:4^I MTSR54RW58-35&1XA&I>"IUTKW5(!]5Z^V!,`Y3A5?#JPY0X#)NFT#=QG3(WO MJ%']Z;CQ[\I(OZ$8"1UA*-(%D]NXE$DBS?=NL)1E#V2BH^[ M.B^_?^N2UI.J3M]=^F%#OV#[@7DO#V@?9ZRQCS__A-#[7UJMRT7XS\L7;:R: M3QC=JPY&EHG.53+F04-YX7(9P+35\EY?],+;N!O-6V`-W)GLK;XY9/\$WD4: MY2*EXAZ//C0T%I%#DB79L7BIUY8:R#5U[^E725(::(@U?:(:Y$.CU6Y\I(R6 MI,#X8O0LSI#EQ9#E"$-./=S)U+!F&*,';/_0-?IO((?J>2"':A/=,F\DPN+- M]I]5>TB::&`YJK%2B_X@#JWIH!EVT#W6K">3SHGA!H?\;OU>>:=GK,]@8XL. MO?YX;\'GK"_:U?]B9]G1%@2%,+%+<=.6I%7DY$7>DN^FHSNSUI_ZD.(+_\"F MBYOHL_J/9:-SEU!EA.TFHA.3A6-1GW#KTR7Z':N&,]98=-^_/N/)([;_WF`K M;Y4UZK?)6YPWN&QN"Y4]TG_1R?=/>$F`U_TJ5SM!KE[?7E%LOCD) ML#0B::)R2%YP2,Z20\>G]6'1FK+.C$6=^K!H3;EGQJ(T$ZU/"*;K$%O8#%U] MU`W=T:EM,\$J<9F_J>J@D:K;S(1R\3HGKNB3;^R!UPI=:6Z6;7SVF[@SJ09T M;9L:&[0"U9OV_"=5JCH9,/MG87R$V@`??=,H_N:_]`#P!/GQWY%NCBQ[XJV9 MZJ/E.CS<.EL^5'/V&Y5&'*'0VLQ@8\\9S,:&N_]`FL>!TJ&/=$VE&QM`3['H*9HD$"&(L!!"8WI([#^PB6@,)3!(LNTW%GZ$ M7Q>HQ=O76&I#(5:%I!H#)+Q;PG?.&-L@W9I*5S2[#F2";9_<+<\$'$]1?S5M$#(=1$&\5Q3MW<*R`@&,:!;ZCQ>(NDS)] M*1<@)(%($1!2`"$!D/T3:`!&` MR`Z(A">[%Q<=2>*\A@@D4:"0).+@?WC&GC0>+6.X4T)13A'$L_^+(D$(`QTD M`!(`"0@H`>&7WR/75-VA[N!A7C9:;@LN>GRBG+?L#XU?-0WCT:@1<0E>#SB6 M+'Z7?%*DG'B@#QP(UJ'/0V#H)II8)IZQ-__%#AJYYI"@(]W4#'?H/=?FX4*T MM59"9!Z#B7)HU+;FG`(T)2#A5:*>N<`679\FZ_JT>=+N9#CWTC%BGRP` M&@5#HP6P`%@`+``6=5I(=MASSV-JD,:UYK:>]E3)Q+OF%MW$B\E"MP:VP[W% M'<&%2$A=44`&)Q2,QD<( M$PUQ55Y9HQZ]AG\[S_BX/G92RQI],QBM/:Q%#4.8#$'(E@S+#24(=H`=! MF@]%T!#%%\0+XJVH>"^PAB>/V$9MN7*!FK.X4P2AFZL741-"-P-$HD$$0C<# M1"!T%0?ND(`<8`XT1!7Y94UY=7),+_(/.W0.-ZK8DP0 M2'&5_<9=#'&+006`#D`GM$0!=``Z`!V`+M06?>OPP#+S7\'/MG[Y_5N7M)Y4 M=?KN2M7M;ZKA8N\21M\:ZYMT['0"K>6:<]_ MGJE$)P/6W8"._HQ]SO[X\T\(O?^EU6)-(]XVNM")9EBL+8+^8C41K_IWJ^75 MWJ`F\,*B8:11AM`?]WCTH:$IDDS_DV3'XJ5>6VI\]+_%Q_\L'WX#9L"E`27:$6NNI?WZ-O_9NOE^CS9?_AZ_WEY\O;P<.ZT-:'L8_HQ:[C MT49OMR%@!T_^<8FCCV9K;&GWBN3+8(S1N369JN:,BGHR-2@"Z6QQQLBA3Z:V M]4,GNF5RWX7^PSDZ4234"(#,1RMW6.!NJ`$0-=!1PW^G\?I-8!(M2E_IF.UY MNTTT8NW^X.WJ!`WQ2#?Q$*G$IT77,"VI#GJV7&.('C&B4P+K/V@=QT($&P:E M@%:G,W<,V@C7 MA,;,>U?5',H"VI_SC+$Y]\6=JK:C:SKE'!NYPYN:++F!AJJ#WT1$PI;943P, M1I9A6,]4OR"NR@AE"2:>&\O(LB6'W4_$8\CGO2-Y9Z;,Z,(6-. M0+(\1!/?'#/BHH6L6!\II_D/U\2H36'#=)&'O4!L![2XFLA:8O7?113&_*:N MQSOVG%+ET(=:J2+:-G^@!"4H00E*4(+2:NF(6G+.V'()M0PV?6D#16[MT%7? M,/RMXX>&U."_R535YK_7_)XD*>%6DG^V"-^+QVL:^5MWQYJ^0[]V'E5-ZR'I M37?JK$0G6?`F^K>)?.G8)"-Z():0/L+MN_(BL8B7NRJ]X``_AYOTX)#04S1) M($(082&$KOA5A,L50E"+MRY`,JNZ2QB26=59NJ+9=2#C[&5"-$9@@QA"<&%1"8KX:!^0!T`+HR0`FZMX,9G!F3E[*4.$O8Q7GM*6&U'6 M&)`WR+ND$Q8P(\1;8"`$<]TE#"&8ZRQ=,!#K+^.*AF"&DX9ZP`^",M=?QA"4 MN?8BAJ#,!R#D2@9EAI.$.D`/@C0?BJ`ABB^(%\1;4?%>8`U/'K&-VG+E`C5G M<:<(0C=7+Z(FA&X&B$2#"(1N!HA`Z.8BNXX?&4`\NI*[;"B2+%<)0EF&)TH7 MB2B?J<__D'<,:/"H/G2/:L`&8`.P`=@`;``VBC_IRM\X@TC@-9V4)09PE9MM MN2W^-`1H%`\-"/D,L`!8`"QJM9"(<]1VN$&_ZS?O1-A591NA%+;:M0!%E;;: M@`W`!EAT`@*E$BL+A+DN^*O]H0;CE)L=)^H"B`/$`>(`<:(A MKLHK:\JKDV%^D7G:H7&\5\68()#B*ON-NQCB%H,*`!V`3FB)`N@`=``Z`%VH M+?K6X8%EYK\"GVW7/U3ONP&R,&`?;?2V\,9\/O[C$DRX>X8YC2IVA@-,?O&KINT MDC.V+?=I[-=IHF5L(,^9TK)MB\X'E35(+-?6,'F3JRSFY?=O7=)Z4M7INRLZ M_&]L]!_ M6RVOUJ)!W:1[I!O]!QY>FXYJ/NETN-X]H$^V12A/J7!H!_=X]*&A*9*L2+VV M]'W/:V>SS^H_EGUNJ(3T7W3RW:.#>`0TD$O?Y*U]E22E0?FOZ1/5(!\:K7;C M8Z=W*DE28+PAY!4R9%E6VK)X0_8JMGA-M*SJAYIIHKZFN1/7X'#M3RS;T?^K M.KIEIN92H.%@NT5#1>E%Y=L.@JO#R9P1*+>+XN0M=E(SC;91--0B\X?25CHO M\@5+-_*L"_+BT]W=Q9_7-S?K0_MD6<-GW3"V"S2$E/9I[V2%F'EKR;OEO`OM MMGT:K]L=?YH3P8R+#7R@Y0J/_F)+/.)K_`8XYJWTS0T!+%M8F`A;^"Q+LF,M M./[1-V+B>U2&7U[.T!2\O1M5-;MVQD/9O8)F]0G_;A;T06?3(VJ@85,>>4/Z(E'R]I M'U/N#$SP$_LWWUU$HME<_,YNR1^+1>>G0EQH1-73B%1W$9TXC-V:.M4=2OU_ M*7^GWAJJL36T2>O27BGOG\F[,F;_/*2+-W+V_!WBE&JE,CAP6@$E*$$)2E"J M<>E(9\:;Y1)J?&U>&MI>Y(?5=`$S#/^X_$.#[L#8;S)5M?GO-5]O24IX?,Y= M-1)^J$G8WY:3U70?C%+2L93;7HJRC4,7T7XI+R3=RN9AUXEXWM^&BI$L8$V@ MP+]H$;>NGGA;\9&+Z*Z9:@M9J"2#!ZG1A9AGK.Q,)U^5)M61:ZKN4'?PKT3G.:FIDQ+:HX`70`NF)!ET-4TJ,4`"<#XL.'?S,D$$`$DQ%]-S7V$*O$67[RS,\W)=*91G/1ES/^@5 M&C-"$P>`!D"'KC*[KYSN*N?J%5M7!WO_Q@R_01J,VNRY+OO^RKKIN[)KGFLS M)3H]E>?4RT;+IU*3("U+D"*3TCCO=W$A1I$X,KG2[[,9=;ESI MQ.!*NW-R$DK*M4FG.$9'-_31:^^F"9W;CFZZ;,[?3;'-IRU!CYA.'8S\^@/U M!9,FNGQQ;)5?25'M&;IV\(3=#K1,1KAM&09KXYIY=6"R,5"O)=;O%>UUV>FR MSS/>I5>/=[C2'>]MM:]Y5RF1W9+E8V6%F"2B#>Q6W)'`4GD-2?BZ#6Y MTP,YY#0CXBCUUFFW4Y8@Z,N4JY[Y=G2&34P7DM?;64>K^C7]>BE5LBQO@]]& M+[E2'$]UE4QLO-E]NDW)%LW=.-,@$;T.`S_=]>K#G41B\H4^3@E6I;.#/*_U M[,B*A\AN5**\J\A'%]@KO6;;P0L\PK;-=GYCNJ_$9`NIO/+\I6MS_H;_0DJ> M=C9YNK^_X@<43QKR6@2(6`,*PF;&CDW"J>]KFNWBH2_PF7=C*J69?"J%#&%+ MIP4,(ZZ-F6(0_K/YJ0;A!P?>44K@[GWD8=T$[NNGU$%2.]JP`EV6,:J8LNI) M86I@S[`&MCK$6'?=>(9]'P-WS3PM/C*7?+)Q$6_XU.\QY#/"$H MG;!)M'<,'I0,RWSR,I'&LEOXR^Q,Q!-Q=E99JQT)6EN[+GQH,9?X[FF8(1UA M;(M=F8U_8-.-`+WY&_?>"VD%I(2J[M7^OC3&&*YTD[O'Q%(?_DL9ZLLPJ6SV6-;`8JK#%`-[4%G_COH2W<[] M8EM3;#NSN6;-\#0UU#+[H8NPB$4%#N\N)-JXQ-SPL%=Z(;+7.<0'HVPQN.?DK%JX]:C2KPQ MLP-FSS&0!7[C#\FV;X@V9N%F5>.!&]R1V^TMTZGN/-K[.;\@!'G. M,$_T;\8,4=WJ\B7-XT%J=@0;O_;;]NH5K&MV$R(<(_)5*Q5B1#P-HC#]$5N# M5(@=^2J+"(Q8..=Y$?\?G;E?T^;(O8K48F75YMY/*4W_->%NZR(W4N/NC7+MFX>1*=UGF^`>=(TD8FW?/9<-,9M=M_I)CU>MQ,@\S<,3$Y(=.V[QY/$?L`2+W-I?M!4W.Y5$N;;A MZK^K]6))#\MP14GO2;%)7U1ILB--G8SIOHG=N_/2G+$=U?R5G:3/W^.OT9?N M1HG9SZ!RO''Y*+2?DD83)>>8+'77OPM''\Z]^HPF*ITK.FUO)\6TUN=YI?3L M/VVO*]^P;G(C-PI_3S8VWR]O!W?WUY0.= M/)<#<2Z,%\J/P+_BJZV0K-8!4WZ52A8RX_"PJ4 MH`0E*$$)2MM+D?-DU34Y%O)C,SG6]!WZM?.H:EH/26^Z4V[R#0;O[R9/D*/SL*CON/D4@F=4E#KN,SPC7L$WU@ZZI M#B6%SJ(AGEI$=UA4@67.03*V;,<+8JHOWB:O6U>J;B-V90\WT;4Y=1W21#>8 MSC0DH[\^\^F]]6Z2WP![G;\=N-:T58#?%S7/9HOB[SJV55L;SWB/_1>=+*MY MQ/`'LD=':-Z:];O2^ZC,@Y<9L$GX,1:`%SY[`"^1V)3/&*^POV(;^$DU$-,^ M.M5&K0O=INLP_?LN2=^P^OSMD$OYWP/QV&<#6S6)JGD9M&;!)US$\UY#I2HU M/IZLWM!G>'%L@+-S.X/R!.KL#\$=+J;-J#FPVG#5=D0!_ MO)X]+RI=R["O>T@+!+)-PK5.;RV>Q]:F\Z$ODDUR>Q9="=+?'J)^)D6Y&ZW5VD;NTF;ZJC\+?=:4L[T1E"M445"4.! MP\#@1?W?&C$[Z@5SWB!OCC>V)8!UW6^>?T(MU#\_O_MZ.WA`_=L+=/?_[7U[ M<]LXLN__M^I^!UQOMM:IHA-1;\T^JAS'R?B<3)P;>V=K[]:I+9J"+.Y0I)8/ M.]I/?[L!\"&)DDB)DDBIJ^8A2R30:/RZT0#Z\?CS[7?V_?;F]N[7ZP]?CAB, MGL&?P^[W'],1YDS&M4UQ,^^(DN6P@$YDJD,/5B$L;_FICXTSC&>,ZPUP5NR'= M6M50BC:%-!)"UB*D5#?OHWMTGYBFO<9S?5%1$"_"T=L_&(7VW)']>M5+LG1` M6=K+9O#@;"%LG#LVJF/6-GN'U+9)M4EF#-&76[A?D6U;38FZU+5!MSKF[5O" M1H6PT=3T;JNRV"C7GMT425YY(W>M`XJHK["[#J88XS))*R=EF3;HEWD`3)'M MA+H<9\L-K3NH:T*%'7..I`/7CW6Y3P;/N6\O"1N$#8H+/[B?^*(_!%.!;\R8 M2/-[&,IC9G]L3:=\B&&VP]!4=GD4?@4M`/D>'[[+\ER^5DVI^!-[)AH-\0WA M=?[Y]N<;=OWL<5&?FAD>9W[X]"]N!BQP4X3^,K+<<&3Z;@LAJXF=A?OA4'"8(6/4NT.+(YRM(< M1U^0_3X0"+P$9L@1`-A]UW&XO83,Y9P'6X4&Q9%*7XT`8X]@7NZA4Q$EXJ^- M1)(OW(]2CY]2F-$UNV+WWS]??[W[?]>/=_=?1:C1MR_77]G])W;_[?:[^/;A M7!7&KX8/"ZL8"Z43-8@TM`PM[ M(LV!9:-'>$-CKQS^\7A*I+GS#$V+,0^Y#[,$^DD#WCGAR#!!3M2?WF]<*$2Q MB(93X)3X\_;VYAO.-S)_O4.JG)D>1NV\8`P[4!VA0H`A<*=S1E6O+4&%+^/7 M0.@8]\@(T,RT8E=7EQ\_.G"WC",,.`L\G,-3&:#09C M.2/#$W';48OR32,(#/,WC5W^'#!#8S@2WVT3*>'1>&8?H*8,/W3^\-\>// MW+"#,9`":.<_H&&9>@!@B7W))<#C*H)/SLY3"&L?2L^+98C.C=B">K6",2Q. M+&D5.(6+%;(*&QPG/\3-8.0K3LUG[H`>M]DM+DT>,"5:#R^__OWA]B=H%QMQ MV9-<__[@8UX@&UIYR2+T11H2T2C$W'-L62Z>PY@G#"3H&64@-C!Q]9YR$],S M*(F!5Y\C6T,TV>X+O6$]AV[H(ZA4&@?\[:\.^L.S!_DESC1^^Q'U@F6*D=ZX M=CAYLHS,"9^;>A&6A*O7?(8DX?! MC!9:3J-EF,J._62`1OOLN:\@G+="TX+Y"D1\L28"J9>?A&@9[(,'D^N/V:\6 M]L?N?!M#/G%>I5V*&YAYO9->H0!CKTYDJ#N!Y]HPV:\NNQFCG(,$2C,-T"$; MQ#CZ*R!BQ($JL28("#Y&2AU__Q(,Y7+XP7)_@.X"&0JE(-ZX[\2O\UF^H$$$ MD%!D@D"Q1.`B)5J96PY!`4_G(_KQ54F)>'

+#IR7Z#4 M!L.E=.3:EIN]%;5!$5OK)PP&`L-#ZKB@911ZXOI)0$Y0%.O,Q)!@\3N"&AM6 M+)DQYEE..%HC`8<5$G]UW%-( M$PBDUJBTFEY:;'!=F%M/UBCN/Z9-*?;9=I_@?S=@#KY+#SH=;(X[*S0:KF)9 MB<`:0_2/@G'IAA]`>XO=AEI,Y5Q$P' MRUZ$Q:FLB962E8([I@!Z41I*[&)4=JBDAP[B>*['F0I+4HXY:/]2HFWE1MT8-WL?G`(758/QJ:5I_T%D>4LZ>*S+>8BJL MW>WF6M77CM=UDK.JFWU378S]S48U MJ"ZVUO3T:E!=;&'J%B3ZT]W7ZZ\W=U\_SR?S=);+(@@OAVMG*%P>$@<'$*4= M4_UV%DC>W,VAJ,^51GF1XT7(CVWCQ7B+_.3ODIIZ23`W='(0PG,Q?;`EX>)) M=',2IPWH&Q>X,`:1:QR^]I:S&XLWOLD74DG),4>V;?B^-;+X<)ZG>+:YBPQ> M1;?VJPB.+9R'Z'J_D$&R2'!SF=ZE'F(J$Y-0+4)+5,9/1`_L>KK1&+3FC^R6 M>BB5NF)F45_O'Y*XHCOMA:3Q^^9<$2.GW6[W"Q-W:8NS9DN802LI+/,(I]G- M)C)C]U@BF<5/Q)K'(+.@,;X"C/MF9;$SH6YC9RJ3VU.E/U<>CVS!Y'^*Q01; MC4Y+(B4MCDKBOM6WN6H#7>F#%5JLP*@S;W0/SP!!QCP515C1[>L[<^(F\N4] MX+#C/O-->+LQJ!C,%^1T+S!OEZ""]@;S8@S8$>97K?[N"ULY."\V[H(X'U0- MYHM'WON`>6OA0K!2,"_&@%UAKNN[2WQ9ZKS(N`O"O-=984L?49WK>U?GO?;N M:_4>U7D1!NR*\[:^.P#*4N=%QET0Y\U^`O?9\'J^OPB8?D,SL=``X6 M5M.E9DLG*U<1XT:S(%D3C*SZ3^S$_!&CO:2#L>$]9QP*B`93+]V/HE?4&SON MP)>(7]?7X0=3;)_>;67,1KX!B5)MUP\/MX\/:["RXR6.WE@-XXR;C]V)RG4. MW5H\_EM+U"?7XQAW(+\W9PS#&GU;@D#INV?#C]>;.N MV-'AX=@6+V1FD@>!RT/S(E8\$ADO.*X/ZI2O6#?V8;TOLFN1DERCWW?7/5)>\`^^5FKY%ABQ]5 M\LK?+1]/\G(Y%!:;`KFERUDB7CQ<7AU[7<_8@:RO%;\O=]L3 M+<8RY>^X&J,MMHU9\$PL:;`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`E+:)Z%4EZ<82:2J^=8MD[]KARZ&QL#-.P%I=O MZ=S[LC6L!=%22?TS&?V05"/""[WP&112](:>G1]^=0KV&;O\[@ M.U7((374"K!^E8`I3M@S;0WHL`:7XXK,Z3"6N'Z"%I=NB!CVZ@$'KMS12!7Q MFA@65ED!J\"0ON>8]LNPHQU)[`SR,852X8[!AE*;BJSG_(4[#%1%,`9E(\IO M?.2F3!$?3=O9)N>&E>P3?_)"3!/?[&LJ9_Y'X\4:)O/\Q>+`K`GJ(K2XA\^P MMGRW7%]6R$F2GSS-!,,_N(8W%/,#X#=A3D2F]&'\AP*SFO1,9/WBO6-QK[BH M33TTNT0*(".`5AP^BRJ%B(,L;!09\G=100#7HX0LK+3%/:S"(;/3_XJKV,W8 ML,20%#6"Z$Q:?A8UY)*5Q(#6'`N0AKEN'*P>(#.;V\8KK+VR:,<';OXF*$]8 M)QK$?]D'P\,J,#[\^N6;IE++B#=A104;&_1<5(;#YL^@J>):?%$B_W6L$UM0 M(`'&[[D_H@IG;_I-#:QG,8%O]/9`_"&F[\FR[63N!!E)W0*N:A>(8D;6CWDI M2M<7:*$C\6V(DB;"?L45.D?+ M4YE6,1$/6:EKHMB9.L)!V\WW8;&86W7P')CSWY`=3YYK#$4]>FOR!`951#HL MG="BF)R#K;Q%>EE9:76A=D6VLG6Q+*>JQV38*+TIGHE:B4]<,2Y:5%.\$VK# MQ>*2`E`>-_R?XN9*LHIC49E5,:"S:G$M M5K9(5RO>_IAD7X"Y14,\&4/HO M5V[?<1L-UD*J`EPPMKSAECP*#HO`6 M6+FXTL!SMFT\R:`$6=[IRI^"&`A#P`_"H3JY2=<"BI?Y$:Y7YDR3GRP1E@>- MO!?]@\C%.TU1K4D9^BLD%1O]^O>?KV-1>P_2-E^3DH2G"L+3.EWA&5EX[R@V M;B^(\ZBD]HTX?93V[2]""%0M.OF'-60/T0X1S/)?'L!VS[\D!6"PR1KLV/R* MQ8:@7P7HM\\+^H!D66L2CVB339@J"8E;OG@IF-^OK0;_(L05O$4)0H)X!2#> M(8B7`/$#&#)G<41W)X[2\&1.W<_%E52C]596RYZF:I*DCDYD"CF#X] MP03BX@1.'%*+&U19DBYN`L_S\#I#%)SGW$\?`LX=\.J-WT<6;MK)T32F5H!' MR.)>=_[D792LEH>T8DSA$[XF[L9$U7I18!W#:TUE/O>;OW^+IY7JF%IE4N5?#7$P#Y';M;<1"98D8+SZ'%671RKRN*]%IFH()\XTMIX1D_Q(/E M-[K6:#:2(VQU]6RE;I?U5??/0)'#5Q,T=_&@J@U`TUU%I62@S]-$2LI7GE.F MYQK:<[TAEY=>((R1NW]4.GPN&F,>",)LFWI\BN:>BG@6>@*O_^7E6'0N(?8^ M`%B0WAE#E2(/\J-3U?C(=R7)Z>LV2:#EJX*GSY8\X#<0X";)F[8Q#CI;N[2#M]3-UQ;KB; M25T/*.&5K(^F:]4-$X`%T/(L4_`MW"CI0B3.EON/J4NRY&K%2,J!(7P_?;[- MJDENH3S[X41I`EL%O,O%^TVSWQ?*!EX,03),X>S@S%7=4#X><]=&7VX?A8"@ M0Y`_=4.?IQ3\FT%'ZDNAA802@>9C69)DRM9I7G1$D:^:.DB+J)^B#"%D%6IHNMIX+W1.ZD+2SPR MXD+S#O,*P*&K,1?P&4QY*DZC.'&8M7G%^I$_+;FV)L_?C]+]X;.[UK%82#2S MKJO#T+^UKW\YI*/+CS6T\")47"@*JP1^7Y=`IMCX8/>GQH=.R$52 M,DE8'H?Q06#=`6C\D)#5O6P5VH+1B@. MVBN9O()DGXNE!Q>O(7_AMIN9!B5Z[MH9?DR>*J=,8K/77"!Z35][IKP@NQ?" MNHY)>;'`3KVY*(W'Y'FA*,W6(L3S4'YMFN$DE,IVR/&Z*X-H]!GCPUO#0Z]) M/_7*1_G&5J$Z5YU&J[%(\J:>]DQWGE"=J_:@T5UQRZ"#8S' M=R;L/-P)]_P".?2BIC`H[58U=!.UW85B424-85^R?X#"0K*D>BUE_Z!5 MA]J-WEYT9-FRO\^21!63_6)F5D??SP3N;]W?>[6E5FAJ MH1A7186_&%=J+?P%3S!;O?9>EKG]K?Q[KT'5;#;J:O4?M$!5KZ_79.7?7_6J MB@E_P:0PC<;2X5">,=Q+YWP9Y2[OV[EG(H1DZ(^XL)\8WF\\2*7I&X?.T./# M8(QI+VW#P0NGQLHI%MF>A,\$WAERQY<%-##F75Y\?9@ECZAOAC>,@M._ M(771X;7,QR>)S$B6&3%-ILU$XKX:$RXS9<(?^$L6&N:JKM]]_00<35BYOP'$ M\X#RB_Q667MOYCQPODG& M82&[43&*DR.XA>)BPX@_6*\&H_%\:/?*YC`Y3X;T$GH*+1O]A[)X]B5Z,-67 M*M$&!%CN\#,T"R2YS\Z*9,3%SM:76%"0@*KRH6CJQE/E0\%S_]:I\J'H+4)I M?$AL6ASPTE*MS"FQ@GYVW>&*`C:%A+JS4-,[JX]2Z2MJ02R4G-X[?06%H-$Y M,'T%SUX6:ORN)4]]OXZLW1&WO"%<:']7@3?4"[M546['6YT,&#RT2X&CI0ZD\F*%@(S7(R? MF0\#$K5?Y69A:4SFF`]#W*\Y@`0_#0><8(FM"6CH;H^HTAS99CVN%01O*(!!OIJ)&;=-3(31PU M$A^[B);NIVJ*)/!NTG5MHX3]EU]$L5[QN^&/V2?;?4T"']"17*:EP[Q7ZUS* M5\;[9-+Y046W/&!T2V9PB\='Z-?NJZ$OQA%H23J#=#R!MCK:Z7&AG2QP8V#0 M>H`++_\WK7>#WH`!)&SAP2^#"L0[/HY3-16G`-=9PJ;043I7/AO9G!# M.KJV2.]ZX0&73.L*\I;S3U6%X`P"!59C"@<;*02Y#/@5XA!H=-Q7SYAFD+V8 MCDQR:+OAK!!L/-#G7M0W_OX3PT!4RRPJV'G%^%(L&F[H@_;VWZZ*T5GFNN32 MGR_D_U>BNJ*P285K!QY[>C9=V_7^?/$[T^2P7&0D`MBKXB@SS=L2&[?7\+C, MYP=$Q712WU"LG,K8(V6[JH9%TIJ:7CW)+U.P=S<) M:BW:JJZ$/U<,(RWO)-T5HJQLZ6XUVJT:-_`+AS7J`1%X,2-!AWH))N8HFL91>-F(;HK9GR"#JDG\)!B\*L8X\6 MW7EO?>.][F*L$H5PZ!-]HD_TB3[1ITI]6N_@41D'K2+;F+W<`\<,8[OML?9+ MW#)ML&V%^0'BFBLM_4V;EB(7Y>N,L^,=;\^YA!YR=W3HV28D5AR)2WGV3Q:- M<^=GFR%:R@W/%DJZW'X+H;[R8+T,'2,<8L#9\LU>.3`MF=G5F^-#D5")&=B+ MCTRO^_N->OW8U^??C5>&!3P\R[#]ZEU\%Y>8LD_8WQSO!GO0ZE?GJGK-3!`P M#@R,?KM9?6#LP36I#@KU;Z[W&\8K3CT7RZ212BV=A%)$*'()JK0($4*.B9!F M#5;?L[5;/UF.Y8\Q-Q>F#R(M6TT9ZO5J8*@00HZ($%UK=/3J8V1'E[IU3H&H M;4L_,CR61VMQ1!W<=37_ONWP/JI-K=DOTRX]\!03ZFJ*NG:S3!U\R"G.;P#O MYNV\%RU]0`_GDD1DGZ[,^R6Q')_E?=QC5&.ZJT$%@>X$05?(]3W+W7V]JWF2 M2U.]@+[8UTY@#2T[5.G1S-`3CO"895.FE!-U*3`?7!C$";^C,I"BEH"H6L#^ M(?IBV!D3O2UG38W)3/>9=!GUB+4F4OW=CZ+>H#/1U\GF^(M]XIGTQ/.B4BS^ M?%`N_W=H`8#%#\'8"&1Y=SXW8^AC;\[/FF`Y_,ZCV8NC>EG1)'[B(?1MP6KW MIA'Z7+PN$^TI%W_+DWD)?>S^U0WM(3P++P;6533Y&\O+%_7]/UH"//ITTI_J M[4*K^FDN=;,Y9]S>/&`QPM3^B3U>VG'_^T2 MF++5S4B)/(&UKKSKD.8),"2]W*_G3-UEND$ROG48$9.2D96+7`%[(%F#H@>>[F7I5M=49%W@[M7!51&$6,LQQIZ;.8? M_Z`J[R==Z^L;LO968(TO:*L3/`X&GNZ&M+`UTRTU4.S'G_;BGYK=G73,06PD MTC$5_[1)VYR)8??\DI!B&Q'@E#9H#L?2U,4*$?[FMT[#! M2.U4Y=-&!530(LL9I+Q%4JM]QTT7SW]SB/P3%2.I73F*].K-6_4HTJLG;IW* M450^DG)EAEU>^<`MTQ`I^&8'&`8C-DU_!T*UW/V$``'#6_HLQMW:(TLR0UV>7']<'/Q MEO4;'8U]"'TPXGQ\9/)D.>()7SZ"#UR\U42&U\`-#)M-%7^1A;X%(B$;M&!J M)+-AT@)7O.#P@$'WS\(K"2?20OX`$<(-WG*2W_)-.GN"?H?,=52*60[,GX@. M1RD0&0)'#WP:R%+,39D>A%TB2:(+WQ(D#^'5M^^R[!E,R!N/H!I M0F`@(]>;2#:8,OFR/6/&BV'9.%!-#&=BS$0*W"%"!HD[,;G5AC.&1^/D,J[K,*4_7[! MQ*7[.!DKL8CEC>&/A>U@XH=4^8-5NY;=+G0+3V%Q7L\!OO`I;(G570J3_F9G MBG54@$I(:_8W^*(=JW)J.2*]NWU0(Z&.REI9&1D32&9/ M1V;;O0T9B.HMLV>T#'_SW"GW@IE8>]%>GTZ`"!+>"E%6MO"V*F=CTWJ[I?1^ M=MWAJV7;)*\5HJQT>=4&F\)RZRVR9[3J3%;L>6-;MW(A#YIJ;[4M6:S MFBOQV[VNM(MUFMNI.LV[2W.S=TAQ_LJ#Q9OS!KP!.\B[NNWGLB0NS'4>S#7+V45U^OX*8XEUU5]@BE);U):.BTAPZXAC/[@Z^V`8&0JQ]]HD_TB3[1ISU_RG`EK*+WX);;C:IL M>PYC=L/^$28`2&H6BRE.=@\%3I*VK(Y;XE'2^GK%!]J<''4O2%@[%-8^Y";S!36#^25PQ:4>Z%EHC?'42JLO0,<*A%?#A MDN&Q!W$ZJJ:N'E".3%F5IW$O?C*];KTNZ@HJ2+I/+_/6;:^>J-U]7:D=_(J$ M0$>@J^:5[0DO#->F&4Y"6Z1%,":N%UC_$9=:M%94B++2?:_:S6K&+RQZ7A&\ MZ@FO3>G5*P*O_%N#+=S3<"78ZY$U^<^=E_]<>U]"50V0$)S/"\Z=?9D@%0#) M87Q!][["D"]H52DG7]`R.5]IX@C0!.@#.#?G]CZ.'9RC=]$Q-\J,[WPCWCF3,G%$X0,'WB79^Y8>!C!EZ@S#(Q]>Y0C461$"+!EB0X8WBF89MX6ADE M\3VL,ZKH+A>EJB^>\SQG>J]X+@L7B5I2Y<R;K\,3K[Y:,1-X/XV/A*'C+CF3-W_&SG44+9 MT3Y=D=8A/)2%![(@*HX'76NUVB3Q)SS#Y4K\F=@N-ZZH+RMKG5J^'\KZH.)( M@8R5ZGPB8X7P0,;*N>"AJ;4;#9+X$YYA,E9V\.X[R!7(QA"0@,<)0K9JO4V)5U05^%(JB2P*]P`KI^QD:68SBF9=BP5(Y<;R+#T\&&F?CS)V*U4S0OV8O%7GUF!SYY"'VP- MWQ>A3Z]NS$!V)2*A;J/"M-$/HFX>_O)@V$`9L!%VAO"]G`+U4&8PUF-FV;`^ M&:7D40_75=C7!I9IV-'\B&D)W.F<$/7:$L;X,GX-A(X!=AC^]B/@G@/P$S4% MN3<-;5\Q8.8'?`)L=8,QF$PP>:(?6Y;YM1SQ'CZ)WXGB(:_'>;VN&$Z&%8:-@*.G7AN^#P6G?UJ^.[/W+"#L8D!;G[X MY%M#"\5+D.I'=1&!]FB&0$5QO,=047(_N!E&877!7$45(&**Q5-$/44+H^L` M\AYS0X\9SQ[G@JI7"WCT^?;GFY6#BN#*09>&8@#1B&!`0FQA.I)80SE,9)_E MF,#[[)C`X<1R+#_`)U\X&X6.B6.`ID-S+.+ZA'+A&AN'T#X.!<@&UFMJ"A.% M$W!S[+BV^PPLPQ!!(,PS9(T8?-3C,KL9_X'^*5P$-6+E'O@J+!B,2X&ICBSX:MJ29`38XX MCL=R7@"?\*>@%)F@)64Q_3ETFB`P!LR[JHQSQ::>!6@%'<5,PQ_#'-C(-/P% M6>$)[9H$5-ZX'GP!0V<8T1G,V!.WW==W#"89GL8W'%=*1S3!'G_A3K@"\)O7 M`>PT5F46XB;`[P%PHN>-09OSP>%2?>#/E2BN0\46"L=+S3.CW%Q`!Z$ZD8+\ M].^>7+\JPSIF\ON]#:J&\")$U1%1FZ9D&Q5:;BQ3F7EE?6$\>[$9$*P.[2U8 M\H46!Q)E6AQH<:@AH@K>45`5M'.K3)6CH^WS/-*@AZI MW/,1@?A0E/!..-LKSAQ!-=X\G##4"IJX9=?KV$8&J)Q?6:`[JBJC::1I)(U` M4#HZLV@:=S8DD_7@CQ_YB'N>K-\YL7P?X[]5ID2RUD]/>&F] M(,@=^I!':P\V5'FJ#^S(4B]36Q?)P5*5 MI6T3[XX-C7(H+UOT\I)>;GJ7JG"^TL01H`G097.>%A"2-Y(W6D`(T&<-Z/P7 M"EO@?N^+2YZ-?0683())@DDK#0&:`+WK5J7`-?7QT^<6+2BS[)-("Q_I"=(3 M!.C*4$Z`+FV+E?0?N@[+:;1NKPD3"'>'NK*(#2`Y(#BK$1,(=X>[X)\,%XE=J%LM+U:/. M+\9'U_3&:<3X$.QJ!+NVUCB1],H5--M)#.HB!A342Y`[,.0ZFGXBFI?2[Z3K M1V'=*#+03T]>+]L5%5>J;5)G5+7ZW;J@BLQK0OF6*!]062@"5>F@ZE;SP&P1 M572@366?3EL4VUJ[74U9I".4$X9=5VNU3@9V9%V3&&Q'44_K]JM9T9JT[PG# M3N]K[8V4]H9H= ME'^3\F\>.>]558@C0!.@R^8\+2`D;R1OM(`0H,\:T*F-ROL`G5XR-?J::X%U MEP`Q14\>>U]*8Y>6PX*Q&_J&,_3?9C27\5$,BYG M.`AH-+;G?VKOM\\\JTS)1N!.?V*_:S\9IMEEC7>=:;`F'>INQR1'H7J;8Y[= M<\E695C'3/BZMT'5$%Z$J#HB:M.4;*-"5UR,'S^C]%*1*=_ZL;K$U+(K&BT- M),A''U0-X46(JBZBYBYB#@*S_1V/'68W>V9E&*C"$N'MD'BC"DND!UFI6TT*F8Y03AIVN:YV*6A?ES2C9V"0'F^5` M[[5/10X(=W7!7:NI-3K5/,,H.J-TC$VE9\Y2AF'IZ)#S"<'NP+#K:?W6R>P8 MR7(G,2#?$X)<+2#7UP;]T]@KTLDZE9\Y,^&E]8(@=_#HA/;@-%P5R5(G,2#- M2Y"K"^1.1_/F/5W?,EL=U0[8GG?'AD8YE%.J]3(Y7VGB"-`$Z+(Y3PL(R1O) M&RT@!.BS!O3.53+7C6'OBTN>C7T%F$R"28))*PT!F@"]ZU:EP#7U\9/?%BL& ML^R12,L>:0G2$@3HRE!.@"YM@Y7W'HA*,YQ;RGRJAD-X.R3>J!H.J=PS%P&J MAD,XHVHXU;E3.)IO*OD&[H.RVFT;J\)$PAWA[JQB`T@.2`XJQ$3"'>'N^"?# M!:)7:A;)2Y6?SB_"IZDU&Z>1/XM@5R/8];1^15//GX#93F)0%S&@D%Z"W($A MIS>T1O.D8WK/*OL.E7XZ=8&][%6T-"N5+ZDSJMIZ-=/64^DG0GEY*&_VJYGB ME71GG5&E:^UVLQ:XHD-M*OQTVL+8!ED\C>TLP:Y&L.MJK=;)P(X,;!*#;>]Q MNOW>J8@!P:XNL-/[6KMS&KBC0VPJ_'2F4MQK#TY"A`ET-0)=2^MTJGEV0X8[ MB0%YGI#F/57(M;56HYHWV279[&=TJDY%G\Y*=&FU(,@=/#"AUZCFW3W9Z20& MI'E)\YXJY$Y'\^Z<^82J=E`.3LK!>>3<5U4AC@!-@"Z;\[2`D+R1O-$"0H`^ M:T"G-BKO`W1ZR=3H&9__]#[TKYX-8_K3@SGFP]#F]R.5+/@[G[H>1H;>.2/7 MFXA$PA]FZL='X,('O"+XR__^7XS]Z?]<7:WWP;FZD@\N]Q:]]]4-N/_%-1S_ MVAE^LAS#,:'O[W$3<8_,!([!']_YZ,\79K.APS\-/7#%IVZK,=LFMVVE2/Y\T;@0?_M3 MPXS^7CCA:C2V5RRI0XU])A%F2ND'[O0G]KOV$T"TRQKO.M-@+M=OS#"VVR*] M7^*6:=L]UW%.&C8+X?&N<>L:0IW(M%*$M*\-^F4> M`!]XB@EUM41=LZ%U!V6:#8>Z9__`YYEXX7^6G-,7'."3UW9R0B_-;"_1 M8_KK_>,MNV%7[.'V\R^W7Q_9]]MO]]\?[[Y^9M=?/[*;^Z\W\.WWZ\>[^Z\/ MB].V.*9U(X@7MB>/O<_"P&9>X6&.-9H=W5%?>=VS%XN_^LR"/<]3Z(-Z\]%5 MGP6O+O,E@'S@*[KIW_X[M*8"BNH'L4G"7QX,],X'H$E??^GCKQYZE^55_IC9 MG.4S[CP;SWR(%`RY#_P"W&HP"B<<&680>NI/[S59)'/70_?^'PLFG8T?R(:0GF MH>TK!LS\@$^`K;"/!!L2)D_T8\\$V98CWL,G\3L-@QM>N8TU&@1/DT&Z([43 MG?`A-@"<>;%,[J_D[+KI8*ZHE,:Q$\\-G\>BLU\-W_V9&W8P-@W0*G[XY%M# MR_`4J3XS0\^#MX'V:(9\U^;PIP@/X,`%;H:B'Z!V/J8#B)BZCF\]6;856-!Q M")#WF!MZS'CV.!=4O5K`H\^W/]^L'%0$5P[+0B@&$(T(!B0B2_!JZLGP@38D M(RX(9SDF\#ZSW>OAQ'(L/\`G7S@;A8Z)8X"F0W.,$S$2"IIK;!Q"^S@4(-O$ M@P`YA4E$2\#-L0,6\#.PS./".=,#0/T'J,%'/6X#S<,H.9@/.S:0S+_I^B",CAN`GO"XB;-A!(%G/84R^`):2H8=":\6#T;X:FJ@JY\- M6U--N!X;<1R/Y;P`/EU/4HI,T)(S$'\.G28(C`'S+HN)@'*8>A:@%704,PU_ M#'-@(]/P%V2%)]8?*=,2&1Y\`4,'*`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`"]%D#.K51>1^@TTNF1E]S+;#N$B"F MZ,EC[TMI[-)R6#!V0]]PAO[;C.8R/HIA,9/;MN+WGR\:%^)O?VJ8T=\+!P&- MQO;\3^W]]IEGE2G9"-SI3^QW[2?#-+NL\:XS#=:D0]WMF.0H5&]SS+-[+MFJ M#.N8"5_W-J@:PHL054=$;9J2;53HBHOQXV>47BHRY5L_5I>86G9%HZ6!!/GH M@ZHAO`A1U474W$7,06"VO^.QP^QFSZP,`U58(KP=$F]488E4[IF+`%58(IQ1 MA:7]^!IMQE\5:G@T93`Y:9QA%9Y2.L:GTS%G*,"P='7(^(=@=&'8]K=\ZF1TC6>XD M!N1[0I"K!>3ZVJ!_&GM%.EFG\C-G)KRT7A#D#AZ=T!ZHD!J1Y"7)U M@=SI:-Z\I^M;9JNCV@';\^[8T"B'2-YHP6$ M`'W6@-ZY2N:Z,>Q]<`U%IAG-+F4_5<`AOA\0;5<,AE7OF(D#5<`AG M5`VG.G<*1_--)=_`?5!6NVUC59A(N"/2-UI`"-!G#>C4 M1N5]@$XOF1I]Q>?%*X)U%P(Q=4\>>W_PQA3;_Q7Z@36:%;Z_>!2\_PJ\_[[K M_<4G50(D&'N25@-1&.?;]G/W+"#L6EXG!G290F>QVHB_<;OQ9.] MP>^QQH@G$^EH\,&?Y="0OSI4YY2)'FIZ+45%?V"5"2?KFW?7=_) MF]Z['H/YL"W7T;":2K_[>TUT^T8?+/PTZ,!/0(FQUK^+&4'&<#_"`Y,G>+*E M:VKL\^/8)W"CSW]Z'_I7SX8Q_4EEX/[.IZZ'X=8?+=^T73_T^"/T]@&;_G_7%T]<&"!\ZRQ9^YP#Z-/8#S&<&(YEA]@M/8+O[J23R?-BU<^RQ>N MG>'UW..W\FJ-F0`1Z.X['_WYPD16-?2&'KCB4[?5N&"A8\E?_]IH-"_8D)O6 MQ+#]/U]ZW4ZCT4B/*D^W1QB8'@],SS&PWJ#=KL>XFHUV@0GKM%JU MF:]V@?EJM_3=YFL,>NGJR?#E!33^*/+D+PT&G_N`C]VDGMI1BIHM?9[VS$[V M16LQP6@V6J70^IW#5%@FK@$/`:@Z]H]?A'+^GZTY/B<&_[Q^-;SAXVS*KW]8 M_C^3WD1GLJLU(VV@:FM6=*!ZN0,M"WUE#W1!`>P^T%ZOHN/4RQWG#B(Z1^BU MYQG.,Q>5:IYF+/W<-V,FOA:T:@PKV@0S=N<`K2'^X+-[89,%8\-A]U-LSM<8 MF*8C;B'C+(=]XY[E#G?E9HK&#[/D$46?($\2EZ)-D/8(E"G"8K+N'$E4^3*G M+T*QT\DQ17L97#SOW_G$0)/60WOZ!<:`*7^FFV;EHP5V=@"6>.GS)/[SJZ1# MDJJ7,1'_C!S+5I#S-RL8WSE@G5O#T+"72/,_S!ZMP.;WH^0AT5G$"#7=?_FF M_[V$^P.:U96S6M@`J\*LMBH[J_50M^NYV]0'556%]1"1#2KI<,P]W/X&C9>J;6XD M3;EV-JV67H+<=$J:V8(CH^G.-]USIOONTWWTF6;?@.+E,V?\2?RRK,KT9DN? M'U0K/2@=!O6NLS`LT51FQP]`$_?9+?P9!3#EF/MLTAI"MSX$1B#X=6,;OG\_ M$LV)^9%]W<8]K9REN0$U<4!Z=^V(H@5H&'K)IG)N.5K:4ZT&^S<;I`2'>QP5 MOFW8%XZ0NPI+$7-WQ51YMN_^0%53V!1>?FNL&;Z&PMO"':E)8T88C%W/^L_" M3F>/$R9)@#54='6=])^]].[(ZS*8O8KBF*MWOA\>?*LHJ9%=KT2W'J-;;PS* M,"[+XVH6_>LX^C<#VPPJR4A%6ZY==FDZH"@#MS.+]\C1^?.+$FSL15X/6KW% M7<-9,KJ];T;O'O;7SIE7.*E MR=DC0Y?T\[$X7$!5K^=^6&]T%;QKG.;K2EK"IEOUI2_:+/,O3NA[:X@3>>/2XAG-;+-_*!M48$ M:CRI@SZ*?8[40VG=],GU0$^^P.9N_9D\GF5\YS;H6L"#%\P>`2J^80KK_,,L M_8L`7T)'1V%GDUJY;#B]_->R0BZV56.R?Y7YY%Y\( M?%QMN].$B(X$-4^+"JG.C@]+WI[-C&G9@AW;3U`^?)WVF0T MNLWV\DCF&CX0N?GV'=R=RO[H!9TF$(/L'Q@@R$228#<:YMO'MC/#"C6%+ M?UG(!E'=Z-NO]X^W[!=VQ1X>[V_^^^?[+Q]OOS\`]_[O7^\>_W[4B&0Y`GS@ M)V8%\*MY3#Z!7IRXCEP+JA.HW>H>D@?WC@P.UGN:/#+"<.D/+A[OP/H9&3P^ M,Z93SWV!E0%_%P_*)52<-5WBEQ?B6_S[XJU8/]0UMZ_!8%0S&N/J6E8&*YNQ MQA;G6=@,+E:&DQU(_8BAW*);7*:$M@I%#$!,E"`'EC+;9D\\6M/F6_[#W-T; M:#U45W+5HL.5Y$R,']8DG#!G\7X//J4;8*]CRQS#XS,D M3/671;SELXX&ZA'_56WM-QB[PN!\7.0,QIYY%AZ)XIR^NLSG4\,#*X!QN30` M2,':FP#0D*OJ2I8)$XE]D[]IBNUR0CB,UD(@30&I^*R:(64S,E6[X/!;=6I,)'UK( MC)A2A&,(O47->"IL.5S. M,[("?U%M0X/6U.(I'1J!%N=6>1LH:"9J:NF93!4725`D#ED:2R%7(=("R#L8 M5:X@F^K'<9VK?\->VAI9"/'TSROUJ_P=>(\^@K%BUQN-WT>#'1F6AQ/X&P\P M*4T8\WQ.DFDHJR<$!Z)D*E#W!#,Z9"^NC%US7^7$X!#5=ZKWN>5+8[IJ M2TCVTNC?KF2EN%G`#H!TQ58U=2/K!RZ%LW6@MH*Y=3-&N":64&"@XS+,B!*H M60(T\Q\FQ[TD,G+&#;`B1IX[F9L'P=&UR$/O4OZ#>Z;ERP5_BG!0%V+0K9`6 MQ2+U')=PT1)(XLR.U43/P4*P;(@I4C)@-`^9N/$Y(3M;W7@MM,U<8AF-M;3> M0%HNWM+)PI)!!"O-6KT"4N:DO"5WLAPSJ>UU.BDKBXT-P.D3YV)1E''"F6W= M.>P7`Q98U4JG4>:(X;]JP"*UCS06FAW9Q8MRLH\6>GLF5PRY"D0!L5$T+)CK MN!:YCI0^Y3BX:DB"-W)$34U7LXBINQ#EJ.'B,:4&NGIX*R=/2*#SK]`1QS@) M_8!D,$KP*S6=GV]_OF'7T<&3%@_+0/F$D82^RA86V4#_%0(_9#:CUNI1PC/S M\U;2P%9,EQ@@C#F>A6@E3N8K_@F5%3=&H*?/5JM\=>/%5G!]S49)N<,62.]U MMEP%X#_P:2`3?LED7RF%&3%Y<=NY3B1$IB.Q`Q/(G?LMWGV\*L<4W&/HVH*\ M@1@;SL**C3V^:;SK-%!7R0=QPP);O,`2)A,H"`!"LG/!48C]NB_4%+[_Z?/M M*N&/M!GLQ*8HQTVMO33@^5%Z,BX%<`:S9L^28P=_[(;V$#N#@00&*C7NB?^[ M4T$@(A,F@\/R%!$:O'+[)9T-#Q]:RL.VTGQ+9DOLX&PN.D&SC*.]8J08\`=X MQ+"A!Y@:,3_8,,XEK)AR^7R"_2=8:SZ::="@;?V&BTF\L8E(3Y;$"0]BU:6X M)?8O\99U)=W&,^CP9S2BYJQS`]@B-#N0S3&]I"-LM/DY]O"('\U'M2$5_$[- M]RN@XTU3&_0&.(W'E>]JG6TN>$">J^:+CC>;;7F\.:_X1I:-QC^[`=F%3:FI M+/V/W(I-PQE>WY'3L1O\0.IS>N\X*-H&Y8=#Z]O%C3_L5;#55< M^D1R]39L&+T(@M_J+*HN5`5ZA@Z?QO0HK>;GI7O9G_;B[3OV*/;6^)XPU[R8 M&^+L:]D%UY![8-@/&M%15*P[S%3_8D68":,.]UYXD(*V$/LOPPD-+S+MX+]* M2LA7^!5Z.13`>*A_^@SL3"EYYX M1+#&K)$V-W4CUX9Q1J99?`KZ$<`ON1FS?NF0!E=*;*?5$.L`-T.I_#U#,&-H MS'P\Z#5L<9PDCQ=\E60VV@MPMCA9\;H%BYEG/...WL+%3K7ZXMJA(-M;N"58 M(@U_7DN:(JC9H=-[7()"#^=>2(@EG52C><&C*'5&GX%P7-6'N.T;+@`\03,Y_%`"?NMT^VJBK9&9L#*4EE/*0:#6Z6K??2;VR/)JSG?[Y'-`H M@VNW:0M[$A^4.VN(UP9:J[>>Q[&-B:+X1I?B)^]C8.W$Y.I#)HYJH5M?GK^J M)W5YS('IE9O2B,R1S_G.,>UP*+,=B$/8I&W+CX[DW6<=28(Q,&3]&''1>S-( MS8/>Z8H_1H7QLW'B8#2^[#':;J3'@->^"`O'C<^7Q4DC%S$8,EEE1/UJ:V=! M,QT\D79>?Y?8Q>;1^`%#^&;,<-(T=A-Z6E_F#.]2>CV3T0 MELZ:O.I+^8QCX8OF4NDAR]KMZ>CW*5;XKW MBF52UI<GH\^TK5YF)='JK<;"PEM:S/2M2G+,^:TW^@UZSG2 MM4G,,^:TJP_Z^Q[I?;+7VF:XJ=>/(;&+W5=HX/L5X`H/?+_R7.&![U>\5P[\ MBHF#EX5(\'PC^RC?7.KA8&*\BH##CFY?LEJ-T144R*[>;W3K,[I]2=W&T27Z MY16V&_;LRGW%>QP_?/*MH67@OB@:ZXOANS]%#?]-/GV/3S^D'LZSFV@O!N/^ MZ7VNMC.(OAE;#FX&D^LZ4YP\("61!W`F_>K%^^B]F^BUZ\1ON/!`F@L#V=A) M/**T#[NRV\3.^28)WHE]*.8G1+Z9"GKYY'K)6\E+.]9S::BAY>WNF",K5OT% MTQT(4=IN?/')>,85#>H+F'A_)(.=5)$O+TR=8\V-.&KK?C2?0N3.>4@U.Z6:#4;3Z]\C3D\F.=3TLECTL>C^TWU<.V(5&>B_71XV*,;*Z4OHNFO M/.L@J%#%IY04E4G6"3&T&!J[K;TSU/3P2_1>B3XHGMZ,T77$9RHXDXGHS`5& MR7>B=^-8;?EF.JIS1V!=-?O]-"=R]WO\@1:;\*MF8\>!WKA^P.Y'>/TRL7Q? M>#Y\EP4N%Y96/P#S)'E*/;2K"FAWNNFE-+N3_5%;M.Q;>W!,:HM5.=3;@]9Q M>5ND=J&NZ\5XNT0E^[J@F9=?WWW-@F<'@WGC;ZF+/1!9L&YG7^\8Q^%BHGF:CEYN/#P88#&+%?,(BWJF,!A]?%V_O<@_73@94M+]*C37/U5Y++V&PZQ=^]M5US(SQK5E[DS>VFL!H0+EZ M.,HH\DQ-/R58I8XD"VQK.MA%E%JM0:Y!%$1422/(,PL=O;'5"!Y51.'U1/IC MH'#A,&`3[\-S*J]EG#LF/1)\%;;`\D7QWOQK\5N;\W)\PV2=Q1J-1_`A]/&D MS6?7B5>YAA';6)]S8K!;PW-@"^1C51-YD:+N3F01=7E(>O7)`)L)M,9K,&:W M0*TG@M1]]L6:B`J?EY\^W[Y=RI8BS%7LW+RQ MG')TN7=NU=/WHR@!](8"/^MSL;:;_4Y/;T=F\OJNEBR`)$%.;KTN2)3E.-J[;CFR-Y^IHTD+2:P9U2,^3-W4K>??TD:F4I M+FU%<,Q+^&J$\B=\DX4[[7P:)TUX^?KHMZIA,$Y>-J;:%0D\YVF*FCPN!_O1 MY6Y18C-NK1>R'*W)]#YWG2P=@54>HN5KSX+U7C9=7L_W-J_N6?%G/+1Z0(2N0!I;K[79S'G=XPKD2%SP<@IJI0 MI.+M/LF@CGD=/7<)KJHR).^H5S9O\RE(\I2#)*,U,A=85H/RFV&)^*3_ML1N M2`7WK,$COG#GX./QTSO<%F#IH]1A\\:N#CZ0O-='HEY6=YN1W&'8&YC*TE4:Y#N>";;^'M^&YVPT'L$O*J5G*AA"2/5?11*:6\Q3A(>==^GL@/75;*0.;[?H=6G<-Q@8!XL'J-B, MT:9-^81R7-"RAH]MR:86^T^U$SWUZAKWSM6CB1K80^UT]JB0\&\IL@;+3F[\L[,$*M`_4_>G] MCR?/A@__'U!+`P04````"`!UAPY!BU9&Z4D1``"5^@``%0`<`'9A`L``00E#@``!#D!``#M75ES MXS82?M^J_0]:Y]DCVY/,9J8RFY*/F7*5,W;9SF;?MB`*LK!#$0I)R79^_0(4 M*/'`T:`HL3G)2R86NQM]?&A<3?"GGU_FX6!%XX3QZ./1Z9N3HP&-`CYAT=/' MHV5R3)*`L:.?__7WO_WTC^/CSS2B,4GI9#!^'3S.^#SAT>">+E,A8#`*`AH* MEF-)'++HZP?YGS%)Z$`T$B4?7A+V\6B6IHL/P^'S\_.;Y[=O>/PT/#LY.1W^ MYY>;AV!&Y^2814E*HH`>#03]AR3[\88'),TT++"_C.,P%_!VN&G+2"'_.L[) MCN5/QZ=GQV]/W[PDDR.EHGP,:"0G?ZG1*YM.W[]_/\R>;DB%(&81O3%;>&\P M6/LOYB&]I].!_/?7^^L-]XHD?$XG+"#AFX#/A_+Y\#/GDV<6AJ-HCA,T7(.3T[>??V1/KE M.XC485.5SY<)BVB27/#YF$59A'=0U2:ML8K7T8I&*8\93;[0=`?M#((:*R9Z M&U]&:9('YIX&E*V(#,QNB@(%-U;\@D<)#]E$IA'Q_Q,:)73RD(H_Y\)!R>WT M@B2S3R%_3GZ-R'+"!%D3,QHULS^C;A M[-E>3PW:=<4Y"65R>YA1FN[!3I/XHA%"R6`99AZX$7^7FJ8O*16B-@I)0]JS M,E,B5R/D0:GI4`YM/"Z;K5K.1H@I2<;9,"&&UB="%D/ICB$-TR3_)7/0\U]INQIEJH_NHQUO!2)FXCA5B3I.4ODS-P8!G)@`23H$*&-_C`890DMKG`A8*Y1DM!=:@N\T!!%HK1`7W!SS! MO:13*I2;W-,5C9:&^-J)E$],1%BC##(*$&B3'!7K=VW$NKXLE;]D*?N&DH2. M2?#U,2910H+U-M1:I<^$19]CL.%0H[.@*8]OU:4/#Y)[Y4 M(3*;#:<:S3U#<=BS2=#S!J)F6TS4FGGY&:;>P(X!K%Z_-2HW4F<&\9 M-+/3HC1\P,[._R#H=A,J)]D($6,`;!\,!#9QP#W('HP!WDZ"#`,-7'7(/3O7 M&9OS5`W5.=I=K+)5IM6_2;BD%7LL%,H@+45W6+:CUVU.";MZM&J%X$ON\OR# M1\;(FAXK/]0?8XVIPQ!`0.L2\&6>T63"I`TDO"-L:F?*S?AWIXV^W%CA=-N;H`D M'M\&@"=76)<)SGFP]QI!)Q%?UAXE"4V3:B/-)[+,OTDS4JFJTMW"TF^>->2((P\P!9[H/4"$"Z+K"\S MV"MI03R5PEH'#T(H-+'6C@V@1(2#LU)\JW#YQ,Z`$Q=Y!2)FPS(COOJY[+Q=9)X;3J("T(S)'DQ? MK'BPTR,,MZ^5=@P`I+59;-?N8?8%3TRK&AM)Y0B[3((PX@!;[$'6"VBS"LY0 M1+EI>$;B)YH4AHA71]B<#-4@6A@PAQ1J)S#`%G'XJMRR&:5M:\),4"Q!L&Y2 MH(BVTPY[='7L",O+*EM?W+ZUI#$YFU=JS42TNW`7\P45_>HN)%$J7S;Y?A6?U9&;W_&%#6#LH8(;:GQ M+>S-$U9C19L/BW-I@*/*K1[A!D8:H@^3U.;RWG_VZ*Q?!?&XYY!8H]W$3$.X M@:+P;0\4ID7V8E8337T2B37<$#,,X36P.A;U/PVK5M^(OP][`TOS"V\Z+,.K M*F:HQ0!0;HOSS)3=C<(TW3I^M"(LE$/$(R^4UZGS^W.2L*`Z(#?CSL=F7VX< M7K+YP&9AIQOFN1*?1&(2'3-ET9)%3]O>>$ZG/%:PS-[*OGI)8R*2"XM(_'HM M^F^6=02GZ.="OZ?K**4Q3>K[[WMO:;.=O\>6NAL+U]I+70QXLU#DXZ".HGN+ MKEX6V MTB*%AX^%;E0XI"%\>I=LI65+1?J,G2]XKCC+3EYG<-=S*>URGC- MDWQCKOBDVYN@\A=&:SO&AJ?%FYZ*3U%8(3<+$[LI51*-/5N2#NO&#=[G(&O* ME>%E49O;J6HB\`TY13T?:+QB`76$5T.EB7")"GV0S3;YQ+DDI M1'..L=(4W@C4T*",&L0>5\P,,H"G'X=TA&Y\XZZ!HV1^04(5KD@SDBQ;N9UF M.5.^,J+ZU`,/)S5HNP@W^#838C#3;IO=()T5AT0H(`C<94X)L&:!ZZY;$805 MO[GBVKA6'Y;"NGW8CZ@:C/$.ZE;.089.V61](-"&RTQ6"IR.K!\A=!KH'4R= MQ/Z,K^"1Q3;4VH3H$*Y;9"/:;C`OM2$;#25NA'LMASB1X)!M^9(S]ZA5:?>G MJ`V^`548P,N:ZG=$G72;:A\C78=G;^NP9+N38\.6KYUH<^*E)^JN;[GCPH&V ME3J'4>SZ91>].(2[FP55U7>ZI"WFT&N(ZJ$O$?4G]&;;&H6^)`Y?J:GI*F-5 M#WU'8\:S^XSO:<"?(O8'K2X3=Y#@N'K:*@$YH';W"AQMC=I".!,^T`0(.D8? M\C=1I:]RK+Q=9#RI9J7;,4F-)HD:Z4W5;_7 M\X48."N]I@FK]O)2%VLO4;6#=W8%G5_3&'LSI"2[VG.]:YOA9FR6*=E?ZG`3_ZW7-]*9*BEWV\CQ9=$]M`(>KP? MQ+L^W6)?"CEF]MC>B-%\\AK7[7SKA:Z(32P7PY=T_6_U.*T!J_6N/A-K9RGP M:CJE@<#8U4LP(]$3O1/M<,DU"3^?"?7E'.-1_LR^?BU MBV]`EO?Z""WO8BXG:)/SUU]%6KF./HEU=A2(=?5(),L5TUR0YL^X?9<)S-CE MI0X!I9-L?^(Z29;RR^^WT_*<5@1X_0.5GX67O]36)KL(V5X$T4A(I^L57V3P MEIQ57;0`]5"74#1J'U^7OJ<+\JHF!<67M^4I5P6A$-+-"R(VTKZASX6`QN"2KE%G0G01W#I)@K?R.Q6$:E5R\T MEA_9KDX3(*2:D:Y.VC?(>!C>TJA5;P5X)4L?YO>-IYL[S>Y]6L57/�?GVK M=X.YO871/K?7,G:7O52B?>2C0(`@IH#[X;UX\GP&XT&7V&QAYLU<`D;9AHX8@9?RJGOE#E)MSME%M*^`) MUM>T%I+Q[;1R,:^NZ@G$4+KFUL[0-RQY.V$'1$':PG=)\H-0C9Z+S)K=FDM% M8M7,R>Q$FP\BZHGZAAF0L;N,90;Y!_C<3G69;;G:NX*`!IS;-Q3@G'W#2G.W M[``@KT9U7_7I_/75LO[7D>4KD@X<@G@-2'3P]AV+/JYI$8V.9G7?)4*'Q\LE ME2>HY2]6ZC]!U8S9B$@[<_\AZ>&<5C%I;S??.#M!CJN(*C63`PC3>6-=Y76=`O497WU*UWKT;K\\2,CKLPL1FCI6/J/ M+J80^X'U)#+%\JJ MMOLQ)I/Z+5X^3,Z-CC)3__$&<,9>MC;*[>5H,WTL#P78LIYR-5^$_)52M0Z^ M863,0ET54F-^>\ZS\?$V*\](.EF<66#&LL_0>? MTQ%M)\)::SG$?L0,L;QD-]^8<99O_^@_70"F=V[.(?B80=N;'L$K%V\TC`5^;7H>F7OP-.-0HT?@NE%KLUK_9O- MND>;!4OQ48>K-:7&/7G^1:PP8T;")+M<^9XF-%YIUFA0AJJA%H8NOY:CB1!O M8&;E.S=;J>N5E%L:OO%_H_5O//Z:;>@'-(&!P\U118>-`S$\P(;"\&$3AV\F ML%'[$XM8,J.3[!NI(("X.:H`L7$@!@C84!A`;.()`^7R8L$BB^X/,Q MB\CZ`HMN1^IR:J(1)E>Z6<3`C";V+64#EK"A8XR8K6%/7216/T\6#I3"U M/M3O1;:"1LNR.\L7<#M*I:J@2_?W(MO;_R#9W66K_8"4[]?[I<38J@4RL[:L M.;Y97$,#S6\CM2=PM^Z%Y$TF;'T*^"H4EHZD>Y<*T12WH56;^5H[?:> M4Q#W5[]Q^1AEKRDHB^^.3;A-T*MV6Y3HW7-07LZ+H/,TNMBWP_[COA08T;5B M<+/D1L`S"\/17&[>-^XW>C'>G:4JYD_=0ZP^Q=(MJDKBNPK->X@L>J7\8MBN MLS&WY*83,YOD/W4G\O4\EGX%T%MUM7=(3E4WF4`='E]'*8F>F%R9=;UQ*W>] M4WK#5K(>+M=J';+Z3BR,6,'%1=Q9UK,H]CFN7](.)7>;K_-!;B19130^HSMN3YN8AQ0 MU`/YG[$8RL0O_P=02P,$%`````@`=8<.0>#2MFT5(P``JS$"`!4`'`!V87-O M+3(P,3(P-C,P7V1E9BYX;6Q55`D``SV\*E`]O"I0=7@+``$$)0X```0Y`0`` M[5U)W?M@?@+_\]>LZ>?.*2!;C].>W%]^]>_L&I3,\ MC]/ESV^WV5F4S>+X[5__^]__[2__<7;V$:6(1#F:OWG9O7E>X76&TS>/:)M3 M!F\FLQE*:)$S1IS$Z3]_8G^\1!EZ0X6DV4]?L_CGMZL\W_QT?O[ERY?OOGSX M#I/E^?MW[R[.__?3_=-LA=;169QF>93.T-LWE/ZGK/CQ'L^BO-"P4?SK"TEJ M!A_.][*X%.Q_9S79&?OI[.+]V8>+[[YF\[>5BNRS@I":_&N/OK+IXLT>(-^_N7Q[M]N=39)YU;Q)4_[8B:/'S6\:8.O#B_;L?/KQC[ON3"M=S4Y6?1L6*TP\#;LL4H`O.(9BA^C5A@[!15 M9&RL^&T4DU^C9(L^H2C;$E2T>Q;ZBOD9JWD3D90VP]D]SK('1%@;C=.G541L M*KT"4_.&GK%A_2OM0=8;1!L]R_HD86BN*%JR&#VB#2:LIRO[O!G]B42V+;\Z M;V/UIV09I?'O!3O*_B&)TNEBND'VRJMR=M5[/1>5VD'G53/RT7>9*ZG`U&7/ M9:ZH@)FC?LM<-YB/IU[+7$TUOF[[+'-MA>P\]%CFFLIY^NL&S+569FTQ:6'< MDMU=EFW1O$(?E?1`<$K_.2M#:C9W4>-LK+I@MNEX\NITUNIFNNIAGNIR@NJN M;W?0J_OISQWWY&[[<$>]M[-^V[[']M97N^^E7??/SGIF+WVRV][8^;S1W831 MYQ#!R^#`IDF)LCB;+AX(RBB_>B)W1>*6"6%/AUUY-#=RZXC)*V+[/TPJA_"#E@;9#*>U@BAKAS&@E M6<` MMUN-\3J*%8)MHG#%VH6^!:NS-5J_(.)2V39?!YJNJ%)DMGU!9WM'.-07Y-[4 MFH(D3F-6W^[I?UN"T=<A2:Y/@64N%A.7$8`+6FJ+&+*+LI:@VV^QL&46;<]8OG:,DS^I?BI[J[-U% ME03SI^KGOU_'KS%5<)X]1#LVM:7FHSNJZ'ZXG$0O*/GYK92.5A#F%P'=>2@V M7FT)*>OU9SJ5*O\C,5=4A&,Y7*3MA`/L)J3M#MJ@UORKMM6PFU@0O%8)'S8R M^F#`3V^X,M[DN/<1YHW)')$J-RT8N!3+[Q)\M&@X@*AH?"*@,4"TB#MDC'&@ M*V959-^SR.87/\UPFM.&]28IFD0Z+"B7.0:,^KY]ODJBC+;1Q6K\Y&O<;0BE M=)7#!'0^$2`8@,&(:`<;JQLH0D3!E*%!P"R(NMY4Z[HU%ZC"S2>HW``1>&WD M.7.7,KKRX&$%FYJAY7)DX84XC36N?W\?3F3;\VBKT/;,L@@NX]5LR`<+[P.I M-O\*Y3ZU!CQ5@$4DE2=@DH%&:()*B96L:<:USXP%%&;2KZ]_.0?F1+XF2UI+ M[$XEVVU-.%5%$U,,?'*L5?UT]..V[!#N7U':FV]BU9. M'#UBR^M=O#P%V7U>8RS?]YSMA#D MA/7$6T`XV)13W*Q<@;L(6F4JXQ7+##5+E<<0F]G=FKYRI;!IK"+W,-:ANI;0 M+IC]$"W1A:QZ`*2\"M(B#1H:&E:J(T+,-(@5JYZ*T*Z2F(@7_"'VE0R#+=M9 MT@QS>V_I0[![2SW%+W>7=.ZS6D<$VF)2)>X0T`TW`A`$$:N;UHQT MGR.+LH!3$#78.MB]SF_X<$.]O&&\A5V[9L0=].?]H\3LE[]_1']#49*O9A&! MI^U\@LHLB&"@GE=>][""0DDY35NAN#UX#I%ZI9!JF0`R+L+89C2N,O9VQ80(IO`!'*Y)J]]\HQ=+?3A\[?K]A@BIYX&Z?F*C> MXN`0#3N4[._T*1D#=.:''3X>AR#JVQ4FM`>@X()SJ>"O^XRZSM?08B=67QBT M7E$_]>DIHK-%V@DWKO81U2Q5\KI)E)*'%C%-`X4AE//J+VX<]48I\4N0@_7` M3*O+KE830J)T679!NP/)0[1C/TV^1&3>FRC5H'7&L(:U`X;##7!,E9]N&&'V MD1+FV5WZ@$B,YQ])?ZG:HP3;`(@D#-44N4,G/H;O6TV>M>Y%.^E#YR`&-\7% M485Z:'Z])>P^I4+'XJX?N/4%*Y0EF_UZA"F;TZ@:;KSH`?_&B@6QEV7LA.*/ M7U&6[RWNWO3A@[5M%P*R/HT*XL_;`74:H+)!G#LP-JGX-2NO[JN[05.U3ZVM[:'RR5+"N9H#FMY\Y7] MLYM3H5>HSD53+'024#/RD'OHJ:I10?'/PQ[96F\2O$.H:EQAE3_C])4.OU$Y M$L^><1XES>\L?^DSSO\/Y8]HAI=I_#OJCF:]RZGW"/W).8DZ$8BADMHA.&ILCAG[\LF_%MZ*"VW&'0;U"*.I M91HUS67JPUF;O9;)'>)RO^^/\O2^!_F\N,R.UM6WX-OB`(<@ M*NCA^@"P9_DMSE=WZ3Q^C>?;*.EU,K3C>68>F"X.1,"8P*^0*@:^A)S>:.0H MX?`VE/&E?1#)H#W=F#G%V]?4RFP5;Y[Q37%C'-B9&I:N(J9=>KCAE6<$8UM7 M-L'O1U=6$[1U#*+'.2K$>Z.N4$$.C32#0[EP#!L,SH,9'4\7BWB&"#@R!K_5 MMUVUOPTT(C9M`;'8N"9D-$44=UZU60?1HEW'!,TH;S#0\,=ZS-KY.+Y0"\VS MC'67=[]2'_7<_$U$TCA=9NQ"R0?V1$TQHV,-V=!GYR?4;Q*WI"LRVA M)J/LYNLLV5(+V0VHK%'>EI<13!>U(=2(0OU[S@EZUVSK!!EG;(?+#;(S8;)F M-SBZ]7:;IQM7USP':I:!K1@5=\7=CCH#,4VQ%$%PDKR$V(5"47UIU`4G:/@%%N55!+YO6G(1_2WVV:M[POBYD2!!,R6R0Q#4-%B0U2BR M2XX6(#&QPS"(MNBWB.TMP/>5@M\J!W2^C2"F(FMTP]GA%41EO:)S)]H*T>E2 MLF,7=;`17WG##">G2(U\GV(D(Q\!!#1MUD6%G'T0R1%7[&`VR6.JW0.I=AM% MN6=*U`>8B*G'@1(-BPU`(N8>Q/U/IY.1J!=Y]?Q$M5CSLA6_'VCS[3:*27&5 MTR<495M2YHH-O>^V5ZI\MFR2SN_CZ"5."H]6BLZGZ2/S,KN1BA)\QBFI_WL9 M97'&VWSSPKN"@V/>PU7V*%M1W=A?[+6#URAAJ-A;=QUGLP0S8[J-@&ZYNG%0 M+S=0H^$'-=C<96^ M'.VU5CA4NCEW#7([?V_KY6[_S[_%B%"HK';WZ!5!YZ[T"G7KAJ30H/OE[O&* M#=WE&N'[#6]5;8(8V8+3\[[:X#:A4=DN6-7*#K?%K8DM;.<6$)1"R2W$J4G\ M8P&OM^\:)O2@G6O/V!/N2'M"7S`[S7L%[]+--L\*BR[`E6<%RBZR(,JAYU=: MK1'6,1N$C8JX%GH@,6&U5`T-WRLCY;TR4MZ?$E)@LYTCY7T'*>&U*1^4D?)! M&2D?3@DIL-G.D?*A@Y2A'G&=S&;L=`>;8TSS%2)T3H'B5S9WR#ZCO-X8JS5S M+Y\M>Z84__&1Y-4/D%_A]4N<%OEK0^_^U2I-9O_:QEEM*+B9IT):(59,.EB; M!*AUR!JA_\IB6AV*L)2)(W4:B=P16FSX3E)D,U!3IP0`[,P_S69/))JUJSO8K*.[ M=,'^*@*AWB')"PMZ&E'AP$%BY0O;OD$DR/*=3+8D58#GW0\?WA708;^(<-,[ M6AEE\6R2SJ]9YKW*?%.3D1Q/4D;CQ9:>CQSA3"HTB!" M#[I^B?&A2V*U)8SZW)LO(@:)%]%`1[N<`G;&-4`R]8`K',$#JXMWH<&),X>[ MVA+"[OHNIG+PP0[CE0`-WMHK`$J\QP==9Y[T,^-7TJ.N`L%M4*@8U=C0=8-[ M@*$=V%L,3Q/A?)\=`=8MX366@]N-4+&D3A;8N4%RCYT=CAOL3A/%/'\=`<,- MT36"Q[)%0<=5&T3R'7N)+Z?="^M:-N4I$$,02SEJXUC`\62@K.HU/V@62*\! M/>Q.@KHI'S&>?XF3!+Q]VI:--G2[;$X&KT+_^`%I5V2-S&'W1;2[C.;&797> M^!#MU++(;#F;#B%$G$\&TKI>]#JP$&E1`S^\[23CC6N?Z0\^TQY."/[ZGAPL MS>%0!4RWNHZ:ML:6;!ZB6&$[3*6T7G+:H?3X@*KA#0\I:`=)-=B"V^."U`:3 M0.F07B=5W9RK'CCE7$\#M)K>\P!FN08UR(/;F).FASI(`':0^'LJ6!7YQ7>B M[R$;/;C]O"+Y01%N?5H^KIJTXP,0UU)+I#3YUI`(Y64G:'?Z95(L?]<(FY1Q9.R]H)=%JBZIQ%NYC1X`EP'5($BI^4Q3`A4?&`(&;)^7G M>]2D<1JK@"XH@K0KNUOX[1)E>@%J.O3#73XD`P`'(R)[)2U.?:F+`MO3A$?O M4IQP``)=$>0"(<)[@&PPXN"R'TX"]VV4Y1\)_I*O;M@$<$/B#&7W\3K.T?QV MB3AW;FB4V=^^H50FG&$NI^YC,_-E0&@)*V_>4!(21-/17D#H'BV^W#U3!8#! MB&ZQRI7JQ48[7#'TC.WX15UL$`?#Q>HR9<&.2[>8$NR:Q88;Y6CC1HHUKCN: M6%,5*\=84]P(FC9KC/4&#,&A#!HJ^829<`CE`VC!W*/X2-4D\2P7O>@DI*D< MQJ$9:&2EW;Q@-2O587&0P6#!X1U$8W,Z+S>91%WG!2>=B/-?X\]*I8>$7[L/&/> M?FA*[5^OIL-6]F-3**%VR1PN'?RV.68GNXU$ZK4F MC2+U4I-2D>'NMN6K]Y'TCQ6KDLN-K\B'NNI6)Y!8V^[6-;<*HHHU-JF(((:% M`C4GL]EVO4TB.IR=K#')X]^+MDD=0A(&R>A'@D,-&RV00F M,@%A7`&XWZ,0F"7.F%(MV,N5DA<\[K-VF@`R]H`)F'2$->\C##)12F#"Y>Y3 M]`],BID=]):Q#/PEJ5,MJ0C[,L,?1Q_T+?_NKT< M?:+2<@3"I0=\)\X`3&(,*OA'L5GL*B`!(BSXCP?&_LMQ@<(1?#ON*'@4/R'G M%9'![(`^T%EO2G6$5L7!;Y6K.M_"FP,(&R`L-DX1!Y`(AH4.ZW[;<]2UZ6NT M0(2@>77CX]#KT1UU)FPK:5F,5'G+T1HEJO@IE1BLRGW"KX4N=VE'ST><)+>8 M?(E(]VBR3I'*!VI%!JJW.B'%1N8WJ[""-%9MU:0$,9+H*%C=42&N-QTBN*KL MB<8!#"43#:#`XQM$E]U1[C-.9RKQ[]/!$&C2C1(%7$/M@=!D'<2J;T<_,0+$ M<1]IM)W'.)"%VJ[R\WF91BX9''7).".B`]DH@\XSTS[Z#H@10DSA-)F2-#'">H?'@IJU M=A0%%[UUBBC!:/B]%@U02"$DW5>1"Y,C**@]%$\8ZFT%!(4B:(O$/8R$VR'N M@.3O7/U-M3;^A,AK/$,LB9Q$,\[FAAIQ?4100AS<*!E.YM>R63WZAYT/F0#+ M)H03][OTK!(X2>?/A.H2ITLPZ`J4E?5"RI&$6]U:DU@+N?NIX+6\@TIPW9;2 MU:EI?+J1A%C54I,`"WA;KGURPLM.#<89Z_(JU>#HRL@:)S-ALI'$5M%.D]#R M60]\D.H1%6GXFXCD.]JFI!GM/=AJW-"[UI5>#QV]>@L+^S/C:N3[X^,R5 MK#J\^8S(NJ,T\*5]_+7\,E#M478I%EG2K"PRCHVCKB6G("9`1;[)=%$I-B6/ M\7*5?]XRATT73VBV)3&[G/TJ2A(TO]Q5=%E%V`6J(VYUDVO+;038K3 MM%9B+[\[5U"CKF<,,NH1P$//8ETD2+D'L;M^CY9115MXCQ*BHM]]C=W8'9'QS:A)/D#K>U4DVC9W6.VXE&YQY#'"&#A MPCNZX#&4V=RG=@K"EYPQ'4>++J9<)AWTQZ M('B!BB5^<*+#^UQWB;W/(\"$Q";M+JW'KHYL<*]&<)[N_(QS5#]3.TGG]SA= MLCG#-7HQ?^!5@:?VPZY"GB,`G@_OZ:+5D0XUQ(>^EWD3[8H=Y^FB:3R`7!72 M_3:;B'0$.-.P51<^8M8U*H8^[/22WZ593K;E,^5$S!SC[HU]0G`D%%@SDTC83G&$+%S71::1%.=Q3 MEQY$VE-K3`J=\N`3`-`:_A200?BQ@I$*31<@HHN(H$[\&$2^=Y)EP-A#9W=< M!5]X8LG;CJ? M@XR2Q`IY9/H,_.0J/A#$GK=)\^GB:?M"_QE'9#==E.]G49WHETDZ?]K@;0:_ M"VS.8+_3H\\@R)A;>T*."A,10:0[\K2%3\\I$=?K!Q+B(*&B9:$<%C)V05PD M5"R\LO6$\N$LJN<&IVR]'YB^*]'N4PN$M..>I.LXPLF\7"(PB/%X1S7!8[P< MFM:[NSV:X>;D:M'&:M:UX"!B?'@XM\'TVRSF MP4RZ3^&E5%X%U7X6M<.(_P;J4'=\%QEJ+,$6D>IAS*$/3%<'P@K%[CFGI(4T M[4-Z79H!T^JJ(_:%1F6VZ62;KS`!;F-4(SY,Q(3$`U4E<9"PII'-N@5RKJ99 M0HY!=(M7.'U%)&>O`4#ZEGFAO]!FHR1L#DX/2RVF'`ZK,?H<0L61O3N4P&4D M)H@NN5"PR.7K3M=Z'YJG5:L/H8:=J[Q2-)NE@[B0NU"H.`'#!@UT[!F53FY< MWG@@>2A3[B;L98$F_.[2,L,?:']$,L7=SJ+*-I8\NJ(T*UZC5+!PL+&VQZ]LN7V>M7OJ MWH:CD&J_U\BA"A43:F8I!9_+*H@[R\LE\]X8K#=:%E(U+GT#J4*-LII9BB-; M#BO+,]LNYTML.%WIWM3Q`IP:R8A;LR`^<;BAUS!28V[#YVAYY)J_A]UH5-A1 MHHSM@]6JW*(HWY+>D7VM0N`2";]0J!$W,MI@R83/V?(4M!("'J*8CE#_)T[G M^WY'&'P!/1AWD'X<(9>;:A!MD&D8AY`/^Z"%II>[PB3Q608N9>_$`D!YU',) M\F&]LE%J8W@1N];9Y"!/$^QWQ)H&BK(/>'3=S(,^72!9!_RH8W4SX;R"'NM6 M]D"?91AKY@VUP'UD/@&P'110P@`WA%C!)G#7N,NQ<K]_F4`0SFP*OV%6WC=>:MJ_7Y MO(*HT@K!5O#$B,+K)*["@`:P>VBR\=`;V=KN1O6'RI9;4/"ER3JM3)B MHLJ)/**30*"2!]S#B"K MC+>8/*.TTKLH7!X>.%K=5%3`7U65*O"MYKJ(W"@JLM2D()+AC-U790,4_W:U MJ@#QM%U):/,\G?KGV+\!K1BTM?3S^DPA^4Q!N[.>>N74]7`/:3;-5X@\KZ)T MNBD.87]D1_C0_!E?1SEXJ.*8*#1`G3]7P.)8$D1%J[#4U:S/7 MIV@,Q=IVB]IB3Z=:'S]*`76NVH:$\:"2-W/I*'V!XMS]Z3ASR=ZK-B#Y6^VV MBM68*CA@2QBO6'FS^%>4#5'!8;'>:W=7[+>J;1ZE,=7KKB&"7/T_&@C*W`/E M8]8#1QK65O!*V)C#*;NCP6$LVA<_3!VK;7`EF? M#HK]>#N@-@E4-HSWNX`GZNJ^LGP@JFI*IZ1^.+B=D@:>"W?+E/]TH1'3DZ@W M7CSLOL:X4C.,]\BDUG2-*5ZCG619O$SUZX@2,]6Z(6'VQZ@3.AX=H"Y(U+-] M(TV2\?L)I_F*+6_<+M$SGN0Y#=H5(NROZ::XF"9=/D=DB7)>.K`!ATZNL!:' MD\"LO>_\91EKZ=1Z."V$L^TR5V3<#73Q27@W?/OGYFWY'O64O>-)@"?O>I@! MN-.TKC!_#O9N@(B?E!XH5=/A?+5C" ML_[B<#DXVL^[BHG*H;^^@T]L@Q\;_F]^'&C,RZD06*(]Y/O&N>Q.T2`JRW5U M5IS35/\6YZN[=,ZN=-I&2:_5IBWY,S-]NC@0`;VG7R'UW9J>A)Q>CWZ4<'@; M&_C2/H@SI3W=F#G%(TULSW85;Y[Q39K'G$=H#4M7$=,N/=Q`QC."L:TKF^#W MHRNK"=HZ!M'C'!7BO>%1J""'1H#!H5PXV`P&Y\%<635=+.(9@I^,!K]57NU\ M&V@,;-H"8K%Q3#4BH%F.^`WRJW=+Z=WNQ"9+RW24%'Z#A>X>&:=;`FG0M7LWR* M4,WA,A(QW-0!AJ=*9I:]+YOP;^FAE&QE)#^((?](:T)ON#OJN@#-,(Y:&82S MAZ-4AV!F!H\HRTD\RT4WFPII*@]R:$+-%+%I0;&:1[2VP`WT8=#DZ!%$4_L; M]*;P:)Y,]HT@D0>.@9R.?'Y;=`H3`PG!?*7"!KIM4=]*IO=^Q/GA144 M)U'L*KOFLKMG1CMD M6YFE&:?EL955NT_%C@E:@FUV282;I)QV/_T!P#N)*[E`PL[\T5U.T+6C^0?4(B=(T/*36`YIL-WE&5]TQX%T:__YG]WVV0 M8$2=1,F?GY/PW[][2-/'/__PPYG]\ M\OZGXS\^)]OO\B*RUP9."O'GCGS^FX[_]*<__<#?EJ+44*@P7?YL^O40RKY? M3';X&M\A]M_/UTNI]I]^8!(_1#B]"&[QCKKDZNG+(_[W[Y)P_[C#Q;.'&-^) M[>SBN#3#OLZ?V--F>*$OH3ZM MJLB7D%^9,A*/\)5K;H87^@K'(=DNHJW[@K==017^)@WB$:#2=3;\![@OM:"H M._;H@O[5\(N?4QQM\;;PS&PK8B=WS8,MMUS:)IN&U1UK14@L_#G<8((W?[PG M3S]L<4@-'Y^P/]ZS/][_>)PW%/^3/OKO^9Z6COXO_;`+[@MS_)?\^W?"=VF8 MLA_0>O=#L[1,OU'>&"?D$&]PRT.G!/^]N]U9?:E&16=%DQG=[ZA;E@O@Z/WG MF^]0N)7)SLI'B#W[MQ^J,G=_YSQN5DT0;XH"T3\U/R*7^&%#:'OYF+YO_)Z[ MF.QEM4`T'R__%MS>GU%##*4$271_&`=T9X[+KWBW^\^(?(EN<$`[SWB[3)(#CEL@,Y+-?[U& M=@#,E9:AX&[B1`9[O>XL$T%,YOWO3`@54B@3FY8'9A5-+.NCR0NE6L$/`]NC M\N07LCM$M'OS\B'[+=RA[Z0/: M9=5&#+^R"-TM\2:JA;9&17.>3UWC1Q*G871/.^[I00QJM6@#VS+1P1`7&X9% MNM*'&O`*U0+W15)?RJ!,R`?\:VJ8V-6$B`UBK28I5)9'Y08GY1G-QNY)_"*D MA%"BP826Q&`"-.S!XEYD6@WWKD:!!OLVE%0B#>2V109#MVD0%KM"VVKP"E0*]%:O$'OG`WPE%4;, M/K`(P$WI)H)%EL9-2V@#$`>[9;3%S_^)Q<%7(M-,1-HRPS.0ID7@U$-H7)-S M"'3*9"-[A_A+1-_Z`&59O1'#SRS,*YKBK81"9&M<.)/]GD0W*=G\?O,04(RM M#BF;5&>+&<38-E!H`EVI,!SU"O/`%-![TO!!9Z`D!Q=$7/((9;*H)NP%5TQP M0/K4E)!%"MT6I;1>1AZ*KR8$/M`G[0ZL1JHU'-^1`AB0;]F$'I(7F]<-RHNT MJF'Y^K03?^_'P+RL#HGQ!Q0%]6G$/223Z^"?4U%#/R.S9&AOZ9F)6BOOVH!/'L% M@&EF"!K&-9LZY):B%5C9(S_0V?C^1/W=Q!AD4FW859H#D787)+?\=QV2]_=! M\)C!#>_2I'C2QEW^^+_G7X)XR\HQ?P[;H5;XKEA,U7S7$W["4D!@4&58!$2Y M_(P_XE!$O[&G_W?BM57"2B$&W[*UOJHNQH"IT)\.G9L-.41L@/R*[,)-B)/Y M+1NSV:1MJ&H%"]PJ!(>"6&H:%-$Z+TIXJY5GI_.;Y0U:?4!7UXN;Q>5ZOEZN M+M'\\AR=72_7R[/Y!9J?G:T^7ZZ7EQ_1U>IB>;9Y%:FYH8>!<2VOEJL MD>HT**2Q/#6?DGFT7:4/.+[&&QP^!;<[G%SB-)^4$E/+3*?),IT.#.'47FRY MEW8W2`@):.35@(L&=F:%*`JB+2),&,65M!><,X1'EW[FM2=DHEI=0$H3?V/A M\M@&F$\XOB7M724]H7D,ADA2EB,$.&DR\PA"C!,C8KQU M<)Z,#O/:_X:6QP_N1!YE\53IOPJT1;>;Y8 M%(B)(N/.LGJ%,Q/62=5GZSC88O_HI:QD`:MTE2'FDDA+1"&Y=<=8LLK$33(- ME:,A0*HGW)7,$:)21\6ZV[>%+$V".Q1:W71V_*!\%;RP@JG#L5BH%8C;0D"T M:9JU#;X6/5>A(Q.^"!0KHCQF+_W@A:0>!8R0?W4Q%9KR(A*(+#J#"'A,%;OH MAXYZ',W?>A8_A^!$$S/[`,6'.%G%\&N\XP=Q!'$:XLZ\I:&X-(EMBX,G'TT' M#N.IQJ5=)B(P,:MU=M#V@!'#,,URN2"-NUS2#SYIT:#,2>0UIDM+FIKJU$3D M903P.>2Z.HM`\\X(1Z&/+\"_B<^JJ\-]$TQ:8`OQ,"YE1EV M,-\O\V''I)IJ<_"/#URA>C#_+9/U8T9?7L-*[G1K0T>93$--E;K5*1D2'_#V M)J!U=5;.F4E[D'K9BBLJV>&$D5MWDP9I_6D8I-&?Y2*UBK(J"-S*Y+-$$'9+F7WD"J!>*:@%\Q&``_ZM@[`$`3Q]S#_L![M.?X M,<:;D!]@3O_>8?;'/-K.]^SDE;_SYU<1Q^G)%D9+2=XN_'<+'O3!$@YJM M(CJ0V>&4!2D( MT+;F9O*``@MMXA96G6@%XJ$5W`!+[4,HY(,\-#^F/^:!9D;A$UY&M-N*+TC" M5BJM[M;!LSSBV6AW`YN9-ES\,O'G*$Q9N#:,1L869S6E/.7=U-50R/70NQW5 M_-Z;B&,%+7%@L:UO:?PP,20)$^9EF"X:;+Q^O@MZH@5&A11 MV9R0"N7VDC6YQNSSA7QQ6$7:-3D+D@?:LC^%6[P]??F<8%K\U2.[A2F,[N>; M-'SBW1[9KE2'+DH2NG`QF,'PA8*EO[/RJ6.'([>SFF5&O+BPS3=?L;:>/65_ M;ZAU])B;9]>(D<(T[9<4MJ<.5@Y)0\8#:3M,PGMKQEA7OV:Z`+WCQO&6G[YU M&M#BLN2*9E:\P[7(AG?;(==*J0BBADI#PZ*1&]!`9^-1&;K,# M?71KM+70!6"OL3=C$JLN@>MRV=:_CM)V]F;SWANXIV>\/<@(0-UW^6]LIAT& M+/V/C7:X&;T^GD&!;G"H0?^C#+XV)LCF%T>CPJ3SD+4)@M7=,DHI1D-:O'F2 MX+2S;<%(N&C[-,)#Z:\T#YJBFGA2TEMO8%:7*=:%3'U%IE%EDSY5TF*:4J]! M+0,/TU$I2L-MN#O03BJ^P9M#S+NJB^?-[D![LQ_H1V6)\2'-2[\(XHAV:I,K M'//4F?ZV0S?YA+19$!/&YE#^0I0"E.:`!5)&`S`_L[HIE)2V:/S(C&5[G3:5 M.79*$5=@B\]RP^B1I@Z\'XS>A5'VU^0S;Z"P)PY1UXID$.8;`0^NO*\U+EZ$ M$5ZF>-])1H#-PD3'FMEI`V19$(]B9+M,#L-DTU4S4E;FT*(1*<^:D;*PRZN).P53EP'XXZONS#3,N$+'P<\8O)T&^9J)Q(6O9XX+FBKDEA^]18G92H-1JGMNL0*W`RFSDMOH!P7 M2#E"3`)Q$53)O!4`R28-!R-HTLE`7K!\9E*V8E@ETPBE'1D0:K2L@F9\"@=Z M0HCT9F>?KZ\7EVLTO[E9K&]\`+^LYCK`5WQH$>9;XEV\"^U-#'4EQI7@!D:U M.SA;X[BU;ML;X.H1:PI5.4:]`J=D.:+HG2CNPL9;1ZFJQ6+`COQLS7R@3;X" M)_`F054M3I)]4T5(E892P(33R3(YD66K*JXEDWZ<:6%=O;+HQT\048.!Q$#/-0D<>(K*K\B?_JJE*&!'%= M31D$3H,D3%9W5Q0--"0%^;D2-^%]%-Z%&W:21.6?KM$P&P2J!QTPS:`RQ6@\UPTLW,:7`FB"( M@KAD$VWNN`FV/JENA._GJ)FIW0.,"D/H-V8*<5L3S_#Y1B])H^P+OR9-``Y) M&.$DF6_^=@@3?DS&%67R0Y#@JSCVPO=9E'>U\`-YRD1Y`6AX: MVN#*XF#/)GSIE-$/V%OG`J7:;KAB7,B;$U5=P)TXQUDK(,(Y:<1'Z++[Q5FX M[`2^7"/2E>4NN454,WF$"J.(6T65V7+$IVRTV/2O)-SRL$;$J]W0L*N(%L?)'8A M5_VH75CRNMHN(&*M%WL%=!6J)IQZC;Y$0<,6#];&"SFO'L^1V=$-6NA)X M%0/$XVL?"=E^"7<[X3%30\U83[NUS8PV7M]T[#I66)0!9AQ>8'I6//,O-%A! MK->0N+RZ^PY_-RWV&^L6E>H5A)!\CT2>"]5'ZI/DL,?;2RS;-.;4AW7PL?(Q M6F2R*-4T8WR*SDF1CE[C)QP=#"8891KRR-G5@(^#;1]CS!!* M?%H&*J&56?X/[X*'M/;5H4!5/5IBMY4U-!7[&@=R+N?<9/X`\"9?3!,3Q(71 M5P!(\WDP`$3Z-KN5-5_B8P&-Y14S7BUY!W-?#0^N9\%$SFSGP[HV)"PL)#TY M'-`<#IKY,FF-Z6?.&JJZ.32!'Y^X)YH6:.::QAUA:U-V\VP24^-,N@F=3S`# MIRH'P'2N;IMD1!O55%8AJ1\D=CF._^Z3VN+6?[=/B MI]?4G]!JCWE`1>E\BE6"V0OI#MU^VE;3@H#[<.W\C3\Q:+7-MH=%@ZE![\*& M$9ZL)P1-]LK:&;*?$E3OB'VE`_HN!_)=#N#[-7`/?J2)B]*--EJ?Q2[Z1WMH MWK]@-1S;KL;;1QIG=S:^/O(^/<,23;!3SZ)DHS*TSVZ]_!";PC9Z5[..P+SM7+=L\%3]2[$_!BV('F81UOVGP55I)UV=CUJ[XS(PG;?8PS4 MML?>%*TJS1B3?8-+![HW6NN/K^/.[N5E?^#J]6L)EC8('[+#V118`[!1`-,@R7?$@K MS7S=1\.$Z>H/@5^?Z,IW8//`HZ=H5U9.R[HL/!4KZV/T`CK>+'G7TI]E%\$^ M\C:>79B]);M=$->NT9[X[FRSJE?S3EQ#6JY5:AI^M>V[QIC+]+7K:1#`I.EE MACLN]]8`9I[%]4289UD6RP'3EV5$PQE.4GZ"!MZNXN(DCQ1CC*:E?[$L0T1?1[/L#5MIE&3'Z-"_-O7SJ4(NC&*\ M"_A9P91506W)$FO@,DW_6K4A@%='IX%PTT:Q'O8UX:YWB;WAJLLF>D"1QB'J ML0%3A2?)?2-H+XR]'H;ZD+F2:BK2Q#+`H4CT3&78SU*/R8 M1`ZI^NST\\WR^"AY^H#K8WK>!:P^0+49'C"&B^6H@-*NU6B`00DGY]1XXW-&17%+*&F& MD-E!A2&4#_V0N#R?_@AQ:Z@P]XUN4B3YRS?/\@+1YF/A>.(\VMI<.]/?JMT9 M!'JKXQQ'H"O'!"<3&!8)X)`"(T^S/,"%A5@Q0<@6JWI\?$QN4;P56AV79D[\);7^`.'].10`=D4*=F&V!8IU-2GT+9!7VP3/'> M($AU1.7AIR8*'UA*XXY#1MN/93!HJDMN*6)"B$MY,F^JK&\U:X7UHN5CJ:5A M6LNZ3QS2'L#4K\,C-#'@A+5)3E8;8Q[4M!#0QZEEQ%[S<](>B_F91R]709OC M:^!):+`GH`T]^_;RZV:'S?V8 M(]##L_%$24)]25)7UA7@3+&2S33@[57+#-"2]]`)C7>+XQIRNH'PR9(-K3E&8%>?1*-PB#]BYGD MO%Q\XZ4%QEX#,7W(+FH;P<[#9+,C">V'ZJX\,%.2[V$4*L'O9A2XL6WIGW!\ M2\S&&XP<6VYTE!D2;GGT(RX88D.]XU%3<]J]CP)]S2Y(J/)JYA$%D MO9&K2:-*'/W&%!#7\&1JV254-0V1"ZQ.V9R(#VVQ'O'7$2MH2=Y#MMB3.,'MB MC]E%M`5![`D48D_4B,5L[>S7@M63L;%ZXEW6<\4K>AEM8APD^!QG_S5*?M2J MRAQ(INJ$R&)GX,/H/9S;$UIA;G:Y6*/EY=GU8GZSH'^@L_G-SVA^>9[]L?BO MS\M?YA>+R_6-C[36@$G+;GTEFW!<;$5/=97WD3$-UC/OXQ@2T/74JGV;PA'* M]%"AB-X5JA.?EC-_Q"$,6]OJX$'H]9,H:=LRH1Z3C@O\.2^ M6R]W:L]UF:V,Y_4\-(R><)+B+?T#[4F$7]`^B'_'*;H[1-N$G8VYV1VVV?N- M+)OU,A*H8*8-`QH$F(0`@0D]_Z5^I^/^+DB2U=T-.T#U0K()2RE3<%HL,Y2_ M(JN@7%4X4/)2JC?CKUC7C[_T:&^5NAJ)Q5=O\4,DWN""W-[4N/^5=BR#*%W% MU^']0[IXQO$FS*=SRY=)_E9"BUXFFJRQ-`%#*BNG#CC7Q[\!)>W-S@JA_,H2 M2MTON9R7UY<,PEV7YKUQ((P"5M8$0:)':::.(3RNG9-]$$:*AK,I(&@U"P'` M)C,SZ:J];%@W;2QK2IV6,GOG42O9JC-)$]G]RO+V,9.5-8YU2U.CNDG$\O!U MMF,E9'<7GP6['=Z>OO1I).VMJ=I+&VLNFDYS_^"[GF#*8]VJ6GHPN+F!JZ/; MEV;+Z\6U#5`(UK6\_6!DT`B;&]:VQ[9EG)YN<*.X,&5QS+7C6JN:OV='+W*! M(U3QL+*&SDKN%09+C:E7A7C)/-E`L5?4FW0XF4;V,-WSF=MH>U9+D'L50!F![`W.SE:?/BW7G]A\:#9)NKI<+R\_+B[/ MEHNI9TC[@8E`5'$K.EC9:02#'B48'==PK6POU["09FUHI91-F];5_%S>/`76 M94WAB&#WOJ&37`?62]>FF0.[,,S*&^A84P_'@R-!\XXQ9=OFS65C_;!DRWS] M=6169JQI[\F%98JRFE/-#SB MRB*&W[>+[H9H&],".RYJWZH[HQ^DE[FP!L%Q"P4?L^&ZUPX&13?"#@U3=P;R M`F4W%*\.:9+2SB.-O/(8)Q7MACN!*!SV.\8=C59IW!DR0JQ><(-/*1V54TV5 ME$=S2B8($--&65-2`G6T)%R26'<,--#A(YVC(1AK!>`CE$D=H9K2/._L,??_SQ&#T&<7:QXK^B MDW_Z\>C''_G_BB`<'-('$H=_Q]M_1CX M?_WSTOCK!$`/(FG6:S/ZD.7 M_#:E9'EO(06=B61V'77Y!2ZLLH^:ICBYS0.EOWEMJW)5B4>W)C0I1WZSJ"K; MJ-MTAQQGPP4B1ST!=-Q$4(&C'4:W<`LUX"CFLR'HX"M M<6?(/:655B`O\V8_MYI8X$-,.I,*E/)/IBSAHMJ7#[3,HL6\[`WI-55/7TA;G2U4_U./&3%#IJ@9-7#N:-JU24K9K;=M3( MRK(.")4^0O,TCLHS5"LG!Y)+:ALUW=&[4U%)KSQH"B$D@)N++KEJ#FB;65=)FCE2I MR1R-;7^(;:C*XN)$WF,B'P/(Z9=9O"U3S896^E MHK`5XJ]](TJS*I796OO#ZQ*UHI=G8M$?`IR^E`R=/X?:)$TB+FUPVN+@#4[3 M@=L&1^C+KL$1F-`T.$S.-Q;)4*!L;N0UI6MNFIKJYD;DQ2>VL8Z:&=':DG*. M59+P]"IL.V96RXTEJ1K:\E$$/ZG4J6\*[$&_G"3ON.7V1;&[LI5V1T$Y[."]M_`%3M8=K#7NM+_!\V7S7#UD$I+H[-+9F2;_DZY?R\W/KB M6T%V:R!<<4TI/)QI"O/`/--[TK!,9V!VX^OF`Z,:)WWJI<,IA5Z+45H/$_,I M#2G+KXJU_JJ3.8RD&XQ22(-02FH?GE,Z5WI2J2W,:D*HE/(MR31"0(=A1M4D MHIA4L_MWP(!C92-7'*;1X$=E MX&OFA'2I\!2DF'9I\COB0EV[%@E=@GIX]Z#C1_B6B)&G[8-W(9@$[@"&SX`=QYM;W#\ M%&ZP!L,2P2Z<.X)PR&Z9=K#=3N/*$/0BY=F:>:>]@HP%,7["T0%/?0V+OG[% M1%#4A)03+1T)/826G4((,"77N>F/G^,J@'(1OO2@$$),ZNT@29H3#X?2M!DN M*UE1(F&D;;]L1-?J)0@="G/PJ4++LA[T#842YV6&@-C^T&"783[)97V`>Z>Z M.A`7?601JDLF=Y#^O7*K2NLW@E>87Z MK@J;ZC%M',2W4IAYFHYNAR0E>QQWULN)1T?,I`NBZ:2'LDQM'Y1B1JZ4_#*P M,"N$FLL<\PT]?HR_&"*`]*JF%M74B@V>F?B8C&3G^#9=1I3O!Y9E+*,44V2G MUT&*LY.FJK6I+:3;*^9?T$9Q(`O-78'/S5F[5A'4TMBLD$!\=-2KI=@]8$.& M5FB3NN8VZBRV]3PJ_=,`54:1Z@$,E,Z0ID:JO2^'BQ+Q@/& M`/.4XP7G^<0=.P\(1PEO.^?L/N![S(K^:Y@^+*-M^!1N#\&.3^R=!@G]`<$+ MOQWJ]&7-/M?JKA(2[+!SZZ1L]MPX&1QH7!0+,K]U6D)U^'+F>,9?L;YJ]=*+ M38B.J4#&!%X[4KKPUXRJ[GZ1!P$X29.S0\R&(:7ALRO2"7YU$;#051FU#3P& M]SHIW)A%CY;:K'B#-NP:PX2O6\'/##*3YS.*BA125_SA9<2KI,6T:5MSA`_` M;%GNH`\TCFO8X.^.4/[V=>-"FKOV`X8/^>AU-L2LO0?;6+X5*!7R0*R0>G"1 MN^FG*/KQ2^+R\\+;ZZO-H>`@$I&M22FE515Q#&-'U_X MIF:7FDO0S+'ER2..0[*E'>PX-4DWFEXL"-)*,O+),':[6/J`T2V^#Z.(73=& M.Q_L058LKRAB0`AC^"O`#IIDU&Q:Y1?9YU]$6TM,F.88#14A*C`[O^/N%>-` MDUZ8`6'X+EB!T1-'[6AAVQ(`)S4`Y(]?8WV?0-3WB3^-VNE+;92@:H'7^#D] MI:7X7=WHF6J+&T6]-BPK=/X<)I^&KBTX961Q=O;`1!+$[C]JA=^)5ZCT19*< MGC;5JV2OSI""W69E\(7\UGRWIO@(K`8@LL5`G-9IK]YDB[7M[J173.U'SB%\ MM*.@*>O=Q*1]P0R'1@22GVXC"O4SJT(*;"3I>:->$C=/N2GR+KP[GF=D"14U1? MCTJ2BM45/%7Y\X:IVVW(9G5E"TAD8A(^5F+`%"P,NV1=RX<-T1JJL_*??_:+ M.)U*5'!%],'5]"@T5(QH6O6&!!51I3>?V:AH&RO`N]!,G(S35%G=CF9L1ME0 M^71AFA5`C!HIDRO43+3-FBAO+E63%_%"2%Z+XV8U^^,/*2?F[ELCFIG)A]=3E8SE66W0_> M=7Q9T*REVYG4](I#@FJ5,T=<`TJ^5"H*EK3MNL2-U>B;P38JC:O>N#G^;G9! MHOOWM`C[SL2,W_/B`S!E-L+6`U3@\^=-\ZYFTKM>>@-*,+M^A"J1MX(@L]GW M'@CR:$:^E>@KM@SI%8RZMZ!;>>0NQNO:6FZQT1@QZ=9ZM'G&`!3&75JS32UR M7?/NK$>;3?("JK>;B(7$=(/>0PL4&E*YIITERCYTH(LW9!4Z2/[\]H)BEP%9(\6@RN?S/AMQ' MX=]Q^S1+4W%Q'!6(PW*DX\!A;)7YLB",V,2L^C<*DB+H^C6]):]X.8F4E:-D M4T=3P2N)E\D)M@Z>+\+@-MR%:8@U6V&5LBUJ262!>"6T[G!\3^7/A%AR_2J+ M28-GM,N%7HY0A#WI7*MK7<`K;>6(2254$S%*8=\UO,`7X2D]#4)6?>D=%4(U MJ2-TB5//=N'"H4R3"0V'V;1YT6.,-R$_A8'^OINK ME$'<1&4PV?1.G(1T8[=J_AF:F=4E^3FW04V$C\7'Y!''Z0M_Z1L(J8/M@[A`"IL=-G!ZA4IBCLB[^MH$I;3W<('/:MB39Q.%C MRN^YO,1?YIL-.?"[9*]B$M$_-WP4-;DDZ5]P.M^2QU30\1Y@HVQM>MD83.D> M7IVT1_W+H69^7[NSZ\79XG)]\1>TO+GYO#A'\[.SU>?+]?+R([JZ7EW2O\\6 MGZC$S=2A8`CV""`4VK&BA[EF\.A=GJE(`=CP#2B!$S[PIK'490D;U4:5.FKJ M(VH`O>`4%17KTR:GJ0DC;5VG8LRD[6](4P1J6WCPN_AET6*V7@YE?<.<;1NG MG\@1F5=2M:LP*YZA]^@\>`JWZ"+$].4^B#PYIUU28<3D,[?8T)!KP%Q@`;SN MX4*YT+1=Q1_7:O[UUK,L[%E4]+2!JMALNKJK'P-ZC7?L7&5^DEWWY$_ISG\8 M:V4H'&AM,'\&^7?1H0`ID9JFPSW,;GZ>7R_>G\YO:`?C;/7I:G%Y,U\O5Y=3 MLQL&G,0)0MKA8Y#A9KP!*./T3`)LND#*XIA$O'$L#U.@'9.Z'90;*LY MWS)CJ+#F4]_$2^))&VZ?F/O%EQ\J"&+--#"3&QHIF0O>@ZX,@2@(2 MR>0.I-F`/^?=PF"S3WC2(J1G$,H/#@\`J+.OE#M1DENG-RE]Z@/E^V M,H^V\AV[%BH23HA5@"DB":[K*4U-/I*UBHMS;2)@$[(B:.X0`Y+$@S+]M!$J[>&X@.&UGK5G& M"]E9*CHY23-P`7=NBLRRRQ2I[<2&3Q>MDU&ZJ=*%-\>A:&M7P2)A1:B9C1D@(C1\.N&VJ(7)@1HZM9HT6,-R3>XJE/H-#4 MHY`(TH\NHT%#04P"@P?=^0%2_<$J:4*"LBDAE)`;!>4`DH7 M2@HH-&?T)6+@0[AX/3$%-/5(K#YZBP)BA08%5#8GH\`BB-EE0LD5CHNQ]W!# M4[GS<'=(\7:5/N"X&AR3#6<,SNH&8W7I(()\SWN&RS%^@=N]*&['9!G+!CTC):?^\UE7M0 MMC)K#?RBCW(=DU%5J!DC7'JDL>L-20R[5X;])V<=I+X](.L&:4`_I]F1>7=! MVYOO$AC*+@0D?,"F#W5.^F+G6!]@O5FY!84CP^3$ M%DB3IB-W=WB3KNX6SQM^G>=UD.)5=!8D#S1E8O]9_.T0/@4[MJRK'7U[J!81 MV4IU*,TLG%E';I(&.V7DMG>N9*2MN5FFP9:&XUP'Q52)=CCHBQA3SB2(1OL- MU9V8I'W@1(97L"MZRE&@G=D[9H^432#8Z?P@VN=D[4UR]?DN@))RG>SK\$\399LS!>?\\6 M-F<[Q:4'CCKW4[25[OP,#4&N2@;??W)<4F5\<^I[]CF*J\-'\3/3H"U\OO&+ M4A@_APD_HR*I[?X*JA/2IPZ,SEE$1@9L*^*ZI@_)U'.CMJ`APRJT%2<,+31H;^5U1,S" M-?"63J$`RYI?+OZ>R5B,G7;>&\(=>`L\#"Q*A=1C2-IQVU99(<\'85L_^RO7:G+Y+K/VW5&D@W M40/A@-X1/#N,?>IY8VAJEDFC0MR?^T"M4=+AF5T-BABHM]#EIJG7B5G+1E)( M1%/6<[(/PO9E+DJ9!A\[,B#D:UF%9YK8@9Y6(KV"0^4[]%OVU@L&R2JQ0Q?% M-Q=QHR7>)8+0GJ=M%:.F@@CF:D9M55W-:5M5.1JOK>KX[-]6M4QUVJI,'M%^ M4J%QE+=?'O'/`CO&+9BX7FU:L,J">0O6]CH9ES\$8?Q+L#O0-K7\\^<0Q[1. M'EXN:#=O)\@Z[93R;VFJ-)#%9FX@.6SE4<5@"T,S)H"XQ!$J9;Q(-BW!0894 M79.F9OIUDMIXG)ZB\R3!:3*/MK5+#C_A@.V5W:ZB:\S.+`JC^^P`H[CX)]M/ ME8B.4@2WVR;Z<+M0L6!H29R$"Z!"&444$%^UH(-R9;XBZ0B5!OA2SKH)/PZ< MA(>Z*&Q!HDP2V8:Z$`8_F'*__O@HV]KIS@%TQ(3;3`I?)"]CJ,WV54=.9YDY M'CEWE4&TSRVB($5W+/`^,=]O)(XJ=\^ZQ9ZCR"KIQ>#`_U@Y8HY-C6N"2: MF)@1!@IS_]/'@`%![4*R=L:);<`LZP)L'0YH:7S+K=H%J.H:-J!'I6L@D8.AE]$UFV)9'`#J8D_6T*UACDDC/*/1F9C$[J*T1-) M/6(@M^\:6F`[.(P\#4+5<6-.HB;ET369\!"3[,2`P]B4>R[*PBVCQT.:\$G8 MGYHW=[>CM5RR':M%DE!TZMIVDO!(W1@12:+=Z#%E,D>(2Z&?/+G$W:2V1212 M5XN$05TE(7]DMKTBS[$Q>8Z-R7/LD#S'XY#G>!!YCLW(<^PQ>=JUK2&/H%KT MY#DV(\^QM^0Y,2;/B3%Y3AR2YV0<\IP,(L^)&7E./"9/N[8UY!%4BYX\)V;D M.?&#/&$4IO@B?,+;9912-(2WNWP,+MLEN`N2Y#+8BY>&]]0N2&:K/91X=OY` MR=C+M9*@/2S.,J7W7`M5:OE@>[GCEJDBINO+-&%/F!&0NF\QWLY0(PKT*8./ MD>%C3)+.#*"AN)[[N;@[LG,'([&[[JLGG2L3,WX/O+=<;-:S&?DZ=6',-JYI M2*^:%Q_Y="&;5;=0T?/J`FX.W,#)2/QJ^^O)L8O61+2RG?1I7MD&(6:,%-:@ M,2LOA).[QMY\9.?I2]4ZBS95V6OJN=K5=$?9MJ^1F"MQVY/`0FLZ'M^^-#)> M+W9A]4"3&:]5U6Q,[[810Y:+??M(]OEF<]@?^*F^\SV)T_#O_*!%<\YK#.BI M+S7@+@)(7!H'@C]E@2#"]\R$`.-X?>VST\TH_U`S]U*LR_44$Q63\!%R:=UI>7^!)W5C,: M">N;0"[LCO_4O/4IO;K[AXS<]:1V86!6(VZ0$S?"J;<Y&1];-6-,/:IG M2+/2@W-XC=&4U%P-PY9!$W'Y%I%F'^6MH39E]/Y(R/9+N-NU0-Q^G/_XZO%` M_+B\NI@5OYY,3]>=JXK&0J".OJ0588[!W?+KN>7'Y>G%XN)%_3W1).`B_9U+":LF1T1K6U* M,#JPP=+2?JYA,5UK)/@>T.X0?Z7HT=:"*<"N:9[&0+OW39UDDV8O79N&#FP; MIY4W%]FYC>/!H:"Y\U/=NGFS`;0?F&RIK]\B:F7&FO>>;"+EZWZN8G(7=CC= M?5,PMOYF*!\K6^`CCEW;2D*UI&?9\JE'_F1B1@BJ@FB_80O-E5`#JVU=V/J$ MRZ6Z=BTJ\[BHS:M75YNRK,2H.J?,)Y;1ANSQ!2W/!_JSSTB4AM$AC.Y7CSCF M$S?)*;XC,<[DUL$S3A;/-"22>!M&0?S"USQ=TL](->DGI>6[+\Z<;F%O!$_Y MQW?J:2#S')8-/#*[+ZLJ.+CV/GO';'^/0JZ/;KFQXE\I,S=M`!J#+V1T8#;C MHT.G]7CK_+?Y'13`FO<1RCEA1#AF$].<_7ED8#Q$E1M4^2FB12[/71VAAK-L M636_'[OFK[SPXEML<8#OMQA((2S MUSXP05Z='28HO[V("1V%+A,D-MUA!3CGE/KH"9,JUZ.O4?X>OTZB%09R@1_K8$TRW MJD>$Y>XWE4`X$Q1"MVYC2L3&.$CP.<[^NXS.\1V.8[P]>PCB>]S>@FDL7Z%: M)S\@+,@8X=VE)39:6=,_(UO%%3A04E#377IF"A05[-1 MZL\_0M8N:##EHT!%1\>&BBLVUIR,0L:NOUY<;)N9Y<^+7"R[/H6D#SBN7U'G M*3E%X##AIJ3R#*E9OUS&A)D=;QX1\_R`U^0:\TW$5T',RGAVH&U[)!@JM5:5 M]YT4JO"YK-296^)J_5KFMVISLW4<;''1F*+M@;<:<29/'\?IBV\D-@"0.M\U MJEAMYBNUHDF"-=[](CF;,.U-"[5$DU_"Y0YM%Z$%YL M:%:\\7@V3`X(W9"[LKH,!MT[^MIA=XE'CVC)0P?;BY!%#YN9,;VJ.J63J+II M487.W-)5Z[='^RHWE^=Z.Q+=OT]QO/=YVLP`.?KF55NC1JVLT(I!:ZOP[A&[ MBQ4RU_@)1P=]>RN1URX^+.6=K0#+/3B>*A,ZZ[?^JVZC6G489T]](Z2LWHW6 M>0FJQG295ZYJMLRKX<!MEI$3O MOU\.++-7I<+52I2XDO&-P29`,LJ/-?5KFB8+S)AERU+_8R/:X9"+@6=0,,L' M81H@SS+(ZZ\7Y,8#-*Y0[M>032O1M1GAEVF9]@C=CO.W_8PWU"_Q/*@GV!WP M]WB@7PH,FPY?S^'^M@&K;I[[07^1+]?C_C*?0(#4C?Y7.CY/``!CUFX:``BT MGK4LV4DIT?U9\!BFP4Y^SHBEHKQ]D2K"DUGBRO%HH]JK):%5QF9G#]02S70H MC4DAF+NC)(-=?W8$;>O/:@\\N%K+K*J55)/4B(Y=-34UH3KV76/*82HG M\#0(3O*TK2;XUA!FG);UA9A?*=B',`KHU[49K):K2*.V2`6<:%TGH\1PJ5L[ M[DG,S/+G/@\Z*P"A9)ZZPG3\ZVJK:2CS-A(.'<9]N4,(",I;@0*:'@\5PT+3 MN&V`P:9?+<55S'IYZ4LQ9FUUG(6)LK3U4"N#\U?ESFWGW<"S':.U!F-\!XKU>D"]OGH*2*7O M9MA=[G&$Y8%:YST&XC4VRZ,VJA/0O&N]3:&D'X`WJUVCD7BY*8,Q>5TYIHT# M[,3D8'=&`4&BFX>`$FF>IG%X>TCYRF7"GYW27[.EP8L?KQS';`R8_2D,#"`& MZY%BH$&(T#&H"."Q!*(TVN`RW,GL/-P=TO`)(WQWASM8I2OCA($JN_B%]A#/\6V:G[_>B3\JH3*LB(4&1PN162<#[`I' M:HI+%6?E]3UL7<(='VQCBQ4V))E^K9&R3HE-#;2Y)9)O4D9NT1E<`,?!52[Z M(>6X!17VNK@DXO7C1#I\W1\HTPY1EZ7B?>LE/\97'C,%0MV8V1""(T'-+&SB MI/!@2(&V8I,!V8Z7D+_V8D6)LCK%-)!\?"D+:O(2%G0L3DX"X<4HW5%&C6JD\*_Z%[DB,\/,&)_E.Q=N$EBME]QKG M!J8F@+:ZB6W%M,DATVE216UY>N)\"*,P><#;CX1LDTN\,H`!"*"F=62A&ER92'E=+[&01Y@ M!]38'P#LCJO%W2]'J(0@%SY"5)Q-J10*;QF3TEZL"U!.V[_-BW@=?/D4T"`8 M!CNS!D&KT&X/%`I0I)2Z<))JZ;P9$5)M9$9?HWWQWA/&Z6M>1#BCNI'03:HK M9)O&T_1<.P^3S8XDAQBO\7-Z2EW^+F.90K3-+Z$H%+,$QFTY973ZNM:=$:ED MZK/EY2^+R_7J>KFXH>W98NT)HU2U+.*2IC8D+!)H"?DCM>X83/!)D\+1$!S5 MTR14R:#?F!3B8O_W;2%+EP\-A)87&1!M*F11N/:J'77Y*RAB4&,NHVIEW@C] MA;AW&SX%M2+"C4BJ);:P)5K%>52D@8[F[HU#FVE_"NO75UDTE0O MQ*T>38N`=W9T#=M4[4FC,W_YVBI6>@.&6<5.>WM%I[F3GCJBE92G^8#GBDAM M.^DX2]U8)F7-HT+:N3WZK7CO7S*F/@K$J#:TF9CXL`^-[>DY\RN)?^>[F=@T MD]%(E%ZCS2&5!A27Y#Z<<$KKSHA;&BLS]I[MRGW,)#SAE0$`1/PRJR$)S^3* M0K[I?$W*NR3EZ^@_!&',9BQQ%1P$E-,+U]BF$@8@FMP\-,>TGG3TTAB853*, M7QL(KP0G<9H=P!]6'B9?&6X$$=*G M(KM4E.NU6:CS,!D!+_!]L/N`.\U;YWG^ZVO/!S*HM`1)EK91%2^:LC/V%U]B MLF//$0N/X6;J><9N-1#-%VRBM!2I`[*E-QWVJJVAXKN1Y0(%&@4"0V'9,6F] MED,W:B)UH42K6&FV9M[*B^^\N0I%477$]&.WH-R1;6!:8LD)&L"F"N3F[:%P M_-VL]L*3RTN'P$`RMM8'!U..\-=*5!U7*P]T79ENK*O+P`&\LNHRXG6\&"*] MI9?'/0\O@5+7I1CUXD\OQ7WM,&DQ]-OV7('$12#L>NB%D'8XK-Z^=GCHXZ(E M/CR)CL6UGN*Q:KV@-"<$&ZF6FP;MP^B\V.4&K1.M/U]?+R[7Z&(Y/UU>+-?+ MQ8TW?)#5JS)3T`].RW74B8,G0]-"VNI)(I=5Y1,NJ-*U[H@M4D?6#4B3,Q>K MRX_OUXOK3UZR1E'1NM;$BCM=-6WCXA^#YM'V)B6;WQ_(;HOC9/&W0YB^Z,ED MI-;EE48-CF)*1X[89N+3D'AZ4[,:\]#\\AS=K%=G__GSZN)\<7WS![3XK\_+ M]5^\H:097,3L-*Y**5&5%B2<-?#J+7TM:6M)5^,-0T_?Y0;`V MZ4@`"2*:.Z8X6]N=S<_. M5I\OUUG>MUK_O+A&UXNSQ?*7^>F%%QMIAJ&.`(*@%1WZF&N$C/[EF8H.<`W9 MD!(X80)K\I@N&\M.V9`VUQ??9^SGOJ#IB2)K1R=CRI0M[J?@KR0^.]"$?4^S M@/ESV%X$)!?(/Y](8"#SNR8AQR^DUE6,E2C-^'-4OD"_L5<34TQ19<3T(S>Y MT96M`U]F:3I0DR=^1NHR.L=W.([Q]AH_X>B`K\EN]X'$7X*X?8J8C4H!?".5 MH50P<`)*#G-_2KJ8FID5DOR"U6TNC.),&OW&Y%&N,#6M;"!"^E=ABWH&V@TR M&GN;C)Z7P1ZO[AI1XYSL@S!J<4`KEW\IA=Q`]DDM0U).YT3%,[7NC+UFB[>; MK13Z+9.9F$_ZZB66-=%DCE2E3A>-W0DYDM(T<767WX1,HG9>)A")5FJ^N/\\OE_S=?+U>7?.S@ZF)^B58?T.IJ<7M0'+.PR%ZPP%C[2/YTD8=@0M*Y[0.**;NE MES@]"Y*'JY@\A5N\/7WYG.!M<8%D&-W/-VGXE(UCBR?N^QLHPFW(EP0Q3M0N,PA*C8E)VA]@!*K*6QRWMM6(`3U+,F6( MR(XFOR!),G\*PEUQ^0F_%J4VMW4:).&F&Q_Z:%?!P4Y[>&2P\0>^G*"??TU@ ML+8X8P=NO-M1A>_SH_I1\/BX"S?%U:0;KMQ8?3!YD.B%,@)2]9WP8&.H%1OL MRS`^Y.'2S7Z^@?%^G`$^OZ'AW07'?:G*ZB=31G7M(\3UOT;8RU+?47'O8=*< M[3UO-.%FR;)"49TD"Q7=),<"5RY:/SO7/3)BF3$>`C8L&SXDV9D+82'I>RJL M@H\^!=94K%'J*[!AD/)*/8^*8,C&S-(M''SS)HSWY@H5=/N"WGW.P/P]*A71 M_"M$L[S)<@YG#QLJ05^S]ZA.[]&<$4=QQFJHY*YAAFY:#=5CG>B'@NBO>01G MV,@-Q(A-OY$:E\V6Q)WK9DOA%@[,^F:K5/2]V7*"9KMF"Q3.'C9;@@;6;E+" MP(!U?\OUI(3"Y0B3$GKO,#FL>E+B-??$>DQ*&%9YWU368E)"6Q+?0D0^L=H_ M1!@84(<(I0$W(4+A(T3HC'9"!"D4?`\1)@#3APC#*C<*$0I;!B%" M6Q(_YBU5LY*J.4?8Z17KCJCNIDJ1=>/9D:H[R:;Z)F>+H$)D\Q2&DV_2*0;X MB3-WTV+6DUZUCM5KK%>3V25EQ0Z_YZ-CTNJB#[M)_L*\5?6>"*;H7UL]2R[] M,*_G*:_],&\,>Z>=O=/-$=/,L096Y:YAOA5(5;.`CKAU-+1=^'4YV@V6XX%13.TPZG?IEO-N00L6+1\D;TSTVV%W`> M;<\>*/APLHSJ,C2E"!]WBL$3,(ME\P9@<7#$&%P&V/$6J.*H(PR,EQD[)N1R M??$7M+RY^;PX1_E)(LO+C^CJ>G5)_SY;?%JPHT5\N:P+$L7$&8S:L6JP\680 M`RKK=,&-UB\-P]5(=;0M9[26*=Y+0YBM7A&HS/6&AB-33Z!!Q]*I,K18V9K= M?+ZZNN`A8GZ!;LY^7IQ_OEBP+827J\OW9_.;GQ&[]N^&1Q2VP_##\G)^><;_ M=;9>_N+!0;'VF"(#J[L5'$Q--$*`G=\IB5[VQ;*!@,7S(XZ2-GVTD'5WXA0T9DDN2XICXF9!K*3\GEA]L5QUC=XE3 MZ256-BHEXTQ4!I-.[P26=\;^U-0S-#.K>AV-4T]Q#:-5)9F23G!' MHZ&?:>EV%;RP0EWC79#B[540LVF3LUV0).%=B+<*XMEIUBEHJ@E!1C-?X+2T M.JK`_I@ITU>^TH5T-C,2(?0-KZGH_9A M?XOCU=U-RNZV7T:_/H2;AT5$O\)+-DO:71UCKE%0V41C*(7U/D"I:^Q.25E# M*[-,D)W11OF2AO<'[Y?WC`M6TS\/@/B))&F[0BV"!?Q(;WRTHH!>N<%^4U^3L[Y<"'&#[_F$HH3K4KD6PP5R0+SN M6';!9ID3$PZ+=6O,3?+G?M!'7J,"TB@_OI@J'141021V)Z/%ZNXNW.#X$V;% M:P%2^"[_[:UW`R'?L`8)SCQXA!QG1"#3]D$;4.L#E2! M_G3@+,B2CXO*%DUHY0K0RN6&`EAF&13,&B=*8"MU9]4"S&+@?F*8:VN46'[\ M%OQE*@TJJ.WZ0PL='70T@(<_^)("F06$/B.>".D6R!^Y)9?OOJGW)6ORR0=&>L0J(=U0!WR0IL.FG0K3;+RK1J MH/9H!YZJXD38-ME-*Q`6PAMX9ZW$KE6$,V_H[+;:2M5JJ,C@\$,&CM>,"EW, MLX+%I'$OO@^B\._\SH4S$B5D%V[Y/^;1]JH MQ&D>K%=WQ26<9P]!?-\=J3-6:,1`M0(($50NG,5(`Z=ZMFB-S.HB;)JRO'5V M&]*F,KP]4'B@#4G\B*Q&Z.@PS+3^1(13Z78)J/7&- MYC)G.R/XQQ@\X8BOOJN&V#R3&X7V4 M96N;EW4<1`D[OHIW9/F_=EFW=OO70Y*RWNLE3E=WZ^!9Q!1G3NI4<^`$@JO@ MQ0(GNZL2:J.%&\>S7#_O>F]>4%KI%/,M]T$8>1"*W!&C'Y\QLF\8TFY).&[_*OAP;DZ'%%H4DF4P]RG1E M(`)'VRIX+)`XT-);J#;1?TZ>.^FRS8 M*Y;8-E<<#'Q35\:L^%/&B@C?LV,)5,F%M7,UVGG-9 M%$1;A`O!J4EF#1\RM&+;]#2UT>2NG>=1$0R6U-B[A0/O,6L47LI=S[D**G2. M$-?'U@EF1*8Z!YVDRJ5=*;!Q*G:]JQRHYU%IV_8*4C:YW$.M"T%GD9 MHTU2^+5BM-1.LR5*F%C6'0XK0<_(JT2)BK>Z2M0P5J2N)*O*J(28?M(7KAEP#P`(+DP-U_AQV4AO!JQ9( MLU=`$&7&7`"T9M<$GJ5X'9SLH2?0;%2'`)CMSRB&)9,2@;+2G@Z2<3ZW=9.2 MS>^_!+M#&SD*B0*@(HFA..W:M#XW1'<3M=R'$KH2K5GY`B7LS1'ZAS_^>,Q. M#D5/3.A?T?'1CS_^R/Y'T^:`_GX4'%+:G(9_Q]M_15&X*QZ'27*@5EA_F!S2 M)*5_L"W:08K^XQ!A]-./1XC59M9C/L>;;#SRIV/^^'ABXBC00HRKMT6CKG"# M33);;B`(ER++[??`WW$=@#<9`/G+([3D>'K-N)"EL[V`,6FJVBC2#>?[O(P" MRL@K$Q8&X:XP*!G:YD$S"1-/Y@01&NC&ZDY$1N]H(ID]G?@\#$,82%FDJBP5 MG]IZE-0$=`+ M00?4RDR[#N0-+[9.WM-I59U:VC4K1@]@S(='7OJECTASE40KV)^ M/LF6YVM7..9E59)(IR0DE%P)E%PR-^Z(IO%H3CJEH2X!RXXN)]^6['9!G*!' MVC/E1/2*AUK$2#EI4I\J?LKTY5Q5>_2$M^?A4[C%T3;)MA"4)PPM]X_=;4)] M5(4N"ME&GS!VV?>NPK:K1=H->FT!:T75K M2#OHO]7LN^[$=5W9]N3:%J3=N?K\A]=].A$8-!T[28WI>W!-VK^,P$2VAKQ(=3`&Y<5@J:/VH*:%1GQ42B&$2X?PE M6ZKZ)9.?FB,&]4WLZZ7-&;E6DSLZZUYPB(U3!O23KNZ:9,]..*8/,'W)GRC8 M96]$P#L;(X",-'?KBJO6)3!EL:7A%K_#7#O;%-5((?WA>0_D22)`/QS(8X.Y M/5G4L"W1E/'D#O,#+8+=!RQJAX6OJQC0>CV5;S/QP?_=,__MA9NLM7 M[M)W__(O_\C>>;>&UP!%Q+ZV.Q24:K7HJ+'N&*R0T5GK:`A2LZA=WU3=W%-] MA*C@VX*6/+R#8&OBL/\4LE;H`XG/R>$VO3OLYIL-.0CV11N(5F%?(3J<25+C M#D[[,G"GH9-:?59*H#L2HVTNPP(^%^+LJIV4%Y0'O$Z?+.GQ0.SKK4,RJ5:+ M9!KKCF$'&<"UCH8@[K@-N4((%5)O"U?RZ`T"K"FC]S5-Z<*GX'8GO9A>(9%_ M#J'$0*X(;$*.&QY/^@JH$E5[2#TY#Q,-CN2'&*\QL_IZ:X[ M5M]#LZ2)A>9@^AC[A!%>IGC?[FB;BJM;IIJX&SJ7#F!3.R-?/6C;-"&G M*OJ-22(NZB<]NT#0>4U=6!G$OSG62-7C2GK^9N*9_`S@FH'8P0BMB-UI@ M8$+16?%HQ,`0!P:)G4(*/^9'BZ[N&NTYONTVEWK1 MDJ8JT<'$E!MWL/W7P)V:@QKU62G!%JI$),4)H@_8:#+:9@=IQ3DO'YGBU(0T M``&QKZPVZ>1:39KIK#O&&NS11R;>AF#MF-TL1[]@3.7"B0^B@P:2=.@,!DG= MP3%H*)W`I1!Z1T-0=%(+6?SP^6;:P,3>%K1.W$+KQ)/F_Y(U/5=9RZ-H^D5B M@F:_*0;(G;IAQ\V]P)4I<3JJW6:^:.7](8NP:B5$D56#G"-U#1D_NE8=(@=P M5DWMI"]HCMN1E@N@J[>$&X-VNP]PIIW,2C#]@@_S:'N.G_".\*6LB^S^WDYD M-9`MPZM2=C!3%-9AASCTCM2,T>G/"A&^,G1;"4U-&9.Z)CVJI,T=A5J30%K[ M4Y(HC<--JCJH0BE3D48D,YPL7:O`))$ZT)!#HC>K7GEU7(6Z$HG%-^^PH"O> M0K_,WH2H3X,PPMM%$$=A=)_,JSU-Y_@NW(3=03E3A9(/>H7!Y-"Y@&6*H3&VKS2Z39)9N9I0L8]X>B`^2[ZQ7.*XRC8G1V2 ME.QQW)VV,I`M>::4'4PQA758=ND=J8FETY\5(L51,9D0VA124Q/,I,Y)CZII MTTJAUF24UOYD9.*'G=T&"=Z>D3W+(OD&W#D[T>:>GSEX^E*)Y'?:S;\$\;:X MS/**-LAX=4>U]R3*CMW%E`6=2[+=.\IKQZ6C@3'`7=$@`XCS4JJBCV/GL]4C M7P_YR*10D*"`G;/-7@?W_"R:CBUTKSTU\3LIMXMK@GE@A$#;4)Q/FOU&BMX#@NT<&/_O5FXSL, M6,S"HR5:)@^7[!3B9W8#SSIXSM>5Y]TK4=C42]?#ITH:@B1R^Z["J=:CECD: M"WP@/T%I\.S'MAG36F]3R*QJ!$R2*W88I?/A'F*P\5CO:R"ZC@MX\6/:N1RB M@L5&FR.4R[Y%R*FB-QCF)H_F>2-SD]^I4DMY(*D">W=049-E-Q^9T=-@\X.V!3PCAIATL5O\""\+B,:^:F7ESP/,HR;9FJ=@*A3`XMT:D=N M0IB13[/89&!J5LA0B)67B]'O0YOPR3,:6Y@(8X5Y%8AQK:M]D=MGC+-MVP-=Z'E#ITWW,_QF@.#;.CU%4:& M20=XRU_T(8S"%%^P_07+**5\"RE6LQ[D6G"JG;UB)]?2*X)%3)TK-UTO0Z]F M\N^EXND MS-CG-+VQ?LF9G=79*GV@<2BL.F-9BN9+++('5J_>F%4F9FRL7__,OXSL])"$ M$4Z2VOJ-Y/2E]B]USF6GWHD,INI@8<',H9N88.7;+"!8F&QD-X4>JBL>H=N7 M^@/? M&O$M-\!"&3>!2AL\O)5F4&''M\QI.*S%D0P"5]*HUM>X),(-*ZL'T2XO55G* M971'XCT?A#I]R5^JHYNUA4XTL[``%KV,?;J)5K;NS:*3G=5&-,K?UL).39D' MI$+"LRAD#S]AU.F%!UF4,38FCBJ69?$ABK#T[E1Q`G:2'X%]VCX"6Q-;8.QV M(\Y0NW!Q:%A)'$4GD$(9QBP`7\U(QH3?\[/64=TDJMOD`:TFF-M%W+!W(0Z( M!>+`!P=`:3@.M3?*,-G#AF!+K84-P(VSQEY= M;8^U+8#I)E@[NZVN8?U&[;IZWC6LO_8L6/7!HF1+:R]HR#>N&IN3;4^U+(\' MP<4HD]2.L?>RTJ^7YV",W=;ZR^M:3$=5I4@IUU:2T$ILVP/JS#<; MDF*VBZVVINQ+9WA+79Q$49X MF>)]^YYC&Y4BD!BI#(T8!DY`0X.Y/V4,,#4S4T["H-^8-.+B4[?W-@`A_2NP M164#[09GC;UY0T[9T>P:,0D)X0YGEQAV23:;<]E5JK.;Q<=/B\LUNEYNIA5L,CC!7:*A8HWR#/?IF'(>)IL= M20Z*(Y?,-23\$6H`4TG@P\4AW<9>;7@FLV)$.;]XI@*'@G*:VE.S3Z"L(J+4 MUSB(A#MEQ]P?`!B/15E5)8M^\V=9L%-(R@Z;<8+)28^#R8IX3O9!V+F27/2N M&?R+=S"DRJPY2),:A@UH4I,O^?!;]M`/V+?JI`OP[J<4(CD3$V"VKC\A.'?4 MYOU''.$XV,VC[7R[#Z.095AL7_#BF2UDZ(RD6RF5<#93&HQS$S>P!+#PJ&:& ML:%9+GN$[C-I/AH7-.2G9I$51LB0&FSSSD2_24ASCQ,RE9W_N[B*\XMN^6S" M)[R_Q7&'GEK)DI,*R<%$E-J&/S55ZTO-.[7V+!-`"W1&(MJW2?DF\U(\GP#[ M+=.8O/'2USVQKJ0VP:1*359I;+L%&&#W0.MG`+J.:_#Z&B`E3?LA,#5IFB]< M_MD.S4JA(BI+A(;R16@6-!-2>5!R1*XXJR^*WM3>3DP*=442F\_>8H)0OD$" MA45G&+&[S%?;8"O]](/*L1PK"&MF2>7?.5OBPC MFJ,?^-)`?@C0^B&(5H]\$>P'$M_A,&4'U%S11H-LC2*Q4\_*\.[(LY-XX*2L M\)V"TFO4*34_5N@@*XWX`95"YG+0.,G>S M:\SF-+0**GM/2>$72,T:MAI1N3 MIS1-RQ^^[KQI(FY"9SXCD_-5YBYY,O:1"J9)D8E]C$G2V2KBSL/03$;E8:IX M*2^3%WF-MGA.PJ;&ZXR_>!,#:P:@APBD9B@#"J=R9R!15?=;7E]LO9#MN@,S M.#1R7L#MV!MOUN%&QKZ<655%14XV31Q8G M$;0Y6CI:IUKLUGFGNNW6VYRW65`O1C;[E7F:C%=0E')N:'N(J[4O7T/W6L*U M4?)2.8['2DN;)1@G+17]ZM?7=EP>V.[-_/J,9'Y('T@<_AV#-1(Z^T-;`[G] MJ<*^K$1>Q'=-X9P$U\(<(T":(`XK$,E<@(5?] M.UY?;,U^QS))#O`S6BK;0V.JV/94\514&B]BJ:)@3N*HU-\L>_8&PJ42U1"A M4@GJSY5A5O5)86@VD)2LCN&U0%?BLBBWPL.XE<; M_(3(A0AZ,N``Q;JZ>9`8URVO+Y2;?OV(J$2C\`UFY4?)6?[O;T0UA-MK8:K7 M68CTLN;LI]#RS:/M%6729;#'XK.]';HPS5%ZN7`=/WL4:M3AEO[E&Q1;^[J= M90QE`KZ4/_NEG3!^S2IQNT^H#.YC<_HP\7JU]OT+M#%!RV[$2G[_VY M9;/8:=I,9%M4TTL"\4UD74G M9%,X,F*;5']6O$'%*THB^M(7`BGK6L0@795(*"12$W)(;G]Z$F5+S%BZ22(= MB52R;1*)9:%()++NA$0*1T8DDNK/\CU-U2N_2*2L:Q&)=%4B(9%(34@BN?WI M2;2ZRR_;#G97)`EYITV;^FE5NBF@0@4N%90Z<902ZOP9IH9J,[(4\71^,;\\ M6Z";GQ>+M?>)H1XRX@31J$JEB:)46Y(P:KQ-3]>S79`DJSM^J!`>QCG03#U.]#(#$3%Z.`:/'?W+H(TB M?4W/N!3?-L/;^?O,C@>!8@C@VB%C8.4+@DJ'8/*7X]EJ] M9#TLR"0AF"^V#4YNI1LM?Q7:LRP#;ZR^8B*^7"QJ4--M/NJK1$`YL5*'52K; MTQ(GW_`KYXM0H$Z3E@`$.QHFP4DALJ[E0EQQJG75'4Z9KIO^IMC;"-U-I>,>O4V%/?O.I@>,M`:5OG^I MKVNC[J78C$'O4N5_;'0#[\?KXQX4Y,=%XY(A^VL#L&RY^6@(GG3Y."OL`]EM M*4RSN4GIE)].L-XT200AF"HT#=[HJ+QHR2=7GMVL5V?_^?/JXGQQ??,'M/BO MS\OU7SP@G+IBV^S25H&`24*=#FT4ECVBB)8:6DHXH(+UWDB2!CMMPR1R88?_ M?-U+S]E@HLHT2!OE'FJ463;2^RZ9[H4*45EO#P*T&X)"D^#Y/-CB2'&*_Q/B>U^F*,RP0/K46(N`2KT&ZPP\.(<=7"MAY&H8 MYEA[4`JQI1J96-Y)>,-0DP5[0*Q-&]8?'W=\VB38%3OTEM$=B?>!:ON!G589 MZ`VU!E//R`_HD*652S45S2W-;CY?75WPK:GS"W2^O#F[6-U\OEZ4VU27EQ]6 MUY_FZ^7J<7`4O;,#F[!"SH-)BA$(B M_T9"B8'\$]ATT(.7>U'12Z8U6T8;LL_18R8P+6=4E4>,OW:3"P+A.NZE MMMP@`BP#4MCO`0::Z_`W*']UA/*7KQD/DCRF'R"FS%C6K/RKNV6T#9_"[2'8 M_1JF#]=XQR-S\A`^K@GM$M&.M/`HK9[:1;2TU1[*&SM_D!E-/]=*MO6P..-* MK+]1J:$O5`_5%1EB,U5/CJWJBS("4O4MAML9:K"_3QDF"PR_!NR`*_&`E/!= M_IU:[P92MF$-DI`BPRJZ=>5G^2-/>NOB.B$&G[()\(98';X"_>G`BYQ\WJ0U2%-TH"R++H_#W<'MA^C'`!>IG@O.P`*UFA!!R"C0WD$4@Q0 M`D*62,E<.$>SPA;*C:'JCJ+\"/^:0=JH,KZ&NS#;X>'+T07`."9ID(0;FW@G4#.):`TUES&KY@A\TLG2<>_@TS8UXW^B+T60 M"?(@DR_4)[70XLT.<&L0F88+205;!(2:!6/*=[R.B&&P\1M;IU``/C9I(#.= M(\2UO@[L2@:+7(-WRF$ETW;5NEV2Z5JFVR.T4&UO#@;M^_B'2)5K3=9[=,LQ M^CH:)"EZ>B2Q0YJFMID^*>E(C93(XS@MEC6BO,R0`>G591@?SW;[H77;SGH6`!C6M)G+7[^)X07'R+=K[1Q!OU^+]Q0D MA+=C/_[S3S_R5HP]^>_"X:\/9+=[>;_Z$E&OQ5+*L'.6AZEX_GWTXCU9;%1V MVS9H2S8'OAB-C,HC+3_)+)$B:+DIHPRA[=OJ"4*F`^ M03PM)XW!07I48)-Q.DU&,0L7KE$XN%]DY6D0_FB#<*D'WQL$FB2V@R+-2>@^ M>V#75>#5(VU!V!$][%2T(*(>YYN_'<(8M^]>MM9K!7,#/0@^:=TX"^^FGK4\ M,S/4"OB;0@@%N10-\#$YW#^@V^(F%RIS&T;\A_S1#RJ:@ZG-2:MZ%G-3:Z)# M4D.GH^$8MH$P=@F#X$:3D6L@4J@(`/U50%;3GCC";+>%<0?:$Y#)]7Y^89![ M\@VYJGH=%;DGD+E1M@.P=D+9!Q*?E8<8SHLS#-O=6UNU_`.9JPWAIJD7\+S( MTK&4FE9VJM/*-]D6V*1V=%_[4,HD/V5NXF3(&CYD0-4VR6EJH>2FGR345H9PN*=3\+QI6#FD!!]B=G85DPW&VP0Q1G&Z M,U,LS7HLC!69%@T*-7M,),@LHFUNFK&BI\$R=`PJT$3,@7N+WUT(7IHFD&-3THZ@"6!+X1AR^H$>8LR7H/E(9/81I./CSCA$S$,8A;(1/02Q5'P8ON4S0`2DP@V4'CBJ!ET=RF1Z:94?&0G-8%#-VY*`; M8NM;$8+L3/%.1)@KH7?;7.U[M.6W?O'EQS%^)#$/((_\$C#6+]@6`R4;DJ0) MV@2/81KLPK^S'08)"J@.&PMG'9,XF<\LAF5]]P1]><`Q[;Q$.'^Y"2*$ MGW&\"6E9:/A(Z>=#)$9)>!^%=^&&G;L41G>TQ\/':VCLI[&/T"+&F8%_9;]D M=^#+\(.[.WX&"XMW;(EKG#!+A#[=L+]9S*2*88S"_1YOF2"Z"_94A2FPBV?9 M>$\:'^BO.^+2"6$S)^G#Y/T<>RJ181AOQSUC([6P9NEX1"9#=2&LG4)QF'<` M<@(7*JC00;D2RK405_MJ("Q-RYUC>'!2;>7-+&?^4P;B"-\S947.;.T;"LLT MXYWO66/S]Z`8<*^U-.6<-7YF$7KBLX5'A+$T!74.8^"%>TF:'>`?)JQ]I=YH MNGMH$T`G5B[,DXD-6R,BMNI@X9W2D6()B$(OOZ(P2\J*S(M6_:821SB(V8Z? M0[1E1SW2_"X)=IA)/]+ODI7X"5?+0K*C8C\NT,\XV*4/FR#&DZ_$T^"#6-1E M>R&(6*.V\$-ETA7PH%;.J3WT@AQ?&9>D:)5=9U*`+)=X`T"1KG,;@)3!Z]CD MIH'7K:D=]4+,28Z8?/5O+O`&D")=7#8`*>`+YYLNNI/22IG:DGB!S-"EF1V3 M3A:[R[PHUUR*E6;S>]I*LF2:MIY9G=:&3?+!$KX62]#^\N>OL_E5(8285FAW M!69'O+'<4F+,">C@5JI+S=O#+5^#WFIAT>74@_D#\:!81]X#$``KQ(5VP9># M2[W8`^.D`8Q7#0;%^NP>8`!M/&]HF.9S*[?!YO=U-8Q==*`_!F'T,29)(KY& MJJ]Z<>^;M?H0&MAZ`V^H>Q9`RIU>]OC<2+`GAX@GJZRMOF>W>\1X0^(MYO,@ ME`H1SA:'\H::"=7F.-A**;)[*E("UM1GZTSSJ5L*X<8,1C$OD4W5%EY+<59Z MIL-MX=TNNZOA%O,BW4=\^H45@Q:,S:J\T%2#S7HP\8A=O+:K[W]]V;!KF<([ MM"/1/8XGSBIZ\X,`8+9UV9VEI3(0]2O"V$2%26[Z>@:E*+M1E5&JU$,UQ6H. MA*DBKNO'+6238%UV">N88!^8G?5Q"9JX]2T`*.AINE6HV`=-1A6S-I?TVPLS4"N=_$,9Z@PA MM9$+\`33QJN4O>9&6JGDU[MZABU/Y/EHOJ&`IJ0)K:5LJ&M+_SBBOROZ-"=RD[_Z66"]_B%Y+G MV+ZGQ':$)7WYU(R)1NIE(+1P-DJ,@,EMK=P-CP['M09=N%P'5?)O&I&2%-41 M)`;-XT]"49)".H#E6KB@>JC17T&>)(,.1>OMCYH>&0XZ&%KYEAK:9 MX9=PMV/I8);^;;OYWRL=`;6@G4'XTHYRZG5-XA;82*:9#^?YG>EHI:D)76;G MQ7BD,^39)W3]H.=5PLRVL! MVUHO_S`6>D,H9^P&O!]EZUE*03M#>:^*"Z.4JB;%6@JNBIJZU<&M$WU2QCLTC:$R3.\YAH:S'X5D)6T*(XQ.[!?8>4+ M\,(%:[\PR.6;-ZN0RQ#<7=M.D1M\5TYU$>.7*#[]E_/F%V]4,+ M\6JA_,?+A(:P3&P3/)-1NI$22*'%%FT_D@AG`[]LB#;K+;#SN;.1SI2/XX9L M5)6=.\K&B%EO/<;\8HT"'-GQ'"C!M%O/AUO+\=.PUN]@HZX/0\G M[KX.1H8DH>@-#=!NJ""ZJT*OJ7AM+X%:?.@B395U)WL%#!PJUV!J];\%:Z.5 MG48H)#V0TEVXJ=)L+-34NW`-=[@5]R:>!@$]7U'?Z6WZ%?V=0$VQ0!X,:Z"M MQ$=<[0D6M@MR@?PGB@2&D*%K#SS:2UU(82_1F#7V5+/`W0BP.SZO0T/P(4G) M?O+%`8JJ)$8?OPGJKFP)8YD9>%S`A$6Y;4M$'+LZUWSDGAF7?6@,>M# MD*0?8_(E?5A$*8X?XS#!R46X#U.\_7`O#F-6.OF/-=09`FHC%^#QS\:KE`#F M1K*)%':39Q*65Z`@JO!$L\[=R_L'O-LB9@YE]E#-(,HMHG????BX^.[[(ZIY M&E,SR0/Z)8SO:4Z[3&@!MTE^&>M+EO62+U'2N)`^S[#I(K(C]R_H(F5N+Q;K[[[G.J4;+*$EC_GD3=$;^R(3^2*78 M.U8Z6MELOT'X1'_8$5MN]U@-A3H M^$]'B(+^>.+6PHXQI"^@FX'%2+V,-1;.1B$I3&-DY6XX/6F3I>4>I=[WGC1E MCF$I:?`S.Y"S27L7D`QL06.3+6J]P?,/N<3P-DG`SC[;G MX>Z0XO;-?L,-Y1]OB*$AA.WO%[RI'5P4*<$'6N:-\F/,%T[O`W3+1'@KM\V$ MV`'_;,DV[;?P-HS?_\F'JH+B5"K:NH79@HC;O"RL#;X-HWP`*J[_,T$/P1;= M8ASQAGJ'F8]\M?8MINTX*W&>&7#S$S=_`"0@H'!L!J3^-LLH-;18TS$4IIT= M7@9'W*0M8< M<*7(\((XXM$)Y5&G6=NQ$URJ!NT=NX>"['9!7'OZ_3?F-$'B&7-@%Z8\I]EJ M&!P_A1M\Q@8&@DV:B!>H&`D7"U4TPH/6`2AMPR]<,7$G7QV@UY[-$?O1C>V+ MQ7FHMR\HB&-J.1LPX3M0^&EH!.'<,DHRT]FX#K,]]:H3,Z`0Z^IL+350ZE5+ M#@S,NT4CT.H4(S\#<,A6JQ20RJ50*>;)"`@XM&3+6*"P!7R7\OO<$VT3UG$0 MLL9"&*L-),L+PA22PVY@D1H&#]%Z7XH+5M2J/8-S&+TOPC+?TIT;GOSR*STL MB%W]M6]4D2K5;E#1&':(.JC+JK1.^N*-7T952'#H%#*>1&!`"$DOEQJ,(=C% MA+FCBNGB_%@K5RP?E,L-6D@E,PN_8%#C2;Z`2JG8,]*68;9F=>J5?%HD$)M* M:ZVGDJE4"ZG41IV!#&B9GLY%/WBQA7DY4NH"GD15(,3(EN`-@PQH-*T.F\_/ MFA<'4YU8YR:5MAC,+09-J^"15./(X"H#@5[/.%I=L5)(3QU&M1CH7H<@KR_9 MA0A-#<&=""*3KL`%?6^*V$,O6#5N3RDN3_$E?((@17N12@^H@(;.\S#&&RI\ M'CR%VXL04Q_[(!*&3Q/1XL`2I>B@@TH4EL%#J8$S^?$D.MT9?X/*5^C+0Y9X M4@:0;&?)+0GB+8^YN;$$O6-2&[+;%8OBT$/PA/DR.1(EX6VX*W;`W+,SXZ+B MEHML#?7W4Q^G9@(A8EG5K?-,%%K5.29:TRXQ"G2(CH&7WNADA^;D(JB-4S_" M,RB49&?C0&!IZ#EH&O.`$\\FKGHCZJ2&J/=HL;T/8G0=$E]:>U`XR8XR@X`3 M\.63_+BY0+*'5?:Z["BU7P_+89O6''2,A`X4F:M`GB_SP]%]D/=V^(6IA1R_ M.HIF;4FV#.\L6T`_>8]'4HG$X,.WT]:F9"U=%9F`1@-43T9LV0H'O.=25KL? M(:Q714L[*!8U/?A^QZY)P%9-9MZJOD\:]?TIB`)VRO'M"_*Y3>L%".EMCQ:` M`&VCKBAVPBV-M:N[FV+_T4MV-3.)K@)VK.<\VMX\DD,BWJK6WT#^"?H8&$(( M>W_@;67O(DA9U=/B[)H--R;%!8N/A97FB0^':)MO"RM/4K_++W?<\P/7F08[ MJST_03U7>\>WMH7LT'/$6FT<%YO>L@UJ#V'R`Q-/>*DF;L<'P)B``*L9$.QM ME2&C;S'&YQ1,QM'?-S";:-9R52=0IMV63XEZ1(HQ-@ M8)K5SRE@(M:_`,`T.&G1X&*QYG#_.4R^05Z5!(X.>=!$\E<^2YFR(QM;_!"\ MR7]XX\T0]M4,@2=K7=M2PK1%9_-B\R&_8:8\-0L]D!U+J?(TZDNFAAZ"[$26 M.+Q_X*,=MX<7M"YRGRTD&$H7BSAU MTH-6V:F-PR_H-/(G7W=GH#Z[//`<@YUIG34_(9=GT^?EU6H5U*=>>F0*!F)? M8ZVE>6K%:H&>B0/'F`-:WVGF:`C:V%I/`Y"].8C)EG_"86Q@0VO@`?26,$-_ M0[!&F^D;?KQ5#C6VJ3J+60^F(AT.N#7%\2 M9'D54//"G_+@U:S76%Q`$=2NFZA/E+-A>.[DRA0]@/!RB+>W*%_A,V$)-]L]PBV/^ZZ=>>-D7E@0`*JT%.):6JN4W MO8HP-C^`EEOV]`S*C&/>9@JA7[211Q5QCFK,^0K!+EMA.2;:AZZN[.$2@F._DB=+@7S887B6&DV!?MM1R3.S#)H$44/3IC^*].,*710+7>CF(CPU; M\,F7R+R<3%UIGCBQ9XB]1%_8YI3'QY@\9=O*6.IT6IS^<%Z>_L#.=2!W=^&& M!H.CZE2((X3WCSOR@G%27,94)E/-\<&I4REQ]1-MI;7(T9"KH"]0A\404((B MM&N!'I9<,-1P_'BR5-VV9F5MOFG5#FVO.P8A6V.A<8L*IBUI%1M>:07+&C;3 M"@9ME+*5@JL[=E=X^G(5D_LXV"N-#-@#B-FZ.HC%971;3*3W2XR59_K:O9AMSSMVCD&O]O/AQ!;-YQ7TK` ML9T12SQU4&++N-92:,K[&KK. M9C]AS(;$I$3?.M9P;';8WECPPWGKHRF+R\;(Z#.\OM#F;1_=L.R>!37W/7A$ M2X%H,8K>.ZH5Y.UVZ5]''!ROP^]W(/1O.,"@T'Z/#AC^`,_"X&#U(:NXK1@J322D197B?#>_,C"J\CT(TWWN!WH(,^XCZ[4S$;_,#Q/F'E MB9XH.>AO^8"#]!!W=DM9*55'V1LI#3QHV,`'_))<&[>J$X5-K!.R-=%)0C9AD-*O_"5,'X0U M=<173O.K\I[950!1?E5ZL">'_+H!=(LC?!=N6I_Y+L/$U$NK[<(!Z4W6SI'0 M!OKU8Z"-W8T3@\".^+?P!Q!]LJ/\\]!13/`6$:?20+G*&\>F_(A^-^`:9I@95#!.H2L@E=>(J8,"JE MWR3FC!*,P:`#32LD/IQE%`I_PZ!'\XA35M9RD`[0[-DL+4O+SB(IU[V,A*()=F08Q"#YD6?@N=P?]A7UQ.Q M^?;/[)KZQ7-*N]]XN\B/[%I&;$U)^-1FQ@`+^6?K96$(CWLX!,^?^I=!2NZ^ M)OGQ./M,N;T2HCHI^\`,Y0L/,FN91'YB3G&R&UL.DME&C[28$R=@0\!)8-#2 MC`T]C)51HG=!)N`*3,HVP#DT2V@:EVOF=[Y5MRUP951HHT(=E?I?+0E#\W1DY($DD6 M.0%)7&269T'R49Q?]K?3S#+[V`&('/9N766R3[YXY)$;$26<99(IB2K>))P#T$H@@2,,*?8FVX&E;Z$F(Q)H.MJ_ M"&XH5$M-F0&461`DI/6;'JI&@YGY1AIMMCH5:V`RUWZ^X?/7_N5PPYU:+ENT M/7QDSBR+_<:<%DZ\8@[\23SO3_7[]S*9^@:^[(C<9;F%*%G1I"9>/P11MO4T M^:6';[#-MX=HC#]'I',%Q>=^M[?\>E* MIF2"8'?U&$5H;JH>[T>_FD@%>&C.F$7V(T851^2\-SPCY[WPD)S,+ZHY1JLJ MAN6^CU#NG2&:^?\6O<9DQU<5OB#.O!FKK-!'W8Q9;C^"&.W8UD++]EMH&1FX M7U5H@;T#BT3O5]GE@44O7WA'HU:NN`E++C?H"B.96?">HLZ3_#HCI>)L'E43 M*GEOBPV@T*3ERP-AYYQ$..09"]NZFU_GR`Y,"=`>%_TWIG1;7`!97O0X]5U9 M6F00FTILW8LD4ZFN1E(;=08ZH*NS="[ZP>TXVQU>P*BDWF:!F%TAF/VG]4CO]`^NE\'\3U.9=.\R:*^KLS59N\INSU7YL8MU<4'_H@^+1_3_V%@U??+_`U!+`P04 M````"`!UAPY!0MQF]%1"```(9@0`%0`<`'9A`L``00E#@``!#D!``#M?5MSY#:2[ON)./^AC_>Y MW6Y[=W8],7,V2K=>QX__^___E]_^3_OWW]".2J2"JW?/1[>/3SA78GS=W=H7Q$&[Q:K%4.$OSW_],__.8E.@=J20O__RU3/_ZW5-5/?_YPX$_L\E^_$&KY**2=@K_O6QR%H&/WWH MZI)2T/][WY*]IS^]__CC^Y\^?O^U7'_7B$@_`RIIR;^.Z!N=/O[\\\\?V->. ME#!*%:P[M8GUWKVK[5?@#-VAS3OZ[]_OKJ6E?_Y`*3[DJ+I)'E%&JF3%J\,S M^NMW9;I[SE#[VU.!-F(^65%T;*AU?J;6^?@G:IU_.7+^,$6\+87.`ZZ2S(V< MC-]8UE$UTX7^[,JT*I$_N[0RZ9'H%:S[M-JAO"H7^?H)D5.W'!Y@\N2#';41^/\_BDIIG1Z`%-[ M1T_9T+4!&4%VSX@XO8G]2Z>LQ;D9^*9*KGA_.V%O^V MV"9Y^@=C1]@OLR2_W=P^H^G"0SF[&KT>6*=V,'BUC.88N^R%!#!U.7+9"ZI@ MYFCF43!A?MV.6O;1*=C.,6/:2ZGG.-PS82PUF/6'10KEEA^NR MW*-U@SY2T[+`.?ES53>IW=H%QGF.-:SCQ:O35:N;Y>H,ZU27"U1W8[N#47V> M\=SQ2.YV#'CL;MZ>/V+.-U>Y':=?CL[.1>98QV>UH['S=Z&[!..<489;) MP127DI1I>;M9%J@D_-J%W'F15I2N-YCC++4=<,WKF&NI.\,:=]*\)B^)RFLZ ML)*_UP1_B!Y05'4GOMV<)^7358:_E'_/D_TZ)61V\QV+:N93ZF@ZAN/= M"%'Z@JYSP@515S&OOH82N#7%69+1,^O[)X2J8RU+XH=R,L"P'N%,:5!=KZ'> MS!I-F83BU9["@B#ADCBAZG"=;W"QLQY1U/SZ8C[WW.$-^6%0&?I:(:)R9S@J MZP1%6+5MQ1E>#>K*:*0(+G2:T5_^H:IE\5B2`6G5S;,R>G3YU^],BI#/5$]8 MD0_F6C4&9(>P)5I]O\4O']8H_4`5I7\PC=__\+$)?5 MYV2'.!55)(U*8I*A"GU$+(JA.DFQ:CF2/P=P&`?&-!0?GEE/?[]Z2K,.29L" M[PP;!8,T[$O_YW>0"MY5^)V8,2[(`OBOW_U`8ZL(WWJ1=U,;6ZHU4SGKGY>_ M$C;.V4PLNR8=]NO?T$$(#@G-`!TCFLC@H=9Q"CY&G!N`?`P=(.?[@MKX*BV) ML_YOE!27^?J"C&@<1G1DC0GE9-$@!:BI'5CDS!N\_!@Z7FKU?D-9]K<YVC-ME8+H6/1T`XK-$-% M*020A&8`G!%-9(!1ZS@%*"/.#4#^-0Z`-!ZSVUJBR^2]&"=JTN%$1D(:&6I` M&D^:UD@J:##T;W%@B"'_G`RS6UR()[]"B@%B.(K(@*+2;PH^.+X-+/X4!RR: MO7YZH,FVV9 M_A7YA1^W-%3<9M.(*AH`P?2T0XV4=P.5_X@+*O4E$#U8!'1"N`SH(@6,7%<7 MD!EP;T#S2!L)3CI?^*@47^*#@T"C:8!H&;8;M4%OYF[(#*O&7"SA)^A M"+\U1N*^1=/N*IWL&I[CV+9\\+NTK7[=#4?!%JV2AG,`'$TTB(#H.,TE<)Q; MA$S=E_W+AY%I;\@/\YVVFAQ.3\/P)BD?F>K[\OTV29YK(*.L*MM?>$0W/_^C M"WFXW5RE.9$L):,Q+E/%6:U)D08/L"(3.[*]$19E21I#HJ[X8^O6N8^>56CV MBI2:2&@&"HUHO.E%PXYH``[YAX8ZOR09HI&6U7E2%`>R'&51C?Q!F4F9]M0, M5L:;EU:W';93>NBFA56P$S,8:]_G\1.T"U%R;/<=DISV]T*4C:?2XA2;A(`:@$!(>8D_W!_&0_ M(XO3;^5\2HHM*GOCX$'3ZMH"/`84!2)`!%1=4WPH^-H?L@\.Y#+`C\CXO_IQ6%V3O;/??I,]]'&2S@(:6-&-6F`V##030<1 M-2O[O-P0R;R**%7NT MOD\R5+)$L25]YDN*&#WM$3@JVO#Q`];4$$8JOO9;.6&A:6P$,9+D=$,4B>CB M0)!60POTB'A&'SO&N@3=V_RZ2DOTD'Q5CEU`ZC::54<=.);,M#5!E)9S]`%D M1">DG@*Q.<"+E%OV?$95-7!XJ(B;@]1YXH<)"`=#/!B8RA MCPTER38T=7DW*"G18[+Z_>&8V;\5_5.2YI\*7$IF+K;%>T.16?'`(331'J:# ME5E5'N/4W'HHXG^U>O)+2!8\Y$4QOO)>$;?1P;.S)L1O'A38'S+"$K MT4V*UHHX:[.2_2-;:,G`<6=O!1,4&M7B.RN-RZU8[1:L=NLU>`0Y=5<*'Q5K MJ)WQR8/0IJ#3(&A58DN?V.G0\?!7?QXBIQWW2Q&M]\E4LSC1!IU(Z<2+OB#" M!6#M-%[Z`2,(E.P%"T!!4$&\1R4L6$)H`5&7FWS\@">:&VR\>A? M7XT$7'"=[:&EK"/>\'APZ!4XV"K(\*IEVRA,.E$^*P5%=]%'0.$Q'!'2,_1: M\9&(JCX@Y&8_>P[BED\O#;B)@4KMMJP+0?)R[B?476[ M>4B^CD,8;4H?`QO-2@<.PVG6,')TIC7Y?J#*Y:I!NUK0KA*"1Y)6)Q.PB)C9 MQR)%NRT$7E7:+]Q55<0[1.@L(-^X59(#+TQ%AC)#[9WL/THJLO?Y0?1QTTN0 MEA?V[*Y'PBMSM!$<\F,'2]:&3ZBB'-Y>/O!ZZ?'MY8-07SY89!G^0GO/%2XN M\/ZQVNRS^K3&0;(C[GL9D6TLZJ=1P9 M$/",_"TMR5M:DK?P`&5X`%DZW18,_&MVL+E$!7NA61DQH"LD#"*0%PI\+]1* M=_M0`WD%\?J:H8;U$^"+??6$B_2/XYZ`$&LR8B'&QL1184NCJSVFQHSC#0\4 M:79=EGL0CH:$"@RUA!'B1ZCC5.RT3.,-9!!I=;NORBK)UVG./[T,I%8@:$`= M(8SDVD[%TH!SO,=2O9@PX"S*H,0XYB[:^9.YUI:1>=J94X31!SWU--,F`.48 M5-%-F.!:6H)(.E6*,`_O2"WA/$E#)0--)#,DF':3P,+-C2P2G00'%/G$"$(J M@TQ,4R(#/2>!1S09*1*#7D<2?6],T!@8IQ7DM,<\N^^J(5[Q[[7U][E'QDJZ0!A8"*@$R!E2Q M@$.NFA4^!NQ\;*%+TFD>LYCWE!!,W*4T_6OR8YJ06QNB%KBM)&>K&TDDTMX@^6:M2JNH$`_\QP$(2,#$H`72<.+R/FIS^5-9YP@6>U$,[Q1M:Q9QN6 M!=Z,_A`P*N0K@UA^PF".OY6NFT:W/)O+MY==G>G`AN[*II6N3 MZ,KI_.UZH(SPW'Y".9$MHQ=DUKLT3ZE<5?J"&DGYS1"C0NT>";"0MPZB;T9L MJ?JP]TCK87L"0/[QKH7NB"U(8SP1W2[(]"W#[,J5&&@@VBY%EI(V;%B9*&J` M)@W;>(?AD=8ZEZQSQ:$#1*>0`2@$K")/0`V8VD#':/!$1\$PWG#M3JEC\(6L M8XTI^*[5IX@"&E*5S$'19Q5O8/5GG..A1@W8)1-A,'WWY):6WIONUWF%2+-7 M;.A\E,Q/U$1=P(^8R%N?@#<3!JHX["!:_K2KR/A:3&Q_KGM+CK8TS,SWJK&G M&$O[6%M`#AP!T1@X`Z+H@"-7<1IP!GSCGNB*'KQVKV1-%C]/T9VN"BB;E_2+ZB\O(KT9IHG.9)<;@F M]F(O*)&21*&,V:@>AD<3F]EK&L31SU13R%W@]4P,[CRSBF1_93"(4Z1.Y\:? MG*$K3C5#K`G865P,#&OE^!E5TGTWX;=VLC3\%C(65&K` MA^HA$_N7Q8/P#\/L'Q?I2[I&^;KD]+_>/8_WVVR*"K.QZ(J&#*D)1@`CSJP. MBZ?-`W9$BYZ0O!9T+>TZFW6,CO!=V&N4#UO[(0'F<,^P]F3V08I'FOR#0^W3;[6*M# M;VMKD:_9_V5UYUO_S[YD[Z-*GJ6:MQ)`,TRIQ%^P@#N@XE=J`RXT8;("W;UB5P!B2C@>@/%YUE5.>2!>`6V,.'"MKG_!\:B2[NS3?\GF1;IR!JKR\F"49!-?&FL09KMJ]'Y*9!:HNZ(VEN7T[87-M5U MV*%D_&F/TO*--XD4P),!>PK8/\GYM5[')E@SA%>U-3AACODB+5<9+O>%],[% M1"ZPGBSGXLUZOY&I[1,1;?&"BF2+/N]WCZBXW8SRY(DV9JS*-I8R+!N,!S3% M!9YF)K6[!`I#^[^A$-%GC)#HVUA*EW#3LK0:V_+2)XANH*GFQK= M-5%QE@6F9VKKL\/?2<-I2$\6Z@86>AU,JP6*/FD=VRCH#V"WFXM& MC?.GI-B.TW*`"_3C=S0%3A;.QM9Z'5!#Q+*_B!8(M-M],<0>)4%D,!),S]5$ M[6Q$0G2RL`59Y97F%!)1?*3DD&2/Y<-+N*YTAS(Z35DF177@T&=1\GB-"%[R M9'%J;[_7`:^1?!9W4\.:"//:]LQSGCRG59))-J+,"TIZ@:I@0&9IYX]M_@N" M.)2^T(!_?K9E559J'&59GX=KIJTOZ/HFEAF=L@'K%W5I3;TGD`N'U_=BC^@5 MX9[S(EZO6>)KX0LI+,6ONG#T`#:PC5L$JRN.?H-FK/!U_D)4PT4*<+@"6BE` M![31XU&NN5OX#>JQV%$)'6WU`Z+(9)27%Y%B3U0D>@AJ[>`6B:+J+/9!0@>D M>HC24[<29;':$CL+Z[4\\P%F6)1BBAJ+6#6S2*JCO%G0JJ)DU?9(Y)62DU+,>E3@.9&FO,`,YQC1;IID+'9[O) ML$P.+#%$D:S'"6E-"FDWB8:%H@,')]0NSH_'I=6Z MNDX=!&2Y[33CM;RR*'0[]+161V"[S+HQ*EHM?705.GO"\:3@0$0_X:0J\>R? M7/#=R-,NF+_"I687]]3G$3/>!]3@5N2&(O."QDDCHNT+UK9QE(D!7'GDCQ># M)<#=*HBT-+BRGI*$!,%![%"4#?[>6DT,S^BQ6_]RG M!6JW*9=9DM.7.2_)K^RM>_^$B^H!%;O:2NRC#KFJ,C+0BLN<"EX!%ID%JN)ZH[]Y`+>.]5AD/09% M"UIKV[A`KDGEW_:L%CYO-N$"/O+^'D`K`-B8] M`H;D@`T=1',@8\6N2C4+XC/WS+^1MK/B4"+8-<:@9>Y]YV6^_WS<\9,D62M*:[S#2YV=9M+7@\S M*]7FLX:6\G@WH4($*-4R2?G'142?NKL%_4_^.I!AHV"E4ER'@?&NH\7[/.,] M8:DCHIM;B@(X"+\>;YL,O\8%"I5J$W#!L8WW74[H4&7G)LV&*G`=\::`H1>* MB&;'4(M\W>W@7!/C2&,03,NU^Z+P-?XND')1547Z MN*]8@A_/*>B"3!( MGZ&K&[.K#X-%;!PO+7S,'Z6=$@/`+9DG\CS9?H:`5[SF4_MK#'=Z0PL*V;(I MMIQ=O,M;7MN;-$=L,J$9'$=TD@&R1Q>,CFT^X7Q]S%&@45=51**YN$@PO67< M@-A*;77GZ6IA+QB#N-OWI0H5DIEF2%X)VI.`7DG!+MZ=%:N%&&3^/F%%)6'O MXW*';.]`$B!WG=\3A\V&\8SP6ARER?[+AY'%R43C]_J;\-.@-=#7BC@=U!EUT![4 M!^S0.ETEV?!VT[1(DG6M*3N@<,JS???<#4]_ASU)M2_0H,FY4QTI07M\(R#PYC_<-C$& MJ#_T*$[J9ZY'4*_;TX%7=S5G29F6;/YT1$.^/B_2BM(U#VD0S[HD1EO1*'U? M?6(LBL2AZ`D;D*@(O75]<7O.85^X9Y25C[*U7'TU,5I4]@9I[X^>XK,JCR&V.+$G?=\.L.SF9 MQLSCP1)0\+.^X#(?XXB;J5%EW#R>H#C!%G9M4?Y`9HJ4]8'"1.DB]X^729$3 MUU_2;--+5#2[B51A;SZR%8F(PP21>#\=67LE5DKF[VXP)Y+,%VGI)"J&X#^T MK8/A^@W[O(PSN\Z!/+@OLK=]LF,2CL8HE M#V\.0-7.V(U)AOY`4"%U`Y851>X>>K=%?+J#5HS#T<82MP"@Y*XF"2D]WBH= M227S!A!2N:XA]&U(8V$C18==6<&_?Q5*S#?RGGNV+],O"E)_9U2CL72]V6S0G(#A-6_08V)+;4?=G555>Q$$5A%Y+W^$\;K M+VF6M=.3:\(ZWZ9T>N*M]_=D.HJS*$M4E=KAW*IL`Q##LMX.P*VQB MH1`W[FC3#;I MT2*X@$[[$-P$O"FQA>K<,9^N+G:2!Z@C\F[?'$H^T^SR+*%$?;'$WW2CG^Z^ M+Y!T'Q%&WFTJZL@]OL8@%DWO!2Q*:LP1EE\`MS&>8@M^&U%=9_U*@T%=D?L) M=AOH"6=$B9(FF*D._@[S6?6R(WSAQ_94F_OH,;T+;TVZ-0T(5S0MUZ5_`9?S M=[PO;CELKS5WR#_@7R=^`/.-O/?2&)RT?O^R#D>FL9DH]WKK02&3=M)O5;9W M3]2@K+_T2!`Y98["KK")A4)P&78PP!/-PZ4T,I&AO5UK4G?DKH>>L.95=JAO M$O9\F)6WU+(]L<,BQ>\C'`4>/FQKE MJDB?ZUN("E7(V/O?J%JL\7-UQ%>WSS&!1[?U8<7#X\M([G"$W9B0RRDP7^>S0?)0NR*9Q:V9.;&-P]\RVOECCN.47+3P[CY._;G&$&B_<19KM*_H47=T:+*6DWGE8<1DY M#T,N05_D<&,;^#4/Z_KB31%Z5'E!IEMKJF;Z@N[1:E^P-Q,OOZZR/7%(](U6 M>H]MWZ82@5XVFJ^"$?3=51!)KYC)HC8=QITH]CD7QRE"P[A5Y7D@_C;O5M5! M.F1%=9,FCVG&X-@TROHVOZ,0+>HEUV><%^W_LJ0EK+VT%[*<5\`;UF$%\5S] MFLNJEO?%'(H3ZP)#?;O,LV\[O3MFO2&U,3R[L,2N+O5301ZE!LR\;#F-IUCF MG$*]=>;./*"[9Y.JB]5W#*^>>?85W\X%M"/6.OF:=/S*J8UIL9%WT!4+_9*: MI0&,+JS!ZXBUTPNNZ7CN^=_4W;4CP,A0@K=Y^@=:7Z])^Z:;%*V;">WJG_N4 MH&DXL27?]J0U@3["*?>1*W'$/?AK<_/:T^Q^G7-93F%;=+DO5D])B99%ND*+ MC-79>C1])S$J/>H$P-(1@=S&'K8@!M;EXXT7M\,:ZY-E2I5;%OB*GG+V#CMU MUY4-2W.#'[AT\""=9@^[F\S@NAP]Z!+276;/<\*W&\W0$?`JS=,*W:0O:"0Q M;JA)MYRMA(@UN4I=Y_3LQMZN^GEAZ;& MUYZAI<5VT9>.\D*TH5&FWX[65QBKV]"\676!JB3-WIZN.OFGJ_;T87+Z/C01 MJKS.?WM*5T^7.='N4(,!C=ZR@I=HKWI`2IS0:U?&!AKZ*7?/7T$$\;&G)7E: MLY7W_(DN)E'CC/(MC;0B%D'=9IT$D>!R'"X!Y4X/G:;&FAFC`'%0<..7DIX=)H&EFAJ)&*B.T)75O-A3/!(>\3JO.1TL> M7E,;JJAI>STW1^L+'R8$#:E8/39Q]E.Q[#W+VK)R[#!?TW@3YFK8;#K#F=B\ MXCK%G++">$^`FHH@&/'K]["`CY#MAPQQ726:_8>X&+768#@>0X8^-S=H?HX&!4`N[ MEF]9.9X[OF8[*R_D-I>)>!B8E&E1`BL3#X@L;&"),5A-#01_B@^"3*LV](>] M94Y?%N2&)A5-.SB)::*!%$1'RP%*S+F!S+]^>XLV\W6#F[4;J%['NU*!'4)- M/QN9+7]?75>\5WAZ&<=8G-%OZ1IUH92_)/^#BVXA6 ML^?HS<)#`06G6W*"1G\1@;^#\61'&F(@DO!,2TO7'HS+Z=SME']"_X62K'I: M$391E/-DK=`)>\6[?*CHJ.R`-2O!5,N.R$DDL5Y\F]G[(<]^Z%*U<=&7>6,B;S^&X:L*DP6,NA MI]15T#\I&3..=X$&[OS8N+_H##RLJ`Z@U%5P0H8>3<\,_;#&O-U42\\VWK6L M0+<'4B=LD.,IY>/;D3(<3:E,L%%M3"F=N/0H_6G:S#I'THDCSF'4K<8ZZH#< MP[C5L*FZ.A?15<'\A([U"?E>0><7.6!IS]$.;2U[H0/NLSTAHT(&-(G/G3"6 M'3G&NU6@-Z7AQK?<@HJ][%-8Q,NVK_6$LC%1NDGM$Q_";=CI(6/R>LP#Q9SN MN?J$U'$_^:,.5`)2&:P&I($#RT!/$SRIV9ZR-P=[(^MQ<;R#[BIP,[`==-`. M+7Q37,;.D1%?/SD(?:_N,2EI6.;N&>4E8^P[(\@QU][MIB_7'78XTC0J++XDQ5J3:L(-WW$"BJE\ M_>VZ,R'$^TW";^W^^O";/\Q86_ZH09UZR,S7Z-J(ZB]-& MZ"F[U#L*RI,%*=P^KP-5I3SQKL#$@R]^E>%HV'`#29C%9Y$@WEUD]_-+K)Y\ M22]:3:N>;9`-JXW9X3*.)S5"E! MNZ]3;/B$?$+E3;"S$` MS9+\3#Q/9CT!KXC--\<(!/6,,XY&"A'BO8)ZO&0NM,IO:?5TG:_3EW2]3[*1 M@8C1'JC=Z7.V+9%@6)NW$NY-%]>5>&N:D3Q4!;9O2C0KG]+G!WS)`LV%HZUE MZ<:8QJ7]):/8;-(5*H1CM/!;FWQB^,V;M[1M)ZQ6;^@'#2MA*2B&S..=>U^D M!5H1WD*$B#]V9Q?#CS%B1*G@9)#PW./=X9AYB,)3'?*PJ>:1EK:HL91O\]3! M//55ICHS3G+GDC_>D#BM464VO9$E077&$'I@!V`8GWEOGYE+^D0(J_(Z7Z(B MQ>M/Q3A+YHPU3&T`50WAGMG`\0DY(9AL?<.3':WTH%,%&ZGCG4.SK0ZF$UI? M[(LTW]:*_9ID>R0.B1+VQ(EL^D>=5FQ.I4^YL>,L'<=:M'CWT*PMQ_[S*RJK MSDQ\1/0&J"ZIX3^V# M8M[?>B<$6#RH7BB6-][$T&SPK]49C?WUSU>XN$?%2[H:/?AJ5;8_(827/95N M,L%BLTW]X/+8)[,.XEJ;V&:@L0,T")P.3"$V>#VWW`'OWR(%WB)CS-%:K-_E M5_HG?^O$K%![K0)8Z$2`:F6C.8`+%:0!\I_BFRA<[IXS?$"H&0W$>G[&^0M9 MH:!ZL5(^T%=V^M_IW;'/N/IO5-VA%=[FZ1^(G[O/7D^;AG2^>DZD<[U62\S1 M'V>4O>G"_QY]/E67H7ZNS\?FC`ET(&N\]\D=W13&V%37;E$Z1+^;.C7\8T\.<_1GRWR M*EU3K=(7,M%9[8NT2E%Y^765[8E[H(^K4C^WKXUVN^$-HTYUX)+Y*-^!&^;^ MUO/3Q#\[B!F(4BC,7U.[^XYQN MKA552E1:MH*KKF:#J(_X4E/'`B\#G:W0I>8?;]3"*=WT-X.,R;U_&$AD60"< MGO)[MZ?;)1,V7BI`6L:)C.PT4BO;*5P!<[I#(6W1.=;:LM,-%QK)V]^1)O&N M>R::9716Y6:/1G8$YHYMK`9?[&BN=;?6'O)T8^J69ZQ#WAB!T[VAT,Y.!\&; M0?R-&VG?AD7GPZ+,O04^!MZ,#OLCS)``.8:;]<0'?FKG6HQXM^9^0^GVB08E MD<5[LD6?]W15U@0OE+?[JJR2?$TT;LXSCP$2#*Z2`W2W3-O]8$=,PS1U'?_. M3H]-C"DH!C'7H)@WA^$8)MC:5D/'X48LMH$/%B?R*('K?%6PF"86TMB&^Y2+ MJBK21^(\B9-\P.-@IUXL%`=Z=PR;)G;!\(0ZBG/[SM6%7`@:[^@,TEY^KF/3 MJ?3<3'J4BMNWUIW`EO7:EU12QGL^*#%B8[.1+6%3,%UI]4Q,7OJ$.L8TR[WR MO$PNE?W9946O>?@^I(*LS&=9L\%7Y*ZJ=^2B7CUH_BI)"W81^A>44+78U,5W MO'PGU-'7+U)D\KI<(->D"A9N%DAWEJ: M0OY-T7<`8U&%@<1697G#P,KZM\]U_DR&`]9D'X7A.`!*7G<1I;?1VJXUL8GB MPW'9J$(Z6"LKBO?$7J36CV"(_0B&V(^G!3&QXC-`[,?X(Z%%:OT$AMA/8(C] M=%H0$RL^`\1^FBD4VH?A8=,C/&WZ(&D#9=T#X\/JC#=4POWT'UM.@25--56N M06MJY#F!N<$$<]U(0OIFX>UPE7@30'#?>5(^$=GH/Y?_W*M!#XV MW[1<&[,/+Q>U:QGC!ML;S;V'N>F'W1F(%:^CN699@G8P=,.(NP,[-?'IX=C( M/#.#5R=+O&N:VD)ZL&KIVOAH.=WI011JE)G1J1##?B44Q-G7O//O&69LKS%- M=R-VO*'*H-,J1^VLCU162>.JV2+/*;98K>B=":K[;?6$"J(K(A-`HE/Y&56^ MSTE[TDB.1Q44#22$%/[&],;>1ZF(F<\)GM#XBA2`M!W9E:3>O(&J<;"1@L-^ M+>#+QEHEOPF1P-+A]C4?4]TC>FFBS8A:BC&CH6J?5Y51A8H4F%H@D$A91;Q. MR#+\)EG*#LJ&":XH)8'[)K`*+=<'/-1!S MM*795'V[*O6<0CW8@_GJ\U:ZZY,3_*9!S%-; M:0['A89DO@J@[.TJ2BF][J(RJ>Z2+[\09U.D249;X'9S1]JW>!'.>]S[]$R[WW#Q^W6^+/`*E3"(Z4OP&%.5B`9D M8+7M4*9B'^^DN5/O*LW3\@FM/V&\AL%,7X*'F:I$-#`#JVT',Q7["5OE8=SB M;70D:LE`U?O$HX=]B@8F8T7L\,#XS'$_R$?#TUWFYL$+M6^1$O*@$!!&`Q&= MDG:`$7"USX'H=U?^;%^F.1EMS_'N,!NLX(V$[0PP'+VTU=4'T:!JX@W6UGD`;-YY]&9N(N(! MC.,UK/50([$X/,LMK#Y9`T0>M4[#9*O#->VLJ*SJC%.W19O6X^SP0`00#(2F MQ=H7PL#%`C4(%5`X8IH6`QFD7\R;0<@BI"K25:5Z+D%)TX6O"&G\I;PP;3$, MTY/+:`&LA;H7"?=XG
  • SYQ%,H")_)B'"'>S8WW^R@0;\'2@36(C? M@XHP&]M%6=M%\SR44>G1:U'`TE$!;YIMIG@L MPWKC?=/:>'*,K>>/)NUQK)@]2PNN\-M<4UJN<*8O,N$5QSOB"ZQQ([GZ#"&5 M[T+V2$-25N(,CVF?!7OQ4]G(C01D$]*>VQ@"XFT@&PMI]^.ZRB5[0L!*(\_H M+5!\Z+I*WG>)LIOK03Z!J1SR5DQC[`#3K3>Y.UB)8#^VA=HYSG%9W6Z:#?OU M)7$1U6&Y+U9/28F61;J2!=JZ8*7R_6!6H1N39GU8)BG`I4!*FYGL6#HD)V&. M$]DH"K:7UEN`99(.KBI9XMTK!:HJ=*:+?&TR:;3G:M8I]%R_EA/H/=0Q8Y53A-3)9AIS]#+.D`_[ M'5I_1A5\3>NN#KECQNT`XAV2PW*(6;&G<]8( M6MUI/Z]'86)`98%O@9%63-E"7$#/F:#O;/-.&Q M=9_3?.;3:^93BC)4'F'7E"^1V/W*?G:)@/BOP8/2+4^9E`:\8IWKDS$O\Y7>(=N M<,F?4`B_-0;CO@7?_"I=S!J?XV0Q!PO]6*O`5[C8)=?YAO[#&A%^\J\OK)A# MJ0J[RSFEJ/DR*?(TWY9+5+#P'/J8SFJ1KR_2;%]!+K@8,M+;0LLHI*X':7W) MY,#*;OHIH%P@V9P`*LCIG6>7K>[-T*9'NZR$'-;C$J>!7XTE9@#JN,;3NV;5 MZ:B:IAB7`Z`SX.F-`XQ.F@Q-0*IXZN0JK#+`6>>D"=+TY:VJ*OM]"-_&=YQ< M<-QP,V88[%46/_J5F93QY(3#8OR+*F5KH2K3QV=;M&P5*5AGW:B#OMY$>N MD:^^CMZ*/C!2H9OT!8ULH$[B#BTX2M^N+^C-+`K1S@Z_)/^#"Y9B3)##UJ)D MFQG)'(V;@)/[3]@\_,BL"3\IE7'VS@68YNZ;32>7[;"T]6N M:99QK?$F,E&H.5HWZ\<:V5(;5B1$(WPJQON14'*]\@UYB-Y2N-UEJ#G8+PXV MNO25G&1W6ZQ6^]T^HU%[BQTNJO0/9C`TYD,&(&W/KB*,! MF9'6=B#351%O\G?G*Q+9#'BFI_1#J MHA&U"3[Q??#$BZ,[;`+3-X@`T'L;!#G9%O35F"VBMV'K]P5$QPA&9<0VD)4) MT`Z2=^_@!;06"."M.[5PPF,!DR(@$[A_'_:R\4SWJ'A)5XAFXZ?=3;S%#R-N M7^O3$'L;[XQ:!1MJ/1S:(%6Q9TPT5?C8<9$`YCI_WTA)QNN'@BB0YELA6@"4 MW?/V"LIH<`+7UPXD2OX^4A!)$-(*>=1#[$VT=.W)NIPN&FQ`=;5#AH*[C]2: M$ES09QC3LB2:-?J(8:$CZSUW*2:+!A1`3>TP(6<>[W:!P8026\V^3$S='B## MJHGWU-AL*:.UN_:<&%2?WO"QGPS+M1OM<6E7&[)=,5`);Q;X!;\P6:YS3LX[ MG&57N/B2%/R%09,BC0U@14*!@;K)U;PI87N/VGQ7>YND? MHSO94'(QH@3DL2)+I[D3A`DJB?>Q!*.Q[!\_GNIH-M+,[7AFL:ZKQ[/+7!S4 M$L1:8SR%Q5;3/>A:XZ9_``^KYV36&DUF/'7_Y(C$G;0CB@51("6M,"3C''E2 M`4ZMSSA?0=`SIA,#J$\7*8:DJKJ`49_YA%BS$-ZX\B>4G7-RDB0NZ27-F>*E*N=<6D@;S\[:ZD\9@Y.4^JY*\DL1> MB#]W,1?\YT#;6*,'I%W'+.987TUIRR71(ET3/6XW]_M'\F>:%(?;#0W\P/F2 M66Z1K^^?\;Y$XHP-U@S:M`X6#`)%S&1;0#!E4\D<+U>_YL1:HJ^:MFS%$Y9RLDMY M!G+PS:&K/]XSFGMB)[8!1M_BJPZDIS_CG$;Z"A;7(-K6C:IIO>G+B2-<12MI MVFLH8AIO>OV6T+U,\?@G_-;HP7WSYB[4-L=J)88]7LB*]FB.1<2^%=01,0S) MG+M4L69WBL0L(S;FU('*Q"TZ&ILT5<8;-2:QPXTD-AE*KM[DO9D4E2Q91C?. MY@$5.[$[[G\9.N/Z2VA3X[%1L4H7T$SXIG\&/>`5>:)8ED7N=M.H=%O#CQDD8Y6^X*]3':>9!E:GQT:NK(AY&'NB%N[W3:56Q3(=&LSR4&%=RR)>@)M9QQ&JM94&=%N4/0I57I?E'JUO M\U;R3FA^Q0NC;M>\.NHH<&6FLSF$M/SMMZ9?4/&(_;N^&[1-LBN$>'\V^KVQ M8>_W*!`BT\,<"SU./M[BE/@(.@.]W2RV!6)K+*X5)5\;&XR^1M&B:IW,VW7$ MS]MSFY(FOMU7997DZS3?GB?/:95D]Q5>_4Z]$EUC/^#C.>V2."BJ_98/S)K$ MHS&M)8\H0.7"/N;0LZQUPOO>\YS"HX*]_I6OZ!.6:#U4@A0MGW"VEF+3MGA[ M`F]LK@'K?\2WSRS1]-;A#S\F!92L]U?K%'5Z1U>H:BY\S"]`EVA;OTRF:%HT#I)(N8(]6TNA:M M%L#^ M717*F?SZ@_CBK?!C3Z;^1V^CC<1R6"/_<-`8,F$;?5SA.0*(/5B)O]&AQ)W8 M1NW-#;[H*5S9<.5RL=(AR>:0$VOO-TKL]PC;S%H20_R65D_7^3I]2=?[)!O9 MA-CI@9J:/D/9$BE>_IJG$BY5H.M*O#7-2!ZJ`ILMTXGS4_K\@"_S*I6D%+(L MW8;#F9;V9J7;S29=(7$N(N&W-H)K^,V;3[1M)ZQ6;^CZ#"MA\5A#Y@$].?89 MY^\;Z2YWSQD^('$^$RU=8RH%78RH@*H]&2&*BN+/?CG34(6G.F9Q\DRWTK)( M8%,IWV:EPFRTLTYY9IS?SB5_O%><:_N(G[85?FL:B?OF;Q_-&A1'#?*U<<9)*H/F(22 MQ+LC$'M&FKFA!T]H,Q?DQ/EP(IQLBX=-_"H#R;"I!I)TMUV=2_`V21Y,DE73 MIAGGMERU\;Z@U:43:J[WLQ%(E0!.1L/H6@7;*+=T!&,N38OGLNY19Z2"``5@!6C`H_&,<`=2O(&\CQ[66,&O-ZF,.(D@IJA=<;IC$($^Y0LWJ#9^$\UOIQ_N!L6<&1"ELX3 M+6^XQ:&5';38-IH.05KS[#Y!4/.; M6YC86G%Y!H$V]HG$3WR^\"LJ?;@'<;6S^P:^VC?',*6=XO(*O"KVB=OC=@EU M"$J=R=YUOU?QGMJYQ;R_]1X,L'A0W50L[X24^4%,WMEQ@*@3#3[T>T#SX93@ M*])U-NPUE<6>2M[:(NP_=$CK'BCYZ,J)*UA/]>%"UJ?4!^:Q=U`>7"AN[.GW M!2];M!/*.K=[^YYLT3ZN-HSHK;]R/=`M4_FK)U9,3Z37S6+C.?J;*T$G/"?@ M>ZJD-0%O`?;FUJ(LTVUNWKE`S*"=2L/L6^E,)C;UTHDT`DYXW6">`(&VC_^" M\^J);EQ>;=$#7E15DN;GJ*#_W#ZC(J&#[4-2;%$ENX]AP8&[K&'$X400/]UZ M9PV[&1PB=OBXC=RK( MB2-SN1*:0/*N5S-^?<5X3TA>&^FN9;IF*VNPB0G_5:%6XGPH:%`P;U%#-`46M81^07[BYH.GJ4K\OA",/A3T/5/CDD MHPH743#%@-"1,K._,.9]=76\>JHX@M10==-`"56X\(`I!I[.29A%?LWH./ML MM.YKQ\>+P(@'"P+"R#\+).4K`/^EN;K;H150D=!+T2-D#X6P.B5 MM<**D.T

    SA[;U#=HN-]MTE#./-O`PZ1=,[)@7-`";<;GV&69XN6C`9FL+.[`9U#;'0=(4L/V2 M?$UW^]UY4CXMDP/>5Y?-\-N^MKM$Q087NR1?H>N<9D-+7Q!]<8H#WV0^30-, MX!,-.%W9R@ZL$VJW/]F;%;S''1LZC_T[T:7@=>H4$#0``;'T``!$`'`!V87-O+3(P,3(P-C,P+GAS M9%54"0`#/;PJ4#V\*E!U>`L``00E#@``!#D!``#M75]SHS@2?[^J^PZ<7VZV MZAPGD]VYF=1DMQR;)-0ZQF> M#*A;ZM9/:G6WA?CXR[/G:H^8<>+3R][9R6E/P]3V'4)7E[V`]Q&W">G]\O-? M__+Q;_W^#::8(8$=[6&K+=:^QWVJS7$@H`)M:-O8!9:^)'[F%]Q>8P]I`K$5 M%E/D8;Y!-K[LK8787`P&CXC['G:(C=P3V_<&;T_/WIZ^.Y<"N-C#5%S[S!OC M)0I<<=G[$B"7+`EV>AI(3/G%,]_5]/3T=/)T?N*S%51R>C;X]]W$4FW'M+*I M"NV&Q*"!V&[POOHEX@^J\KA$L?1/S_KG9S&32^@?*7F>'Y@;2W0^D,4/B..= M\!GZ2/ZS#Q\^#%3ICA0J(@55$\H%HC9.TCMBQY`D_FD0%L:DA#YB?D#*L7VR M\A\'85F.IC3P\J5Q!!O([AD`!6;$WC'XM`*/3_L'?`XF^:)!05(N&&V:)L<; MHM072,!`5H^BAYL-H4L_>@+/9-]>Q'C,\5)3O7TAI;CL<>)M7-F5ZMF:X>5E M3XZ7?CQ(?M\P?`+RQ23,=W$!.+)X`"PZWU4?6LP`- M-'EQ/S>.FELET-BW`VGBA]31J2!B:\`<99X:3#V-.)>]0HI=VW'K>]1^/H45 MX/14ZVMQ#+GL8XO`B>D4^Y[Q)'KO1P[6`*;5TA5ZXSUAICP>\I"APBY'(LT:K#4`@> M0*?`LZ!_<83>R)Q:YL08#Q?Z6-Z,]:D%5U?#R7`ZTC7K5M<7EO8FB%OXH<.S M.9XSQ*`SUEC(&FJ#F^8N0?KLY4AK;U(M=LA70G[7Y=Q@ M3]9`1!ZQ`6&`AR<^KS39F]=9.$K>5K<'U@(>W.E3&"'FM6;.]/EP80"I-IQ* MLKO97+\%2N.3KAE3N->U-Q/3LG[H+,=+QL\(\?6UZS_5'B0YC(4CX;SI2!@- MK5OM>F)^[M:((J1-MD*4_%=)"M-V!N8].9-#5,N("A%\%SMFA-NNSP.&X<:< MWPRGQG_45%4S=0:V/CV!.Z@.H+I"G,`,FB4TE8:6$;4(#FW;#\#'I:L93$`; MW/80N]I<)6"^S8)Y-;0,->?`UEHP__:HCN;&PA@-)]IP-#+OIPMC>J/-8.J. M#+W#]Q!?"Z^D@9OCC<\D(FH5!6>+BM1D+"IDSS*#;/9\J&$)$"LI+4/DIBXH^G$]AEEBQ+PF+ED3G#LR> M`JQ#YP"=:T38)^0&^`XCV8?*&PR!R2\JP>1=%I/KH3'7/@TG][IVIP^M^WGH M"W90'$`1+?DR2#,A@F9S;&/RB!Y/^)E M!YQ0S#DL$`^$)I;TO(*2_O^0XRO?6\94MRRY7%P9TVXMS\/@QO>=)^*ZL?DQ M0%VZ(M+\A%@4$11C3&-,>?C>+WS2(_R#F&'4Q8&X,*'S[C[7O.IAQ_4M`Q#:* M_[+/2W#(B\H7YNC76W,RUN?6WS7]7_?&XK<.@4RJVO.(4$%#F`F1.1%,]PFP M(H(23'+B<1GE&8LPRQSE2&2^1)]V*:UG>F(LB5XI50EL#9)D'62ULF5)M(H(2H"JGCGK\&F60DL"58FR!+%F MZ;0.O6IYM21:N24EZ%3(L750U$BV)?$X7EP"2L7$6P=,@PQ<$J!RLF*@ZF?C M.L@JIN62,.47E4!3(477@=%P6]48"T3<:KNK8MI"N#XTW&2EO8FJ[R"L'?RF M0*Q,70)CX_"WP['6-ITT>(4D)8C5V+33H=0@2Y%"JIRL!*U&>8H.M3J)BA1@ MA10E6-5)5700-?S3"J%-ZDRD\(RKB6^KRM+G%>4R#K`K>/RDOZ_J MY)D[\:DJA>(4'854*,XAC[QXL0`YQT15D2'!%EV_6!(5L;)M;5&2?/'-RX4) MP%FA=@-IDHR[NQ?+@Y_M=6U9=DSJZL4R4$1L=73:61TA]ESA97]?03,Q.+%K M"Q'SR(LF`AP>R_0A7!HH7B%U8,(1&5)L+F,IKKZLIP^0G+U[N1RBM@RB2?OI M3A4;5A^)F$E=?0TLDB?H5>D#Q2+O^C&?[(ESV1,OD.+'`9/'(LJC:',FH\V16ARCUR&EZ_U[%>+PE#UUJ.:%YX,=0VQK".Q)EQ'4"AZX M("*02MTP/]C$I`1(>AHEKBNSX)<]P>3[3@BH&6AVV5LB5YWNJ8@W,"Q\9Z%: M"HV$B(L>PF.S+GL.?B"BD=Y3G]IU5$_2_TFTMY"+)QAQ_(#L/Q)9A5C+&T2D M@)QGQT!]UK;TB0W2%76*"A"Y/*>71UFPWZ ME4=_?@G(1AT#*@0C#X&0LBW\:$\47:F9SM/SX.M6^^?I3`IU5ED_ M@UI0(5^&9M!<#FT;9''&Y)$XF#K)CFM:0VOZJ&3R19M$E$[JW;)KG\ESZ@)7 M;=1:,9Q\#6UG5*NQM*83R@8*>,\/F($97>V[[K9O/E$8UB`&<0ABNW=#4UH>)VV;@BNC%V$N=Q[>-DPM@+U69\K#G+!F(FU9\QL\&S`(<]%#MIZ,MZ_]T M3EHNBO(C(CZ-OEUYC9$(&$Y[:9484IZ`8+`&M4G1&2*.07\E=)=OYT=US*7] M?GGI&KF^G7V&JJQJH-7C:!^H=>B9>X.V#*=G"/6C"XH2?[FU-RTK]JD@'^;$J6%;]0!R*GG#==UI(KS?;#TWJ^&Y[4PJ]H/Y5N2<2 MTB1=D="%-J`%%H3?`).OW"W6B)H;60>_D9&Y_*=^C`0^='Y>I\V6C;ZI3_OF M<@FN&XO'2B;$*J!I:[1UYU.QYN"`7J\@MA\*`8*-,),_NW^6%^JKX7FA6"WN M[VM3U;LFX59)N/L?4$L!`AX#%`````@`=8<.02UG>>ZENP``.2P.`!$`&``` M`````0```*2!`````'9A&UL550%``,]O"I0=7@+``$$ M)0X```0Y`0``4$L!`AX#%`````@`=8<.08M61NE)$0``E?H``!4`&``````` M`0```*2!\+L``'9A`Q0````(`'6'#D'@TK9M%2,``*LQ`@`5`!@````` M``$```"D@8C-``!V87-O+3(P,3(P-C,P7V1E9BYX;6Q55`4``SV\*E!U>`L` M`00E#@``!#D!``!02P$"'@,4````"`!UAPY!6*`H?(2%``#P>0<`%0`8```` M```!````I('L\```=F%S;RTR,#$R,#8S,%]L86(N>&UL550%``,]O"I0=7@+ M``$$)0X```0Y`0``4$L!`AX#%`````@`=8<.04+<9O140@``"&8$`!4`&``` M`````0```*2!OW8!`'9A`Q0````(`'6'#D%8Z;&^'@T``&Q]```1`!@` M``````$```"D@6*Y`0!V87-O+3(P,3(P-C,P+GAS9%54!0`#/;PJ4'5X"P`! @!"4.```$.0$``%!+!08`````!@`&`!H"``#+Q@$````` ` end XML 56 R20.htm IDEA: XBRL DOCUMENT v2.4.0.6
    RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
    		 6 Months Ended
    Jun. 30, 2012
    RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS [Abstract]  
    RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
    NOTE O - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

    Other Comprehensive Income: Presentation of Comprehensive Income

    In June 2011, new guidance was issued that amends the current comprehensive income guidance. The new guidance allows the option to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single or continuous statement of comprehensive income or in two separate but consecutive statements. The amendments in this update do not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income. The new guidance is to be applied retrospectively and is effective for fiscal years, and interim periods, beginning after December 15, 2011, with early adoption permitted.  The adoption of this guidance did not have a material impact on the Company's consolidated condensed financial statements.

    In December 2011, the FASB issued authoritative guidance to defer the effective date for those aspects of the guidance relating to the presentation of reclassification adjustments out of accumulated other comprehensive income. The adoption of this new guidance will not have an impact on the Company's consolidated financial position, results of operations or cash flows as it only requires a change in the format of the current presentation of other comprehensive income.